Saturday, November 21, 2026

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 152 Results Generated From: Embase <1980 to 2026 Week 47> Embase Weekly Updates (updates since 2026-11-12) - (152 records) <1> Accession Number 2050207992 Title Single-port robotic thoracic surgery: a systematic review and meta-analysis of comparative outcomes versus multiport robotic surgery and uniportal VATS. Source Journal of Robotic Surgery. 20(1) (no pagination), 2026. Article Number: 1191. Date of Publication: 01 Dec 2026. Author Gritsiuta A.I.; Yazditabar J.; Radfar P.; Ross P.; Zervos M.D.; Petrov R.V. Institution (Gritsiuta, Petrov) Department of Surgery, Division of Cardiovascular and Thoracic Surgery, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, United States (Yazditabar, Radfar) John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, United States (Ross) Department of Surgery, Lankenau Medical Center, Main Line Health, Wynnewood, PA, United States (Zervos) Department of Cardiothoracic Surgery, Division of Thoracic Surgery, NYU Langone Health, New York, NY, United States Publisher Springer Nature Abstract Single-port robotic-assisted thoracic surgery (SP-RATS) has expanded rapidly, but its comparative effectiveness remains uncertain across platforms and access strategies. We systematically evaluated SP-RATS against multiport robotic-assisted thoracic surgery (MP-RATS) and uniportal video-assisted thoracoscopic surgery (uVATS). PubMed/MEDLINE, CENTRAL, Scopus, ClinicalTrials.gov, and supplementary sources were searched through October 5, 2026. Random-effects meta-analyses with modified Knapp-Hartung inference were used for continuous and common binary outcomes, whereas rare events were analyzed using fixed-effect Peto odds ratios. Risk of bias was assessed using ROBINS-I and the Joanna Briggs Institute checklist, and certainty using GRADE. Sixty reports were included; 23 provided Group A or B comparative data, with one study at critical risk of bias excluded from the primary quantitative synthesis. Compared with MP-RATS, SP-RATS demonstrated broadly similar perioperative outcomes without a consistent disadvantage. Lymph-node yield was nominally lower (MD, - 1.18 nodes; 95% CI, - 2.31 to - 0.05; P = 0.043), but this finding did not persist across sensitivity analyses. Compared with uVATS, SP-RATS was associated with shorter chest-tube duration (MD, - 0.49 days; 95% CI, - 0.85 to - 0.13; P = 0.013), with additional favorable signals in lymph-node yield, chest drainage, and conversion, although these were less consistent across sensitivity analyses. Complications, R0 resection, and mortality did not differ significantly between approaches. Certainty of evidence was low or very low across all pooled outcomes. SP-RATS appears to be a viable minimally invasive alternative, achieving reduced robotic access without an evident trade-off in perioperative safety or immediate oncologic outcomes. Prospective comparative studies are needed to determine whether reduced robotic access provides reproducible clinical benefit.<br/>Copyright &#xa9; The Author(s) 2026. <2> Accession Number 2049639544 Title Pooled Periprocedural and Short-Term Outcomes After Transcatheter Aortic Valve Replacement With Contemporary Self-Expanding Valves: A Systematic Review and Meta-Analysis. Source Structural Heart. 10(11) (no pagination), 2026. Article Number: 101106. Date of Publication: 01 Nov 2026. Author Shaji S.; Saravanan P.B.; Sarkar R.; Kharsa C.; Aoun J.; Zaid S.; Kayani W.T.; Faza N.; Little S.H.; Atkins M.; Del Val F.R.; Kleiman N.S.; Reardon M.J.; Samimi S.; Goel S.S. Institution (Shaji) Department of Medicine, SRTR Government Medical College, Maharashtra, Ambajogai, India (Saravanan) Department of Medicine, KAP Viswanatham Government Medical College, Tamilnadu, Tiruchirappalli, India (Sarkar) Department of Medicine, Guangxi Medical University, Nanning, China (Kharsa, Aoun, Faza, Little, Kleiman, Goel) Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, United States (Zaid) Section of Cardiology, Baylor College of Medicine, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, United States (Kayani, Samimi) Department of Medicine, Baylor College of Medicine, Houston, TX, United States (Atkins, Del Val, Reardon) Department of Cardiovascular Surgery, Houston Methodist Hospital, Houston, TX, United States Publisher Cardiovascular Research Foundation Abstract Background Contemporary self-expanding transcatheter heart valves (SEVs) have incorporated design refinements to reduce paravalvular leak (PVL) and pacemaker implantation (PPI). We aimed to characterize clinical outcomes after transcatheter aortic valve replacement (TAVR) with contemporary SEVs in patients with severe aortic stenosis. Methods PubMed, EMBASE, and Scopus were searched through October 5, 2025, for studies reporting procedural, hemodynamic, and clinical outcomes for patients undergoing TAVR with the (1) Navitor or (2) Evolut PRO/PRO+/FX. Random-effects meta-analyses pooled single-arm event rates, stratified by SEV group, using the Freeman-Tukey double arcsine transformation. Between-platform differences were assessed using subgroup interaction testing. Results Fifty-two studies (n = 21,349; weighted mean age 82 years; mean Society of Thoracic Surgeons Predicted Risk of Mortality 4.8%) were included. At 30 days, all-cause mortality was low among Evolut and Navitor cohorts (1.4 and 1.5%; p = 0.63), and device success was high for both platforms (92.1 and 93.0%; p = 0.73). Moderate or greater PVL occurred in 2.5 and 1.1% of Evolut and Navitor cohorts, respectively ( p = 0.12), mild PVL occurred in 31.1 and 19.9% ( p = 0.046), and new PPI occurred in 13.4 and 15.3%, respectively. Mean gradients remained low among Evolut and Navitor cohorts at 1 year (7.7 and 7.3 mmHg; p = 0.65), whereas effective orifice area was higher among Evolut cohorts at 1 year (2.1 and 1.8 cm<sup>2</sup>; p < 0.001) ( p = p -interaction). Conclusions Navitor and Evolut PRO/PRO+/FX both demonstrated high device success, low mortality, favorable hemodynamic performance, and low rates of moderate or greater PVL at 1-year follow-up. Mild PVL and new PPI remained frequent. Observed comparative signals should be interpreted as indirect hypothesis-generating findings.<br/>Copyright &#xa9; 2026 The Authors. <3> Accession Number 2050245465 Title Robotics in endoscopic spine surgery: a scoping review of clinical applications, workflow integration, and patient outcomes. Source Journal of Robotic Surgery. 20(1) (no pagination), 2026. Article Number: 1201. Date of Publication: 01 Dec 2026. Author Serdoura F.; Goncalves dos Santos D.; Correia M.C.; Silva J.D.; Nunes B. Institution (Serdoura, Goncalves dos Santos, Correia, Silva, Nunes) Hospital de Sao Joao, Alameda Professor Hernani Monteiro, Porto, Porto, Portugal Publisher Springer Nature Abstract Robotic and endoscopic technologies are increasingly being combined in spine surgery, yet the clinical literature remains fragmented across procedures, platforms, and robotic functions. We conducted a scoping review to map clinical applications of robot-assisted endoscopic spine surgery, describe how robotic systems are incorporated into endoscopic workflows, and summarize the technical, perioperative, and patient-centered outcomes reported to date. PubMed and Scopus were searched through September 2026. Human clinical reports were eligible when endoscopy constituted part of the operative visualization or working approach and a robotic system directly assisted the same spinal procedure. Study selection was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). Of 374 records identified, 122 duplicates were removed and 252 records were screened. Sixty-six reports were sought, 13 were not retrieved, 53 full texts were assessed, and 24 studies were included. The evidence comprised 11 comparative studies, four uncontrolled clinical series, and nine case-based or technical clinical reports. Applications ranged from discectomy and decompression to interbody fusion, pars repair, infection, trauma, and thoracic or craniovertebral procedures. Robots were used for trajectory planning, localization, percutaneous access, guidewire or pedicle screw placement, drilling, endoscope stabilization, and interbody instrumentation. Comparative studies most often showed gains in fluoroscopy use, access efficiency, or instrumentation accuracy; patient-reported outcomes were usually similar between groups. Robotic-endoscopic integration is clinically feasible across an expanding range of spinal procedures, but its patient-level value remains incompletely defined.<br/>Copyright &#xa9; The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature 2026. <4> Accession Number 2051510911 Title Viscoelastic haemostatic assay-guided transfusion versus conventional coagulation testing in critically ill non-cardiac adults with active bleeding or clinically significant coagulopathy: protocol for a systematic review and meta-analysis. Source BMJ Open. 16(11) (no pagination), 2026. Article Number: e127127. Date of Publication: 01 Nov 2026. Author Palhares Ferreira D.; Salvador Oliveira A.T.; Nepomuceno Gorini S.; Ambrosio Palhares S.; Murta Junior I.C.; Moura E.L.B.D.; Passos M.D.D.; Amorim F.F. Institution (Palhares Ferreira, Salvador Oliveira) ESCS, Brasilia, Brazil (Palhares Ferreira) FEPECS, Brasilia, Brazil (Palhares Ferreira, Passos) Unidade de Medicina Interna, Hospital Regional de Sobradinho, Distrito Federal, Brasilia, Brazil (Nepomuceno Gorini, Amorim) ESCS, Brasilia, Brazil (Ambrosio Palhares) Universidade Catolica de Brasilia, Taguatinga Norte, Brazil (Murta Junior) Fundacao de Ensino e Pesquisa em Ciencias da Saude, Brasilia, Brazil (Moura) Hospital Sirio-Libanes, Brasilia, Brazil (Passos) FEPECS, Brasilia, Brazil (Amorim) School of Medicine, Universidade de Brasilia, DF, Brasilia, Brazil Publisher BMJ Publishing Group Abstract Introduction: Viscoelastic haemostatic assays (VHAs), including thromboelastography and rotational thromboelastometry, provide a dynamic whole-blood assessment of clot initiation, clot strength and fibrinolysis and may enable more targeted haemostatic treatment than conventional coagulation tests. Although VHA-guided strategies have been extensively evaluated in cardiac surgery, major trauma and liver transplantation, their effectiveness and safety in critically ill non-cardiac adults with active bleeding or clinically significant coagulopathy requiring transfusion support or haemostatic intervention remain uncertain. Methods and analysis: This protocol is registered with the International Prospective Register of Systematic Reviews (CRD420261427727) and is reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. MEDLINE via PubMed, Embase, Cochrane Central Register of Controlled Trials, Scopus, Web of Science Core Collection and LILACS were searched from inception without language or date restrictions. Google Scholar was searched as a supplementary source, and ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform were searched for ongoing or unpublished studies. Searches were executed between 8 August and 6 September 2026; full strategies and yields are provided in Supplementary Appendix 1. Randomised controlled trials and comparative non-randomised studies evaluating VHA-guided transfusion or haemostatic management versus conventional coagulation testing, laboratory-guided transfusion or usual care will be eligible. Two reviewers will independently undertake study selection, data extraction and risk-of-bias assessment. Risk of Bias 2 will be used for randomised trials and Risk Of Bias In Non-randomised Studies - of Interventions for non-randomised comparative studies. Randomised and non-randomised studies will be synthesised separately. Random-effects meta-analysis will be undertaken only when at least two studies are sufficiently clinically and methodologically comparable. Certainty in the evidence will be assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Ethics and dissemination: Ethical approval is not required because this review will use aggregate data from published studies and publicly accessible trial registries. Findings will be disseminated through peer-reviewed publication and presentation at relevant scientific conferences.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <5> Accession Number 2050123597 Title Cardiac Damage and Clinical Outcomes in Symptomatic Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. Source JACC: Cardiovascular Interventions. 19(21) (pp 2837-2853), 2026. Date of Publication: 09 Nov 2026. Author Tobe A.; Gallazzi M.; van Royen N.; Amat-Santos I.J.; Hudec M.; Bunc M.; Van den Branden B.J.L.; Laanmets P.; Unic D.; Merkely B.; Hermanides R.S.; Ninios V.; Protasiewicz M.; Rensing B.J.W.M.; Martin P.L.; Feres F.; De Sousa Almeida M.; van Belle E.; Linke A.; Ielasi A.; Montorfano M.; Webster M.; Toutouzas K.; Teiger E.; Bedogni F.; Voskuil M.; Pan M.; Angeras O.; Kim W.-K.; Rothe J.; Abdel-Wahab M.; Kristic I.; Peral V.; Garg S.; Thakkar A.; Chandra U.; Smits P.C.; Andreini D.; Genereux P.; Morice M.-C.; Baumbach A.; Serruys P.W.; Onuma Y. Institution (Tobe, Serruys, Onuma) CORRIB Research Centre for Advanced Imaging and Core Laboratory, University of Galway, Galway, Ireland (Gallazzi) Department of Medical and Surgical Sciences, Faculty of Medicine and Surgery, School of Cardiovascular Diseases, University of Milan, Milan, Italy (van Royen) Department of Cardiology, Radboud University Hospital, Nijmegen, Netherlands (Amat-Santos) Centro de Investigacion Biomedica en Red - Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain (Amat-Santos) Department of Cardiology, Hospital Clinico Universitario de Valladolid, Valladolid, Spain (Hudec) Department of Acute Cardiology, Middle-Slovak Institute of Cardiovascular Diseases, Banska Bystrica, Slovakia (Bunc) Department of Cardiology, University Medical Centre Ljubljana, Ljubljana, Slovenia (Van den Branden) Department of Cardiology, Amphia Hospital, Breda, Netherlands (Laanmets) Department of Invasive Cardiology, North Estonia Medical Centre, Tallinn, Estonia (Unic) Department of Cardiovascular and Transplant Surgery, Dubrava University Hospital, Zagreb, Croatia (Merkely) Heart and Vascular Center, Semmelweis University, Budapest, Hungary (Hermanides) Department of Cardiology, Isala Hospital, Zwolle, Netherlands (Ninios) Department of Cardiology, European Interbalkan Medical Center, Thessaloniki, Greece (Protasiewicz) Department of Cardiology, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland (Protasiewicz) Department of Non-Procedural Clinical Sciences, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland (Rensing) Department of Cardiology, St Antonius Hospital, Nieuwegein, Netherlands (Martin) Department of Interventional Cardiology, University Hospital of Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain (Feres) Department of Invasive Cardiology, Instituto Dante Pazzanese, Sao Paulo, Brazil (De Sousa Almeida) CHRC, NOVA Medical School, NOVA University Lisbon, Lisbon, Portugal (van Belle) Department of Interventional Cardiology, Lille University, Lille, France (Linke) Department of Internal Medicine and Cardiology, University Clinic, Heart Center Dresden, University of Technology Dresden, Dresden, Germany (Ielasi) Department of Interventional Cardiology, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy (Montorfano) School of Medicine, Vita-Salute San Raffaele University, Milan, Italy (Montorfano) Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy (Webster) Department of Cardiology, Auckland City Hospital, Auckland, New Zealand (Toutouzas) Department of Cardiology, Hippokration Hospital, Athens, Greece (Teiger) Department of Interventional Cardiology, Henri Mondor University Hospital, Creteil, France (Bedogni) Clinical and Interventional Cardiology IRCCS Policlinico San Donato, Milan, Italy (Voskuil) Department of Cardiology, University Medical Center Utrecht, Utrecht, Netherlands (Pan) Department of Cardiology, University Hospital Reina Sofia, University of Cordoba, Instituto Maimonides de Investigacion Biomedica de Cordoba, Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares, Cordoba, Spain (Angeras) Department of Thoracic Surgery and Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden (Angeras) Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden (Kim) Department of Cardiology and Angiology, University of Giessen and Marburg, Giesen, Germany (Kim) Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (Rothe) Department of Cardiology and Angiology, Campus Bad Krozingen, University Heart Center-University of Freiburg, Bad Krozingen, Germany (Rothe) Faculty of Medicine, University of Freiburg, Freiburg, Germany (Abdel-Wahab) Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany (Kristic) Department of Cardiology, University Hospital of Split, Split, Croatia (Peral) Department of Cardiology, University Hospital Son Espases, Health Research Institute of the Balearic Islands (IdISBa), Balearic Islands, Palma, Spain (Garg) Department of Cardiology, Royal Blackburn Hospital, Blackburn, United Kingdom (Garg) School of Medicine, University of Central Lancashire, Preston, United Kingdom (Thakkar, Chandra) Department of Clinical Research, Meril Life Sciences Pvt. Ltd, Vapi, India (Smits, Morice) Cardiovascular European Research Center (CERC), Massy, France (Andreini) Department of Clinical and Biomedical Sciences, University of Milan, Milan, Italy (Andreini) Department of Cardiology and Cardiovascular Imaging, Galeazzi-Sant'Ambrogio Hospital, Milan, Italy (Genereux) Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, NJ, United States (Morice) ICPS, Hopital Prive Jacques Cartier, Massy, France (Baumbach) Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London and Barts Heart Centre, London, United Kingdom (Baumbach) Cleveland Clinic, London, United Kingdom Publisher Elsevier Inc. Abstract Background The extent of cardiac damage in patients with aortic stenosis (AS) is associated with worse clinical outcomes. Objectives This study sought to investigate the clinical impact of cardiac damage using the updated criteria incorporating the echocardiographic probability of pulmonary hypertension. Methods This post hoc subanalysis of LANDMARK trial, which randomized 768 patients with severe AS to the Myval transcatheter heart valve (THV) series or to contemporary THVs (Sapien and Evolut series), used updated cardiac damage classification: stage 0, no cardiac damage; stage 1, left ventricular damage; stage 2, left atrial or mitral valve damage; stage 3, pulmonary artery or tricuspid valve damage; and stage 4, right ventricular damage. The impact of cumulative cardiac damage, defined as meeting all criteria for stages 1 to 4, was also assessed. The primary endpoint was 1-year all-cause mortality. Results Cardiac damage stages were assessed in 596 patients (stage 0, n = 36; stage 1, n = 88; stage 2, n = 284; stage 3, n = 84; stage 4, n = 104), with a mean age of 80.2 (5.7) years and a mean Society of Thoracic Surgeons score of 3.3% (2.4%). One-year mortality was 0%, 1.1%, 4.7%, 7.2%, and 20.4% in stages 0, 1, 2, 3, and 4, respectively (log-rank P < 0.001). The area under the curve for predicting 1-year mortality was 0.739. Patients with cumulative cardiac damage had the highest mortality (23.6%). In the multivariable analysis, stage 4 was independently associated with higher 1-year mortality. Conclusions The updated cardiac damage staging stratified 1-year mortality after transcatheter aortic valve replacement, highlighting the importance of comprehensive echocardiographic assessment in severe AS. (LANDMARK Trial: a Randomised Controlled Trial of Myval THV [LANDMARK]; NCT04275726 )<br/>Copyright &#xa9; 2026 The Authors. <6> Accession Number 2050149305 Title Stepwise versus one-step intubation strategy for tracheal injury in thoracic surgery: a multicenter randomized controlled trial protocol based on a combined visual lung isolation tube versus a video double-lumen tube. Source BMC Anesthesiology. 26(1) (no pagination), 2026. Article Number: 656. Date of Publication: 01 Dec 2026. Author Li X.; Yang H.; Luo J.; Wei J.; Chen L.; Lv X. Institution (Li, Chen, Lv) Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Shushan District, Anhui, Hefei, China (Li, Luo, Wei, Lv) Department of Anesthesiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, Shanghai, China (Yang) Wannan Medical College, Wuhu, China Publisher BioMed Central Ltd Abstract Background: Tracheal injury remains a clinically relevant complication during lung isolation for thoracic surgery. Although video double-lumen tubes (VDLTs) improve visualization during intubation and bronchial positioning, visualization alone may not sufficiently reduce airway trauma if post-glottic rotational manipulation remains necessary. A combined visual lung isolation tube (combined tube) was developed to enable a predefined stepwise insertion strategy while maintaining an external diameter comparable to that of a double-lumen tube. This trial aims to compare a stepwise strategy based on the combined tube with a conventional one-step strategy based on a VDLT. <br/>Method(s): This multicenter, prospective, randomized controlled trial will enroll 192 adult patients undergoing elective thoracic surgery requiring left-sided one-lung ventilation. Participants will be randomized 1:1 to either the combined-tube group or the VDLT group. The primary outcome is the incidence of moderate-to-severe tracheal injury, defined as moderate or severe mucosal injury at the subglottic region, tracheal shaft, carina, or bronchus. Secondary outcomes include site-specific tracheal injury, vocal cord injury, postoperative sore throat, hoarseness, intubation-related variables, lung isolation quality, hypoxemic events, airway pressure variables, and perioperative adverse events. Bronchoscopic recordings will undergo centralized blinded review by two independent assessors. The primary analysis will be conducted in the full analysis set using mixed-effects regression models to account for center effects. <br/>Discussion(s): This trial will evaluate whether a predefined stepwise intubation strategy can reduce tracheal injury during lung isolation. By comparing two strategies represented by devices with comparable external diameters, the study may help distinguish the effect of insertion pathway from that of device size and provide mechanistic insight into the role of post-glottic rotational manipulation in airway injury. Trial registration: This study was registered with the Chinese Clinical Trial Registry (ChiCTR; Registration number: ChiCTR2600125149) on 21 May 2026. Details of the trial are publicly accessible at: https://www.chictr.org.cn/showproj.html?proj=321664.<br/>Copyright &#xa9; The Author(s) 2026. <7> Accession Number 2050246383 Title Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation. Source Diabetes, Obesity and Metabolism. (no pagination), 2026. Date of Publication: 2026. Author Aubrac G.; Raquib R.V.; Le M.T.; Webster-Clark M.; Platt R.W.; Stokes A.C. Institution (Aubrac) Department of Epidemiology, Boston University School of Public Health, Boston, MA, United States (Raquib, Le, Stokes) Department of Global Health, Boston University School of Public Health, Boston, MA, United States (Webster-Clark) Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, United States (Platt) Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada Publisher John Wiley and Sons Inc Abstract Aims: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits remains unknown. The objective was to compare the effectiveness of semaglutide versus tirzepatide on the risk of major adverse cardiovascular events (MACE) in individuals with overweight or obesity and atherosclerotic cardiovascular disease (ASCVD) without diabetes. <br/>Material(s) and Method(s): This active comparator, new user study emulated a trial using national claims data from Komodo Health. Eligible individuals had a history of ASCVD and, within 1 year prior to initiation: BMI >= 27 with a diagnosis of overweight or obesity, continuous insurance coverage and no diabetes or contraindications. Prior GLP-1 receptor agonist or obesity medication users were excluded. The primary outcome was a composite of myocardial infarction, stroke, hospitalization for heart failure or unstable angina, coronary revascularization and mortality (revised 5-point MACE). Secondary outcomes included revised 3-point MACE and individual endpoints. Hazard ratios were estimated using Cox models with inverse probability weighting. <br/>Result(s): There was a non-significant difference in risk of revised 5-point MACE (HR = 1.21, 95% CI: 0.99-1.51) or secondary outcomes between semaglutide and tirzepatide. Sensitivity analyses showed directionally consistent point estimates for revised 5-point MACE but highlighted sensitivity to decisions surrounding early events, off-label use, analytic approach and outcome definition. <br/>Conclusion(s): Among adults with overweight or obesity and ASCVD without diabetes, there was no significant difference in cardiovascular risk between semaglutide and tirzepatide.<br/>Copyright &#xa9; 2026 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. <8> Accession Number 2051561452 Title Left atrial appendage closure, direct oral anticoagulants or warfarin in atrial fibrillation: a systematic review and network meta-analysis of randomised clinical trials. Source Heart. (no pagination), 2026. Date of Publication: 2026. Author Pancholy S.; Maqsood M.H.; Saleem M.S.; Zalavadia D.; Khattar K.; Patel T.M.; Bangalore S. Institution (Pancholy, Saleem, Zalavadia, Khattar) The Wright Center for Graduate Medical Education, Scranton, PA, United States (Maqsood) Department of Cardiology, DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX, United States (Patel) Apex Heart Institute, Ahmedabad, India (Bangalore) Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York City, NY, United States Publisher BMJ Publishing Group Abstract Background: Pairwise meta-analyses of left atrial appendage closure (LAAC) have omitted warfarin or pooled it with direct oral anticoagulants (DOACs). We compared all three strategies simultaneously in atrial fibrillation (AF). <br/>Method(s): Systematic review and frequentist network meta-analysis of randomised trials in adults with AF comparing at least two strategies, searched in PubMed/MEDLINE, EMBASE, Cochrane CENTRAL and trial registries to April 2026. Two reviewers independently extracted and verified data. Risk of bias and certainty were assessed with Risk of Bias 2 (RoB2) and Grading of Recommendations Assessment, Development and Evaluation (GRADE). Primary outcomes were ischaemic stroke or systemic embolism (IS/SE) and haemorrhagic stroke (HS). Secondary outcomes were net adverse clinical events, major bleeding and major or clinically relevant bleeding (MCRB). <br/>Result(s): 10 trials (78 711 patients) were included. LAAC (OR 0.35, 95% CI 0.19 to 0.65) and DOACs (0.44, 95% CI 0.34 to 0.58) were each associated with substantially lower HS than warfarin but could not be separated from each other (0.79, 95% CI 0.44 to 1.43). LAAC was associated with less MCRB than DOACs (0.53, 95% CI 0.38 to 0.74), but not less major bleeding including procedural events (1.00, 95% CI 0.76 to 1.32). IS/SE risk was numerically higher with LAAC than DOACs (1.36, 95% CI 0.97 to 1.90), ranging from no difference to a near doubling of risk. <br/>Conclusion(s): In a three-way comparison, LAAC and DOACs are each associated with substantially lower haemorrhagic stroke than warfarin. Compared with DOACs, LAAC is associated with less major or clinically relevant bleeding, but not less major bleeding including procedural events, and a possible ischaemic excess cannot be excluded. This three-way synthesis complements recent pairwise meta-analyses. PROSPERO registration number: CRD420261362040.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. No commercial re-use. See rights and permissions. Published by BMJ Group. <9> Accession Number 2051531707 Title Micro-axial flow pump vs veno-arterial extracorporeal membrane oxygenation for high-risk percutaneous coronary interventions: a randomized trial. Source European Heart Journal. 47(42) (pp 6314-6328), 2026. Date of Publication: 07 Nov 2026. Author Zhao G.; Zhou S.; Fang Z.; Ma J.; Tian F.; Song D.; Xu C.; Yuan Z.; Guo N.; Zhao L.; Zhang T.; Liu J.; Yang Y.; Yu X.; Li Y.; Zhang D.; Gao C.; Ye F.; Zhang C.; Yang J.; Xiu J.; Wang Q.; Luan B.; Tao J.; Bai M.; Yang R.; Guo Y.; Wang Y.; Dai M.; Wang J.; Qian J.; Chen Y.; Ge J. Institution (Zhao, Fang, Ma, Qian, Ge) Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China (Zhao, Fang, Ma, Qian, Ge) National Clinical Research Center for Interventional Medicine, Shanghai, China (Zhao, Fang, Ma, Qian, Ge) National Clinical Research Center for Radiology and Therapeutics, Shanghai, China (Zhao, Ma, Qian, Ge) National Basic Science Center for Complex System of Panvascular Intervention, Shanghai, China (Zhou, Tian, Chen) Department of Cardiology, 301 Military Hospital, Beijing, China (Song, Xu) Department of Cardiology, Wuhan Asia Heart Hospital, Wuhan, China (Yuan, Guo) Department of Cardiology, Xi'an Jiaotong University Medical College First Affiliated Hospital, Xi'an, China (Zhao, Zhang) Department of Cardiology, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China (Wang, Liu) Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China (Yang, Yu) Department of Cardiology, Xinjiang Medical University Affiliated First Hospital, Urumqi, China (Li, Zhang) Department of Cardiology, Air Force Medical University Tangdu Hospital, Xi'an, China (Gao, Ye) Department of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, China (Zhang, Yang) Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China (Xiu, Wang) Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China (Luan) Department of Cardiology, The People's Hospital of Liaoning Province, Shenyang, China (Tao) Department of Cardiology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China (Bai) Department of Cardiology, The First Hospital of Lanzhou University, Lanzhou, China (Yang) Department of Cardiology, Nanchang University Second Affiliated Hospital, Nanchang, China (Guo) Department of Cardiology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China (Wang) Department of Cardiology, Xiamen Cardiovascular Hospital, Xiamen, China (Dai) Department of Cardiology, Mianyang Central Hospital, Mianyang, China (Wang) Department of Cardiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China Publisher Oxford University Press Abstract Background and Aims: The efficacy of prophylactic mechanical circulatory support with micro-axial flow pump or veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in patients with severely reduced left ventricular ejection fraction (LVEF) undergoing high-risk percutaneous coronary intervention (PCI) remains unclear. <br/>Method(s): Patients with complex three-vessel disease, unprotected left main coronary disease or last patent conduit and LVEF <= 35% were assigned to receive either a micro-axial flow pump (SynFlow 3.0) or VA-ECMO support during a non-emergent high-risk PCI procedure in this prospective, multicentre, randomized, open-label, non-inferiority trial. The primary endpoint was the incidence of 30-day major adverse events, defined as any of: all-cause death, myocardial infarction, stroke/transient ischaemic attack, repeat revascularization, major bleeding, acute kidney injury, cardiopulmonary resuscitation/cardioversion, cardiac surgery/limb ischaemia, or serious device-related complications. Safety endpoints included adverse events and serious adverse events. <br/>Result(s): The primary endpoint, 30-day major adverse events, occurred in 8 of 109 patients (7.34%) in the SynFlow 3.0 group and 13 of 113 patients (11.5%) in the VA-ECMO group (absolute difference adjusted for centre effect, -4.6%; 95% confidence interval, -12.6% to 3.5%; P for non-inferiority < .001). Patients with SynFlow 3.0 had shorter post-procedural hospital stay (4.1 days vs 5.2 days on average, P = .047) and fewer device-related adverse events (3.7% vs 11.5%; P = .041). Anaemia occurred more often with VA-ECMO than with SynFlow 3.0 (20.4% vs 9.2%; P = .023). <br/>Conclusion(s): The prophylactic use of a micro-axial flow pump during high-risk PCI procedures was non-inferior to VA-ECMO in the incidence of 30-day major adverse events. The use of a micro-axial flow pump was associated with shorter post-procedural hospital stay and fewer device-related adverse events.<br/>Copyright &#xa9; The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights) <10> Accession Number 2050198184 Title Robotic-assisted versus manual percutaneous coronary intervention after contemporary randomized evidence: An updated systematic review and meta-analysis of patient-level procedural and radiation outcomes. Source Cardiovascular Revascularization Medicine. (no pagination), 2026. Date of Publication: 2026. Author Razvi K.; Ibrahim M.; Irshad U.; Ishac R.; Shah Z.; Al Taweel A.; Shabaneh B.; Aldeiri M. Institution (Razvi, Ibrahim, Irshad, Shah, Al Taweel, Shabaneh, Aldeiri) University of Houston, HCA Clear Lake, Webster, TX, United States (Ishac) University of Texas MD Anderson Cancer Center, Houston, TX, United States Publisher Elsevier Inc. Abstract Background Robotic-assisted PCI (R-PCI) reduces measured radiation exposure to the primary operator, but procedural and patient-radiation benefits over manual PCI (M-PCI) remain uncertain. Objectives To compare procedural/PCI time, fluoroscopy time, contrast volume, air kerma, and dose-area product between R-PCI and M-PCI after incorporation of randomized evidence. Methods Randomized and nonrandomized comparative studies of adults undergoing PCI were included. Random-effects models used restricted maximum likelihood with modified Hartung-Knapp inference. Mean differences (MDs) were calculated as M-PCI minus R-PCI. Risk of bias was assessed using RoB 2 and ROBINS-I; certainty was assessed using GRADE. Results Twelve studies, including 2 randomized trials, contributed data. No primary pooled outcome differed significantly: procedural/PCI time, MD -3.90 min (95% CI: -16.15 to 8.35); fluoroscopy time, 0.17 min (95% CI: -2.61 to 2.95); contrast volume, 7.79 mL (95% CI: -3.08 to 18.66); air kerma, 232.01 mGy (95% CI: -145.67 to 609.70); and dose-area product, 31.31 dGy.cm<sup>2</sup> (95% CI: -49.45 to 112.07). Heterogeneity was substantial (I<sup>2</sup> = 72%-93%). A direct-report-only analysis favored R-PCI for contrast volume (MD: 17.76 mL; 95% CI: 4.62-30.90), but other sensitivity analyses did not materially change interpretation. Certainty was very low for all outcomes. Conclusions R-PCI has not shown consistent patient procedural or radiation benefit. Operator protection is supported descriptively but was not pooled; contrast reduction appeared only in sensitivity analysis. Future trials should assess patient benefit and team-wide occupational exposure.<br/>Copyright &#xa9; 2026 Elsevier Inc. <11> Accession Number 2050852675 Title Catheter-Based Left Atrial Appendage Closure vs Oral Anticoagulation in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Source JAMA Cardiology. 11(10) (pp 915-924), 2026. Date of Publication: 14 Oct 2026. Author Laudani C.; Bujak K.; Giacoppo D.; Finocchiaro S.; Cutore L.; Mauro M.S.; Redigolo P.; Mazzone P.M.; Di Leo G.; Nasisi F.; Spagnolo M.; Greco A.; Capodanno D. Institution (Laudani, Bujak, Giacoppo, Finocchiaro, Cutore, Mauro, Redigolo, Mazzone, Di Leo, Nasisi, Spagnolo, Greco, Capodanno) Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico Rodolico - San Marco, University of Catania, Catania, Italy (Bujak) Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland (Bujak) 3rd Department of Cardiology, Silesian Center for Heart Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland Publisher American Medical Association Abstract Importance: In patients with atrial fibrillation (AF), oral anticoagulation (OAC) is the gold standard for preventing ischemic stroke, at the expense of a higher risk of bleeding. Catheter-based left atrial appendage closure (LAAC) has been proposed as an alternative strategy to prevent stroke, but the efficacy and safety compared to OAC are uncertain. <br/>Objective(s): To evaluate the efficacy and safety of catheter-based LAAC compared to OAC in patients with AF at high risk of stroke. <br/>Data Sources: PubMed, Cochrane Central, and Web of Science were screened up to March 2026. The websites of leading cardiology societies, news outlets, and reference lists of each eligible study were also inspected. Study Selection: Studies enrolling patients with AF randomly assigned to catheter-based LAAC or OAC and reporting at least 1 outcome of interest were included. Data Extraction and Synthesis: Two investigators independently extracted data of interest and assessed data quality. Catheter-based LAAC vs OAC comparisons were pooled as incidence rate ratios (IRRs) using a frequentist random-effect model. <br/>Main Outcomes and Measures: Primary and coprimary outcomes were long-term stroke and major bleeding. Secondary outcomes included the composite of cardiovascular death, stroke, or systemic embolism, all-cause death, the single components of the composite end point, ischemic stroke, hemorrhagic stroke, and nonprocedural major bleeding. Periprocedural events (ie, stroke, major bleeding, death, device embolization, and pericardial effusion) were also combined. <br/>Result(s): Eight trials (7434 patients) were included in the meta-analysis. After a weighted mean follow-up of 37.9 months, no significant differences were detected for stroke (IRR, 1.08; 95% CI, 0.82-1.41) and major bleeding (IRR, 0.96; 95% CI, 0.81-1.14). However, catheter-based LAAC was associated with a higher risk of ischemic stroke (IRR, 1.34; 95% CI, 1.01-1.77) and a lower risk of nonprocedural major bleeding (IRR, 0.73; 95% CI, 0.58-0.92) compared with OAC. Periprocedural events per 1000 patients were 5 strokes, 9 episodes of bleeding, 1 death, 5 episodes of device embolization, and 9 pericardial effusions. <br/>Conclusions and Relevance: In patients with AF, at long-term follow-up, transcatheter LAAC was associated with similar rates of any type of stroke and major bleeding compared with OAC, while increasing the risk of ischemic stroke and lowering the risk of nonprocedure-related major bleeding. These findings do not support the routine use of LAAC as a first-line strategy for stroke prevention in patients with AF at moderate to high risk of stroke.<br/>Copyright &#xa9; 2026 American Medical Association. <12> Accession Number 2049095687 Title Metabolic syndrome severity and the effects of intensive blood pressure lowering: Results from the STEP randomized trial. Source Hypertension Research. 49(11) (pp 3022-3034), 2026. Date of Publication: 01 Nov 2026. Author Zhao J.; Dong X.; Song Q.; Cai J. Institution (Zhao, Dong) Anzhen Hospital, Capital Medical University, Beijing, China (Song) Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease of China, National Center for Cardiovascular Diseases of China, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Cai) Capital Medical University, Beijing, China Publisher Springer Nature Abstract Several clinical trials have shown that intensive systolic blood pressure (SBP) lowering confers cardiovascular benefits. However, whether baseline metabolic syndrome (MetS) severity modifies these benefits and risks remains unclear. This post hoc analysis of the STEP trial included 8231 participants with complete MetS severity data. Baseline MetS severity was quantified using an age-, sex-, and ethnicity-specific MetS scoring model and analyzed as tertiles and continuously. The primary outcome was a composite of stroke, acute coronary syndrome, acute decompensated heart failure, coronary revascularization, atrial fibrillation, and cardiovascular death. Cox models and restricted cubic spline analyses were used to assess treatment-effect heterogeneity. During a median follow-up of 3.32 years, intensive SBP lowering reduced the risk of the primary outcome compared with standard treatment. The absolute incidence of the primary outcome and major adverse cardiac events was highest in the highest MetS tertile. Across MetS tertiles, event rates were lower in the intensive-treatment group, with the largest reduction in the middle tertile for the primary outcome (Q2: HR, 0.66; 95% CI, 0.44-0.99). No significant treatment-by-MetS interaction was observed in tertile-based or spline analyses. For safety outcomes, no significant treatment-by-MetS tertile interaction was observed, although hypotension was numerically more frequent with intensive treatment among participants in the highest MetS tertile. These findings suggest that baseline MetS severity identifies patients with higher absolute cardiovascular risk but does not significantly modify the relative efficacy of intensive SBP lowering. Careful monitoring for treatment-related hypotension may be warranted, particularly among patients with higher metabolic burden. (Figure presented.)<br/>Copyright &#xa9; The Author(s), under exclusive licence to The Japanese Society of Hypertension 2026. <13> Accession Number 2051245324 Title Mortality from extracorporeal shock wave lithotripsy for kidney stone disease: Systematic review of literature from the European Association of Urology Endourology. Source Urology Annals. 18(4) (pp 290-298), 2026. Date of Publication: 2026. Author Dassanayake S.N.; Corkill J.; Harrison N.L.; Kamal W.; Tzelves L.; Skolarikos A.; Gauhar V.; Yuen S.K.K.; Davis N.F.; Somani B.K. Institution (Dassanayake) Urology Fellow, University Hospital Southampton NHS Foundation Trust, United Kingdom (Corkill) Urology Registrar, University Hospitals Dorset NHS Foundation Trust, United Kingdom (Harrison) Urology Registrar, Liverpool University Hospitals NHS Trust, United Kingdom (Kamal) Consultant Urologist, King Fahad General Hospital, Jeddah, Saudi Arabia (Tzelves) Associate Professor of Urology, Sismanogleio Hospital, National and Kapodistrian University of Athens, Greece (Skolarikos) Professor of Urology, Sismanogleio Hospital, National and Kapodistrian University of Athens, Greece (Gauhar) Professor of Urology, Ng Teng Fong General Hospital, Singapore, and Asian Institute of Nephrology and Urology, Hyderabad, Telangana, India (Yuen) Associate Consultant Urologist, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, Hong Kong (Davis) Professor of Urology, Beaumont Hospital and Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland (Somani) Professor of Urology, University Hospital Southampton NHS Foundation Trust, United Kingdom Publisher Wolters Kluwer Medknow Publications Abstract Introduction: - Extracorporeal shock wave lithotripsy (ESWL) is a widely used, minimally invasive treatment for kidney stone disease (KSD) with a favorable safety profile. However, mortality associated with ESWL is rarely discussed. This systematic review aimed to evaluate the reported mortality following ESWL for KSD, identify contributing factors, and highlight lessons learned to mitigate risk. <br/>Method(s): - A systematic review was conducted in accordance with PRISMA guidelines and registered with PROSPERO (CRD42024606297). MEDLINE, Embase, and the Cochrane Library were searched from inception to May 2025 for studies reporting mortality following ESWL for KSD. Data on patient characteristics, procedural factors, complications, and causes of death were extracted from eligible studies. Due to heterogeneity, a descriptive synthesis was performed. <br/>Result(s): - Ten studies published between 1989 and 2023 were included, encompassing 25,947 patients undergoing ESWL. Twelve ESWL-associated deaths were identified with an overall mortality rate of 0.023%. Mortality predominantly occurred in older, comorbid patients, frequently with cardiovascular disease or anticoagulant/antiplatelet use. The most common cause of death was hemorrhagic shock secondary to retroperitoneal or renal hemorrhage. Infectious causes represented the second most frequent cause of mortality, with patients developing urosepsis or septic shock, sometimes following pyelonephritis or pancreatitis. Deaths typically occurred within hours to days of treatment. <br/>Conclusion(s): - Mortality following ESWL is very rare but can occur. Our study suggests that safety can be improved by refining risk prediction, strict adherence to anticoagulation guidelines, and ensuring multidisciplinary oversight for complex patients. Further risk mitigation may be achieved by developing validated stratification tools and research-backed optimization strategies.<br/>Copyright &#xa9; 2026 Urology Annals <14> Accession Number 652078200 Title Transcatheter Aortic Valve Replacement or Medical Treatment for Paradoxical Low-Flow, Low-Gradient Aortic Valve Stenosis: REBOOT-PARADOX. Source Journal of the American College of Cardiology. 88(19) (pp 2168-2183), 2026. Date of Publication: 10 Nov 2026. Author Mehilli J.; Steffen J.; Rudolph T.; Haum M.; Giannini C.; Stark K.; Ince H.; Conradi L.; Joner M.; Schafer A.; Karcher A.-K.; Landt M.; Adam M.; Thiele H.; Geisler T.; Jochheim D.; Hagl C.; Zeymer U.; Windecker S.; Massberg S. Institution (Mehilli) LA-Regio Kliniken, Klinik Landshut-Achdorf, Landshut, Germany; Medizinische Klinik und Poliklinik I, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universitat Munchen, Munich, Germany (Steffen, Haum, Stark, Massberg) Medizinische Klinik und Poliklinik I, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universitat Munchen, Munich, Germany; DZHK (German Centre for Cardiovascular Research), Munich Heart Association (MHA), Munich, Germany (Rudolph) Klinik fur Kardiologie, Bad Oeynhausen, Germany (Giannini) Azienda Ospedaliero Universitaria Pisana, Pisa, Italy (Ince) Klinik und Poliklinik fur Kardiologie, Department fur Innere Medizin, Universitatsmedizin Rostock, Rostock, Germany (Conradi) Universitares Herz- und Gefaszentrum Hamburg, Klinik und Poliklinik fur Herz- und Gefaschirurgie, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany; Herzzentrum der Universitat Koln, Klinik und Poliklinik fur Herzchirurgie, Uniklinik Koln, Cologne, Germany (Joner) DZHK (German Centre for Cardiovascular Research), Munich Heart Association (MHA), Munich, Germany; TUM Universitatsklinikum Deutsches Herzzentrum, Technische Universitat Munchen, Munich, Germany (Schafer) Klinik und Poliklinik fur Herz- und Gefaschirurgie, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany (Karcher) Medizinische Klinik B, Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany (Landt) Kardiologie und Angiologie, HerzzentrumSegeberger Kliniken, Bad Segeberg, Germany (Adam) Department of Cardiology, Heart Center Cologne, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany (Thiele) Department of Cardiology and Leipzig Heart Science, Heart Center Leipzig at Leipzig University, Leipzig, Germany (Geisler) Innere Medizin III, Universitatsklinikum Tubingen, Tubingen, Germany (Jochheim) Medizinische Klinik und Poliklinik I, LMU University Hospital, Ludwig-Maximilians-Universitat Munchen, Munich, Germany (Hagl) DZHK (German Centre for Cardiovascular Research), Munich Heart Association (MHA), Munich, Germany; Herzchirurgische Klinik und Poliklinik, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universitat Munchen, Munich, Germany (Zeymer) Medizinische Klinik B, Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany; Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany (Windecker) Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland Abstract BACKGROUND: Paradoxical low-flow, low-gradient (pLFLG) aortic stenosis (AS) has an adverse prognosis in comparison to other AS subtypes. Transcatheter aortic valve replacement (TAVR) has never been compared with optimal medical therapy (OMT) alone in a dedicated randomized trial in this population. <br/>OBJECTIVE(S): The trial sought to determine whether TAVR added to OMT reduces all-cause mortality in symptomatic patients with pLFLG AS. <br/>METHOD(S): In this multicenter, open-label trial, patients with symptomatic pLFLG AS (aortic valve area <=1.0 cm2, mean gradient <40 mm Hg, stroke volume index <35 mL/m2, ejection fraction >=50%) were randomly assigned 2:1 to TAVR plus OMT or OMT alone. The primary endpoint was all-cause death, assessed 2 years after enrollment of the last patient. Enrollment was stopped prematurely for slow recruitment. <br/>RESULT(S): Of 783 planned patients, 120 (median age 82 years; 53.3% women) were randomized (80 TAVR, 40 OMT). A total of 19 OMT patients eventually crossed over to TAVR, most for symptom progression. The primary endpoint occurred in 29.0% vs 37.1% (HR: 0.83; 95% CI: 0.41-1.66; P = 0.60), and 5-year mortality was 44.9% vs 56.6% (HR: 0.76; 95% CI: 0.43-1.35; P = 0.35). TAVR was associated with improved symptoms (NYHA functional class I/II at 1 year, 83.0% vs 59.0%) and lower cumulative incidence of first endpoint-related rehospitalizations, and there were no differences in functional capacity or quality of life. <br/>CONCLUSION(S): Although the effect of TAVR on mortality remains unresolved, these findings support an individualized strategy with close surveillance and timely TAVR upon clinical deterioration in selected patients with pLFLG AS. Adequately powered randomized trials are needed to define the effect of early TAVR on prognosis. (accuRate Evaluation of Benefit with Optimal medical treatment with or withOut Transcatheter valve repair of PARADOXical low flow low gradient aortic stenosis [REBOOT-PARADOX Trial]; NCT03863132).<br/>Copyright &#xa9; 2026 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. <15> Accession Number 2049709340 Title Renoprotective Effects of Dexmedetomidine Versus Dopamine in High-Risk Renal Patients Undergoing Off-Pump Coronary Artery Bypass Grafting:A Prospective, Randomized, Comparative Study. Source Journal of Cardiothoracic and Vascular Anesthesia. 40(12) (pp 3922-3929), 2026. Date of Publication: 01 Dec 2026. Author Maity S.; Kumar S.; Daga M.K. Institution (Maity) Department of Cardiac Anesthesia, B.M. Birla Heart Research Center, Kolkata, India (Kumar, Daga) Department of Cardiothoracic and Vascular Surgery, B.M. Birla Heart Research Center, Kolkata, India Publisher W.B. Saunders Abstract Objectives: To compare the renoprotective effects of dexmedetomidine and low-dose dopamine versus normal saline (control) in high-risk renal patients undergoing off-pump coronary artery bypass grafting (OPCAB). <br/>Design(s): Prospective, open-label, randomized, parallel-group comparative study. <br/>Setting(s): Department of Cardiac Anaesthesiology and Critical Care at a tertiary-level cardiac surgical center. <br/>Participant(s): In total, 105 adult patients aged >=60 years with preexisting moderate renal insufficiency (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2 and/or serum creatinine >=1.1 mg/dL) and 1 or more additional risk factors (diabetes mellitus, hypertension, or left ventricular ejection fraction <45%), scheduled for elective OPCAB. No patients were excluded after randomization. <br/>Intervention(s): Patients were randomized equally into 3 groups: group A received dexmedetomidine infusion at 0.4 mug/kg/h (without a loading dose), group B received dopamine infusion at 3 mug/kg/min, and group C (control) received normal saline at 3 mL/h. Infusions were commenced after induction of anesthesia and continued for the first 24 postoperative hours. <br/>Measurements and Main Results: Urine output, serum creatinine, blood urea nitrogen (BUN), and eGFR were measured at baseline and at 24 and 48 postoperative hours. Acute kidney injury (AKI) was defined per Acute Kidney Injury Network (AKIN) criteria. Hemodynamic parameters and adverse events were recorded throughout. Group A demonstrated significantly higher urine output than groups B and C at days 1 and 2 (p < 0.01). Serum creatinine and BUN were significantly lower in group A versus groups B and C at both time points (p < 0.05), although the absolute differences were not clinically significant. eGFR was markedly higher in group A compared with groups B and C at days 1 and 2 (p < 0.0001). No patient in any group developed AKI by AKIN criteria or required renal replacement therapy. Adverse events, including arrhythmias and need for intra-aortic balloon pump, were comparable across groups (p = 0.31). <br/>Conclusion(s): Dexmedetomidine infusion was superior to dopamine in improving urine output and eGFR in high-risk renal patients undergoing OPCAB, although differences in serum creatinine and BUN were not clinically significant. Neither drug prevented AKI beyond the control group. Dexmedetomidine may offer a favorable renal physiological profile in this patient population, warranting further investigation with more sensitive biomarkers.<br/>Copyright &#xa9; 2026 Elsevier Inc. <16> Accession Number 2050642132 Title Effects of dexmedetomidine on postoperative outcomes in adult non-cardiac surgical patients admitted to the intensive care unit: a systematic review and network meta-analysis of randomized controlled trials. Source Anaesthesia Critical Care and Pain Medicine. 46(1) (no pagination), 2027. Article Number: 101907. Date of Publication: 01 Jan 2027. Author Shin C.C.Y.; Karigowda L.; Zhang B.; Sadanandan D.; Shehabi Y.; Wong S.; Subramaniam A.; Deshpande K. Institution (Shin, Karigowda, Zhang) Department of Intensive Care Medicine, Fairfield Hospital, NSW, Australia (Shin, Karigowda) Department of Intensive Care Medicine, Liverpool Hospital, NSW, Australia (Karigowda) Department of Intensive Care Medicine, Westmead Hospital, NSW, Australia (Sadanandan) Research Scientist and Biostatistician, Women's & Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Karnataka, Belagavi, India (Shehabi, Wong) Department of Intensive Care Medicine, Prince of Wales Hospital, NSW, Australia (Shehabi, Subramaniam) Centre for Outcome and Resource Evaluation, Australian and New Zealand Intensive Care Society, Melbourne, VIC, Australia (Subramaniam) Department of Intensive Care Medicine, Dandenong Hospital, Monash Health, Dandenong, Vic, Australia (Subramaniam) Department of Intensive Care Medicine, Epworth Healthcare, Richmond, Vic, Australia (Subramaniam) Peninsula Clinical School, Monash University, Frankston, VIC, Australia (Subramaniam) Department of Intensive Care Medicine, Epworth Hospital, Richmond, Vic, Australia (Deshpande) Department of Intensive Care Medicine, St George Hospital, NSW, Australia (Deshpande) Clinical School of Medicine, University of New South Wales, New South Wales, Australia Publisher Elsevier Masson s.r.l. Abstract Background: The role of dexmedetomidine in patients admitted to the intensive care unit (ICU) following non-cardiac surgery remains unclear. While dexmedetomidine is widely used for its sedative and potential delirium-sparing properties, its pooled effects on clinically relevant postoperative outcomes in this population are not well established. This systematic review and network meta-analysis evaluated the comparative effectiveness and safety of dexmedetomidine compared with other sedative strategies in postoperative non-cardiac surgical ICU patients. <br/>Method(s): We systematically searched PubMed, Cochrane CENTRAL, and Embase from inception to 26 May 2026 for randomised controlled trials (RCTs) comparing postoperative dexmedetomidine with normal saline or other sedatives in adults (>=18 years) admitted to the ICU after non-cardiac surgery. The primary outcome was incidence of delirium during the ICU stay. Secondary outcomes were time to extubation, ICU length of stay, duration of mechanical ventilation, and haemodynamic adverse events. Effect estimates were expressed as relative risks (RRs) or mean differences (MDs) using random-effects models. Risk of bias was assessed using the Cochrane RoB 2 tool, and certainty of evidence was evaluated using the GRADE framework. Interventions were ranked using the surface under the cumulative ranking curve (SUCRA) for each outcome. <br/>Result(s): Twenty-four RCTs involving 2,777 patients were included in the systematic review, of which 22 RCTs involving 2,544 patients contributed to the network meta-analysis. Compared with midazolam (RR 0.11, 95% CI 0.02 to 0.80; very low certainty) and normal saline (RR 0.46, 95% CI 0.36 to 0.59; low certainty), dexmedetomidine may reduce the risk of delirium. Evidence is insufficient to determine whether propofol differs from dexmedetomidine in its effect on delirium. There were no differences in time to extubation, duration of mechanical ventilation, or ICU length of stay across sedative strategies. Dexmedetomidine probably increases the risk of bradycardia compared with propofol (RR 3.03, 95% CI 1.39-6.25; low certainty), but the evidence is insufficient to determine whether the two agents differ in their effects on hypotension. In safety rankings, dexmedetomidine performed least favourably for bradycardia (SUCRA 0.03) and hypotension (SUCRA 0.13). <br/>Conclusion(s): Dexmedetomidine may reduce postoperative delirium in non-cardiac surgical ICU patients but does not appear to improve ventilatory recovery or ICU length of stay and is associated with higher bradycardia risk. Its principal benefit lies in delirium prevention, supporting an individualised approach to sedative selection.<br/>Copyright &#xa9; 2026 Societe Francaise d'Anesthesie et de Reanimation (SFAR). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies. <17> Accession Number 2049823626 Title Real-world renoprotective effects of polyethylene glycol-loxenatide in type 2 diabetes: a multicenter, ambispective cohort study. Source Signal Transduction and Targeted Therapy. 11(1) (no pagination), 2026. Article Number: 456. Date of Publication: 01 Dec 2026. Author Ye J.; Li J.; Chen Y.; Chen F.; Zhu D.; Zhang C.; Chen Q.; Tian Y.; Yang S.; Xu W.; Xie B.; Chen Z.-S.; Hou K. Institution (Ye, Li, Xie) Department of Cardiology, Second Affiliated Hospital of Shantou University Medical College, Shantou, China (Ye) Shantou University Medical College, Shantou, China (Chen, Chen, Xu, Hou) Department of Endocrinology and Metabolism, The first Affiliated Hospital of Shantou University Medical College, Shantou, China (Zhu, Zhang, Chen, Hou) Department of Endocrinology and Metabolism, Longhu People's Hospital, Shantou, China (Chen) School of Public Health, Shantou University, Shantou, China (Tian) Research Center, Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, China (Yang) Department of Endocrinology and Metabolism, Shantou Central Hospital, Shantou, China (Chen) Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY, United States Publisher Springer Nature Abstract Patients with type 2 diabetes mellitus and chronic kidney disease face persistent risks despite standard care. Polyethylene glycol-loxenatide lacks real-world renoprotective evidence in high-risk Chinese populations relative to non-incretin-based standard care. This multicenter, ambispective cohort study enrolled 3305 patients with type 2 diabetes mellitus, renal impairment, and elevated cardiovascular risk at six Chinese tertiary institutions (median follow-up 36.4 months; trial registration: ChiCTR2300073001). Data were extracted via an artificial intelligence-enhanced pipeline. Co-primary analyzes comprised multivariable-adjusted Cox regression and 1:1 propensity score matching (332 per group); pre-specified landmark analyzes at 6 and 12 months addressed immortal time bias. Polyethylene glycol-loxenatide was associated with a reduced risk of the primary kidney composite outcome in the original cohort (hazard ratio [HR], 0.49; 95% CI, 0.25-0.95; P = 0.035), which was corroborated in the propensity score matched cohort (HR, 0.44; 95% CI, 0.20-0.97; P = 0.043) and progressive across 6-month (HR, 0.40; 95% CI, 0.19-0.84) and 12-month (HR, 0.33; 95% CI, 0.14-0.75) landmarks. While a reduction in 3-point major adverse cardiovascular events was observed in the unmatched cohort (HR, 0.60; 95% CI, 0.43-0.85; P = 0.004), this association was not sustained in the matched analysis (HR, 0.92; 95% CI, 0.57-1.48; P = 0.735). In conclusion, long-term therapy was associated with an attenuated risk of major renal events. Given the null findings in the matched cohort, the cardiovascular observations are exploratory and require randomized confirmation. (Figure presented.)<br/>Copyright &#xa9; The Author(s) 2026. <18> [Use Link to view the full text] Accession Number 2050629901 Title Impact of Virtual Reality on Transcatheter Aortic Valve Implantation: A Prospective Randomized Controlled Trial. Source Circulation: Cardiovascular Imaging. 19(10) (pp e018922), 2026. Date of Publication: 01 Oct 2026. Author Kanschik D.; Steinhoff D.; Klein K.; Lichtenberg A.; Ballazs C.; Stadnik D.; Scherner M.; Antoch G.; Kelm M.; Zeus T.; Jung C. Institution (Kanschik, Steinhoff, Klein, Kelm, Zeus, Jung) Department of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, Germany (Lichtenberg, Ballazs, Stadnik, Scherner) Department of Cardiac Surgery, Medical Faculty, University Hospital and Heinrich-Heine University, Germany (Antoch) Department of Diagnostic and Interventional Radiology, Medical Faculty, University Hospital and Heinrich-Heine University, Germany (Lichtenberg, Kelm, Zeus, Jung) Cardiovascular Research Institute Duesseldorf (CARID), Medical Faculty, Heinrich-Heine University, Germany Publisher Lippincott Williams and Wilkins Abstract BACKGROUND: - Accurate preprocedural planning is crucial for a successful transcatheter aortic valve implantation to ensure patient safety and valve longevity. Through 3-dimensional visualization, virtual reality (VR) offers the potential to enhance this process. The study investigated whether the inclusion of VR in preprocedural planning can improve the procedural preparation, impact intraprocedural parameters, and improve short-term patient outcomes. <br/>METHOD(S): - This randomized, prospective, controlled study included 140 patients who underwent transcatheter aortic valve implantation at the University Hospital Duesseldorf between April and August 2024. In the control group, preprocedural planning was based on multislice computed tomography data using 3mensio software, while in the intervention group, it was supplemented with VR software. In addition, interventionalists assessed both tools via a structured questionnaire. <br/>RESULT(S): - The evaluation did not reveal any relevant differences in patient characteristics. VR was superior to 3mensio software with respect to the 3-dimensional understanding (P<0.001). Similarly, depth perception, visualization of atherosclerotic plaques, and iliofemoral tortuosity were better in the VR group. Both methods were found to be useful and helpful in preparing for the procedure. There were no significant differences in procedural data between the 2 groups. However, the VR group had a lower rate of bleeding at the access site (P<0.05). There was no significant difference in the length of hospital stay or postprocedural transthoracic echocardiography data evaluations. <br/>CONCLUSION(S): - The data show that VR visualization can optimize preparation for the procedure by improving the 3-dimensional understanding of the aortic valve and adjacent structures. The detailed visualization of the access routes can lead to a reduction in periprocedural complications.<br/>Copyright &#xa9; 2026 American Heart Association, Inc. <19> Accession Number 2049874518 Title Drug-Coated Balloons for In-Stent Restenosis and De Novo Coronary Lesions: State of the Art and Lessons Learned From Recent Trials. Source Journal of the Society for Cardiovascular Angiography and Interventions. 5(11) (no pagination), 2026. Article Number: 105675. Date of Publication: 01 Nov 2026. Author Alfonso F.; Jeger R. Institution (Alfonso) Department of Cardiology. Hospital Universitario de La Princesa, Universidad Autonoma de Madrid and CIBER-CV IIS-IP, Madrid, Spain (Jeger) Department of Cardiology, Triemli Hospital, Zurich and University of Basel, Basel, Switzerland Publisher Elsevier B.V. Abstract Drug-coated balloons (DCB) have emerged as an important treatment modality in percutaneous coronary intervention by providing effective local antiproliferative drug delivery without leaving a permanent metallic implant. Robust evidence supports their use for the treatment of coronary in-stent restenosis (ISR), where DCB represent an established alternative to repeat drug-eluting stent (DES) implantation while avoiding additional stent layers. Contemporary data suggest that although repeat DES implantation may reduce target lesion revascularization in selected patients with DES-ISR, DCB remain particularly attractive in many patient subsets, including those with excellent predilation results, multiple stent layers, major side branches, and those with bare-metal ISR. Careful lesion preparation and increasing use of intracoronary imaging are critical determinants of procedural success. Beyond ISR, evidence supporting DCB in de novo coronary disease has expanded substantially, particularly in small-vessel disease, where randomized trials and patient-level meta-analyses demonstrate outcomes comparable or superior to contemporary DES. Growing data also support DCB use in selected complex anatomical and clinical scenarios, including bifurcation lesions, diabetes, acute coronary syndromes, and patients at high bleeding risk. Recent randomized trials evaluating DCB in broader all-comer populations have yielded mixed results, highlighting the absence of a class effect among DCB technologies and the importance of device choice, operator experience, and optimal patient selection. Ongoing randomized trials evaluating next-generation paclitaxel- and limus-based DCB are expected to better define patient selection and the complementary roles of DCB and DES. Rather than competing technologies, DCB and DES should be considered complementary tools that enable increasingly personalized coronary revascularization strategies.<br/>Copyright &#xa9; 2026 The Author(s). <20> Accession Number 2050537696 Title Summary of the best evidence for dyadic disease management in patients who have undergone coronary stenting and their family caregivers. Source Frontiers in Cardiovascular Medicine. 13 (no pagination), 2026. Article Number: 1871242. Date of Publication: 23 Sep 2026. Author Wang H.; Zhu J.; Wei K.; Luo B.; Wan S.; Wang J.; Yu S. Institution (Wang, Zhu, Wei, Luo, Wan, Wang, Yu) School of Nursing, Beihua University, Jilin City, China (Yu) Affiliated Hospital of Beihua University, Jilin City, China Publisher Frontiers Media SA Abstract Objective - To systematically synthesize the best available evidence on dyadic disease management for patients and their family caregivers following coronary stent implantation and to develop actionable evidence-based recommendations for clinical practice. Methods - This evidence summary used the 6S evidence pyramid to guide the prioritization and retrieval of evidence sources. Chinese and international databases and relevant professional society websites were systematically searched from inception to February 28, 2026, using terms related to percutaneous coronary intervention/coronary stenting, caregivers/dyadic care, and self-management/disease management/cardiac rehabilitation. Two reviewers independently screened eligible evidence sources, assessed methodological quality using design-appropriate appraisal tools, and extracted and synthesized the evidence. Results - A total of 18 evidence sources were included, comprising 4 guidelines, 4 expert consensus statements, 2 systematic reviews, 1 evidence summary, 3 randomized controlled trials, and 4 quasi-experimental studies. Evidence synthesis yielded 27 evidence-based recommendations across five domains: assessment and planning, education and decision-making, self-management and rehabilitation, psychosocial support, and continuity of care. Key recommendations emphasized dyadic assessment of patient and caregiver needs, psychological status, caregiver burden, and readiness for collaboration; joint education and shared decision-making; caregiver-supported medication management, lifestyle modification, rehabilitation, symptom monitoring, and emergency response; psychosocial support for both members of the dyad; and coordinated discharge transition and follow-up. Conclusion - The synthesized evidence integrates previously dispersed caregiver-related findings into a structured, consent-based dyadic management pathway for post-stenting care. Clinicians should identify and assess the caregiver selected by the patient, clarify collaborative roles and goals, provide joint education and targeted skills training, and integrate caregiver support into self-management, rehabilitation, psychosocial care, discharge transition, and follow-up. This pathway offers a practical approach to incorporating caregiver participation into post-stenting secondary prevention while preserving patient autonomy and addressing the needs of both members of the dyad.<br/>Copyright &#xa9; 2026 Wang, Zhu, Wei, Luo, Wan, Wang and Yu. <21> Accession Number 2047372785 Title Age-related efficacy of aspirin in secondary prevention of coronary artery disease: START-ANTIPLATELET registry and meta-analysis of randomized trials. Source American Journal of Medicine. 139(12) (pp 1683-1691.e3), 2026. Date of Publication: 01 Dec 2026. Author Valeriani E.; Marcucci R.; Di Nisio M.; Calabro P.; Cirillo P.; Gresele P.; Patti G.; Pengo V.; Palumbo I.M.; Poli D.; Antonucci E.; Santilli F.; Pannunzio A.; Pignatelli P.; Violi F. Institution (Valeriani) Department of Internal Medicine, Endocrine and Metabolic Sciences, Infectious Diseases, Umberto I hospital of Rome, Rome, Italy (Marcucci) Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy (Di Nisio) Department of Medicine and Ageing Sciences, "G. D'Annunzio" University, Chieti, Italy (Calabro) Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Caserta, Italy (Cirillo) Department of Advanced Biomedical Sciences, Division of Cardiology, University of Naples "Federico II", Naples, Italy (Gresele) Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy (Patti) Universita del Piemonte Orientale, Ospedale Maggiore della Carita di Novara, Novara, Italy (Pengo) Department of Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padova, Padua, Italy (Palumbo, Pannunzio) Department of General Surgery, Surgical Specialty and Anaesthesiology, Sapienza University of Rome, Rome, Italy (Poli) Thrombosis Centre, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy (Poli, Antonucci) Arianna Anticoagulazione Foundation, Bologna, Italy (Santilli) Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology, "G. d'Annunzio" University of Chieti Pescara, Chieti, Italy (Pignatelli) Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy (Violi) Sapienza university of Rome, Rome, Italy Publisher Elsevier Inc. Abstract Background: Aspirin is a standard therapy for secondary prevention in coronary artery disease, yet its antiplatelet effect varies and incomplete thromboxane-A inhibition has been shown in older individuals. Because no age threshold currently guides treatment, we investigated whether aspirin efficacy differs across predefined age cut-off in patients with coronary artery disease. <br/>Method(s): We analyzed data from START-ANTIPLATELET registry, a multicenter prospective registry of patients hospitalized for acute coronary syndrome and subsequently treated with at least one month of aspirin monotherapy. Patients were stratified by age >= 65 versus < 65 65 years. The primary endpoint was major adverse cardiovascular events, evaluated using Kaplan-Meier estimates and multivariable Cox regression. A systematic review and meta-analysis were conducted to evaluate the effect of aspirin for secondary prevention in older versus younger adults. Pooled risk ratios with 95% confidence intervals were calculated using a random-effects model. <br/>Result(s): 410 patients were included in the registry, of whom 53.7% had >= 65 years. Patients aged >= 65 years exhibited a substantially higher incidence of major adverse cardiovascular events than younger patients, for an absolute increase of 5 events per 1,000 patient-months. Older age was associated with increased risk of major adverse cardiovascular events (hazard ratio 4.99, 95%CI 1.11-22.58) independently of other cardiovascular risk factors (hazard ratio 3.94, 95%CI 0.84-18.65). The meta-analysis of 58,394 participants from 19 trials confirmed the increased risk of major adverse cardiovascular events among older individuals receiving aspirin compared with younger patients (RR 1.41, 95%CI 1.141.73). <br/>Conclusion(s): The efficacy of aspirin monotherapy for secondary coronary artery disease prevention is reduced in elderly patients from 65 years of age onward.<br/>Copyright &#xa9; 2026 <22> Accession Number 2050180640 Title Bibliometric Analysis and Cluster Analysis of Research Trends on Postoperative Cognitive Dysfunction in Elderly Patients After Anesthesia. Source Journal of Perianesthesia Nursing. (no pagination), 2026. Date of Publication: 2026. Author Duan J.; Duan X.; Zhang H.; Chu J. Institution (Duan) Department of Anesthesiology, Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine, Hangzhou, China (Duan) Department of Orthopaedic Surgery, Affiliated Hospital of Shandong Traditional Chinese Medicine University, Jinan, China (Zhang) Department of Thoracic Surgery, Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine, Hangzhou, China (Chu) Department of Thyroid and Head & Neck Surgery, Institute of Micro-Invasive Surgery of Zhejiang University, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, China Publisher W.B. Saunders Abstract Purpose The purpose of this study was to analyze research on postoperative cognitive dysfunction in elderly patients after anesthesia and to identify research hotspots and trends. Design A bibliometric analysis. Methods We searched the Web of Science Core Collection for English-language publications on postoperative cognitive dysfunction in elderly patients after anesthesia published from 1988 to 2024. The retrieved data were analyzed using VOSviewer, CiteSpace, and R 4.3.3. Findings A total of 1,119 articles were included in the analysis. Among countries, China had the highest number of publications. Among institutions, Harvard University ranked first, with 165 publications. Among journals, Anesthesiology had the highest total number of citations, with 3,074 citations and an impact factor of 9.1. Among authors, Xie Zhongcong had the largest number of publications, with 24 articles and 1,045 citations. Keyword cluster analysis identified seven major research themes: anesthesia approach, risk, and clinical management; pathophysiological mechanisms and neuroinflammation; cardiovascular surgery and perioperative monitoring; biomarkers and neurodegeneration; anesthetic drugs and assessment tools; outcomes and neurophysiological responses; and recommendations. High-frequency keywords such as "anesthesia," "surgery," and "dysfunction" reflected the main research hotspots and trends in this field. Conclusions This bibliometric study summarizes the research landscape of postoperative cognitive dysfunction in elderly patients after anesthesia and identifies major contributors, research hotspots, and evolving trends. The findings may provide a useful reference for future research in this field.<br/>Copyright &#xa9; 2026 The American Society of PeriAnesthesia Nurses. <23> Accession Number 2036795893 Title Racial Disparities in Access, Utilization, and Outcomes of Transcatheter Mitral Valve Repair in the United States: A Literature Review. Source Journal of Racial and Ethnic Health Disparities. 13(6) (pp 4506-4516), 2026. Date of Publication: 01 Dec 2026. Author Adeyemi B.A.; Anthony C.S.; Ajekiigbe V.O.; Ogieuhi I.J.; Ishola F.; Odukudu G.-D.O.; Damilola A.O.; Emmanuel A.C.; Samuel O.; Nwaezeapu K.I.; Ogunniyi K.; Fatunmbi O.O.; Oparaocha V.E. Institution (Adeyemi, Ogieuhi, Fatunmbi) Northwestern Medicine McHenry Hospital, McHenry, IL, United States (Anthony) University of Calabar, Calabar, Nigeria (Ajekiigbe) Ladoke Akintola University of Technology, Oyo, Ogbomoso, Nigeria (Ishola) Ascension St. Vincent Hospital Indianapolis, Indianapolis, IN, United States (Odukudu) Morehouse School of Medicine, Atlanta, GA, United States (Damilola) Montefiore St. Luke's Cornwall, Newburgh, NY, United States (Emmanuel) University of Nigeria, Enugu, Nsukka, Nigeria (Samuel) Lagos State Health Service Commission, Lagos, Nigeria (Nwaezeapu) Trinity Health Ann Arbor, Ann Arbor, MI, United States (Ogunniyi) Richmond University Medical Center/Mount Sinai, Staten Island, NY, United States (Oparaocha) Avalon University School of Medicine, Willemstad, Curacao Publisher Springer Science and Business Media Deutschland GmbH Abstract Racial and ethnic disparities in cardiovascular care are well-documented; however, their impact on transcatheter mitral valve interventions, including transcatheter mitral valve repair (TMVr), remains underexplored. This review synthesizes the existing literature on racial and ethnic disparities in TMVr access, utilization, and outcomes to identify contributing factors, proposed solutions, and critical knowledge gaps. A comprehensive search of PubMed, EMBASE, and Cochrane databases from 2014 to 2024 yielded nine studies for final inclusion. Across studies, minority patients-particularly African American and Hispanic individuals-were consistently underrepresented among TMVr recipients relative to disease burden. They tended to present at younger ages, were more likely to be female, and more often underwent non-elective procedures at lower-volume centers. Minority patients experienced longer hospital stays, greater procedural costs, and higher healthcare resource utilization. While some studies reported higher post-procedural mortality or readmission rates among minorities, findings on complication rates were mixed. Contributing factors included socioeconomic stressors, Medicaid coverage, limited referrals to specialized centers, provider bias, and geographic barriers. Newer studies also highlighted disparities in TMVr access even within equal-access systems and identified income-related disparities independent of race. Proposed interventions included Medicaid expansion, coverage with evidence development, culturally competent care delivery, improved referral pathways, and community outreach. All included studies were retrospective and predominantly relied on administrative data. Prospective, longitudinal studies are needed to clarify causal drivers of disparity and inform equity-focused policies in structural heart interventions.<br/>Copyright &#xa9; W. Montague Cobb-NMA Health Institute 2025. <24> Accession Number 2049766812 Title Comparing the clinical outcomes of fractional flow reserve and intravascular imaging in guiding percutaneous coronary intervention: A systematic review and meta-analysis. Source Current Problems in Cardiology. 52(1) (no pagination), 2027. Article Number: 103459. Date of Publication: 01 Jan 2027. Author Kaushik S.; Balakrishna A.M.; Arvind S.; Mangalesh S.; Kumar S.S.; Torrado J.; Alam U.; Gashi E. Institution (Kaushik, Mangalesh, Kumar, Torrado, Alam, Gashi) Jacobi Medical Center, Albert Einstein College of Medicine, 1400 Pelham Parkway South, Bronx, NY, United States (Balakrishna) Creighton University School of Medicine, CL and Rachel Werner Center for Health Sciences Education, 2616 Burt Street, Omaha, NE, United States (Arvind) University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, United States Publisher Elsevier Inc. Abstract Background Fractional flow reserve (FFR) and intravascular imaging (IVI) are both used to guide management of intermediate coronary stenoses, but comparative outcome data remain limited. Methods We systematically searched MEDLINE/PubMed and the Cochrane Central Register of Controlled Trials from inception through September 1, 2025, for randomized controlled trials and comparative observational studies directly comparing physiology-guided versus intravascular imaging-guided strategies for angiographically intermediate coronary stenoses. Outcomes included major adverse cardiovascular events (MACE), all-cause mortality, cardiac mortality, myocardial infarction (MI), target-vessel revascularization (TVR), and PCI rate. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Risk of bias was assessed with RoB 2 for randomized trials and ROBINS-I for observational studies. A sensitivity analysis excluded FLAVOUR II because it used angiography-derived rather than pressure-wire FFR. Results Six comparative studies including 5,047 participants were included: four randomized trials and two observational studies. No statistically significant differences were detected in all-cause mortality (RR 0.87, 95% CI 0.53-1.42; p = 0.58), cardiac mortality (RR 1.11, 95% CI 0.63-1.96; p = 0.72), MACE (RR 1.09, 95% CI 0.88-1.35; p = 0.42), nonfatal MI (RR 1.45, 95% CI 0.80-2.64; p = 0.22), or TVR (RR 1.27, 95% CI 0.85-1.90; p = 0.24). Physiology guidance was associated with lower PCI utilization (RR 0.60, 95% CI 0.48-0.75; p < 0.001), with substantial heterogeneity (I2=93.6%). Exclusion of FLAVOUR II did not materially alter the findings, including PCI utilization (RR 0.55, 95% CI 0.45-0.67; I2=76.7%). Conclusions Among patients with intermediate coronary stenoses, FFR- and IVI-guided strategies were associated with similar clinical outcomes, while FFR guidance reduced PCI utilization.<br/>Copyright &#xa9; 2026 Elsevier Inc. <25> Accession Number 2038742617 Title Comparison of inhaled iloprost and nitric oxide in the management of pulmonary hypertension post-cardiac surgery: A systematic literature review of randomized clinical trials. Source Critical Care and Shock. 29(4) (pp 115-128), 2026. Date of Publication: 01 Aug 2026. Author Silalahi D.M.R.; Setiawan P.; Perdhana F.; Husain T.; Kowara Y. Institution (Silalahi, Setiawan, Perdhana, Husain, Kowara) Department of Anesthesiology and Reanimation, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Hos-pital, Surabaya, Indonesia Publisher The Indonesian Foundation of Critical Care Medicine Abstract Background: Pulmonary hypertension (PH) is a critical complication of cardiac surgery, particularly in patients undergoing pulmonary endarterectomy (PEA), heart transplantation, and lung transplantation. Inhaled iloprost and nitric oxide (NO) are widely used as pulmonary vasodilators; however, their comparative efficacy and safety are unclear. <br/>Objective(s): This systematic literature review aimed to compare the effectiveness and safety of inhaled iloprost and NO in managing PH after cardiac surgery, focusing on hemodynamic improvements and adverse effects. <br/>Method(s): A systematic search was conducted for randomized controlled trials (RCTs), randomized crossover studies, and open-label trials published until April 2025. Five relevant studies were included, encompassing 115 patients with various forms of post-cardiac surgery-related PH. The primary outcomes included reductions in mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR). In contrast, the secondary outcomes included hemodynamic parameters, oxygenation, incidence of pulmonary hypertensive crises (PHTC), and adverse events. <br/>Result(s): Both inhaled iloprost and NO effectively reduced mPAP and PVR across all studies, with no significant differences in the overall efficacy between the two treatments. However, iloprost demonstrated superior effects in improving cardiac output and reducing PVR compared with those of NO. Both therapies were associated with a significant reduction in PHTC and improvement in hemodynamic and oxygenation parameters. Iloprost also exhibited a better safety profile with fewer systemic side effects, such as throm-bocytopenia. The studies revealed that the incidence of adverse effects was generally low for both treatments, and no major complications were reported in either group. <br/>Conclusion(s): Inhaled iloprost provides superior hemodynamic improvements compared with NO, particularly in reducing PVR and increasing cardiac output. Both treatments were safe and effective in managing post-cardiac surgery PH. Iloprost may offer a better alternative to NO, especially for long-term management, given its sustained effects and fewer systemic side effects. Future studies should focus on larger multicenter trials to validate these findings and explore long-term outcomes.<br/>Copyright &#xa9; 2026, The Indonesian Foundation of Critical Care Medicine. All rights reserved. <26> Accession Number 2050082605 Title Preoperative empagliflozin and ventricular remodeling after coronary artery bypass grafting in type 2 diabetes: a prespecified analysis of the POST-CABGDM randomized trial. Source Diabetology and Metabolic Syndrome. 18(1) (no pagination), 2026. Article Number: 227. Date of Publication: 01 Dec 2026. Author Popp V.O.; Pitta F.G.; de Brito G.D.; Popp J.O.; Carvalho L.N.S.; Sampaio L.P.C.; Rached F.H.; Mioto B.M.; Bolta P.M.P.; Asdrubal Vilca Mejia O.; Dallan L.A.O.; Filho R.K.; Abizaid A.A.C.; Serrano C.V.; Lima E.G. Institution (Popp, Pitta, Carvalho, Sampaio, Rached, Mioto, Bolta, Asdrubal Vilca Mejia, Dallan, Filho, Abizaid, Serrano, Lima) Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, Sao Paulo, Brazil (Popp, de Brito) Complexo Hospital Sao Marcelino Champagnat, PR, Curitiba, Curitiba, Brazil (Popp, Popp) Hospital Universitario Cajuru, PR, Curitiba, Brazil (Popp) Pontificia Universidade Catolica do Parana (PUCPR), PR, Curitiba, Brazil (Lima) Hospital Nove de Julho, Sao Paulo, Brazil Publisher BioMed Central Ltd Abstract Background: Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are associated with adverse ventricular remodeling. Coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB) may further contribute to myocardial injury through inflammatory and ischemia-reperfusion mechanisms. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardioprotective effects, including reduction in left ventricular mass, but their impact in the perioperative setting of cardiac surgery remains unclear. <br/>Method(s): This study is a prespecified secondary analysis of the open-label randomized POST-CABGDM trial (NCT04523064). Patients with T2DM and multivessel CAD undergoing CABG with CPB were randomized to receive empagliflozin 25 mg once daily or standard antidiabetic therapy. SGLT2i were discontinued 3 days before surgery and were not protocol-mandated postoperatively. Transthoracic echocardiography was performed preoperatively and at 1-6 months postoperatively. The primary endpoint was the change in left ventricular mass index (DELTALVMI). Secondary endpoints included changes in left ventricular ejection fraction (DELTALVEF) and ventricular dimensions. <br/>Result(s): A total of 118 patients were included (53 in the intervention group and 65 in the control group). Baseline characteristics were well balanced. No significant difference was observed in DELTALVMI between groups (- 1.39 +/- 18.7 vs. -4.55 +/- 16.8 g/m2; p = 0.337), and this finding remained unchanged after adjustment for baseline LVMI. Similarly, no differences were found in DELTALVEF or ventricular dimensions. Surgical characteristics and postoperative complications were comparable. In a separate exploratory, non-randomized multivariable analysis, continued use of SGLT2i during follow-up was associated with a higher likelihood of LVMI reduction (OR 4.69; 95% CI 1.20-18.40; p = 0.03). <br/>Conclusion(s): Preoperative empagliflozin use was not associated with significant short-term changes in LVMI, LVEF, or ventricular dimensions after CABG with CPB. Exploratory, non-randomized analyses suggested an association between continued SGLT2i use during follow-up and LVMI reduction, but these findings should be considered hypothesis-generating and require confirmation in prospective studies designed to evaluate sustained perioperative and postoperative therapy. Trial registration: ClinicalTrials.gov NCT04523064.<br/>Copyright &#xa9; The Author(s) 2026. <27> Accession Number 2050147101 Title The Association Between Chronic Obstructive Pulmonary Disease and Postoperative Delirium: A Systematic Review and Meta-Analysis. Source International Journal of COPD. 21 (no pagination), 2026. Article Number: 644864. Date of Publication: 2026. Author Wang Z.; Xu J.; Xi Y.; Luo Z.; Cheng J.; Xu Z.; Liang P. Institution (Wang, Xu, Liang) Department of Anesthesiology, West China Hospital, Sichuan University, No. 37 Guoxuexiang, Sichuan, Chengdu, China (Xu) Department of Anesthesiology, West China Hospital, Sichuan University, Day Surgery Center, West China Hospital, Sichuan University, No. 37 Guoxuexiang, Sichuan, Chengdu, China (Xi, Luo) West China Clinical Medical School, Sichuan University, Sichuan, Chengdu, China (Cheng) The First Clinical Medical College of Nanchang University, Jiangxi Medical College, Nanchang University, Jiangxi, Nanchang, China (Liang) Day Surgery Center, West China Hospital, Sichuan University, Sichuan, Chengdu, China Publisher Dove Medical Press Ltd Abstract Background: Postoperative delirium (POD) is a frequent and serious complication following surgery, particularly in high-risk patients such as those with chronic obstructive pulmonary disease (COPD). The relationship between COPD and the development of POD remains unclear, with existing studies providing inconsistent findings. This meta-analysis aims to evaluate the association between COPD and postoperative delirium in surgical patients. <br/>Method(s): A comprehensive literature search was conducted across multiple databases, including PubMed, MEDLINE, Web of Science, Embase, and the Cochrane Library, and other grey resources. Observational studies and randomized controlled trials assessing the incidence of POD in COPD patients were included. Data were extracted on study design, participant demographics, surgical context, and POD assessment. Both fixed-effect and random-effects models were evaluated, with model selection guided by statistical heterogeneity and study characteristics. Subgroup analyses were performed to explore heterogeneity. <br/>Result(s): A total of 26 studies involving 43,051 patients were included. Both unadjusted and adjusted analyses showed a significant association between COPD and the increased risk of POD. The pooled odds ratio (OR) for the association in adjusted analyses was 2.08 (95% CI: 1.60-2.71, P < 0.001; I<sup>2</sup> = 67.2%). In the adjusted subgroup analysis, the association remained statistically significant in non-cardiac surgery but did not reach statistical significance in cardiac surgery; however, the between-subgroup difference was not statistically significant (P for interaction = 0.139). Geographic variation was identified as a potential effect modifier, with studies conducted in Asia showing a stronger association. <br/>Conclusion(s): The available evidence suggests an association between COPD and higher odds of POD in surgical patients, including in studies reporting multivariable-adjusted estimates. However, the predominantly observational evidence and between-study heterogeneity warrant cautious interpretation and do not establish causality. These findings highlight the potential importance of tailored perioperative management strategies for patients with COPD, although their effectiveness in reducing POD risk requires further investigation. Further well-designed prospective studies are necessary to confirm these findings and explore the underlying mechanisms. However, insufficient data on COPD severity precluded an assessment of whether this association varied across GOLD stages.<br/>Copyright &#xa9; 2026 Wang et al. <28> Accession Number 2045310179 Title The effectiveness of a targeted education intervention to increase protein intake in people with CHD: a pilot feasibility randomised controlled trial. Source British Journal of Nutrition. 136 (pp 544-552), 2026. Date of Publication: 14 Sep 2026. Author James E.; Das R.; Brownson-Smith R.; Rickelton E.; Goodall S.; Nichols S.; O'Doherty A.F. Institution (James) Diabetes Research Centre, University of Leicester College of Life Sciences, United Kingdom (James) NIHR Leicester Biomedical Research Centre, United Kingdom (James, Brownson-Smith, Goodall, O'Doherty) School of Sport Exercise and Rehabilitation, University of Northumbria at Newcastle, United Kingdom (Das, Rickelton) Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom (Brownson-Smith) Newcastle University, Faculty of Medical Sciences, United Kingdom (Nichols) Centre for Cardiovascular Health, Edinburgh Napier University, United Kingdom (Nichols) Advanced Wellbeing Research Centre, Sheffield Hallam University, United Kingdom (O'Doherty) Department of Sport and Exercise Sciences, Durham University, United Kingdom Publisher Cambridge University Press Abstract Low protein intake is prevalent in people with CHD and is inadequately addressed in UK-based cardiac rehabilitation. This pilot feasibility study aimed to identify whether targeted education increases protein intake in patients with CHD and low protein intake, compared with standard cardiac rehabilitation dietary education. People referred to cardiac rehabilitation with CHD (>= 50 years) underwent anthropometric assessment and completed a food diary, sit-to-stand test and three questionnaires (physical activity, sarcopenia screening and nutrition knowledge). Participants with low protein intake (<= 1.2 g/kg per d) were randomised to receive either extra protein education (intervention; protein group) or standard education (control; control group), embedded within their usual 6-week cardiac rehabilitation programme. At 6 and 12 weeks, outcome measures were repeated; thirty-four participants provided baseline data. Protein intake was inversely associated with waist circumference (r = -0.348). Twenty-seven participants (79 %) with low protein intake were randomised to the protein group (n 15) or control group (n 12). At week 6, the median (interquartile range) change in protein intake was 0.0 (-0.0-0.3) and 0.4 (0.2-0.5) g/kg per d in the protein group and control group, respectively (effect size 0.5). At week 12, the change in protein intake was 0.0 (-0.0-0.1) and -0.0 (-0.2-0.2) g/kg per d in the protein group and control group, respectively (effect size 0.3). Effect sizes for all other variables were <= 0.4. The intervention appeared well-received by those who completed the study; however, changes to primary and secondary outcomes were minimal. Uptake of the study was low, and attrition was high, limiting the interpretation of efficacy and the implementation of a definitive trial.<br/>Copyright &#xa9; The Author(s), 2026. Published by Cambridge University Press on behalf of The Nutrition Society <29> Accession Number 2049645443 Title Mortality predictors in cancer patients undergoing transcatheter aortic valve implantation for aortic stenosis: a systematic review and meta-analysis. Source Cardio-Oncology. 12(1) (no pagination), 2026. Article Number: 126. Date of Publication: 01 Dec 2026. Author Alizadehasl A.; Afsari Zonooz Y.; Mortaz Hejri G.; Hakimian H.; Bahramnejad A.; Amini-Salehi E.; Hashemi S.M.; Narimani-Javid R.; Hosseini Jebelli S.F.; Aliabadi A.Y. Institution (Alizadehasl, Afsari Zonooz, Hakimian, Bahramnejad, Hosseini Jebelli, Aliabadi) Cardio-Oncology Research Center, Rajaie Cardiovascular Institute, Tehran, Iran, Islamic Republic of (Mortaz Hejri) Cardiovascular Research Center, Rajaie Cardiovascular Institute, Tehran, Iran, Islamic Republic of (Amini-Salehi) School of Medicine, Guilan University of Medical Science, Rasht, Iran, Islamic Republic of (Hashemi) Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran, Islamic Republic of (Narimani-Javid) Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of Publisher BioMed Central Ltd Abstract Background: The coexistence of cancer and aortic stenosis is increasingly common in elderly patients, presenting unique challenges for management. Transcatheter aortic valve implantation (TAVI) offers a less invasive alternative to surgical valve replacement, but the impact of various clinical factors on post-TAVI mortality in cancer patients remains unclear. <br/>Objective(s): To systematically review and meta-analyze the predictors of mortality in cancer patients undergoing TAVI for aortic stenosis. <br/>Method(s): A comprehensive literature search was conducted in Scopus, PubMed, Web of Science, and Embase up to May 2025. Studies assessing mortality predictors in cancer patients post-TAVI were included. Data extraction and quality assessment were performed independently by two reviewers. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using random-effects models. Sensitivity analyses addressed within-study correlation assumptions, and heterogeneity was assessed using I2 and tau2 statistics. <br/>Result(s): Five high-quality case-control studies, encompassing over 7,000 patients, were included. Advanced NYHA class (III/IV), prior myocardial infarction, atrial fibrillation, COPD, diabetes mellitus, and higher STS scores were robustly associated with increased mortality. Active cancer conferred a significantly higher mortality risk (HR 1.64, 95% CI: 1.17-2.30), while preserved left ventricular ejection fraction and renal function were linked to improved survival. Most predictors remained stable across sensitivity analyses, although the impact of cancer status varied with correlation assumptions. <br/>Conclusion(s): Both traditional cardiovascular and cancer-specific factors significantly influence mortality in cancer patients undergoing TAVI. These findings underscore the need for individualized, multidisciplinary risk assessment and highlight the importance of further research to refine patient selection and optimize outcomes in this growing patient population.<br/>Copyright &#xa9; The Author(s) 2026. <30> Accession Number 2049988204 Title Controlled low central venous pressure after cardiopulmonary bypass reduces acute kidney injury following cardiac surgery: a randomized controlled trial. Source Frontiers in Medicine. 13 (no pagination), 2026. Article Number: 1846773. Date of Publication: 2026. Author Chen L.; Hu L.; He Y.; Kong S.; Liu J.; Ding K.; Zhang C.; Zhu D.; Cheng Y.; Shi H.; Zhou J.; Ge Y. Institution (Chen, Hu, He, Liu, Ding, Zhang, Zhu, Shi, Ge) Department of Anesthesiology, Perioperative and Pain Medicine, Nanjing First Hospital, Nanjing Medical University, Jiangsu, Nanjing, China (Kong, Cheng, Zhou) School of International Business, China Pharmaceutical University, Jiangsu, Nanjing, China Publisher Frontiers Media SA Abstract Background - Postoperative acute kidney injury (AKI) is a serious complication of cardiac surgery. This study aimed to determine whether targeting central venous pressure (CVP) readings of <=10 mmHg using vasoactive drugs and reversing the Trendelenburg position was associated with a lower incidence of AKI than usual care in patients undergoing cardiac surgery requiring cardiopulmonary bypass (CPB). Methods - We conducted a randomized controlled trial. Patients were randomized in a 1:1 ratio to receive controlled low central venous pressure (CLCVP) or usual care. Patients in the CLCVP group received nitroglycerin and were placed in the reverse Trendelenburg position from 20 min after CPB until the end of surgery. The primary outcome was incidence of 7-day postoperative AKI defined by KDIGO criteria. Results - The trial included 505 subjects in the final analysis. There were fewer patients with postoperative AKI in the CLCVP group [114 (44.9%)] compared with the control group [150 (59. 8%)] [Absolute risk reduction (ARR): -14.9%; 95% confidence interval [CI]: (-23. 5%, -6. 3%); P = 0. 001]. Eight (3.1%) participants in the CLCVP group and 14 (5.6%) participants in the control group developed AKI of Stage 2 and above [ARR: -2. 4%; 95% CI: (-6. 0, 1. 1%); P = 0. 263]. This reduction was primarily driven by a lower incidence of Stage 1 AKI, whereas the incidence of Stage 2 or higher AKI did not differ significantly between groups. Median time-weighted CVP was lower in the CLCVP group (6.7 mm Hg vs. 8.1 mm Hg, P < 0. 001). Conclusion - This randomized clinical trial demonstrated that cardiac surgery patients with CLCVP exhibited lower CVP and fewer postoperative kidney injuries compared to those receiving usual care. Clinical Trial Registration - https://clinicaltrials.gov/study/NCT05855954, identifier NCT05855954.<br/>Copyright &#xa9; 2026 Chen, Hu, He, Kong, Liu, Ding, Zhang, Zhu, Cheng, Shi, Zhou and Ge. <31> Accession Number 2048103084 Title Prednisone in the Management of Pericarditis: A Systematic Review. Source Journal of Cardiovascular Pharmacology. 88(4) (pp 328-335), 2026. Date of Publication: 01 Oct 2026. Author Razeghi G.; Ahmed F.; Genadri A.E.; Abumustafa Y.; Mohottalage D.N.; Tahvildar N.; Shirobokov V.; Carballo C.; Hakimjavadi R.; Visintini S.M.; Cremer P.C.; Mardigyan V.; Kafil T.S.; Pantieras F.; Boczar K. Institution (Razeghi, Hakimjavadi) Department of Medicine, University of Ottawa, Ottawa, ON, Canada (Ahmed, Genadri, Mohottalage, Tahvildar, Shirobokov, Pantieras) University of Ottawa Faculty of Medicine, Ottawa, ON, Canada (Abumustafa, Boczar) Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada (Carballo) Faculty of Science, University of Ottawa, Ottawa, ON, Canada (Visintini) Berkman Library, University of Ottawa Heart Institute, Ottawa, ON, Canada (Cremer) Bluhm Cardiovascular Institute, Division of Cardiology, Chicago, IL, United States (Mardigyan) Department of Medicine, Jewish General Hospital, Montreal, QB, Canada (Kafil) Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States Publisher Lippincott Williams and Wilkins Abstract Background: - Corticosteroids are widely used in pericarditis despite guideline recommendations reserving them for select indications. Observational studies have reported inconsistent associations between corticosteroid use and pericarditis recurrence, and optimal dosing and tapering strategies remain unclear. We conducted a systematic review of oral corticosteroids for acute or recurrent pericarditis to characterize patterns of treatment and evaluate the association between corticosteroids and pericarditis recurrence across different disease contexts. <br/>Method(s): - MEDLINE, Embase, CENTRAL, and Scopus were searched from inception to November 26, 2025. Studies enrolling adults with acute or recurrent pericarditis treated with oral corticosteroids were included. Randomized trials, cohort studies, and case-control studies reporting clinical outcomes were eligible. Risk of bias was assessed using the Newcastle-Ottawa Scale. Data were synthesized descriptively due to anticipated clinical and methodological heterogeneity. <br/>Result(s): - Ten studies (2 prospective and 8 retrospective) including 2632 patients (800 corticosteroid treated) met inclusion criteria. Prednisone was most frequently studied, with heterogeneous dosing (0.25-1.0 mg/kg/d) and nonstandardized tapering strategies. Follow-up ranged from 1 to 6.7 years, and overall risk of bias was moderate with limited adjustment for confounding. Findings on recurrence were inconsistent in acute idiopathic and postprocedure pericarditis, while most studies in recurrent pericarditis reported higher recurrence with corticosteroid exposure. <br/>Conclusion(s): - Evidence evaluating oral corticosteroids in pericarditis is limited by heterogeneity, confounding, and inconsistent reporting of treatment strategies. Observational data show variable associations with recurrence across clinical contexts. High-quality randomized trials stratified by pericarditis etiology and acuity are needed to define the optimal use of corticosteroids in pericarditis.<br/>Copyright &#xa9; 2026 Wolters Kluwer Health, LLC. All rights reserved. <32> Accession Number 2050193652 Title Association Between Colchicine Use and Clinical Outcomes Post Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials. Source American Journal of Cardiovascular Drugs. (no pagination), 2026. Date of Publication: 2026. Author Jaiswal V.; Hanif M.; Raja H.A.A.; Khadka S.; Deb N.; Mashkoor Y.; Ahmed A.; Rajak K.; Jaiswal A.K.; Gupta M.; Hirji S.; Fonarow G.C.; Qamar A. Institution (Jaiswal, Ahmed, Qamar) Endeavor Health Cardiovascular Institute, University of Chicago, Pritzker School of Medicine, Chicago, IL, United States (Hanif) Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, United States (Raja) Department of Internal Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan (Khadka) Department of Internal Medicine, UPMC Harrisburg, Harrisburg, PA, United States (Deb) Department of Internal Medicine, North Bengal Medical College and Hospital, Darjeeling, India (Mashkoor) Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan (Rajak) Department of Cardiology, University of Missouri, Columbia, United States (Jaiswal) Department of Cardiology, King George's Medical University, Lucknow, India (Gupta) Department of Cardiology, GB Pant Hospital, New Delhi, India (Hirji) Division of Cardiac Surgery, Mass General Brigham, Harvard Medical School, Boston, MA, United States (Fonarow) Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles, CA, United States Publisher Adis Abstract Background: Colchicine has been shown to mitigate inflammation and reduce adverse cardiovascular events. However, evidence from clinical trials has been mixed regarding its efficacy in cardiovascular prevention among patients undergoing cardiac surgery. <br/>Objective(s): We aimed to evaluate the association between colchicine use and cardiovascular outcomes in patients undergoing cardiac surgery. <br/>Method(s): We conducted a systematic literature search on various electronic databases for relevant studies from their inception until July 15, 2025. Randomized controlled trials (RCTs) with two arms-one with colchicine as an intervention and the other with placebo-in patients undergoing cardiac surgery were included. Risk ratios (RRs) and weighted mean differences (WMDs), along with 95% confidence intervals (CIs), were pooled using a random-effects model. A p value of < 0.05 was considered statistically significant. <br/>Result(s): Nine RCTs with 2005 patients (990 in the colchicine group and 1015 in the placebo group) were included. The mean age was 62.8 years. Pooled analysis demonstrated that compared with placebo, colchicine was significantly associated with a reduction in the risk of postoperative atrial fibrillation (POAF) (RR 0.70 [95% CI 0.59-0.83], p < 0.001). However, between the groups, there was no statistically significant difference in the risk of all-cause mortality (ACM) (RR 0.81 [95% CI 0.39-1.69], p = 0.57, I<sup>2</sup> = 0%), stroke (RR 1.86 [95% CI 0.48-7.12], p = 0.37), and permanent pacemaker implantation (PPM) (RR 1.36 [95% CI 0.08-22.44], p = 0.83). Length of hospital stay, which was exploratory, was significantly shorter in the colchicine group (WMD - 1.16 [95% CI - 1.89 to - 0.44], p < 0.01) compared to placebo. <br/>Conclusion(s): This meta-analysis demonstrates that colchicine appears to reduce the risk of POAF. However, it does not significantly affect the risks in terms of PPM, ACM, or stroke. Registration: PROSPERO identifier no. CRD420251117966.<br/>Copyright &#xa9; The Author(s) 2026. <33> Accession Number 2051471240 Title Effects of the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin on Perioperative Endothelial Function in Patients Undergoing Cardiac Surgery: An Exploratory Analysis of MERCURI-1. Source Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2026. Date of Publication: 2026. Author Wang M.; Li X.; Snel L.I.P.; Zuurbier C.J.; Stuhldreier C.; Seehaber J.; Hermanides J.; Albrecht M.; Hollmann M.W.; Preckel B.; van Raalte D.H.; Hulst A.H.; Weber N.C. Institution (Wang, Li, Snel, Zuurbier, Stuhldreier, Seehaber, Hermanides, Hollmann, Preckel, van Raalte, Hulst, Weber) Amsterdam University Medical Center, Department of Anesthesiology - Laboratory of Experimental Intensive Care and Anesthesiology-L. E. I. C. A, Amsterdam Cardiovascular Science, Amsterdam, Netherlands (Li) Center for Cell Lineage Research, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China (Stuhldreier, Seehaber, Albrecht) Department of Anesthesiology and Intensive Care Medicine, Universitatsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany Publisher W.B. Saunders Abstract Objective: To investigate whether short-term treatment with empagliflozin (EMPA) is associated with attenuation of endothelial dysfunction and cardiac injury in patients undergoing cardiac surgery. <br/>Design(s): An exploratory study using samples from the open-label randomized MERCURI-1 study. <br/>Setting(s): Academic university hospital. <br/>Participant(s): Adult patients undergoing cardiac surgery with cardiopulmonary bypass. <br/>Intervention(s): Patients received 10 mg/d EMPA starting 3 days before surgery and continuing until 2 days postoperatively or received standard perioperative care. <br/>Measurements and Main Results: Blood samples were collected at baseline (prior to EMPA therapy), on the day of surgery (before the first incision), and 1 day after surgery. Plasma biomarkers for endothelial activation (endothelin-1), vascular leakage (angiopoietin-2), glycocalyx degradation (syndecan-1), cardiac injury (Troponin I and NT-proBNP), and systemic inflammation (IL-6, IL-8, and CRP) were measured. In vitro, human cardiac microvascular endothelial cells were exposed to patient plasma, and endothelial permeability was assessed. Surgery-induced changes in biomarkers of endothelial activation and vascular leakage did not differ significantly between the EMPA and control groups. The adjusted between-group differences were 0.097 pg/mL for endothelin-1 (95% confidence interval [CI] -0.478 to 0.672, p = 0.735), -465 pg/mL for angiopoietin-2 (95% CI -2,355 to 1,426, p = 0.623), and 19,540 pg/mL for syndecan-1 (95% CI -10,016 to 49,095, p = 0.19). No significant differences were found for cardiac injury or inflammatory biomarkers. In vitro, endothelial resistance did not differ between the EMPA and control groups. <br/>Conclusion(s): In this exploratory substudy, no significant differences in endothelial activation, vascular leakage, cardiac injury, or inflammation between were found the EMPA and control groups. Given the limited sample size, smaller treatment effects cannot be excluded.<br/>Copyright &#xa9; 2026 The Author(s) <34> Accession Number 2049885983 Title Closed Versus Open Vent Port Techniques and the Disconnection Technique for Optimizing Lung Collapse With Bronchial Blockers in Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial. Source Clinical Respiratory Journal. 20(10) (no pagination), 2026. Article Number: e70235. Date of Publication: 01 Oct 2026. Author Yao J.; Chen Y.-J.; Shen F.-M.; Xie J.; Yang J.-J.; Huang L.-X.; Tan X.-X.; Yang Y.; Sun J. Institution (Yao, Chen, Shen, Xie, Yang, Huang, Tan, Yang, Sun) Department of Anesthesiology, Surgery and Pain Management, Zhongda Hospital, Southeast University, Jiangsu, Nanjing, China (Sun) Jiangsu Provincial Key Laboratory of Critical Care Medicine, Jiangsu, Nanjing, China Publisher John Wiley and Sons Inc Abstract Introduction: For patients undergoing video-assisted thoracoscopic surgery (VATS) for lung cancer or other pulmonary lesions, effective one-lung ventilation (OLV) is essential to provide surgical exposure. Bronchial blockers (BBs) are increasingly used for OLV, but the optimal management of their vent port to accelerate lung collapse remains unclear. <br/>Method(s): In this prospective, randomized, controlled trial, 75 patients were allocated to three groups (n = 25 each): Group 1-BB with vent port closed; Group 2 (control)-BB with vent port open; Group 3-BB with the disconnection technique. Primary outcome was the time to complete lung collapse, which was scored according to the video clips obtained during the operation. Secondary outcomes included intraoperative hypoxemia, blood gas analysis, blocker malposition, perioperative complications, and surgeon satisfaction. <br/>Result(s): A total of 72 patients were included in the modified intention-to-treat analysis, with 24 patients in each group. Median time to complete lung collapse was 15 min (95% CI: 10-15) in Groups 1 and 3 but was not reached in Group 2 (15/24, 62.5% had not achieved complete collapse by 30 min). In an exploratory 30-min restricted mean survival time (RMST), complete collapse occurred on average 14.17 min earlier in Group 1 (95% CI: 11.10-17.23) and 12.50 min earlier in Group 3 (95% CI: 9.62-15.38) than in Group 2, with no difference between Groups 1 and 3 (1.67 min, 95% CI: -1.85 to 5.19); time-averaged hazard ratios were consistent (Group 1 vs. 2, 9.80 [4.22-22.73]; Group 3 vs. 2, 7.63 [3.36-17.31]; Group 1 vs. 3, 1.20 [0.67-2.16]). No significant differences were detected in hypoxemia, blocker malposition, or complications across groups; however, the trial was not powered for safety outcomes. <br/>Conclusion(s): In patients aged 18-65 years with ASA I-II and normal pulmonary function undergoing thoracic surgery, the closure of the BB vent port results in a more rapid lung collapse compared to maintaining the vent port open. However, there was no statistically significant difference observed between the vent port closure technique and the disconnection technique regarding the time required for complete lung collapse. Trial Registration: ChiCTR identifier: ChiCTR2000039896.<br/>Copyright &#xa9; 2026 The Author(s). The Clinical Respiratory Journal published by John Wiley & Sons Ltd. <35> Accession Number 2038822487 Title The effect of Rosa Canina hydroalcoholic extract on ventricular arrhythmias in heart failure patients with implantable cardioverter-defibrillators: A Randomized Clinical Trial. Source Razavi Journal of Medicine. 15(1) (no pagination), 2027. Article Number: e1494. Date of Publication: 01 Dec 2027. Author Movahed M.; Rahimi V.B.; Tayyebi M.; Mohammadpour A.H.; Zandi Z. Institution (Movahed, Tayyebi, Zandi) Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of (Rahimi) Patient Safety Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of (Mohammadpour) Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of Publisher Mashhad Razavi Hospital Abstract Background: Heart failure (HF) transpires when the heart is unable to pump sufficient blood. A key cause of ventricular arrhythmias in HF is oxidative stress and prolonged inflammation. Few clinical studies exist on the heart-related effects of Rosa Canina, especially in high-risk patients with implantable cardioverter-defibrillators (ICDs). <br/>Objective(s): This study was designed to assess whether Rosa Canina extract could reduce ventricular arrhythmias in these patients. <br/>Method(s): This double-blind, randomized clinical trial was conducted on 100 patients with HF and ICDs. Patients were randomly assigned to two groups: one received Rosa Canina extract tablets (250 mg, two tablets twice daily) and the other received placebo tablets of similar shape and color (two tablets twice daily). The extract was prepared and standardized in the pharmacognosy laboratory using the wet granulation method. Patients were followed for one month, and the number of ventricular arrhythmias, PVCs, ICD shocks, and hospital admissions was recorded. <br/>Result(s): The Rosa Canina group had significantly lower PVC frequency (22% vs. 58%; P<0.001) and lower ICD shock frequency (14% vs. 40%; P=0.003) compared to the placebo group. In contrast, hospitalization rates did not differ significantly between groups (P = 0.180). Furthermore, 86% of patients in the Rosa Canina group achieved a successful outcome, compared to 60% in the placebo group (P = 0.003). <br/>Conclusion(s): The findings suggest that Rosa Canina extract may be an affordable and helpful supplement to standard treatment for reducing serious complications in heart failure patients.<br/>Copyright &#xa9; 2026 The Authors. <36> Accession Number 2048819950 Title The Effect of Slow Deep Breathing Relaxation Exercise on Pain and Anxiety Levels During and Post-Chest Tube Removal After CABG. Source Critical Care Nursing Quarterly. 49(4) (pp 392-409), 2026. Date of Publication: 01 Dec 2026. Author Abu Sabiha A.L.; Salameh B.; Alkubati S.A.; Salameh Y. Institution (Abu Sabiha) Men's Surgical Ward, Rafidia Hospital, Palestinian Ministry of Health, Nablus, Palestine (Salameh) Faculty of Nursing, Arab American University, Jenin, Palestine (Alkubati) Department of Medical Surgical Nursing, College of Nursing, University of Hail, Hail, Saudi Arabia (Salameh) Faculty of Medicine, Medical Intern, Ain Shams University Hospitals, Ain Shams University, Cairo, Egypt Publisher Wolters Kluwer Health Abstract Chest tube removal after coronary artery bypass graft is frequently reported by patients as stressful and painful, highlighting the need for effective nonpharmacological interventions. Slow deep breathing relaxation exercises (SDBREs) may serve as a simple nursing strategy to reduce discomfort. In this study, we aimed to evaluate the effect of SDBRE on pain and anxiety during and after chest tube removal following coronary artery bypass grafting in Nablus hospitals. An experimental design was used with 80 patients recruited from 2 hospitals. Participants were randomly assigned to either an intervention group (n = 40) that practiced SDBRE or a control group (n = 40) that received standard care. Data were collected through a self-administered questionnaire, the Numeric Pain Scale, and the Visual Anxiety Scale. Data collection occurred from March to October 2024. The intervention group reported significantly lower pain scores during removal (M: 5.325 vs 7.125, P <.001) and after removal (P <.001). Anxiety scores were significantly lower both during and after removal (P <.001). Pain correlated with duration, with more complex operations and prolonged chest tube insertion linked to higher scores. SDBRE significantly reduced pain and anxiety during and after chest tube removal, supporting its integration into routine postoperative nursing care.<br/>Copyright &#xa9; 2026 Wolters Kluwer Health, LLC. All rights reserved. <37> Accession Number 2051481548 Title Contemporary concepts in intraoperative ventilation during thoracic surgery. Source Current Opinion in Anaesthesiology. (pp 1-8), 2026. Date of Publication: 2026. Author Yurttas T.; Wittenstein J.; Gama de Abreu M. Institution (Yurttas) Department of Anaesthesiology, Rescue - and Pain Medicine, Cantonal Hospital St. Gallen, HOCH Health Ostschweiz, St. Gallen, Switzerland (Yurttas) Department of Anesthesiology, Amsterdam University Medical Center, Amsterdam, Netherlands (Wittenstein) Department of Anaesthesiology, University Carl-Gustav-Carus, Dresden, Germany (Gama de Abreu) Department of Cardiothoracic, Vascular Anaesthesiology and Intensive Care, Medical University Graz, Graz, Austria Publisher Lippincott Williams and Wilkins Abstract Purpose of review - Thoracic surgery requiring one-lung ventilation (OLV) remains one of the most challenging settings in perioperative respiratory care. During OLV, anesthesiologists must continuously balance two frequently competing goals: maintaining adequate gas exchange despite a markedly reduced ventilated lung volume while simultaneously minimizing ventilator-induced lung injury (VILI) through lung-protective ventilation. Despite widespread adoption of lower tidal volume ventilation, postoperative pulmonary complications (PPCs) remain frequent. This review summarizes contemporary concepts in mechanical ventilation during noncardiac thoracic surgery, focusing on ventilatory modes, individualized ventilator settings, mechanical and chemical power, and perioperative respiratory support strategies. Recent findings - Recent randomized trials and meta-analyses suggest that individualized approaches to positive end-expiratory pressure and driving pressure may improve intraoperative respiratory mechanics and oxygenation during OLV, although consistent reductions in PPCs remain unproven. Mechanical power has emerged as a potentially important determinant of VILI, whereas chemical power represents a novel framework integrating hyperoxia, oxidative stress, and carbon dioxide management. Emerging ventilatory approaches, such as flow-controlled ventilation, have shown promising physiological effects during OLV, but their impact on patient-centered outcomes remains to be established. In addition, perioperative respiratory support bundles incorporating postoperative high-flow nasal oxygen may further contribute to perioperative lung protection. Summary - Contemporary thoracic ventilation is evolving from isolated ventilatory variables toward individualized perioperative respiratory management concepts. Although physiological benefits are increasingly demonstrated, robust evidence linking these approaches to improved patient-centered outcomes remains limited. Future studies should clarify the roles of individualized ventilation, mechanical and chemical power, and postoperative respiratory support within integrated perioperative respiratory care pathways.<br/>Copyright &#xa9; 2026 Wolters Kluwer Health, LLC. All rights reserved. <38> Accession Number 2051359526 Title The role of genetic testing in heart transplant candidates. Source Current Opinion in Organ Transplantation. 31(6) (pp 306-313), 2026. Date of Publication: 01 Dec 2026. Author Silver E.; Reza N.; Morales A.; Lakdawala N.K.; Bui Q.M. Institution (Silver) Department of Medicine, Massachusetts General Hospital, Boston, MA, United States (Reza) Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States (Morales) Department of Genomic Health, Geisinger Health, Danville, PA, United States (Lakdawala) Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, United States (Bui) Division of Cardiovascular Medicine, Department of Medicine, University of California,San Diego, La Jolla, CA, United States Publisher Lippincott Williams and Wilkins Abstract Purpose of review - Inherited cardiomyopathies are increasingly recognized among patients with advanced heart failure, yet genetic testing remains substantially underutilized. This review examines the evolving clinical utility of genetic testing across advanced heart failure and transplantation and highlights opportunities to integrate genetics into routine advanced heart failure care. Recent findings - Pathogenic or likely pathogenic cardiomyopathy variants are identified in approximately one-third of heart transplant recipients and in up to 44% of explanted hearts from patients with idiopathic cardiomyopathy. Recent studies have linked genotype to heart failure progression, ventricular arrhythmias, and outcomes after advanced therapies, including a higher risk of right ventricular failure following left ventricular assist device implantation. Genetic diagnoses can also uncover multisystem disease relevant to transplant evaluation and posttransplant management. At the same time, the emergence of gene replacement, gene editing, and RNA-based therapies is creating new therapeutic implications for establishing a molecular diagnosis before end-stage disease. Summary - Genetic testing is becoming an increasingly actionable component of advanced heart failure care. Integrating genetics into advanced heart failure programs may improve recognition of inherited disease, individualize management, and better position patients and their families for emerging precision therapies.<br/>Copyright &#xa9; 2026 Wolters Kluwer Health, LLC. All rights reserved. <39> Accession Number 2049234104 Title Drug-Coated Balloon Angioplasty: A Novel Approach for the Revascularization of High-Bleeding Risk Patients. Source Journal of the Society for Cardiovascular Angiography and Interventions. 5(11) (no pagination), 2026. Article Number: 105631. Date of Publication: 01 Nov 2026. Author Kumar S.; Rissanen T. Institution (Kumar) Department of Cardiology, Creighton University School of Medicine, Phoenix, AZ, United States (Rissanen) Heart Center, North Karelia Central Hospital, Siunsote, Finland (Rissanen) Division of Cardiovascular Medicine, University of Eastern Finland, Kuopio, Finland Publisher Elsevier B.V. Abstract Bleeding is one of the most clinically significant complications after percutaneous coronary intervention (PCI) and markedly increases the risk of death. Almost half of contemporary patients undergoing PCI for chronic coronary syndrome or acute coronary syndrome have been reported to be at high bleeding risk (HBR) according to the Academic Research Consortium-High Bleeding Risk definition. Although modern drug-eluting stent PCI may allow for 1 month of dual antiplatelet therapy (DAPT) in patients at HBR, bleeding after drug-eluting stent implantation continues to be a significant clinical issue causing morbidity and mortality. In patients with chronic coronary syndrome, the current evidence supports 1-month DAPT after drug-coated balloon (DCB)-only PCI. Because DCB angioplasty leaves no permanent scaffold, it may provide greater flexibility for earlier DAPT de-escalation, single antiplatelet therapy, or antiplatelet treatment interruption in selected patients at HBR or after a bleeding event. Although registry trials suggest the potential of this approach, randomized clinical trials are essential to inform changes to current guidelines for the management of patients at HBR requiring coronary revascularization. This review outlines the clinical issue of bleeding following PCI, its prognostic implications, and the reasoning for using DCBs in this group of patients. It also discusses evidence supporting shorter antiplatelet therapy and highlights ongoing trials that are redefining the role of stentless PCI in managing patients at HBR in the catheterization lab.<br/>Copyright &#xa9; 2026 The Author(s). <40> Accession Number 2049761245 Title Endoscopic versus open radial artery harvesting for coronary artery bypass grafting: an updated systematic review, meta-analysis, and GRADE assessment. Source BMC Cardiovascular Disorders. 26(1) (no pagination), 2026. Article Number: 925. Date of Publication: 01 Dec 2026. Author Qazi T.I.; Malik A.A.; Khan M.; Yahya M.; Asad Y.; Idrees S.; Gull M.U.; Khan A.; Munir F.; Khan A.S.; Sadaqat A.; Amjad M.M.; Kotak P.; Rauf M.A.A.; Rehman S.; Yasir M.; Khattak M.H.; Batool A.; Khan H.W.; Khan B.W. Institution (Qazi, Yahya, Gull, Khan, Amjad, Khattak, Khan) Department of Medicine, Khyber Medical College, KPK, Peshawar, Pakistan (Malik, Khan, Asad) Department of Medicine, United Medical and Dental College, Sindh, Karachi, Pakistan (Idrees) Department of Medicine, Rawalpindi Medical University, Punjab, Rawalpindi, Pakistan (Munir) Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College, Lyari, Sindh, Karachi, Pakistan (Khan) Department of Medicine, Plovdiv Medical University, Plovdiv, Bulgaria (Sadaqat) Department of Curative Medicine, Faculty of Medicine, Kateb University, Kabul, Afghanistan (Kotak) Department of Medicine, Liaquat University of Medical and Health Sciences, Sindh, Jamshoro, Pakistan (Rauf) Department of Medicine, Abbottabad International Medical College, KPK, Abbottabad, Pakistan (Rehman) Department of Medicine, Government General Hospital Faisalabad, Punjab, Faisalabad, Pakistan (Yasir) Department of Medicine, Ayub Medical College, KPK, Abbottabad, Pakistan (Khan) Department of Surgery, King Edward Medical University, Punjab, Lahore, Pakistan (Batool) Department of Medicine, Sir Syed College of Medical Sciences, Sindh, Karachi, Pakistan (Khan) Department of Surgery, Ayub Teaching Hospital, KPK, Abbottabad, Pakistan Publisher BioMed Central Ltd Abstract Background: Endoscopic radial artery harvesting (ERAH) is a minimally invasive alternative to open radial artery harvesting (ORAH) for coronary artery bypass grafting (CABG), though concerns persist regarding graft patency and neurological outcomes. <br/>Method(s): PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched through February 21, 2026. Randomized controlled trials and propensity-matched observational studies were included. Risk of bias was assessed using ROB 2 and the Newcastle-Ottawa Scale; certainty of evidence was evaluated using GRADE. Pooled risk ratios and mean differences with 95% confidence intervals were calculated using a random-effects model. <br/>Result(s): ERAH significantly reduced wound complications (RR = 0.61, 95% CI: 0.39-0.96) and wound infections (RR = 0.57, 95% CI: 0.35-0.93), though this benefit did not persist in RCT-only analysis. Neurological complications were reduced after sensitivity analysis (RR = 0.44, 95% CI: 0.34-0.57). Graft patency was comparable (RR = 1.01, 95% CI: 0.90-1.14), with no significant differences in mortality, MACCE, or myocardial infarction. Observational data showed modest reductions in cardiopulmonary bypass time and hospital stay. <br/>Conclusion(s): ERAH demonstrates comparable graft patency and major clinical outcomes to ORAH. Donor-site benefits suggested by observational studies are not consistently supported by randomized evidence. Large trials with standardized outcomes and long-term follow-up are needed. Trial registration: PROSPERO, CRD420261334767.<br/>Copyright &#xa9; The Author(s) 2026. <41> Accession Number 2050192775 Title Impact of Aspirin Use on Mortality and Cardiac Allograft Vasculopathy After Heart Transplantation: A Systematic Review and Meta-analysis. Source Clinical Transplantation. 40(11) (no pagination), 2026. Article Number: e70742. Date of Publication: 01 Nov 2026. Author Fournier N.; Antiochos P.; Gencer B.; Nowacka A.; Abdurashidova T.; Yerly P.; Meyer P.; Rancati V.; Ltaief Z.; Muller O.; Kirsch M.; Hullin R.; Lu H. Institution (Fournier, Antiochos, Gencer, Yerly, Muller, Hullin, Lu) Division of Cardiology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland (Nowacka, Abdurashidova, Kirsch) Division of Cardiac Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland (Meyer) Division of Cardiology, Geneva University Hospitals (HUG), University of Geneva (UNIGE), Geneva, Switzerland (Rancati) Division of Anesthesiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland (Ltaief) Department of Adult Intensive Care Medicine, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland Publisher John Wiley and Sons Inc Abstract Background: Cardiac allograft vasculopathy (CAV) remains a major cause of late graft failure and morbidity among heart transplant (HTx) recipients. Aspirin is currently assigned a Class IIb recommendation for CAV prevention, reflecting the limited evidence supporting its clinical benefit. We conducted a systematic review and meta-analysis to assess the association between aspirin use and clinical outcomes in HTx recipients (PROSPERO ID: CRD420261399873). <br/>Method(s):: Outcomes of interest included all-cause mortality and CAV-related clinical outcomes (graft dysfunction or CAV-related death). Literature searches were conducted through December 2025 in PubMed and EMBASE. Studies comparing HTx recipients treated with aspirin versus no aspirin were included. Hazard ratios (HRs) and 95% confidence intervals (CIs) were meta-analyzed across studies. <br/>Result(s): Five observational studies were included, comprising four adult cohorts and one pediatric cohort. Participants were predominantly male (66.6%), with a mean age of =50 years in the four adult studies and 7.4 years in the sole pediatric study. Aspirin use was associated with significantly lower all-cause mortality (four studies, HR 0.31 [95% CI: 0.15-0.67]). No statistically significant association was observed with CAV-related clinical outcomes (HR 0.42 [95% CI: 0.10-1.77]). <br/>Conclusion(s): In HTx recipients, aspirin use was associated with lower all-cause mortality, while no significant association was observed in the exploratory analysis of CAV-related clinical outcomes. These findings should be interpreted cautiously given the observational design, substantial heterogeneity, and potential residual and time-related biases. Prospective studies are needed to determine the efficacy and safety of aspirin after HTx.<br/>Copyright &#xa9; 2026 The Author(s). Clinical Transplantation published by John Wiley & Sons Ltd. <42> Accession Number 2038641840 Title Incidence of chronic postsurgical pain after cardiac surgery and the effect of bilateral erector spinae plane block: a randomized controlled trial. Source Regional Anesthesia and Pain Medicine. 51(8) (pp 878-885), 2026. Date of Publication: 01 Aug 2026. Author Dost B.; Sarikaya Ozel E.; Kaya C.; Turunc E.; Karakaya D.; Demirag M.K.; Bilgin S.; De Cassai A.; Elsharkawy H. Institution (Dost, Sarikaya Ozel, Kaya, Turunc, Karakaya, Bilgin) Department of Anesthesiology and Reanimation, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey (Demirag) Department of Cardiovascular Surgery, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey (De Cassai) Department of Medicine (DIMED), University of Padua, Padua, Italy (De Cassai) Institute of Anesthesia and Intensive Care Unit, University Hospital of Padua, Padua, Italy (Elsharkawy) Anesthesiology Pain, MetroHealth Medical Center, Cleveland, OH, United States (Elsharkawy) Anesthesiology, Case Western Reserve University, Cleveland, OH, United States (Elsharkawy) Outcomes Research Consortium, Houston, TX, United States Publisher BMJ Publishing Group Abstract Background: The effects of the erector spinae plane (ESP) block on chronic postsurgical pain (CPSP) after cardiac surgery remain unclear. This study evaluated the efficacy of bilateral ESP block in reducing the incidence and severity of CPSP after cardiac surgery. <br/>Method(s): This prospective, randomized, controlled, single-blind trial included 63 patients aged 18-80 years with American Society of Anesthesiologists physical status II-III, scheduled for elective cardiac surgery via median sternotomy. Participants received a bilateral ultrasound-guided ESP block or standard care without regional anesthesia. The primary outcome was the Brief Pain Inventory (BPI) score at 3 months postoperatively. Secondary outcomes included morphine consumption in the first 24 hours; Numerical Rating Scale (NRS) scores during rest/activity at 0, 3, 6, 12, and 24 hours; BPI scores at 6 months postoperatively; and Douleur Neuropathique 4 (DN4) and Hospital Anxiety and Depression Scale (HADS) scores at 3 and 6 months postoperatively. <br/>Result(s): The BPI scores of the two groups did not differ significantly at 3 months postoperatively (median (IQR): 0(26) vs 12 (31), p=0.166). However, 24 hours postoperative morphine consumption (8 mg vs 10.5 mg, p<0.001) and NRS scores at multiple time points were significantly lower in the ESP block group. No significant differences were observed between the groups in terms of the BPI, DN4, or HADS scores at three or 6 months. <br/>Conclusion(s): The ESP block effectively reduced acute pain and opioid consumption; however, it had no significant effect on the incidence or severity of CPSP at 3 and 6 months.<br/>Copyright &#xa9; American Society of Regional Anesthesia &amp; Pain Medicine 2026. No commercial re-use. See rights and permissions. Published by BMJ Group. <43> [Use Link to view the full text] Accession Number 2040022692 Title Continued Versus Interrupted Oral Anticoagulation During Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation: A Meta-Analysis. Source American Journal of Therapeutics. 33(6) (pp e626-e626), 2026. Date of Publication: 01 Dec 2026. Author Faheem M.S.B.; Zahid M.R. Institution (Faheem) Karachi Institute of Medical Sciences, KIMS, Karachi, Pakistan (Zahid) Sialkot Medical College, Sialkot, Pakistan Publisher Lippincott Williams and Wilkins <44> [Use Link to view the full text] Accession Number 648290255 Title The Use of Protamine in Transcatheter Aortic Valve Replacement: A Meta-analysis. Source American journal of therapeutics. 33(6) (pp e622-e624), 2026. Date of Publication: 01 Nov 2026. Author Al-Abdouh A.; Kumar S.; Jabri A.; Mhanna M.; Alhuneafat L.; Paul T.K.; Villablanca P.; Khalife W. Institution (Al-Abdouh) Department of Medicine, University of Kentucky, KY, United States (Kumar) Division of Cardiology, Creighton University School of Medicine, Phoenix, AZ, United States (Jabri) Department of Cardiology, Corewell Health William Beaumont University Hospital, Royal Oak, MI, United States (Mhanna) Department of Cardiology, University of Iowa, IA, United States (Alhuneafat) Department of Cardiology, University of Minnesota, Minneapolis, MN, United States (Paul) University of Tennessee/Ascension St Thomas Hospital, Nashville, TN, United States (Villablanca) Division of Cardiology, Department of Structural Heart Disease, Henry Ford Health System, Detroit, United States (Khalife) Department of Cardiology, University of Texas Medical Branch, Galveston, TX, United States <45> Accession Number 2050921525 Title Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI Trial. Source Journal of the American Heart Association. 15(20) (no pagination), 2026. Article Number: e051379. Date of Publication: 16 Oct 2026. Author Gonzalez-Manzanares R.; Ojeda S.; Amat-Santos I.; Ariza-Sole A.; Romaguera R.; Otero D.L.; Nombela-Franco L.; Gheorge L.; Sanz-Sanchez J.; Zorita C.B.; Gallo I.; Paz R.C.; Garcia A.J.M.; Vilalta V.; Fernandez G.V.; Soriano J.G.C.; Cepas-Gillen P.; Rollan M.S.; Rios X.F.; Palma-Carbajal R.; Reyes R.M.; Avanzas P.; Blas S.G.; Franco-Pelaez J.A.; Moreiras J.M.; Juanatey J.R.G.; Gonzalo N.; Calle G.; Diez J.L.; Santos-Martinez S.; Ferreiro R.G.; Garcia E.M.; Fernandez-Nofrerias E.; Sanmartin X.; Tirado G.; Barri A.G.; Bermudez I.G.; Rossello X.; Fuster V.; Ibanez B.; Roubin S.R. Institution (Gonzalez-Manzanares, Ojeda, Gallo) Department of Cardiology, Reina Sofia University Hospital, Cordoba, Spain (Gonzalez-Manzanares, Ojeda, Gallo) Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain (Gonzalez-Manzanares, Rossello, Fuster, Ibanez, Roubin) Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (Gonzalez-Manzanares, Ojeda, Amat-Santos, Blas, Ibanez) Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain (Ojeda) Department of Medicine, University of Cordoba, Cordoba, Spain (Zorita) Cardiology Department, University Clinical Hospital of Valladolid, Spain (Ariza-Sole, Romaguera) Cardiology Department, University Hospital Bellvitge, Barcelona, Spain (Otero, Sanmartin) Cardiology Department, University Hospital Montecelo, Pontevedra, Spain (Otero, Juanatey, Sanmartin) Cardiology Department, University Clinical Hospital of Santiago de Compostela, A Coruna, Spain (Otero, Paz, Ferreiro, Sanmartin, Bermudez, Roubin) Instituto de Investigacion Sanitaria Galicia Sur, Vigo, Spain (Nombela-Franco, Gonzalo, Tirado) Cardiology Department, Clinical Hospital San Carlos, Madrid, Spain (Gheorge, Calle, Barri) Cardiology Department, University Hospital Puerta del Mar, Cadiz, Spain (Sanz-Sanchez, Diez) Cardiology Department, University Hospital La Fe, Valencia, Spain (Paz, Santos-Martinez, Ferreiro, Bermudez, Roubin) Cardiology department, University Hospital Alvaro Cunqueiro, Vigo, Spain (Garcia, Garcia) Cardiology Department, University Hospital Virgen de la Victoria, Malaga, Spain (Vilalta, Fernandez-Nofrerias) Cardiology Department, University Hospital Germans Trias i Pujol, Badalona, Spain (Fernandez) Cardiology Department, University Hospital Marques de Valdecilla, Santander, Spain (Fernandez) Instituto de Investigacion Valdecilla, Santander, Spain (Soriano) Cardiology Department, University Hospital of Albacete, Albacete, Spain (Cepas-Gillen) Institut Clinic Cardiovascular, Hospital Clinic, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain (Rollan) Cardiology Department, University General Hospital of Alicante, Alicante, Spain (Rios) Cardiology Department, University Hospital Juan Canalejo, A Coruna, Spain (Palma-Carbajal) Cardiology Department, University Hospital Vall D'Hebron, Barcelona, Spain (Reyes) Cardiology Department, University Hospital Quiron Salud La Luz, Madrid, Spain (Avanzas) Cardiology Department, University Hospital Central de Asturias, Oviedo, Spain (Blas) Cardiology Department, Clinic University Hospital of Valencia, Valencia, Spain (Blas) INCLIVA Biomedical Research Institute, Valencia, Spain (Franco-Pelaez, Ibanez) Cardiology Department, University Hospital Fundacion Jimenez Diaz, Madrid, Spain (Moreiras) Cardiology Department, University Clinical Hospital of Salamanca, Salamanca, Spain (Rossello) Cardiology Department, Hospital Son Espases-IdISBa, Universitat de les Illes Balears, Palma de Mallorca, Spain (Fuster) Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States (Roubin) University of Santiago de Compostela, Santiago de Compostela, Spain Publisher American Heart Association Inc. Abstract BACKGROUND: Frailty is common in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation and portends worse outcomes. Whether the benefit of posttranscatheter aortic valve implantation dapagliflozin differs by frailty is uncertain. <br/>METHOD(S): In this post hoc analysis, we investigated the efficacy of dapagliflozin according to frailty status in the DapaTAVI (Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation) trial. Frailty was assessed through the Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight scale (robust=0, prefrail=1-2, frail=3-5). The primary outcome was the composite of all-cause death or worsening heart failure at 1 year. <br/>RESULT(S): Among 1222 patients with baseline frailty assessment, 47.2% were frail, 40.3% prefrail, and 12.4% robust. Over 12 months, 215 patients (17.6%) experienced the primary end point. Patients who were prefrail and frail had higher risk than robust patients (adjusted hazard ratios [HRs], 1.88 [95% CI, 1.05-3.38] and 2.29 [1.29-4.07], respectively; P=0.004). Dapagliflozin was associated with a lower risk of the primary end point in patients who were frail (HR, 0.53 [95% CI, 0.36-0.77]) but not in those who were prefrail (HR, 1.01 [95% CI, 0.66-1.55]) or robust patients (HR, 1.26 [95% CI, 0.42-3.75]); P for interaction=0.021. There was no evidence that frailty modified the safety profile of dapagliflozin. <br/>CONCLUSION(S): Frailty was common and independently associated with worse outcomes after transcatheter aortic valve implantation. Dapagliflozin appeared to confer greater relative benefit in patients with frailty.<br/>Copyright &#xa9; 2026 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. <46> Accession Number 2051416143 Title Beyond anticoagulation: defining the role of left atrial appendage closure in stroke prevention for atrial fibrillation. Source Europace. 28(11) (no pagination), 2026. Article Number: euag296. Date of Publication: 01 Nov 2026. Author Camm A.J. Institution (Camm) School of Health & Medical Sciences, City St George's University of London, Tooting Campus, Cranmer Terrace, London, United Kingdom Publisher Oxford University Press Abstract Oral anticoagulation has a very strong evidence base for stroke prevention in patients with atrial fibrillation (AF) at elevated thromboembolic risk. Direct oral anticoagulants have improved the safety and convenience of treatment, yet important limitations remain, including residual ischaemic stroke, major bleeding, treatment discontinuation, and patient refusal. Left atrial appendage closure (LAAC) offers an alternative strategy for selected patients by excluding the principal anatomical source of AF-related cardiac thrombi. However, the appropriate role of LAAC remains controversial, particularly in patients who can and do tolerate anticoagulation. This viewpoint argues for a more individualized approach that distinguishes absolute contraindications from modifiable bleeding risks, treatment refusal or non-persistence, and stroke occurring despite adequate anticoagulation.<br/>Copyright &#xa9; The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. <47> Accession Number 2050148906 Title Efficacy of perioperative recombinant human brain natriuretic peptide for preventing acute kidney injury after cardiac surgery: Rationale, design, and study protocol for a multicenter, double-blind, randomized controlled trial (PROTECT-CS). Source American Heart Journal. 304 (no pagination), 2027. Article Number: 107615. Date of Publication: 01 Feb 2027. Author Han J.; Ma X.; Chen Q.; Zhou H.; Li F.; Li H.; Liu L.; Cai J.; Du J.; Zhang H.; Liu S. Institution (Han, Ma, Zhou, Li, Li, Liu, Cai, Du, Zhang, Liu) National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Chen) Department of Cardiovascular Surgery, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China (Zhou, Li, Du, Zhang, Liu) Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Liu, Cai) Department of Nephrology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China Publisher Elsevier Inc. Abstract Background Acute kidney injury (AKI) is one of the most common and consequential complications after cardiac surgery. Despite improvements in perioperative care, no pharmacological intervention has been definitively shown to prevent AKI following cardiac surgery. Recombinant human brain natriuretic peptide (rhBNP) shares structural and biological activity with endogenous brain natriuretic peptide and has demonstrated favorable natriuretic, diuretic, and renal hemodynamic effects in prior studies. However, robust randomized evidence on whether perioperative rhBNP can prevent AKI is lacking. Design This is an investigator-initiated, multicenter, prospective, randomized, double-blind, placebo-controlled, parallel-group trial comparing perioperative rhBNP with placebo in high-risk patients undergoing elective on-pump cardiac surgery. A total of 694 participants will be randomized 1:1 to receive a continuous intravenous infusion of rhBNP (0.01 microg/kg/min) or matched normal-saline placebo, initiated between anesthesia induction and the onset of cardiopulmonary bypass and continued for 48 +/- 2 hours. The primary efficacy endpoint is the incidence of AKI within 7 postoperative days defined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Secondary endpoints include AKI severity and duration, renal replacement therapy during the index hospitalization, major adverse kidney events at 30 and 90 days (MAKE-30, MAKE-90), 30-day all-cause mortality, intensive care unit and total length of stay. Conclusions To our knowledge, PROTECT-CS is the first adequately powered, multicenter, double-blind randomized trial designed to evaluate whether perioperative rhBNP prevents AKI after high-risk cardiac surgery. The study is intended to provide high-quality evidence to inform clinical practice and future guideline recommendations on pharmacological renal protection in cardiac surgery patients. Clinical trial registration https://www.clinicaltrials.gov (NCT07617675), Unique identifier : NCT07617675.<br/>Copyright &#xa9; 2026 Elsevier Inc. <48> Accession Number 2050008186 Title Preoperative respiratory muscle strength, muscle mass, and respiratory sarcopenia as predictors of postoperative pulmonary complications after thoracic and cardiac surgery: A systematic review and meta-analysis. Source Clinical Nutrition ESPEN. 76 (no pagination), 2026. Article Number: 105204. Date of Publication: 01 Dec 2026. Author Mizusawa H.; Toyama S.; Okura K.; Shiraishi M.; Noguchi M.; Kanki K.; Natsume H.; Higashimoto Y. Institution (Mizusawa, Shiraishi, Noguchi, Kanki, Natsume) Department of Rehabilitation, Kindai University Hospital, Osaka Prefecture, Japan (Toyama) Department of Rehabilitation, Shizuoka Cancer Center Hospital, Prefecture, Shizuoka, Japan (Okura) Department of Rehabilitation, Akita University Hospital, Akita Prefecture, Japan (Higashimoto) Department of Rehabilitation Medicine, Faculty of Medicine, Kindai University, Osaka Prefecture, Japan Publisher Elsevier Ltd Abstract Background & aims Postoperative pulmonary complications (PPCs) are common after thoracic and cardiac surgery and are associated with adverse outcomes. Respiratory sarcopenia (RS), characterized by coexisting reductions in respiratory muscle mass and strength, may represent a clinically relevant prognostic phenotype, but its prognostic value remains uncertain. This systematic review and meta-analysis aimed to assess whether low preoperative respiratory muscle mass, reduced strength, or their coexistence as RS or probable RS predicts PPCs after thoracic and cardiac surgery. Methods We searched PubMed, Embase, Web of Science, and CENTRAL from January 1990 to February 2026 for studies relating preoperative respiratory muscle mass, strength or flow, or RS to PPCs. Risk of bias was assessed using the Quality In Prognosis Studies tool. Adjusted odds ratios (ORs) were pooled using random-effects models after harmonizing effect directions such that ORs >1 denoted higher risk. Results Sixteen studies were included; all involved thoracic or cardiac surgery, and none included an upper abdominal cohort. Cutoff-based respiratory muscle strength or flow impairment was associated with increased odds of PPCs (OR 2.25, 95% confidence interval [CI] 1.50-3.37; I<sup>2</sup> = 51.2%), with the most consistent association observed for percent-predicted peak expiratory flow (PEF) (OR 2.03, 95% CI 1.43-2.90; I<sup>2</sup> = 0%). Continuous PEF was associated with PPCs, whereas ultrasound-based diaphragm indices showed smaller, non-significant associations. RS or probable RS was associated with PPCs (OR 2.08, 95% CI 1.33-3.26; I<sup>2</sup> = 0%). Conclusions Preoperative functional respiratory muscle impairment, particularly reduced PEF, and RS or probable RS were associated with PPCs. Given that the evidence was limited, heterogeneous, and predominantly derived from thoracic surgery, prospective confirmation is needed.<br/>Copyright &#xa9; 2026. Published by Elsevier Ltd. <49> Accession Number 2049957486 Title Point-of-Care Ultrasound of Upper Airway Changes During Cardiopulmonary Bypass in Coronary Artery Bypass Grafting: A Randomized Controlled Trial. Source Medicina (Lithuania). 62(10) (no pagination), 2026. Article Number: 1829. Date of Publication: 01 Oct 2026. Author Cetin E.; Gunel B.; Yilmaz M.; Duzyol C.; Kara M.Y.; Yuksek A.; Duman E.; Zeytun F. Institution (Cetin, Gunel, Yilmaz, Kara, Yuksek, Zeytun) Department of Anesthesiology and Reanimation, Kocaeli City Hospital, Kocaeli, Turkey (Duzyol) Department of Cardiovascular Surgery, Kocaeli City Hospital, Kocaeli, Turkey (Duman) Pulmonology Clinic, Balikesir Ataturk City Hospital, Balikesir, Turkey Publisher Multidisciplinary Digital Publishing Institute (MDPI) Abstract Background and Objectives: Elevated endotracheal tube (ETT) cuff pressure impairs tracheal mucosal perfusion and may contribute to upper airway soft-tissue changes. During cardiopulmonary bypass (CPB), the cuff usually remains inflated although ventilation is suspended, yet the relevance of cuff pressure management during CPB is unclear. We compared two ETT cuff pressure strategies during CPB (0 vs. 20-30 cmH<inf>2</inf>O) on point-of-care ultrasound (POCUS) measurements of upper airway soft tissue in patients undergoing coronary artery bypass grafting (CABG). <br/>Material(s) and Method(s): In this single-center, prospective, randomized, observer-blinded trial, 76 patients (ASA III-IV, aged 18-80 years) undergoing elective CABG were randomized 1:1 to a 0 cmH<inf>2</inf>O or 20-30 cmH<inf>2</inf>O ETT cuff pressure strategy throughout CPB (n = 38 per group). Transesophageal echocardiography (TEE) was not used in any patient. POCUS measurements of lateral pharyngeal wall (LPW) thickness, tongue thickness, parapharyngeal distance, midsagittal tongue area, and tongue width were obtained at four time points (T0-T3). The primary analysis was the omnibus group x time interaction for LPW thickness in a generalized estimating equations (GEE) model; the between-group difference in change from T0 to T2 was a planned supporting contrast. <br/>Result(s): All 76 randomized patients completed the study and were analyzed. The group x time interaction for LPW thickness was significant (p < 0.001); the between-group difference in the increase in LPW thickness from T0 to T2 was 1.50 mm (95% CI 1.27 to 1.73), and 1.00 mm (95% CI 0.82 to 1.18) at postoperative hour 2. Parapharyngeal distance and tongue thickness showed the same pattern. No multiplicity-adjusted between-group difference in LPW thickness was detected at T0 or T1, and a sensitivity analysis using the pre-intervention time point (T1) as baseline gave consistent results (T2 vs. T1: 1.43 mm, 95% CI 1.30 to 1.57). In an exploratory, unadjusted secondary analysis, difficult extubation occurred in 0/38 vs. 7/38 patients (absolute risk difference 18.4 percentage points, 95% CI 5.4 to 33.4; p = 0.012). <br/>Conclusion(s): Complete cuff deflation during CPB was associated with smaller ultrasonographic upper airway soft-tissue changes after CPB. The trial was not powered for clinical outcomes; the lower frequency of difficult extubation is hypothesis-generating, and these data do not support a change in routine practice before confirmation in trials with patient-centered endpoints.<br/>Copyright &#xa9; 2026 by the authors. <50> Accession Number 2050184919 Title Infective endocarditis after transcatheter versus surgical pulmonary valve replacement in CHD: absolute risk translation and device-material context. Source Cardiology in the Young. 36(9) (pp 1903-1910), 2026. Date of Publication: 01 Sep 2026. Author Semyashkin A.; Sandica A.; Gherta L.; Ben Mime L. Institution (Semyashkin) Department of Pediatric Cardiac Surgery and Congenital Heart Defects, Klinikum Stuttgart, Stuttgart, Germany (Sandica, Gherta, Ben Mime) Ruhr University Bochum, University Hospital Herz- und Diabeteszentrum NRW, Center for Congenital Heart Defects, Pediatric Heart Center, Pediatric Heart Surgery, Bad Oeynhausen, Germany (Sandica, Gherta, Ben Mime) Bielefeld University, Medical School OWL, Bad Oeynhausen, Germany Publisher Cambridge University Press Abstract Background: - As transcatheter pulmonary valve replacement becomes increasingly adopted in children and young adults, concerns regarding infective endocarditis remain a major limitation of this strategy. We performed a systematic review and meta-analysis comparing the risk of infective endocarditis after transcatheter and surgical pulmonary valve replacement. <br/>Material(s) and Method(s): - Comparative studies evaluating infective endocarditis after transcatheter versus surgical pulmonary valve replacement were systematically reviewed. The primary outcome was cumulative infective endocarditis during follow-up; early infective endocarditis was analysed separately. Random-effects models were used to pool odds ratios and absolute risk differences. <br/>Result(s): - Nineteen comparative cohort studies met the inclusion criteria. Fifteen studies contributed long-term data and six reported early events. In the primary long-term analysis (13 studies; 3,917 procedures), transcatheter pulmonary valve replacement was associated with a significantly higher risk of infective endocarditis than surgical pulmonary valve replacement (odds ratio 3.18, 95% confidence interval 2.25-4.49; I <sup>2</sup> = 0%). The pooled absolute excess risk was 39.2 cases per 1,000 procedures (95% confidence interval 22.7-55.6), corresponding to one additional case for every 26 procedures. Early infective endocarditis did not differ significantly between approaches (odds ratio 1.11, 95% confidence interval 0.33-3.69). Sensitivity analyses yielded consistent results. <br/>Conclusion(s): - Transcatheter pulmonary valve replacement is associated with a higher long-term risk of infective endocarditis than surgical pulmonary valve replacement, whereas evidence for early events remains inconclusive. The observed association is best interpreted in the context of prosthetic material, conduit characteristics, residual haemodynamics, and patient selection rather than as evidence of a purely procedural mechanism.<br/>Copyright &#xa9; The Author(s), 2026. Published by Cambridge University Press <51> Accession Number 2051383463 Title Clinical outcomes in various coronary artery bypass grafting techniques: A systematic review and network meta-analysis. Source PLOS One. 21(11 November) (no pagination), 2026. Article Number: e0360757. Date of Publication: 01 Nov 2026. Author Hanafy D.A.; Husen T.F.; Vidya A.P.; Saisa D.; Rempengan D.D.C.H.; Yumnanisha D.A.; Angelica R.; Abdurrahman M.F. Institution (Hanafy, Husen, Vidya, Saisa, Yumnanisha, Angelica, Abdurrahman) Faculty of Medicine, University of Indonesia, Salemba, Jakarta, Indonesia (Hanafy) Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia (Hanafy) Division of Adult Cardiac Surgery, Department of Surgery, National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia (Rempengan) Faculty of Medicine, Universitas Sam Ratulangi, Manado, Indonesia Publisher Public Library of Science Abstract Introduction: There are different coronary artery bypass grafting (CABG) techniques, conventional (C-CABG), minimally invasive (MI-CABG), and robotic (R-CABG), each with its respective advantages and drawbacks. This study aimed to compare all three techniques and their nine sub-technique variations to provide a reference for the clinical selection of the most suitable surgical approach. <br/>Method(s): A systematic search was applied to seven databases to find observational studies or randomized controlled trials (RCTs) that compared outcomes between CABG techniques in patients. Critical appraisal of observational studies (Newcastle-Ottawa Scale) and RCTs (Cochrane Risk of Bias 2.0) was performed. We used frequentist network meta-analysis to rank and analyze the pooled odds ratios and mean differences of each intervention. Primary outcomes were mortality and complete revascularization, while the rest were secondary outcomes. The protocol was registered with the ID CRD42023480325. <br/>Result(s): A total of 132 studies with 779,773 patients were included. All three techniques were associated with comparable revascularization rates. However, in the comparison of the nine sub-techniques port access (PA)-CABG was associated with a significantly higher rate compared to C-ONCAB. R-CABG demonstrated the most favorable outcomes in terms of ICU stay, overall hospital stay, mortality, and ventilation time compared to MI-CABG and C-CABG. Additionally, R-CABG was associated with lower rates of wound infection, cerebrovascular accident, and renal failure. Both R-CABG and MI-CABG were associated with lower rates of non-sinus rhythm compared to C-CABG. While MI-CABG was associated with the highest reoperation rate. <br/>Conclusion(s): R-CABG suggested promising outcomes over MI-CABG and C-CABG. However, as this exploratory NMA was predominantly based on observational data, these findings should be regarded as a hypothesis-generating framework for future research. Clinicians should interpret results cautiously, prioritizing patient-specific factors and institutional experience until higher-level evidence emerges.<br/>Copyright &#xa9; 2026, Hanafy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. http://creativecommons.org/licenses/by/4.0/ <52> Accession Number 2051328594 Title Therapeutic challenges in prosthetic valve Granulicatella adiacens endocarditis: a case report and focused review of alternative antimicrobial strategies. Source Diagnostic Microbiology and Infectious Disease. 117(2) (no pagination), 2027. Article Number: 117720. Date of Publication: 01 Feb 2027. Author Reidy N.; Lapthorne S.; Kenny S.; Healy T.; McLoughlin S.; Connolly S.; Doherty A.; Hickey C.; Mullane N.; Hannan M.; Doddakula K.; Sadlier C.; Walsh J. Institution (Reidy, Lapthorne, Kenny, Healy, McLoughlin, Doherty, Hickey, Mullane, Walsh) Department of Clinical Microbiology, Cork University Hospital, Ireland (Connolly, Sadlier) Department of Infectious Diseases, Cork University Hospital, Ireland (Hannan) Department of Clinical Microbiology, Mater Misericordiae University Hospital, Ireland (Doddakula) Department of Cardiothoracic Surgery, Cork University Hospital, Ireland Publisher Elsevier Inc. Abstract Purpose: To describe a case of prosthetic valve (PV) Granulicatella adiacens infective endocarditis (IE) requiring deviation from guideline-supported therapy, and review published experience with alternative treatment strategies. <br/>Method(s): A case report and focused literature review of Granulicatella IE and other invasive Granulicatella infections treated with non-standard antimicrobial regimens. <br/>Result(s): Ceftriaxone-resistant PVIE was complicated by DRESS syndrome and linezolid-associated thrombocytopaenia. Treatment with ertapenem and levofloxacin was completed following surgery. Literature review identified limited published experience with alternative regimens, most commonly carbapenems, fluoroquinolones and linezolid. Outcomes were heterogeneous across reports. <br/>Conclusion(s): Evidence supporting alternative treatment strategies for Granulicatella infections remains limited, highlighting the need for further research.<br/>Copyright &#xa9; 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. <53> Accession Number 2051140156 Title Evolution of diagnostic reference levels in paediatric cardiac interventional procedures: a narrative review. Source Applied Radiation and Isotopes. 239 (no pagination), 2027. Article Number: 113057. Date of Publication: 01 Jan 2027. Author Ubeda C.; Cabanas A.; Nocetti D.; Cubillos Y.; Miranda P.; Franco M.C.; Donoso-Aguirre S. Institution (Ubeda, Nocetti, Donoso-Aguirre) Medical Technology Department, Health Sciences Faculty, LABODOP, Universidad de Tarapaca, Arica, Chile (Cabanas) Physics Department, Faculty of Medicine, Universidad de Tarapaca, Arica, Chile (Cubillos) Library System, Universidad de Tarapaca, Arica, Chile (Miranda) Dr. Luis Calvo Mackenna Children's Hospital, Antonio Varas 360, Santiago, Chile (Franco) Department of Pediatric Cardiology, Zambrano Hellion Hospital, Tecnologico de Monterrey, School of Medicine and Health Sciences, Nuevo Leon, Monterrey, Mexico Publisher Elsevier Ltd Abstract The goal of this narrative review was to identify and synthesise publications reporting radiation dose values for paediatric cardiac interventional procedures (PCIP), organised according to four DRL-related benchmarking levels used in this review: typical values, local DRLs, national DRLs and regional DRLs. These procedures can deliver high radiation doses to markedly radiosensitive patients. DRLs are an important tool for optimising these exposures. Publications from 2010 to 2025 were searched, and twenty-five studies met the eligibility criteria, with reported kerma-area product (P<inf>KA</inf>) taken as a common comparator. Reported P<inf>KA</inf> spanned more than two orders of magnitude, from below 1 Gy cm<sup>2</sup> in patients under 5 kg to above 100 Gy cm<sup>2</sup> for complex therapeutic procedures in larger children. Within a single DRL category, procedural complexity alone drove differences exceeding one order of magnitude, while procedure-specific stratification converged on a narrow 1-5 Gy cm<sup>2</sup> band in the youngest patients. National DRLs showed the widest inter-study dispersion and regional DRLs the narrowest. The variability in reported dose values was primarily driven by differences in categorisation schemes and procedural complexity rather than by inconsistencies in the DRL concept itself. The available evidence reflects an evolution from early local initiatives towards national and regional frameworks characterised by increasing methodological maturity and international collaboration. Future developments are expected to move towards complexity-based DRLs supported by large multicentre datasets, automated dose monitoring and artificial intelligence for real-time optimisation, while coordinated regional initiatives and shared registries may enable continuous DRL updating and stronger radiation protection for PCIP.<br/>Copyright &#xa9; 2026 Elsevier Ltd <54> Accession Number 2050436886 Title Artificial intelligence in paediatric cardiac critical care: from predictive analytics to continuous physiologic intelligence. Source Cardiology in the Young. 36(9) (pp 1788-1794), 2026. Date of Publication: 01 Sep 2026. Author Savorgnan F.; Pilla P.; Loomba R.; Flores S. Institution (Savorgnan) Pediatrics, Baylor College of Medicine, United States (Pilla) Baylor College of Medicine, United States (Loomba) Northwestern University, United States (Flores) Pediatrics-Critical Care, Baylor College of Medicine, United States Publisher Cambridge University Press Abstract Objective: - Artificial intelligence is increasingly applied in paediatric cardiology and cardiac intensive care, where CHD, postoperative physiologic instability, and continuous bedside monitoring generate complex datasets. This review summarises current applications of artificial intelligence in paediatric cardiology and the cardiac ICU, focusing on cardiac imaging, electrocardiography, predictive analytics, waveform intelligence, and postoperative outcome prediction. Data sources: - A narrative review of PubMed, MEDLINE, and Scopus was performed for studies published from 2018 through 2026 evaluating artificial intelligence, machine learning, or deep learning in paediatric cardiology, CHD, congenital heart surgery, and cardiac critical care. Study selection: - Studies addressing paediatric or CHD-focused applications in echocardiography, cardiac MRI, electrocardiography, cardiac ICU monitoring, waveform analytics, or postoperative complication prediction were included, together with relevant reviews. Data extraction: - Information was extracted on study population, artificial intelligence method, clinical task, model inputs, outcomes, validation strategy, and major limitations. Data synthesis: - Artificial intelligence is most developed in imaging and electrocardiography, while paediatric and complex CHD evidence remains less mature. In cardiac ICU, models using electronic health record variables, high-frequency physiologic data, and risk indices have been evaluated for cardiac arrest, low cardiac output physiology, hyperlactatemia, extubation failure, and vasoactive de-escalation. External validation, prospective deployment, calibration, and workflow-safe implementation remain major gaps. <br/>Conclusion(s): - Artificial intelligence may improve diagnostic consistency, risk stratification, and early recognition of deterioration, but prospective validation and measurable clinical benefit are needed before autonomous use.<br/>Copyright &#xa9; The Author(s), 2026. Published by Cambridge University Press <55> Accession Number 2051473150 Title Digital Versus Face-to-Face Preoperative Physiotherapy Education in Thoracic Surgery: A Pilot Feasibility Randomised Controlled Trial. Source Heart Lung and Circulation. (no pagination), 2026. Date of Publication: 2026. Author Ball J.L.; Baque E.; Boden I.; Linnane M.P.; Mahoney A.; Hay K.; Morris N.R.; Tronstad O. Institution (Ball, Linnane, Mahoney, Morris, Tronstad) Physiotherapy Department, The Prince Charles Hospital, Brisbane, QLD, Australia (Ball, Baque, Linnane, Morris) School of Allied Health, Sport and Social Work, Griffith University, Gold Coast, QLD, Australia (Boden) School of Health Sciences, University of Tasmania, Launceston, TAS, Australia (Boden) Physiotherapy Department, Launceston General Hospital, Launceston, TAS, Australia (Hay) Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia (Hay) QIMR Berghofer, Brisbane, QLD, Australia (Morris) Allied Health Research Collaborative, The Prince Charles Hospital, Brisbane, QLD, Australia (Tronstad) Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia Publisher Elsevier Ltd Abstract Aim: This pilot study evaluated the feasibility, acceptability and fidelity of digital video preoperative physiotherapy education compared with face-to-face education for patients undergoing thoracic surgery. It also explored clinical outcomes to inform a future non-inferiority trial of digital education. <br/>Method(s): This prospective pilot feasibility randomised controlled trial was conducted at a tertiary centre in Brisbane, Australia. Participants were randomly allocated to receive face-to-face physiotherapy education or watch a 13-minute professionally made digital education video before thoracic surgery. Protocol feasibility was assessed as the percentage of patients receiving allocated education. Acceptability was measured using a pre/postoperative questionnaire and postoperative interviews. Protocol fidelity, defined as recall of receiving education, and treatment fidelity, defined as recall of key information, were assessed during postoperative interviews using a preset 24-point scoring schema. Feasibility measures included recruitment, retention and missing data. Exploratory outcomes included postoperative pulmonary complications, hospital length of stay and efficiency. <br/>Result(s): Sixty-four participants were randomised to face-to-face or digital education before thoracic surgery. All received allocated education, demonstrating 100% protocol feasibility. Both education modes were acceptable and perceived to help with information recall (87% vs 81%) and surgical recovery (93% vs 84%), and included the right amount of information (97% vs 84%). Protocol fidelity (83% vs 87%) and treatment fidelity (median 9.5 [interquartile range (IQR) 6-12] vs 9 [IQR 6-15]) were comparable between groups. Study feasibility was confirmed by 100% recruitment and retention and 95% complete datasets. Hospital length of stay and postoperative pulmonary complications were similar. Digital education was more efficient, saving a median of 10 minutes of preoperative physiotherapist time per patient. <br/>Conclusion(s): Digital preoperative physiotherapy education for patients undergoing thoracic surgery is feasible, acceptable and efficient, with protocol and treatment fidelity similar to face-to-face education.<br/>Copyright &#xa9; 2026 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ) <56> Accession Number 2051414095 Title Individualized mean arterial pressure during cardiac surgery The OPTIPAM Randomized Clinical Trial. Source Anesthesiology. (pp 1-37), 2026. Date of Publication: 2026. Author Descamps R.; Mertes P.-M.; Charvin M.; Desebbe O.; Charbonneau H.; Fellahi J.-L.; Cazenave L.; Labaste F.; Lena D.; Rozec B.; Dessertaine G.; Debroczi S.; Greub W.; Lesthievent T.; Roche A.-C.; Tomadesso C.; Peyro-Saint-Paul L.; Parienti J.-J.; Briant A.R.; Fischer M.-O. Institution (Descamps, Debroczi, Greub, Fischer) Department of Anesthesiology, Critical Care Medicine, CHU Caen Normandie, Caen University Hospital, Caen, France (Mertes, Lesthievent, Roche) Service d'Anesthesie-Reanimation, Nouvel Hopital Civil, Hopitaux Universitaires de Strasbourg, Strasbourg, France (Charvin) Department of Perioperative Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France (Desebbe) Department of Anesthesiology and Intensive Care, Ramsay Sante Sauvegarde Clinic, Lyon, France (Charbonneau) Department of Anesthesiology, Intensive Care Unit, Clinique Pasteur, Toulouse, France (Fellahi, Cazenave) Service d'anesthesie-Reanimation, Hopital Universitaire Louis Pradel, Hospices Civils de Lyon, 59 Boulevard Pinel, Bron Cedex, France (Labaste) CHU de Toulouse, Departement d'anesthesie-reanimation, Toulouse, France (Labaste) RESTORE, UMR 1301 Inserm - 5070 CNRS - Universite Paul Sabatier, Universite de Toulouse, Toulouse, France (Lena) Institut Arnault Tzanck, Saint Laurent du Var, France (Rozec) Department of Anesthesiology, Critical Care at Laennec Hospital, Nantes Universite, CHU Nantes, University Hospital of Nantes, NANTES cedex 1, F-44093 Nantes, France (Rozec) Nantes Universite, CHU Nantes*, CNRS, INSERM, L'institut du thorax, F-44000 Nantes, France (Dessertaine) Pole Anesthesie-Reanimation, Grenoble Alpes University, Grenoble, France (Tomadesso, Peyro-Saint-Paul) Clinical research Department, CHU de Caen Normandie, Caen, France (Parienti, Briant) Unite de Biostatistiques et de Recherche Clinique, CHU de Caen-Normandie, Caen, France (Fischer) Institut Aquitain du Coeur, Clinique Saint-Augustin, Elsan, Bordeaux, France Publisher Lippincott Williams and Wilkins Abstract Background: - Whether targeting an individualized mean arterial pressure (MAP) during cardiac surgery improves outcomes remains uncertain. The balance between improved perfusion and vasopressor-driven blood pressure augmentation is unclear. <br/>Method(s): - In this single-blind, multicenter randomized clinical trial conducted in 10 tertiary centers in France, adult patients undergoing elective cardiac surgery with cardiopulmonary bypass were assigned to either individualized MAP management (target within +/-10% of preoperative baseline during surgery and for 24 h postoperatively) or standard management (target MAP >=65 mm Hg). The primary outcome was a composite of all-cause death, acute kidney injury, or prespecified neurologic complications within 7 days. Safety outcomes included hemorrhagic complications and transfusion requirements. <br/>Result(s): - A total of 172 patients were enrolled before the trial was stopped early by the data and safety monitoring board because of increased bleeding in the individualized group. Mean intraoperative MAP was higher with individualized management (80.6 vs 75.6 mm Hg; P<0.001), despite limited target adherence (33% of intraoperative time) and greater vasopressor use. The primary outcome occurred in 27 of 85 patients (32%) in the individualized group and 25 of 87 (29%) in the standard group (relative risk, 1.1; 95% CI, 0.7 to 1.8; P=0.76). Hemorrhagic complications occurred more frequently in the individualized group (18% vs 3%; P=0.003). <br/>Conclusion(s): - In patients undergoing cardiac surgery, it was not possible to determine whether an individualized MAP strategy reduced major postoperative complications. More bleeding complications were observed in the individualized group. Future studies should further investigate this safety signal when evaluating individualized blood pressure targets.<br/>Copyright &#xa9; 2026 The Author(s). Published by Wolters Kluwer Health, LLC. on behalf of the American Society of Anesthesiologists. <57> Accession Number 2049956334 Title Efficacy of Ultrasound-Guided Pectointercostal Fascial Block Versus Control and Alternative Regional Techniques in Cardiac Surgery: A Systematic Review and Meta-Analysis with Dose-Response Analysis. Source Medicina (Lithuania). 62(10) (no pagination), 2026. Article Number: 1890. Date of Publication: 01 Oct 2026. Author Elnahas M.; Zidan M.; Abusamra Y.; Hassan M.; Saravi B.; Hochrein S.; Lang P. Institution (Elnahas, Hochrein, Lang) Department of Anesthesiology, Intensive Care Medicine, and Pain Therapy, Sozialstiftung Bamberg, Bamberg, Germany (Zidan) Department of Anaesthesia, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (Abusamra) Department of Anaesthesia, Manchester University NHS Foundation Trust, Manchester, United Kingdom (Hassan) Department of Thoracic and Cardiovascular Surgery, Julius-Maximilians-University Hospital, Wuerzburg, Germany (Saravi) Department of Oral, Maxillofacial and Facial Plastic Surgery, Medical Faculty and University Hospital Dusseldorf, Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany Publisher Multidisciplinary Digital Publishing Institute (MDPI) Abstract Background and Objectives: Ultrasound-guided pectointercostal fascial block (USG-PIFB) is increasingly used for post-sternotomy analgesia, but its efficacy remains uncertain. Prior meta-analyses pooled ultrasound-guided blocks with surgeon-performed infiltration, introducing heterogeneity. We aimed to determine the analgesic efficacy of USG-PIFB in adult cardiac surgery by restricting inclusion to ultrasound-guided techniques. <br/>Material(s) and Method(s): Six databases were searched through December 2025, with an update search of open sources and trial registries in September 2026, for randomized controlled trials comparing USG-PIFB with control (Comparison 1) or with an alternative regional technique (Comparison 2) in adults undergoing sternotomy. The primary outcome was 24-h opioid consumption in intravenous morphine milligram equivalents. Random-effects meta-analysis (REML, Knapp-Hartung), subgroup, sensitivity and meta-regression analyses, an exploratory trial sequential analysis and GRADE assessment were performed. <br/>Result(s): Twenty-nine trials (2664 participants) were included: 24 in Comparison 1 and eight in Comparison 2. In 13 trials (902 participants), USG-PIFB reduced 24-h opioid consumption (mean difference -6.60 mg; 95% CI, -10.92 to -2.27; I<sup>2</sup> = 97.7%), but the 95% prediction interval (-22.24 to 9.04 mg) included no effect and small-study effects could not be excluded. Pain scores were lower by 0.8 to 1.4 points at rest (extubation, 12 and 24 h) and during movement (12 h). Extubation was earlier and intensive care stay shorter, with extreme heterogeneity. No dose-response relationship was detected, and the difference from deep parasternal techniques was near zero. No local anesthetic systemic toxicity or block-attributable pneumothorax was reported; one block-site hematoma occurred in a USG-PIFB recipient. Certainty of evidence was low for rescue analgesic use and block-related complications and very low for all other outcomes. <br/>Conclusion(s): USG-PIFB may modestly reduce 24-h opioid consumption, but the magnitude and reproducibility of this effect across clinical settings remain uncertain. It is best regarded as one component of multimodal analgesia, and adequately powered multicentre trials are needed.<br/>Copyright &#xa9; 2026 by the authors. <58> Accession Number 2051477199 Title Vasopressors to Treat or Prevent Hypotension During and After Major Surgery: A Scoping Review. Source Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2026. Date of Publication: 2026. Author Bandilovska I.; McFarlane I.; Chang K.; Brahmanand T.; Perry L.; Coulson T.G.; Miles L.F. Institution (Bandilovska, Brahmanand, Miles) Department of Anaesthesia, Austin Health, Melbourne, Australia (McFarlane, Chang, Coulson) Department of Anaesthesiology and Perioperative Medicine, Alfred Health, Melbourne, Australia (Perry) Division of Cardiac Anaesthesia, Victorian Heart Hospital, Monash Health, Melbourne, Australia (Perry, Coulson) Department of Surgery, School of Clinical Sciences, Monash University, Melbourne, Australia (Miles) Department of Critical Care, Melbourne Medical School, The University of Melbourne, Melbourne, Australia Publisher W.B. Saunders Abstract Perioperative hypotension is common and associated with adverse postoperative outcomes. Vasopressors are central to management, yet the optimal agent and their subsequent impacts on end-organ outcomes remain unclear. This scoping review characterizes the current evidence base and addresses the need for a full systematic review or meta-analysis. A protocol was formulated a priori per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews. Subsequently, MEDLINE, Embase, and Scopus were searched from January 1, 2000, to July 18, 2025, for studies comparing parenteral vasopressors in adults undergoing major surgery. Randomized controlled trials and observational studies were included. Data on study design, vasopressor strategies, initiation criteria, and postoperative outcomes were extracted and synthesized descriptively. Sixteen studies (n = 6,927) were included. Most were small, single-center, and observational, predominantly in cardiothoracic surgery. Vasopressor initiation criteria were highly variable, with studies divided broadly between hypotension-based triggers and vasoplegic syndrome, the latter inconsistently defined. A variety of vasopressors were evaluated, yet no 2 studies compared identical regimens. Postoperative outcome reporting was heterogeneous, and outcome definitions varied and showed minimal alignment with the Standardised Endpoints in Perioperative Medicine-Core Outcome Measures for Perioperative and Anaesthetic Care consensus standards. Eight studies reported significant differences in postoperative clinical outcomes between vasopressor strategies; however, effects were inconsistent, and no vasopressor strategy demonstrated a consistent benefit across studies. Overall, the evidence base for vasopressor therapy in perioperative hypotension is fragmented. Variability in initiation criteria, interventions, and outcome definitions limits comparability and precludes meaningful synthesis. Standardized definitions and adequately powered multicenter trials are required to determine optimal vasopressor strategies and their effects on postoperative organ dysfunction.<br/>Copyright &#xa9; 2026 The Authors <59> Accession Number 2051419341 Title Primary repair during the neonatal period for tetralogy of Fallot (RIFAN): a multicentre randomised controlled trial protocol in China. Source BMJ Open. 16(11) (no pagination), 2026. Article Number: e110340. Date of Publication: 01 Nov 2026. Author Zhongyi H.; Yalun Q.; Lv L.; Hua Z.; Li X.; Ye M.; Luo S.; Wu Y.; Liu S.; Yang S.; Yang J.; Mo Y.; Li W.; Li G.; Wang Q. Institution (Zhongyi, Yalun, Lv, Wu, Liu, Yang, Yang, Mo, Li, Li, Wang) Beijing Anzhen Hospital, Capital Medical University, Beijing, China (Hua) Shenzhen Children's Hospital, Shenzhen, China (Li) Children's Hospital, Soochow University, Suzhou, China (Ye) Children's Hospital, Fudan University, Shanghai, China (Luo) West China Second Hospital of Sichuan University, Sichuan, Dazhou, China Publisher BMJ Publishing Group Abstract Introduction: For clinically stable infants with tetralogy of Fallot (TOF), complete repair at 3-6 months is commonly recommended but the comparative effects of elective neonatal repair remain uncertain. Observational comparisons are vulnerable to confounding because infants repaired early often have more severe disease. The RIFAN trial will compare planned neonatal and infant repair in a randomised design. Methods and analysis: This prospective, multicentre, open-label trial will enrol 160 term neonates aged <=28 days with isolated TOF at five paediatric cardiac centres in China. Participants will be randomised 1:1 to complete repair at <=28 days or at 3-6 months. The co-primary outcomes are all-cause death within 30 days after surgery, regardless of discharge status and therapeutic cardiac reintervention within 12 months after surgery, excluding procedures during the index hospitalisation. The respective non-inferiority margins are 7.5 and 10 percentage points. Secondary outcomes include perioperative morbidity, cardiac function, growth, neurodevelopment, healthcare use and longer-term survival. The planned sample of 80 participants per group was calculated to provide 80% power for each co-primary outcome separately under the stated assumptions. A supportive 12-month analysis beginning at randomisation will report death and unplanned therapeutic cardiac intervention. Analyses will follow randomised allocation, with a per-protocol sensitivity analysis. Ethics and dissemination: The protocol was approved by the Medical Ethics Committee of Beijing Anzhen Hospital, Capital Medical University, on 1 March 2025 (reference number: Ethical Review 2025(5)). Each participating centre obtained approval from its hospital ethics committee before enrolling its first participant. The findings will be disseminated through peer-reviewed publications and presentations at scientific conferences. Trial registration number: NCT06822400 (first submitted 2 January 2025; first posted 12 February 2025).<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <60> Accession Number 2050147763 Title Impact of preprocedural frailty on long-term mortality after transcatheter aortic valve replacement: a systematic review and meta-analysis. Source BMC Cardiovascular Disorders. 26(1) (no pagination), 2026. Article Number: 1016. Date of Publication: 01 Dec 2026. Author Zhan Y.; Mao Y.; Tang X.; Li R.; Li M.; Hua D. Institution (Zhan, Mao, Tang, Li, Li, Hua) Department of Nursing, The Second Affiliated Hospital of Zhejiang, University School of Medicine, Hangzhou, China Publisher BioMed Central Ltd Abstract Background: This study aimed to investigate the association between preprocedural frailty and long-term all-cause mortality in patients undergoing transcatheter aortic valve replacement (TAVR). <br/>Method(s): A systematic search of PubMed, Web of Science, Embase, CINAHL, Scopus, and the Cochrane Library was conducted from database inception to 15 February 2026. The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). A random-effects meta-analysis was performed to pool adjusted hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs). <br/>Result(s): Thirteen cohort studies involving 429,827 patients were included in the systematic review. Of these, 8 studies (4,726 patients) reporting comparable adjusted effect estimates were included in the quantitative meta-analysis. Preprocedural frailty was associated with a higher risk of long-term all-cause mortality after TAVR (HR = 1.85, 95% CI 1.51-2.25; I2 = 39.4%). The association was generally consistent across subgroup analyses stratified by follow-up duration and frailty assessment methodology. Five studies that were not amenable to quantitative pooling because of non-comparable effect formats or data structures showed a concordant direction of effect, with some studies demonstrating a graded relationship between increasing frailty burden and mortality risk. <br/>Conclusion(s): Preprocedural frailty is significantly associated with increased long-term all-cause mortality in older adults undergoing TAVR. These findings support the incorporation of frailty assessment into routine preprocedural geriatric risk stratification and multidisciplinary decision-making.<br/>Copyright &#xa9; The Author(s) 2026. <61> Accession Number 2045458723 Title The link between atrial fibrosis and postoperative atrial fibrillation after cardiac surgery: A systematic review. Source Trends in Cardiovascular Medicine. 36(8) (pp 515-523), 2026. Date of Publication: 01 Nov 2026. Author Nawaz A.; Sohpal A.; Mitra R.; Abu-Omar Y.; Elsebaie A.; El-Diasty M. Institution (Nawaz, Sohpal) School of Medicine, Case Western Reserve University, Cleveland, OH, United States (Mitra) Case School of Engineering, Case Western Reserve University, Cleveland, OH, United States (Abu-Omar, El-Diasty) Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, United States (Elsebaie) Department of Medicine, Queen's University, Kingston, ON, Canada (El-Diasty) Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada Publisher Elsevier Inc. Abstract Postoperative atrial fibrillation (POAF) is a common complication that can affect up to 20-44% of patients undergoing cardiac surgery. Evidence suggests that atrial fibrosis is a key factor in the development of POAF due to the disruption of the myocardial electric properties. This systematic review examines the correlation between pre-existing atrial fibrosis and the development of POAF after cardiac surgery. A systematic literature search was conducted in MEDLINE, Embase, and Google Scholar (2000 to March 2025) to identify studies that conducted comparative analysis of atrial fibrosis levels between those who did and did not develop POAF, using histological assessment methods. Extracted data, included study characteristics, histopathological staining methods and analysis findings, fibrosis quantification methods, and overall POAF incidence. Thirteen studies met the inclusion criteria, resulting in a total of 1222 patients, primarily undergoing coronary artery bypass surgery. The incidence of POAF ranged from 14%-42.4% (median 31.6%). In more than half of the studies (7/13), patients who developed POAF demonstrated statistically significant higher degrees of atrial fibrosis compared to those that remained in sinus rhythm postoperatively (four exhibited p < 0.001). Of the eight studies that conducted multivariate analyses, three identified atrial fibrosis as an independent POAF predictor. High heterogeneity precluded pooling of results into a meta-analysis. The current evidence examining the link between pre-existing atrial fibrosis and the development of POAF is restricted by methodological heterogeneity and inconsistent findings. Further efforts to standardize fibrosis quantification methods and POAF definitions are warranted before histopathological assessments can reliably inform POAF risk before cardiac surgery.<br/>Copyright &#xa9; 2026 The Author(s) <62> Accession Number 2048536144 Title Intrawound Vancomycin Powder in Surgical Site Infection Prophylaxis: A Comprehensive Review of Mechanisms, Efficacy, Safety, and Clinical Controversies. Source Advances in Therapy. 43(11) (pp 5159-5176), 2026. Date of Publication: 01 Nov 2026. Author Abd-Elsayed A.; Troka M.P.; Ortega J.L.; Riad A.I.; Bianco G.L.; Kaye A.D.; Reilly M.J. Institution (Abd-Elsayed, Troka, Ortega, Reilly) Department of Anesthesiology, School of Medicine and Public Health, University of Wisconsin, 600 Highland Avenue, B6/319 CSC, Madison, WI, United States (Riad) Department of Biology, The Ohio State University, Columbus, OH, United States (Bianco) Responsabile U.O. Analgesia E Chirurgia Percutanea, Fondazione Istituto G. Giglio, Sicily, Cefalu, Italy (Kaye) Department of Anesthesiology, Louisiana State University School of Medicine, Shreveport, LA, United States Publisher Adis Abstract Surgical site infections (SSIs) remain a critical postoperative complication that causes significant morbidity, mortality, and healthcare costs. To mitigate these risks, intrawound vancomycin powder has been increasingly adopted as a prophylactic option, particularly for high-risk procedures such as spine, orthopedic trauma, and cardiothoracic surgeries. However, the decision ultimately remains at the surgeon's discretion. This comprehensive review evaluates the mechanisms, clinical efficacy, and controversies surrounding the application of topical vancomycin. The current literature shows that intrawound vancomycin powder effectively reduces Gram-positive SSIs, overcomes ischemic barriers to early biofilm formation, and maintains a safe systemic profile while remaining highly cost-effective. However, serious clinical concerns remain about its widespread use, including higher rates of sterile wound dehiscence, possible localized cellular toxicity that may impair bone fusion, changes in pathogen profiles, and the growing threat of antimicrobial resistance. The absence of a US Food and Drug Administration (FDA) approval, lack of standardized dosing regimens, and warnings from major health organizations complicate its true clinical utility. Ultimately, the available literature suggests a shift away from universal application and toward tightly controlled, targeted interventions guided by strict antimicrobial stewardship. However, it remains for surgeons to evaluate risks versus benefits when administering vancomycin powder into incisions. Ongoing large-scale randomized controlled trials and emerging translational approaches, such as extended-release carrier systems and personalized bacteriological profiling, are essential for establishing definitive, evidence-based clinical guidelines.<br/>Copyright &#xa9; The Author(s) 2026. <63> Accession Number 2047633683 Title Aortocoronary Versus Composite Grafting Strategies in Coronary Artery Bypass Surgery: A Network Meta-analysis. Source Canadian Journal of Cardiology. 42(11) (pp 2744-2755), 2026. Date of Publication: 01 Nov 2026. Author Gupta A.K.; Zaka A.; Tyagi D.; Chang S.; Burton E.; Munir L.; Mutahar D.; Ren J.; Stretton B.; Kovoor J.G.; Bacchi S.; Edwards S.; Kovoor P.; Maddern G.J.; Bennetts J.S.; Vallely M.P. Institution (Gupta, Stretton, Kovoor, Bacchi, Edwards, Maddern) School of Medicine, University of Adelaide, Adelaide, SA, Australia (Gupta, Zaka, Mutahar) Department of Surgery, Gold Coast University Hospital, Southport, QLD, Australia (Tyagi) School of Medicine, University of Newcastle, Newcastle, NSW, Australia (Chang, Munir) School of Medicine, Griffith University, Southport, QLD, Australia (Burton, Kovoor, Bacchi) Department of Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia (Ren) Department of Cardiothoracic Surgery, Royal Melbourne Hospital, Melbourne, VIC, Australia (Kovoor) Department of Cardiology, Westmead Hospital, Westmead, New Soth Wales, Australia (Maddern) Royal Australasian College of Surgeons, Adelaide, SA, Australia (Bennetts) Department of Cardiothoracic Surgery, Flinders Medical Centre, Adelaide, SA, Australia (Bennetts) School of Medicine, Flinders University, Adelaide, SA, Australia (Vallely) Department of Cardiothoracic Surgery, St George Hospital, Sydney, NSW, Australia Publisher Elsevier Inc. Abstract Coronary artery bypass graft surgery (CABG) has traditionally used an in situ left internal mammary artery (LIMA) graft to the left anterior descending artery (LAD), in addition to aortocoronary anastomoses to graft non-LAD target vessels. Composite grafting provides an opportunity to avoid aortic anastomoses by using nonaortic anastomoses to provide greater efficiency in the use of conduits for improved all-cause mortality and reduced aortic manipulation to lower the incidence of postoperative stroke. In this study we performed a network meta-analysis (NMA) to compare aortocoronary and various composite grafting strategies for CABG. A systematic search of 6 electronic databases identified all publications reporting outcomes of CABG with aortocoronary or composite grafting strategies. The primary outcome was in-hospital or 30-day all-cause mortality, and studies that reported these were included in our NMA. The study protocol was registered with PROSPERO (CRD42023402665) and conformed with PRISMA 2020 and MOOSE guidelines. A systematic search of 6 electronic databases identified all publications reporting outcomes of the included operations. A total of 6656 articles were screened, 24 of which (8 RCTs and 16 observational studies) were included with a total of 9692 patients. There was no difference in conventional aortocoronary anastomosis and composite grafting for the outcome of in-hospital or 30-day all-cause mortality ( P = 0.387). There was also no difference in rates of stroke ( P = 0.277), myocardial infarction ( P = 0.09), reoperation for bleeding ( P = 0.500), postoperative atrial fibrillation ( P = 0.219), and deep sternal wound infection ( P = 0.549). This Bayesian NMA of 9692 patients demonstrated that composite grafting CABG can be performed as safely as conventional aortocoronary CABG. Prospero Registration CRD42023402665.<br/>Copyright &#xa9; 2026 The Authors. <64> [Use Link to view the full text] Accession Number 2040020308 Title The Use of Protamine in Transcatheter Aortic Valve Replacement: A Meta-analysis. Source American Journal of Therapeutics. 33(6) (pp e622-e624), 2026. Date of Publication: 01 Dec 2026. Author Al-Abdouh A.; Kumar S.; Jabri A.; Mhanna M.; Alhuneafat L.; Paul T.K.; Villablanca P.; Khalife W. Institution (Al-Abdouh) Department of Medicine, University of Kentucky, KY, United States (Kumar) Division of Cardiology, Creighton University School of Medicine, Phoenix, AZ, United States (Jabri) Department of Cardiology, Corewell Health William Beaumont University Hospital, Royal Oak, MI, United States (Mhanna) Department of Cardiology, University of Iowa, IA, United States (Alhuneafat) Department of Cardiology, University of Minnesota, Minneapolis, MN, United States (Paul) University of Tennessee/Ascension St Thomas Hospital, Nashville, TN, United States (Villablanca) Division of Cardiology, Department of Structural Heart Disease, Henry Ford Health System, Detroit, United States (Khalife) Department of Cardiology, University of Texas Medical Branch, Galveston, TX, United States Publisher Lippincott Williams and Wilkins <65> Accession Number 2048708671 Title Effect of Continuous Bilateral Erector Spinae Plane Block on Neutrophil-Lymphocyte Ratio in On-Pump CABG: A Prospective Randomized Study. Source Seminars in Cardiothoracic and Vascular Anesthesia. 30(4) (pp 238-245), 2025. Date of Publication: 01 Dec 2025. Author Kumar A.; Dheeraj P.S.; Ameta N. Institution (Kumar, Dheeraj, Ameta) Department of Anaesthesia & Critical Care, Armed Forces Medical College, Pune, India Publisher SAGE Publications Inc. Abstract Background: Cardiac surgery using cardiopulmonary bypass causes a pronounced systemic inflammatory response. The neutrophil-lymphocyte ratio (NLR) is a readily accessible inflammatory biomarker associated with adverse outcomes after cardiac surgery. Regional anesthesia has been shown to modulate the inflammatory process by various mechanisms. Erector spinae plane (ESP) block reduces nociception and opioid use, but its effect on perioperative inflammatory markers is not well described. This study evaluated whether bilateral ESP block attenuates the perioperative rise in NLR in patients undergoing on-pump coronary artery bypass graft (CABG) surgery. <br/>Method(s): This prospective randomized study included 120 adults undergoing elective on-pump CABG randomized to bilateral ultrasound-guided ESP block (ESP, n = 60) or conventional opioid-based analgesia (Opioid, n = 60). ESP was performed pre-induction. NLR and platelet-lymphocyte ratio (PLR) were measured until the second postoperative day (POD). Secondary endpoints included ICU length of stay, mechanical ventilation duration, and total opioid consumption. <br/>Result(s): Baseline characteristics were comparable between groups. NLR increased in both groups after surgery and peaked at POD1. However, POD1 NLR was significantly lower in the ESP group compared with the opioid group (13.99 vs 18.58, P = 0.007). The ESP group showed shorter ICU stay (P = 0.02) and lower total perioperative opioid consumption (P = 0.01). <br/>Conclusion(s): Bilateral ESP block attenuated the early postoperative rise in NLR and reduced opioid requirements in on-pump CABG patients, suggesting modulation of the inflammatory response in addition to analgesic benefits.<br/>Copyright &#xa9; The Author(s) 2026 <66> Accession Number 2021608192 Title A Clinical Mathematical Model Estimating Postoperative Urine Output in Children Underwent Cardiopulmonary Bypass for Congenital Heart Surgery. Source Journal of Pediatric Intensive Care. (no pagination), 2022. Date of Publication: 11 Nov 2022. Author Baloglu O.; Ryan S.D.; Onder A.M.; Rosen D.; Mullett C.J.; Munther D.S. Institution (Baloglu) Department of Pediatric Critical Care Medicine, Cleveland Clinic Children's, Cleveland Clinic, Cleveland, OH, United States (Baloglu) Cleveland Clinic Children's Center for Artificial Intelligence (C4AI), Cleveland Clinic, Cleveland, OH, United States (Ryan, Munther) Department of Mathematics and Statistics, Cleveland State University, Cleveland, OH, United States (Onder) Division of Pediatric Nephrology, Nemours Children's Hospital, Wilmington, DE, United States (Rosen) Division of Pediatric Cardiothoracic Anesthesiology, West Virginia University, School of Medicine, Morgantown, WV, United States (Mullett) Division of Pediatric Critical Care Medicine, Department of Pediatrics, West Virginia University, School of Medicine, Morgantown, WV, United States Publisher Georg Thieme Verlag Abstract Objectives Our objective was to build a proof of concept of the clinical mathematical model estimating postoperative urine output (UOP) utilizing preoperative, intraoperative, and immediate postoperative variables in children who underwent cardiopulmonary bypass (CPB) for congenital heart surgery. Methods This was a single-center, retrospective cohort study in a university-affiliated children's hospital. Patients younger than 21 years old who underwent CPB for congenital heart surgery and were postoperatively admitted to West Virginia University Children's Hospital's pediatric intensive care unit (PICU) between September 1, 2007 and June 31, 2013 were included in the study. Body surface area, CPB duration, first measured hematocrit, serum pH, central venous pressure, and vasoactive-inotropic score in the PICU were used to build the mathematical model. A randomly selected 50% of the dataset was used to calculate model parameters. A cross-validation was used to assess model performance. Results A total of 256 patients met the inclusion criteria. The model was able to achieve mean absolute error of 1.065 mL/kg/h (95% confidence interval (CI): 1.062-1.067 mL/kg/h), root mean squared error of 1.80 mL/kg/h (95% CI: 1.799-1.804 mL/kg/h), and R 2 of 0.648 (95% CI: 0.646-0.650) in estimating UOP in the first 32 hours of postoperative period. Conclusions The mathematical model utilizing preoperative, intraoperative, and immediate postoperative variables may be a potentially useful clinical tool in estimating UOP in the first 32 hours postoperative period.<br/>Copyright &#xa9; 2022. Thieme. All rights reserved. <67> Accession Number 2047027471 Title Safety and efficacy of transcatheter aortic valve replacement (TAVR) vs. surgical aortic valve replacement (SAVR) in patients with bicuspid aortic stenosis: A Systematic review and meta-analysis. Source Perfusion (United Kingdom). 41(8) (pp 1376-1391), 2026. Date of Publication: 01 Nov 2026. Author Gadelmawla A.F.; Mansour A.; Elbataa A.; Asiri O.H.; Alharbi A.A.; Alquraish F.A.; Al-Ibrahim F.S.; AlHasani A.F.; Alharbi T.N.; Al Murayyi R.M.; Alotaibi A.G.; Abdul-Hafez H.A.; Suliman I. Institution (Gadelmawla) Faculty of Medicine, Menoufia University, Menoufia, Egypt (Mansour, Elbataa) Faculty of Medicine, Al-Azhar University, Cairo, Egypt (Asiri, Al Murayyi) College of Medicine, King Khalid University, Abha, Saudi Arabia (Alharbi) College of Medicine and Surgery, Taibah University, Medina, Saudi Arabia (Alquraish, Al-Ibrahim) College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia (AlHasani) College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia (Alharbi) College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia (Alotaibi) Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia (Abdul-Hafez) Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine (Suliman) King Abdulaziz Medical City, King Abdulaziz Cardiac Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia Publisher SAGE Publications Ltd Abstract Background: Bicuspid aortic valve (BAV) disease is a leading cause of aortic stenosis (AS). Surgical aortic valve replacement (SAVR) has traditionally been regarded as the best therapeutic option for bicuspid AS. However, the distinctive anatomical characteristics of BAV make the treatment with transcatheter aortic valve replacement (TAVR) challenging, so this population was often excluded from the trials. We aimed to compare TAVR and SAVR in terms of safety and efficacy in the population with bicuspid AS. <br/>Method(s): We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies, searched from PubMed, Cochrane, Scopus, and Web of Science (from inception until September 2025). Dichotomous outcomes were pooled as risk ratios (RRs), and continuous outcomes as mean differences (MDs), each with 95% confidence intervals (CIs). <br/>Result(s): A total of 78,677 patients were included in one RCT, 12 retrospective cohort studies, and one prospective cohort study. TAVR, compared to SAVR, was associated with significantly higher rates of permanent pacemaker implantation (PPI) (O.R. = 2.29, 95% C.I. [1.51, 3.47], P < 0.01) and shorter length of hospital stay (M.D. = -2.24, 95% C.I. [-3.96, -0.52], P = 0.01) and lower bleeding rates (O.R. = 0.31, 95% C.I. [0.14, 0.69], P < 0.01). However, there were no significant differences in all-cause mortality (ACM) (P = 0.948), acute kidney injury (AKI) (P = 0.28), stroke incidence (P = 0.475), and vascular complications (P = 0.31). The PPI and stroke rate results were consistent during in-hospital and short-term follow-ups. However, subgroup analysis by follow-up duration revealed that long-term stroke incidence was significantly higher in the TAVI group. <br/>Conclusion(s): TAVR offers benefit by minimizing significant bleeding and hospital length of stay. However, the benefits should be balanced against the considerably increased risk of PPI and PVL. Further RCTs are needed to confirm these findings.<br/>Copyright &#xa9; The Author(s) 2026 <68> Accession Number 2049202700 Title The role of antifactor Xa monitoring in the dosing and administration of low-molecular-weight heparins in pregnancy: a systematic review and meta-analysis. Source Journal of Thrombosis and Haemostasis. 24(11) (pp 4012-4026), 2026. Date of Publication: 01 Nov 2026. Author Ashraf R.; Mohamed D.; Sayfi S.; Bowen J.M.; Steinberg I.; Shehata N.; Hwang M.; D'Souza R. Institution (Ashraf, Sayfi, D'Souza) Department of Obstetrics & Gynaecology, McMaster University, Hamilton, ON, Canada (Ashraf, Sayfi, Bowen, D'Souza) Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada (Mohamed) Department of Obstetrics & Gynaecology, McGill University, Montreal, QC, Canada (Bowen) Program for Health System and Technology Evaluation, Ted Rogers Centre for Heart Research at Peter Munk Cardiac Centre, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada (Bowen) Institute of Health Policy, Management & Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada (Steinberg) Department of Pediatrics, University of Southern California (USC) Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, United States (Shehata) Division of Haematology, Departments of Medicine and Laboratory Medicine and Pathobiology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, ON, Canada (Hwang) Library & Knowledge Services, Trillium Health Partners, Toronto, ON, Canada Publisher Elsevier B.V. Abstract Background Low-molecular-weight heparins (LMWHs) are widely used in pregnancy for prevention and treatment of venous thromboembolism (VTE) and in individuals with mechanical heart valves (MHVs). Objectives Our aim was to determine the risk of thromboembolic complications (TECs) and major bleeding with weight-based, fixed, and anti-Xa-monitored dosing of LMWHs during pregnancy. Methods We conducted a systematic review and searched 6 databases for articles published before August 2024 that reported on LMWH dosing and monitoring during pregnancy. We calculated event rates and 95% confidence intervals (95% CIs) for maternal death, TECs, and major bleeding using a random-effects meta-analysis. We assessed risk of bias using the Quality In Prognosis Studies tool and evaluated the certainty of evidence (CoE) using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Results We identified 5007 studies, of which 94 (53 case series, 30 cohort studies, and 11 randomized trials) were eligible. For thromboprophylaxis and VTE treatment, fixed, weight-based, and anti-Xa-monitored LMWH doses had overlapping pooled event rates and 95% CIs for TECs and major bleeding. For MHVs, the risk of maternal death, TECs, and major bleeding was 2.7% (95% CI, 0.3%-6.5%), 7.9% (95% CI, 2.8%-14.6%), and 8.4% (95% CI, 2.0%-17.2%), respectively with overlapping pooled single-arm event rates and 95% CIs across different anti-Xa-monitored LMWH dosing regimens. The CoE for all estimates was low to very low, mainly due to imprecision, risk of bias, and publication bias. Conclusion Pooled single-arm event rates and 95% CIs for the main outcomes overlapped across LMWH dosing regimens currently used in pregnancy for thromboprophylaxis, VTE treatment, and anticoagulation in individuals with MHVs. These findings should be interpreted in light of small sample sizes, wide 95% CIs, and low CoE; and not as evidence of comparable effectiveness or safety.<br/>Copyright &#xa9; 2026 The Author(s). <69> Accession Number 2038748993 Title Paravertebral analgesia versus wound infiltration in children recovering from cardiac surgery: a randomized controlled trial. Source Regional Anesthesia and Pain Medicine. 51(5) (pp 584-590), 2026. Date of Publication: 01 May 2026. Author Guo J.; Jia Y.; Tian L.; Kang W.; Zhao Y.; Yuan S.; Sessler D.I. Institution (Guo, Jia, Tian, Kang, Zhao, Yuan) Fuwai Hospital, Beijing, China (Sessler) Outcomes Research, Cleveland Clinic, Cleveland, OH, United States Publisher BMJ Publishing Group Abstract Introduction: Optimal analgesia for thoracotomies remains unclear. Paravertebral blocks are more complex than local anesthetic infiltration but may be more effective. We therefore tested the hypothesis that paravertebral blocks provide better postoperative analgesia than local anesthetic infiltration in children recovering from cardiac surgery thoracotomies. <br/>Method(s): This was a single-center randomized double-blind trial. We recruited children aged 6-14 years with atrial or ventricular septal defects scheduled for cardiac surgery with cardiopulmonary bypass via thoracotomy were recruited. 100 patients were enrolled and randomized to either postoperative paravertebral blocks (n=50) or local anesthetic wound infiltration (n=50). We recorded opioid consumption during the initial 24 hours after surgery, along with pain scores at 6 hour intervals. Complications including postoperative nausea and vomiting and respiratory failure were also recorded. <br/>Result(s): 100 patients (mean 7 years, 43% male) were included in the analysis. The only postoperative opioid used was sufentanil. Total sufentanil consumption in the first 24 hours postsurgery was 0.3+/-0.4 microg/kg for those receiving paravertebral blocks, significantly lower than the 0.6+/-0.5 microg/kg for wound infiltration (p=0.002). Faces Pain Scale-Revised pain scores were consistently lower in the paravertebral block group across all measured time points (6, 12, 18, and 24 hours), with the most pronounced difference observed at 6 hours postoperatively (1.7+/-2.2 vs 3.3+/-2.2; p<0.001). Postoperative mechanical ventilation time, ICU stay, hospitalization, and incidence of postoperative nausea and vomiting were comparable. <br/>Conclusion(s): Paravertebral blocks reduced opioid consumption and pain during the first postoperative day in pediatric cardiac thoracotomies but did not accelerate recovery.<br/>Copyright &#xa9; American Society of Regional Anesthesia & Pain Medicine 2026. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <70> Accession Number 2047601085 Title Superiority of Fibrinogen Concentrate Versus Cryoprecipitate for Treatment of Bleeding in Cardiac Surgery Patients: A Secondary Analysis of the FIBRES Randomized Clinical Trial Stratified by Surgical Risk. Source Journal of Cardiothoracic and Vascular Anesthesia. 40(11) (pp 3607-3615), 2026. Date of Publication: 01 Nov 2026. Author Bartoszko J.; Karkouti K.; Callum J.L. Institution (Bartoszko, Karkouti) Department of Anesthesia and Pain Management, University Health Network, Sinai Health, Women's College Hospital, University of Toronto, Toronto, ON, Canada (Bartoszko, Karkouti) Peter Munk Cardiac Centre and Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada (Bartoszko, Karkouti) Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, ON, Canada (Callum) Department of Pathology and Molecular Medicine, Kingston Health Sciences Centre and Queen's University, Kingston, ON, Canada Publisher W.B. Saunders Abstract Objectives: To explore the superiority of fibrinogen concentrate (FC) versus cryoprecipitate for bleeding after cardiac surgery. <br/>Design(s): Secondary analysis of the FIBRES randomized trial. <br/>Setting(s): Eleven Canadian hospitals, February 2017-November 2018. <br/>Participant(s): Adult cardiac surgery patients experiencing significant postbypass bleeding and acquired hypofibrinogenemia (fibrinogen <2.0 g/L or FIBTEM A10 <10 mm). <br/>Intervention(s): FC (4 g) or cryoprecipitate (10 units) dosed within 24 hours after cardiopulmonary bypass as needed. <br/>Measurements and Main Results: In total, 735 patients (372 FC, 363 cryoprecipitate) were included in the primary analysis (median age 64 years, 30% women). The primary endpoint was cumulative blood components (red cells, platelets, plasma) administered within 24 hours postbypass. Superiority was assessed using deviance-scaled Poisson regression. FC was superior to cryoprecipitate in the a priori-defined, well-balanced subgroups of non-critically ill patients (n = 634, 86% of population; mean 13.6 versus 16.2 units, mean ratio 0.84 [95% CI 0.73, 0.96]; p = 0.01) and elective surgery patients (n = 466, 63% of population; 11.7 versus 14.4 units, 0.81 [0.69, 0.96]; p = 0.02). In elective surgery patients, adverse events (relative risk 0.85 [0.75, 0.97]; p = 0.02) and serious adverse events (0.71 [0.52, 0.99]; p = 0.04) were less frequent with FC. <br/>Conclusion(s): FC showed superior hemostatic efficacy to cryoprecipitate in the prespecified subgroups of elective cardiac surgery patients and patients who were not in a critical state before surgery, representing the large majority of patients with bleeding postbypass. FC may also offer safety advantages over cryoprecipitate.<br/>Copyright &#xa9; 2026 The Author(s) <71> Accession Number 2033501313 Title Oral vs. Outpatient Parenteral Antimicrobial Treatment for Infective Endocarditis: Study Protocol for the Spanish OraPAT-IE GAMES Trial. Source Infectious Diseases and Therapy. 14(3) (pp 643-655), 2025. Article Number: 100213. Date of Publication: 01 Mar 2025. Author de Alarcon A.; Alonso-Socas M.M.; Lopez-Lirola A.; Goikoetxea-Agirre A.J.; Loeches B.; Ribas M.A.; Navarro D.; Sala C.; Ambrosioni J.; Olivares P.; Lopez-Cortes L.E.; Morales I.; Mendez I.; de Cueto M.; Calvo-Jambrina R.; Barquero J.M.; Araji O.; Almendro-Delia M.; Brase A.; Calvo-Fernandez A.; Tauron M.; Recasens L.; Sorli L.; Suarez M.; Silverio A.; Sanchez F.; Ribas N.; Serrat R.; Molina L.; Mestres A.; Mas A.; Ginel A.J.; Horcajada-Gallego J.P.; Ble M.; Lopez-Montesinos I.; Salavert-Lleti M.; Garcia-Bustos V.; Fernandez-Navarro J.A.; Calabuig-Munoz E.; Montero-Alonso M.; Tasias-Pitarch M.; Domingo-Valero D.; Arnau-Vives M.A.; Blanes-Hernandez R.; Vives-Borras M.; Vidal-Bonet L.; Ruiz de Gopegui-Bordes E.; Ribas-Blanco M.A.; Zarauza J.; Teira R.; Ruiz-Alonso N.; Parra J.A.; Pajaron M.; Gutierrez-Diez J.; Gutierrez-Cuadra M.; Gutierrez-Fernandez L.; Gonzalez-Rico C.; Garrido R.; Garcia I.; Fernandez-Sampedro M.; Farinas-Alvarez C.; Farinas M.C.; Cobo-Belaustegui M.; Arnaiz de las Revillas F.; Arminanzas-Castillo C.; Amado-Fernandez C.; Aguero-Balbin J.; Martin-Blanco N.; Oteo J.A.; Garcia-Alvarez L.; Corral-Armas E.; Blanco J.R.; Azcona-Gutierrez J.M.; Azcarate P.; Alonso L.J.; Saura D.; Roura-Piloto A.; Perez-Andreu J.; Ortin A.; Oliva M.J.; Moral-Escudero E.; Martinez-Toldos M.C.; de Gea J.H.; de la Morena Valenzuela G.; Blazquez A.; Hernandez-Torres A.; Vazquez E.G.; Canovas S.; Albert L.; Rivera-Martinez M.A.; Lopez-Contreras J.; Leta-Petracca R.; Grillo S.; Ginel-Iglesias A.; Barros-Membrilla A.; Camprecios M.; Gasch O.; Monsalvez V.; Gomila A.; Calzado S.; Diaz E.; Lozano L.; Capilla S.; Guillamon L.; Guillaumet E.; Castaldo F.; Araujo G.; Dietl B.; Ibars S.; Xercavins M.; Boix-Palop L.; Badia C.; Rosillo S.; Romero M.; Rial-Baston V.; Ramirez U.; Moreno M.; Antorrena I.; Ruiz S.; Rodriguez-Roda-Stuart J.; del Rio A.; Oliva E.; Navas E.; Martin-Davila P.; Moya J.L.; Hermida J.M.; Centella T.; Sanchez-Rodriguez I.; Gracia-Sanchez L.; Blasco A.; Sbraga F.; Ruiz-Majoral A.; Alegre O.; Sanchez-Salado J.C.; Berbel D.; Ardanuy C.; Grau I.; Carratala J.; Escrihuela-Vidal F.; Gonzalez-de-la-Aleja P.; Pinargote-Celorio H.; Reus S.; Plazas J.; Merino E.; Llamas P.; Climent V.; Carrasco R.; Goyeneche M.; Bidegain M.; Sanchez S.; Zabalo-Arrieta M.; Villanueva-Benito I.; Vicente-Anza D.; Unamuno-Ugartemendia I.; Solla-Ruiz I.; Sebastian-Alda R.; Sanchez-Haza E.; Saez-Berbejillo A.; Reviejo K.; Rengel-Jimenez A.; Perez-Moreiras-Lopez J.I.; Kortajarena-Urkola X.; Iribarren J.A.; Granda-Bauza A.; Goyeneche del Rio M.; Goenaga M.A.; Fuentes A.; Eizaguirre-Yarza A.; Echeverria T.; del Bosque-Martin C.; Bustinduy-Odriozola M.J.; Berritu-Boronat E.; Azkune-Galparsoro H.; Camino X.; Alvarez-Rodriguez I.; Voces R.; Vitoria Y.; Rodriguez R.; Rodrigo D.; Nieto J.; Montejo M.; Lopez-Soria L.; Irurzun-Zuazabal J.; Iruretagoyena J.R.; Ibarrola-Hierro M.; Goikoetxea A.J.; Euba-Ugarte G.; Del Alamo Martinez de Lagos M.; Guio-Carrion L.; Crespo A.; Campana-Lazaro M.; Boado M.V.; Blanco R.; Blanco-Vidal M.J.; Bereciartua E.; de la Villa S.; Verde-Moreno E.; Vazquez P.; Valerio M.; Segado A.; Sanchez-Perez E.; Rodriguez-Abella H.; Rincon C.; Pinto A.; Pinilla B.; Pedraz A.; Olmedo M.; Monzon D.; Munoz P.; Melero R.; Martinez-Selles M.; Marin M.; Machado M.; Hualde A.M.; Kestler-Hernandez M.; Gonzalez-Ramallo V.; Gonzalez-Moraga F.J.; Mansilla A.G.; Garcia-Leoni M.E.; Gargallo E.; Fortuny-Ribas R.; Estevez A.; Delgado-Montero A.; Cuerpo-Caballero G.; Calatayud J.; Bouza E.; Bermejo J.; Alvarez-Uria A.; Alonso J.C.; Adan I.; Rodriguez-Moreno F.; Prada-Arrondo P.; Perez-Ramirez A.; Lorenzo de la Pena L.; Lacalzada J.; Gonzalez Gonzalez J.; Garcia-Rosado D.; Fernandez-Sarabia J.; Delgado-Melian T.; Castro B.; Alonso M.D.M.; Poyato-Borrego M.; Sanchez-Dominguez E.; Ortiz-Carrellan A.; Marin G.; Luque-Marquez R.; Lopez-Haldon J.; Lepe J.A.; Gutierrez-Carretero E.; Navarro-Amuedo D.; Vila J.; Tuset M.; Vidal B.; Urra X.; Tolosana J.M.; Tellez A.; Soy D.; Sitges M.; Sanchis L.; Sandoval E.; Rovira I.; Roque M.; Roca C.; Regueiro A.; Ramirez J.; Quintana E.; Pomar J.L.; Perissinotti A.; Pericas J.M.; Pereda D.; Pare C.; Ortiz J.; Ninot S.; Nicolas D.; Moreno A.; Miro J.M.; Marco F.; Lopez T.; Llopis-Perez J.; Hernandez-Meneses M.; Garcia-Pares D.; Garcia de la Maria C.; Fuster D.; Fita G.; Fernandez-Pittol M.; Espasa M.; Falces C.; de Diego O.; Cuervo G.; Canas M.A.; Castella M.; Cartana R.; Brunet M.; Azqueta M.; Ascaso M.; Alcocer J.; Almela M.; Andrea R. Institution (Cuervo, Hernandez-Meneses, Moreno, Sala, Ambrosioni, Miro) Infectious Diseases Department, Hospital Clinic-IDIBAPS, University of Barcelona, Villarroel 170, Barcelona, Spain (Nicolas) Internal Medicine-Home Hospitalization Unit, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain (Vidal) Cardiology Department, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain (Fernandez-Pittol) Microbiology Department, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain (Cuervo, de Alarcon, Martin-Davila, Lopez-Montesinos, Lopez-Cortes, Ambrosioni, Miro) CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain (de Alarcon, Luque-Marquez, Navarro) Clinical Unit of Infectious Diseases, Microbiology and Parasitology (UCEIMP), Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital/CSIC/University of Seville, Seville, Spain (Alonso-Socas, Lopez-Lirola) Hospital Universitario de Canarias, Tenerife, Spain (Gonzalez-Ramallo) Hospital General Universitario Gregorio Maranon, Madrid, Spain (Goikoetxea-Agirre) Hospital Universitario de Cruces, Bilbao, Spain (Goenaga) Hospital Universitario Donosti, Instituto Investigacion Biogipuzkoa, San Sebastian, Spain (Merino) Unit of Infectious Diseases, Alicante General University Hospital - Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain (Merino) Clinical Medicine Department, Miguel Hernandez University, Elche, Spain (Escrihuela-Vidal) Hospital Universitario de Bellvitge, Barcelona, Spain (Martin-Davila) Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Madrid, Spain (Loeches) Hospital Universitario La Paz, Madrid, Spain (Boix-Palop) Hospital Mutua de Terrassa, Terrassa, Spain (Gasch) Servei de Malalties Infeccioses, Hospital Universitari Parc Tauli, Institut d'Investigacio i Innovacio Parc Tauli (I3PT-CERCA), Universitat Autonoma de Barcelona, Sabadell, Spain (Camprecios) Hospital de la Santa Creu y Sant Pau, Barcelona, Spain (Hernandez-Torres) Hospital Virgen de la Arrixaca, Murcia, Spain (Garcia-Alvarez) Hospital San Pedro-CIBIR, Logrono, Spain (Pajaron) Hospital Marques de Valdecilla, Santander, Spain (Ribas) Hospital Son Espases, Palma, Spain (Blanes-Hernandez) Hospital de La Fe, Valencia, Spain (Lopez-Montesinos) Hospital del Mar, Barcelona, Spain (Lopez-Cortes) Unidad Clinica de Enfermedades Infecciosas y Microbiologia, Hospital Universitario Virgen Macarena, Seville, Spain (Lopez-Cortes) Departamentos de Medicina y Microbiologia, Facultad de Medicina, Universidad de Sevilla, Seville, Spain (Lopez-Cortes) Instituto de Biomedicina de Sevilla (IBiS)/CSIC, Seville, Spain Publisher Adis Abstract Introduction: The POET trial demonstrated that moving from intravenous to oral antibiotics in stable patients with left-sided infective endocarditis (IE) was noninferior to fully parenteral treatment. However, it did not compare outpatient strategies. <br/>Method(s): The OraPAT-IE GAMES trial is a noninferiority, multicenter, randomized, open-label study aimed to compare partial oral versus outpatient parenteral antibiotic therapy (OPAT) for consolidation of antibiotic treatment in left-sided IE. A total of 342 stable patients with IE caused by selected micro-organisms will eventually be included. After a minimum of 10 days of parenteral treatment, stable patients are randomized to oral therapy or OPAT. The primary end-point is a composite of all-cause mortality, unplanned cardiac surgery, relapse of positive blood cultures and/or unplanned hospital admission. Patients are followed-up for 6 months after completing antibiotic therapy. Planned Outcome: This trial seeks to demonstrate the equivalent efficacy of the two outpatient strategies currently available for stable patients with IE in the consolidation phase of antibiotic treatment. <br/>Conclusion(s): In a global context of limited healthcare resources and a sustained increase in elderly and frail patients, it is of great importance to demonstrate the effectiveness and safety of outpatient management strategies that could reduce the duration of conventional hospitalizations with their potential complications and inherent costs. Trial Registration: EudraCT: 2020-001024-34. ClinicalTrials.gov identifier: NCT05398679.<br/>Copyright &#xa9; The Author(s) 2025. <72> Accession Number 2048497603 Title Deep versus moderate hypothermia in pediatric cardiac surgery: Systematic review and meta-analysis of early postoperative outcomes. Source Perfusion (United Kingdom). 41(8) (pp 1335-1346), 2026. Date of Publication: 01 Nov 2026. Author Zoupas I.; Covell J.M.; Cruz Naranjo J.; Podgorsek B.; Chen P.C.; LaPar D.J.; Greenleaf C.E. Institution (Zoupas, Covell, Cruz Naranjo, Chen, LaPar, Greenleaf) Division of Pediatric and Congenital Cardiac Surgery, Department of Cardiothoracic and Vascular Surgery, Children's Memorial Hermann Hospital, The University of Texas Health Science Center at Houston, Houston, TX, United States (Podgorsek) Department of Cardiothoracic and Vascular Surgery, Memorial Hermann Hospital, The University of Texas Health Science Center at Houston, Houston, TX, United States Publisher SAGE Publications Ltd Abstract Introduction: Deep hypothermia (DH) has been widely adopted for cerebral and visceral protection during pediatric cardiac surgery, but concerns about perioperative complications remain. This meta-analysis aims to evaluate the impact of DH compared to moderate hypothermia (MH) on outcomes in pediatric cardiac surgery patients. <br/>Method(s): Following a PRISMA-compliant systematic search in PubMed, Cochrane, and Embase, eligible studies comparing DH (<22degreeC) with MH (22-30degreeC) in pediatric cardiac surgery were assessed. Risk of bias was evaluated using the ROBINS-I tool. <br/>Result(s): Five comparative studies with 448 patients (250 in the MH group and 198 in the DH group) were included. Baseline characteristics were similar between groups, with the majority of patients undergoing aortic arch repairs. Perioperative variables were also similar, except for cross-clamp time, which was significantly longer in the DH group (p = 0.02), and circulatory arrest was more frequently used in DH patients (p = 0.01). No significant differences were found in overall postoperative complication rates, acute kidney injury, 24-h chest drainage volume, or in-hospital mortality. However, the incidence of early postoperative neurological complications was significantly higher in the DH group (p < 0.001). <br/>Conclusion(s): Moderate hypothermia may be associated with a significantly lower incidence of postoperative neurological complications compared to deep hypothermia, while overall in-hospital mortality and morbidity rates remained similar between the two groups. Taken together, these findings support moderate hypothermia with regional perfusion as a clinically feasible and well-tolerated alternative to deep hypothermia in pediatric cardiac surgery.<br/>Copyright &#xa9; The Author(s) 2026. This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). <73> Accession Number 2049877146 Title 5-Year Follow-Up of Transcatheter Aortic Valve Replacement With Self-Expanding Intra-Annular Versus Commercially Available Valves. Source JACC: Cardiovascular Interventions. 19(21) (pp 2821-2833), 2026. Date of Publication: 09 Nov 2026. Author Makkar R.R.; Cheng W.; Waksman R.; Chakravarty T.; Satler L.F.; Groh M.; Abernethy W.; Russo M.J.; Heimansohn D.; Hermiller J.; Worthley S.; Chehab B.M.; Matthews R.; Ramana R.K.; Yong G.; Chen C.; Asch F.M.; Nakamura M.; Jilaihawi H.; Sharma R.; Patel D.; Kapadia S.; Reardon M.J.; Bhatt D.L.; Fontana G.P. Institution (Makkar, Cheng, Chakravarty, Nakamura, Jilaihawi, Patel) Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States (Waksman, Satler) Washington Hospital Center, Washington, DC, United States (Groh, Abernethy) Mission Health and Hospitals, Asheville, NC, United States (Russo) Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, United States (Chen) Newark Beth Israel Medical Center, Newark, NY, United States (Heimansohn, Hermiller) St Vincent Heart Center, Indianapolis, IN, United States (Worthley) Royal Adelaide Hospital, Adelaide, SA, Australia (Worthley) Genesis Care, Sydney, NSW, Australia (Chehab) Ascension Via Christi Hospital, University of Kansas, Wichita, KS, United States (Matthews) University of Southern California, Los Angeles, CA, United States (Ramana) Advocate Christ Medical Center, Oak Lawn, IL, United States (Ramana, Yong) Heart Care Centers of Illinois, Palos Park, IL, United States (Asch) MedStar Health Research Institute, Washington, DC, United States (Sharma) Stanford University Medical Center, Stanford, CA, United States (Kapadia) Cleveland Clinic, Cleveland, OH, United States (Reardon) Houston Methodist Hospital, Houston, TX, United States (Bhatt) Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, United States (Fontana) Cardiovascular Institute, Los Robles Regional Medical Center, Thousand Oaks, CA, United States Publisher Elsevier Inc. Abstract Background Long-term outcomes of the self-expanding intra-annular Portico transcatheter aortic valve are not known. Objectives This study aimed to report the 5-year outcomes of the PORTICO IDE randomized controlled trial. Methods This multicenter trial randomized (1:1) patients with severe symptomatic aortic stenosis at high/extreme surgical risk to transcatheter aortic valve replacement (TAVR) with the self-expanding intra-annular valve (study valve) or Food and Drug Administration-approved commercially available valves (CAVs; balloon-expandable or self-expanding supra-annular platforms). Assessments of the primary safety endpoint (30 days) and the primary efficacy endpoint (1 year) have been previously reported. Prespecified clinical outcomes and hemodynamic valve parameters are presented through 5 years. Results We randomized 750 eligible patients (mean age: 83 years, 52.7% female) to the study valve (n = 381) or CAV (n = 369). Compared with CAV, the study valve showed similar 5-year all-cause mortality or stroke (55.6% vs 51.3%, P = 0.42). Cardiovascular mortality was numerically higher in the study valve group compared with the CAV group (33.4% vs 25.8%; P = 0.06). Naive permanent pacemaker implantation was higher in the study valve group (36.6%) than the CAV group (20.3%; P < 0.0001) at 5 years. At 5 years, the study valve showed a lower mean transvalvular gradient (7.2 +/- 3.0 vs 9.5 +/- 6.5 mm Hg, P = 0.008), but similar valve area (1.78 +/- 0.45 vs 1.71 +/- 0.51 cm<sup>2</sup>, P = 0.40) compared to CAV. Conclusions In patients at high or extreme surgical risk, TAVR with the self-expanding intra-annular transcatheter heart valve had similar 5-year overall survival, stroke rates, and valve function compared with commercially available valves.<br/>Copyright &#xa9; 2026 The Authors. <74> Accession Number 2050164578 Title Reversing ticagrelor's P2Y<inf>12</inf> inhibition in life-threatening haemorrhage: a case-based review. Source Expert Review of Cardiovascular Therapy. (no pagination), 2026. Date of Publication: 2026. Author Dirir O.; Elamin N.; Sammut M.A.; Rahman M.E.F.; Parker W.A.E.; Hanson J.; Hunter S.; Ball A.; Storey R.F. Institution (Dirir, Elamin, Sammut, Rahman, Parker, Hanson, Storey) Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom (Dirir, Elamin, Sammut, Rahman, Parker, Hunter, Storey) South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom (Dirir, Elamin, Sammut, Rahman, Parker, Hanson, Storey) NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom (Ball) Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom Publisher Taylor and Francis Ltd. Abstract Introduction: Ticagrelor is an oral reversible platelet P2Y<inf>12</inf> inhibitor that improves ischemic outcomes in atherosclerotic cardiovascular disease, including the prevention of stent thrombosis after percutaneous coronary intervention, at the cost of increased bleeding risk. Areas covered: A comprehensive literature search was performed across PubMed and Web of Science (inception to January 2026). This case-based review outlines the current guidance surrounding bleeding events and emergent surgery on oral P2Y<inf>12</inf> inhibitors, including treatment options for reversing their effects, and describes a novel ticagrelor reversal agent in two cases of life-threatening bleeding, one related to gastrointestinal hemorrhage and one associated with emergent coronary artery bypass graft surgery. Expert opinion: Ticagrelor is a first-line treatment for acute coronary syndromes but is associated with heightened bleeding risk, especially when combined with aspirin. Ticagrelor's reversibility may offer advantages over the irreversibly-acting thienopyridine P2Y<inf>12</inf> inhibitors. Patients treated with potent antiplatelet regimens may require rapid and effective restoration of hemostatic activity in addition to supportive measures in those presenting with life-threatening hemorrhage or requiring emergent surgery. We summarize the current available treatment options to reverse antiplatelet activity and highlight the role of ticagrelor reversal with bentracimab in improving hemostasis in emergency settings.<br/>Copyright &#xa9; 2026 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. <75> Accession Number 2049021234 Title Outcomes and Complications of Total Joint Arthroplasty in Heart Transplant Recipients: A Systematic Review. Source Journal of Clinical Medicine. 15(17) (no pagination), 2026. Article Number: 6794. Date of Publication: 01 Sep 2026. Author Koskiniotis A.; Komnos G.A.; Koutalos A.; Hantes M.; Karachalios T.; Varitimidis S.; Stefanou N. Institution (Koskiniotis, Komnos, Koutalos, Hantes, Karachalios, Varitimidis, Stefanou) Department of Orthopaedic Surgery, Faculty of Medicine, University of Thessaly, 3 Panepistimiou St, Biopolis, Larissa, Greece Publisher Multidisciplinary Digital Publishing Institute (MDPI) Abstract Background: Heart transplantation has evolved into a life-saving intervention for thousands of patients with end-stage disease worldwide. Advances in surgical techniques and immunotherapy have increased life expectancy in this specific patient group, resulting in the emergence of degenerative diseases such as osteoarthritis. Concurrently, due to the frequent administration of corticosteroids to transplant recipients, the rates of joint osteonecrosis remain high. This review aims to evaluate the final functional outcomes as well as the complications of patients with a history of heart transplantation who underwent total hip, knee, or shoulder arthroplasty. <br/>Method(s): A systematic review of the literature was conducted according to PRISMA guidelines. The primary objective of the study was the improvement of various functional scores at the final clinical follow-up, as well as the recording of postoperative complication rates. <br/>Result(s): A total of 19 retrospective studies were included in the review, including small case series. Among the studies specifically evaluating functional outcomes, patients demonstrated statistically significant improvement in final clinical scores and quality of life. However, regarding complication rates, 12 out of the 19 articles identified a higher ratio compared to the general population, involving either systemic (e.g., renal failure), musculoskeletal (periprosthetic fracture, infection), or cardiac-related adverse events concerning the graft. <br/>Conclusion(s): According to the data analyzed in this systematic analysis, total arthroplasty of major joints demonstrates consistent potential to significantly improve the daily life and functional status of transplant patients. However, evidence regarding overall safety remains heterogeneous.<br/>Copyright &#xa9; 2026 by the authors. <76> Accession Number 2049052576 Title Impact of Shexiang Baoxin Pill (MUSKARDIA) on Cardiovascular Outcomes by Baseline Hemoglobin Levels in 2,494 Patients with Chronic Stable Coronary Artery Disease: A Secondary Subgroup Analysis. Source Chinese Journal of Integrative Medicine. 32(11) (pp 972-978), 2026. Date of Publication: 01 Nov 2026. Author Zhou J.-M.; Shi H.-M.; Wu Y.; Jin Y.-Z.; Wang S.-H.; Qian J.; Pan C.-X.; Lu F.; Li X.-L.; Li R.; Wu K.; Wang L.-Y.; Cong H.-L.; Yang Z.-M.; Hao Y.-M.; Yang P.-L.; Chen Y.-Q.; Ge J.-B. Institution (Zhou, Ge) Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China (Shi) Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China (Wu) Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China (Jin) Department of Cardiology, the Fourth Affiliated Hospital of China Medical University, Shenyang, China (Wang) Department of Cardiology, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province, China (Qian) Department of Cardiology, Ma'anshan General Hospital of Ranger-duree Healthcare, Ma'anshan, Anhui Province, China (Pan) Department of Cardiology, the First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China (Lu) Department of Cardiology, the Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China (Li) Department of Cardiology, Jiangsu Province Hospital, Nanjing, China (Li) Department of Cardiology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China (Wu) Department of Cardiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province, China (Wang) Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou, China (Cong) Department of Cardiology, Tianjin Chest Hospital, Tianjin, China (Yang) Department of Cardiology, the Second Hospital of Shanxi Medical University, Taiyuan, China (Hao) Department of Cardiology, the Second Hospital of Hebei Medical University, Shijiazhuang, China (Yang) the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China (Chen) Shanghai Innovative Engineering Technology Research Center for Traditional Chinese Medicine Solid Preparations, Shanghai, China Publisher Springer Science and Business Media Deutschland GmbH Abstract Objective: Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events (MACE) and improves angina, this study aims to evaluate its differential efficacy across varying hemoglobin (Hb) levels. <br/>Method(s): This was a subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled phase W trial. Patients with coronary artery disease (CAD) were stratified into two groups based on baseline Hb levels: Group A (Hb < 140 g/L, n=1,286) and Group B (Hb>140 g/L, n=1,208). The primary endpoint was MACE; secondary endpoints included non-fatal myocardial infarction (MI), non-fatal stroke, and all-cause mortality. Hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox proportional hazards models. <br/>Result(s): In Group A, MUSKARDIA significantly reduced MACE risk (HR=0.45, 95% CI: 0.21-0.96, P=0.038), with a 68% reduction in non-fatal MI risk (P=0.036). Non-fatal stroke and all-cause mortality showed no significant differences. Adverse events were lower in the MUSKARDIA group (15.9% vs. 17.6%). In Group B, no significant MACE benefit was observed (P=0.354), with a trend toward increased non-fatal MI risk (HR=1.88). Non-fatal stroke and all-cause mortality were similar between groups. Adverse events were slightly higher (21.2% vs. 18.3%). <br/>Conclusion(s): MUSKARDIA demonstrated significant cardiovascular protective effects in CAD patients with Hb < 140 g/L, particularly reducing non-fatal MI risk, while showing limited efficacy in patients with Hb>140 g/L. This highlights its cardiovascular protective role in high-risk populations characterized by greater ischemic risk and inadequate myocardial oxygen supply.<br/>Copyright &#xa9; The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature 2026. <77> Accession Number 2048124175 Title Milrinone versus Dobutamine as Supportive Agent for Right Ventricular Dysfunction after Cardiopulmonary Bypass: A Randomized Comparative Study. Source Journal of Cardiothoracic and Vascular Anesthesia. 40(11) (pp 3513-3522), 2026. Date of Publication: 01 Nov 2026. Author Hegazy M.A.; Abdelbaser I.; Abdellatif A.; Mamdouh M.; Atallah A.; Farid A.; Elsayed H.M.; Alseoudy M. Institution (Hegazy, Abdelbaser, Abdellatif, Mamdouh, Farid, Elsayed, Alseoudy) Department of Anesthesia and Surgical Intensive Care, Faculty of Medicine, Mansoura University, Mansoura, Egypt (Hegazy) Department of Anesthesia and Intensive Care, Emirates Health Services, United Arab Emirates, Sharjah, United Arab Emirates (Atallah) Ministry of Health, Aga, Egypt Publisher W.B. Saunders Abstract Objectives: To compare milrinone versus dobutamine for right ventricular (RV) dysfunction after cardiopulmonary bypass (CPB). <br/>Design(s): Randomized, open-label, parallel-group controlled trial. <br/>Setting(s): A tertiary cardiac surgery center. <br/>Participant(s): Adults (N = 88) with new RV systolic dysfunction (tricuspid annular plane systolic excursion [TAPSE] <=17 mm) post-CPB. <br/>Intervention(s): Milrinone (loading 50 microg/kg over 10 minutes, then 0.3-0.8 microg/kg/min) or dobutamine (2-10 microg/kg/min). Measurements & Main Results: The co-primary outcomes were duration of mechanical ventilation (clinical) and change in TAPSE over 24 hours (echocardiographic). Secondary outcomes included RV fractional area change, pulmonary artery systolic pressure (PASP), left ventricular outflow tract velocity-time integral, intensive care unit stay, arrhythmias, hypotension, and vasopressor need. Both groups had similar baseline characteristics. TAPSE improved significantly over 24 hours in both groups (p < 0.001). After adjustment for baseline TAPSE and left ventricular ejection fraction, milrinone was associated with modestly higher TAPSE at 24 hours (adjusted difference 1.82 mm, 95% CI 0.72-2.92, p = 0.001), though the clinical significance of this difference is uncertain. Milrinone required more norepinephrine than dobutamine (93.2% v 72.7%, p = 0.021). Other clinical outcomes did not differ significantly. In an exploratory subgroup analysis of patients with baseline post-CPB PASP >40 mmHg (n = 30), milrinone produced greater TAPSE improvement at 1, 6, and 24 hours (p < 0.05 for each), with a statistically significant interaction (p = 0.010); norepinephrine use was similar between groups in this subgroup (93.8% v 85.7%, p = 0.586). In patients with PASP <=40 mmHg (n = 58), the drugs were equivalent. <br/>Conclusion(s): Milrinone and dobutamine provide comparable overall RV recovery, though milrinone was associated with modestly higher adjusted TAPSE at 24 hours of uncertain clinical significance and increased norepinephrine requirements. An exploratory subgroup analysis suggests milrinone may provide superior RV functional recovery in patients with elevated post-CPB PASP (>40 mmHg), though this hypothesis-generating finding requires prospective validation.<br/>Copyright &#xa9; 2026 Elsevier Inc. <78> Accession Number 2051365505 Title Efficacy and Safety of Routine Postdilation in Balloon-Expandable Transcatheter Aortic Valve Implantation Platform: The DUOTAP Randomized Clinical Trial. Source JAMA Cardiology. (no pagination), 2026. Date of Publication: 2026. Author Autherith M.; Singer K.; Hauptmann L.; Torrefranca C.; Jantsch C.; Koschatko S.; Roglsperger E.-M.; Halavina K.; Heitzinger G.; Dannenberg V.; Palaparti R.; Langle S.; Mahr S.; Demirel C.; Coti I.; Zimpfer D.; Hengstenberg C.; Nitsche C.; Bartko P.E. Institution (Autherith, Singer, Hauptmann, Torrefranca, Jantsch, Koschatko, Roglsperger, Halavina, Heitzinger, Dannenberg, Demirel, Hengstenberg, Nitsche, Bartko) Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria (Palaparti) Department of Cardiology, Aayush Hospitals, Vijayawada, India (Langle, Mahr, Coti, Zimpfer) Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, Vienna, Austria Publisher American Medical Association Abstract Importance In patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI), asymmetric valve expansion can estimate prosthetic dysfunction and death. Postdilation has shown promising results in optimizing valve geometry in observational studies; however, randomized evidence is currently lacking. Objective To determine the efficacy of routine postdilation on transcatheter heart valve (THV) geometry and hemodynamic performance, and associated safety outcomes. Design, Setting, and Participants DUOTAP was a single-center, single-blinded randomized clinical trial. Recruitment took place from January 2025 to April 2026 and end points were assessed periprocedurally (fluoroscopy) at 30 days (adverse events) and at 3 months (computed tomography [CT]). The trial was conducted at a high-volume tertiary referral center, the Medical University of Vienna, Austria. Included patients had severe AS suitable for transfemoral TAVI with a balloon-expandable THV and without high-risk features on preprocedural CT or coronary angiography and were randomized in a 1:1 ratio, stratified by THV size, to routine postdilation vs no postdilation. These data were analyzed from July 2026 to September 2026. Intervention Routine postdilation using the original delivery balloon at the identical filling volume. A sham procedure was performed in the control group. Main Outcomes and Measures The fluoroscopic THV asymmetry index served as primary end point. Further fluoroscopic and CT-derived measures of valve geometry, hypoattenuated leaflet thickening (HALT), paravalvular leak (PVL), and THV hemodynamics on echocardiography, and freedom from major procedural adverse events served as secondary end points. Results Overall, 148 patients (median [IQR] age, 81 [77-85] years; 69 female [46.6%] and 79 male [53.4%]; median EuroSCORE-II, 2.3%) underwent randomization (n = 74 intervention vs n = 74 control). Intervention yielded a 70% lower THV asymmetry index compared with control (median: 1.2% vs 2.8%; geometric mean ratio: 0.30; 95% CI, 0.18-0.47; P <.001), with consistent effects across prespecified subgroups, induced by frame height reduction across the outer curve. Additionally, intervention yielded numerically larger THV diameters on fluoroscopy and significantly larger THV areas at the inflow, midframe, and outflow level on CT. HALT and mild or worse PVL were significantly less frequent and the Doppler Velocity Index was significantly higher in the intervention group. No differences in procedure-related adverse events between groups were recorded (chi<sup>2</sup> test: P =.36). Conclusions and Relevance In this randomized clinical trial, postdilation led to reduced THV asymmetry, optimized geometry, and improved hemodynamic performance, without increasing procedure-related adverse events. These results support the use of routine postdilation to optimize THV geometry and hemodynamics in suitable patients.<br/>Copyright &#xa9; 2027 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies. <79> Accession Number 2038049344 Title Care guided by tissue oxygenation and haemodynamic monitoring in off-pump coronary artery bypass grafting (Bottomline-CS): assessor blind, single centre, randomised controlled trial. Source BMJ. 388 (no pagination), 2025. Article Number: e082104. Date of Publication: 2025. Author Han J.; Zhai W.; Wu Z.; Zhang Z.; Wang T.; Ren M.; Liu Z.; Sessler D.I.; Guo Z.; Meng L. Institution (Han, Zhai, Zhang, Wang) Department of Anesthesiology, Tianjin Chest Hospital, Tianjin University, Tianjin, China (Wu) Department of Critical Care, Tianjin Chest Hospital, Tianjin University, Tianjin, China (Ren) Tianjin Research Institute of Cardiovascular Disease, Tianjin, China (Liu) Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indiana University, Indianapolis, IN, United States (Sessler) Department of Anesthesiology and Center for Outcomes Research, UTHealth, Houston, TX, United States (Guo) Department of Cardiovascular Surgery, Tianjin Chest Hospital, Tianjin University, Tianjin, China (Meng) Department of Anesthesia, Indiana University School of Medicine, Indianapolis, IN, United States Publisher BMJ Publishing Group Abstract Objective: To assess whether perioperative management guided by near-infrared spectroscopy to determine tissue oxygen saturation and haemodynamic monitoring reduces postoperative complications after off-pump coronary artery bypass grafting. <br/>Design(s): Assessor blinded, single centre, randomised controlled trial (Bottomline-CS trial). <br/>Setting(s): A tertiary teaching hospital in China. <br/>Participant(s): 1960 patients aged 60 years or older who were scheduled for elective off-pump coronary artery bypass grafting. <br/>Intervention(s): All patients had multisite monitoring of tissue oxygen saturation (bilateral forehead and unilateral forearm brachioradialis) and haemodynamic monitoring. Both groups received usual care, including arterial blood pressure, central venous pressure, electrocardiography, and transoesophageal echocardiography when indicated. Guided care aimed to maintain tissue oxygenation within 10% above or below preoperative baseline values, established 24-48 hours before surgery, from the start of anaesthesia until extubation or for up to 24 hours postoperatively. In the usual care group, tissue oximetry and haemodynamic data were concealed, and care was routine. <br/>Main Outcome Measure(s): The primary outcome was the incidence of a composite of 30 day postoperative complications, which were cerebral, cardiac, respiratory, renal, infectious, and mortality complications. Secondary outcomes included the individual components of the composite outcome, new-onset atrial fibrillation, and hospital length of stay. <br/>Result(s): Of 1960 patients randomly assigned, data from 967 guided care and 974 usual care patients were analysed. During anaesthesia, the area under the curve for tissue oxygen saturation measurements outside the plus and minus 10% baseline range was significantly smaller with guided care than only usual care: left forehead 32.4 versus 57.6 (%xmin, P<0.001), right forehead 37.9 versus 62.6 (P<0.001), and forearm 14.8 versus 44.7 (P<0.001). The primary composite outcome occurred in 457/967 (47.3%) patients in the guided care group and 466/974 (47.8%) patients in the usual care group (unadjusted risk ratio 0.99 (95% confidence interval 0.90 to 1.08), P=0.83). No secondary outcomes differed significantly between groups. The largest observed difference was in incidence of pneumonia, which was less frequent in the guided care group (88/967, 9.1%) than in the usual care group (121/974, 12.4%) and not statistically significant after adjusting for multiple comparisons. <br/>Conclusion(s): Guided care by use of multisite near-infrared spectroscopy and haemodynamic monitoring effectively maintained tissue oxygenation near baseline levels compared with usual care. However, no clear evidence was noted that this approach reduced the incidence of major postoperative complications. These findings do not support the routine use of near-infrared spectroscopy and haemodynamic monitoring to maintain tissue oxygenation during off-pump coronary artery bypass grafting. Trial registration: ClinicalTrials.gov NCT04896736.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. <80> Accession Number 637379347 Title Serum Lactate and Mortality during Pediatric Admissions: Is 2 Really the Magic Number?. Source Journal of Pediatric Intensive Care. 11(2) (pp 83-90), 2022. Date of Publication: 18 Feb 2022. Author Loomba R.S.; Farias J.S.; Villarreal E.G.; Flores S. Institution (Loomba) Division Of Pediatric Cardiac Critical Care, Advocate Children's Hospital, Oak Lawn, IL, United States (Loomba) Department Of Pediatrics, Chicago Medical School, Rosalind Franklin University Of Medicine And Science, Chicago, IL, United States (Farias, Villarreal) Tecnologico De Monterrey, School Of Medicine And Health Sciences, Nuevo Leon, Monterrey, Mexico (Flores) Section Of Critical Care Medicine And Cardiology, Texas Children's Hospital, Houston, TX, United States (Flores) Department Of Pediatrics, Baylor College Of Medicine, Houston, TX, United States Publisher Georg Thieme Verlag Abstract The primary objective of this study was to determine if serum lactate level at the time of hospital admission can predict mortality in pediatric patients. A systematic review was conducted to identify studies that assessed the utility of serum lactate at the time of admission to predict mortality in pediatric patients. The areas under the curve from the receiver operator curve analyses were utilized to determine the pooled area under the curve. Additionally, standardized mean difference was compared between those who survived to discharge and those who did not. A total of 12 studies with 2,099 patients were included. Out of these, 357 (17%) experienced mortality. The pooled area under the curve for all patients was 0.74 (0.67-0.80, p < 0.01). The pooled analyses for all admissions were higher in those who experienced mortality (6.5 vs. 3.3 mmol/L) with a standardized mean difference of 2.60 (1.74-3.51, p < 0.01). The pooled area under the curve for cardiac surgery patients was 0.63 (0.53-0.72, p < 0.01). The levels for cardiac surgery patients were higher in those who experienced mortality (5.5 vs. 4.1 mmol/L) with a standardized mean difference of 1.80 (0.05-3.56, p = 0.04). Serum lactate at the time of admission can be valuable in identifying pediatric patients at greater risk for inpatient mortality. This remained the case when only cardiac surgery patients were included.<br/>Copyright &#xa9; 2020. Thieme. All rights reserved. <81> Accession Number 637507990 Title Veno-Arterial Partial Pressure of Carbon Dioxide Difference as a Metric of Systemic Oxygen Delivery: Insights from a Correlative Meta-Analysis. Source Journal of Pediatric Intensive Care. 13(4) (pp 372-378), 2022. Date of Publication: 28 Feb 2022. Author Loomba R.S.; Farias J.S.; Savorgnan F.; Acosta S.; Flores S.; Villarreal E.G. Institution (Loomba) Division of Cardiology, Advocate Children's Hospital, Chicago, IL, United States (Loomba) Department of Pediatrics, Chicago Medical School/Rosalind Franklin University of Medicine and Science, Chicago, IL, United States (Farias, Villarreal) Section of Critical Care Medicine and Cardiology, Texas Children's Hospital, Houston, TX, United States (Savorgnan, Acosta, Flores) Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States (Savorgnan, Acosta, Flores) Tecnologico de Monterrey, School of Medicine and Health Sciences, Nuevo Leon, Monterrey, Mexico Publisher Georg Thieme Verlag Abstract The assessment of cardiac output and adequacy of systemic oxygen delivery in children after cardiac surgery require the use of an aggregate of hemodynamic monitors and blood tests. There are previously published data regarding the utility of the veno-arterial partial pressure of carbon dioxide difference (AVDco2) to help with this. This study pooled data on the correlation of AVDco2 with other metrics of cardiac output and systemic oxygen delivery such as arteriovenous oxygen saturation difference, venous saturation, and serum lactate. A systematic review of the literature was done to identify studies analyzing the correlation of AVDco2 with other hemodynamic and laboratory values. Data were extracted, and correlation coefficients were pooled for each specific comparison to create a point estimate for the overall correlation. A total of four studies with 350 patients and 809 paired blood gases were pooled. Adequate data were available to assess the correlation of AVDco2 with arteriovenous oxygen saturation difference, venous saturation, and serum lactate. There was a significant, moderate correlation with arteriovenous oxygen saturation difference and venous saturation. A significant, weak correlation with serum lactate was found. The AVDco2 has significant, moderate correlations with other metrics of the adequacy of systemic oxygen delivery such as arteriovenous oxygen saturation difference and venous saturation. There was a significant but only weak correlation with serum lactate. AVDco2 may be complementary to assess the adequacy of cardiac output and systemic oxygen delivery.<br/>Copyright &#xa9; 2022. Thieme. All rights reserved. <82> Accession Number 2051285532 Title Choosing Between On-Pump and Off-Pump Coronary Artery Bypass Grafting: Contemporary Evidence for Patient Selection and Clinical Decision-Making. Source Cardiology in Review. (pp 1-8), 2026. Date of Publication: 2026. Author Zhang Y.; Ren C. Institution (Zhang, Ren) Department of Cardiovascular Surgery Center, Capital Medical University Affiliated Beijing Anzhen Hospital, Beijing Institute of Heart, Lung and Blood Vascular Diseases, Beijing, China Publisher Lippincott Williams and Wilkins Abstract On-pump (ONCAB) and off-pump coronary artery bypass grafting (OPCAB) remain established approaches to surgical myocardial revascularization, but contemporary evidence does not support a universal preference for either technique. The clinically relevant question is which patient and operative setting are most likely to benefit from each strategy. We performed a contemporary narrative evidence synthesis of landmark randomized trials, long-term follow-up studies, systematic reviews and meta-analyses, observational cohorts, graft-patency studies, and major coronary revascularization guidelines. MEDLINE/PubMed, Embase, the Cochrane Library, and Web of Science were searched for studies published from 2009 through 2025. Evidence was organized around perioperative neurologic, renal, bleeding, and respiratory outcomes; completeness of revascularization; graft patency; conversion to cardiopulmonary bypass; surgical experience; and long-term survival. No de novo meta-analysis was performed, and all pooled estimates reported in this review are explicitly attributed to previously published evidence syntheses. Randomized evidence indicates broadly similar long-term mortality between OPCAB and ONCAB, whereas OPCAB may reduce selected perioperative complications, particularly stroke, transfusion, acute kidney injury, and respiratory morbidity in appropriately selected patients. Conversely, complex coronary anatomy may favor ONCAB because a stable operative field can facilitate complete revascularization. Conversion from OPCAB to cardiopulmonary bypass is consistently associated with worse outcomes, underscoring the importance of surgeon and institutional experience. Graft-patency differences are most evident for saphenous vein grafts and technically challenging territories. Anaortic or no-touch OPCAB may be particularly valuable in patients with extensive ascending-aortic atherosclerosis. ONCAB and OPCAB should therefore be viewed as complementary strategies. Selection should integrate aortic pathology, ventricular function, renal and bleeding risk, coronary complexity, the probability of complete revascularization, and local OPCAB expertise. A patient-tailored framework can help translate heterogeneous comparative evidence into practical clinical decision-making.<br/>Copyright &#xa9; 2026 Wolters Kluwer Health, LLC. All rights reserved. <83> Accession Number 2050143534 Title Effect-site concentrations of remifentanil to suppress coughing during emergence from general anesthesia in adults: a systematic review and meta-analysis. Source Canadian Journal of Anesthesia. (no pagination), 2026. Date of Publication: 2026. Author Kim N.; Park J.H.; Kim S.; Lee J.W.; Kim M.-S. Institution (Kim, Park, Kim, Lee, Kim) Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea Publisher Springer Abstract Purpose: Remifentanil infusion titrated to effect-site concentration (Ce) is commonly used to suppress coughing during emergence from general anesthesia; nevertheless, the optimal Ce range remains unclear. We aimed to conduct a systematic review and meta-analysis to synthesize the existing evidence on the optimal Ce values of remifentanil for cough suppression during emergence. Source: We performed a comprehensive literature search using PubMed, Embase, Web of ScienceTM, the Cochrane Library, and Google Scholar on 27 February 2025. We included prospective studies that used the up-and-down method to estimate the effective concentrations of remifentanil in 50% of patients (EC<inf>50</inf>) and 95% of patients (EC<inf>95</inf>) for suppressing coughing during emergence from general anesthesia with tracheal intubation in adult patients. We excluded studies in children or patients undergoing cardiac surgery, as well as those that only compared predefined Ce targets of remifentanil to determine optimal dosing. We obtained pooled estimates using a random-effects model with inverse-variance method, and heterogeneity was quantified using the I<sup>2</sup> statistic. We assessed risk of bias using the Cochrane Risk-of-Bias 2 tool for randomized trials and the Methodological Index for Non-Randomized Studies for nonrandomized comparative or single-arm studies. The primary outcome was EC<inf>50</inf> estimated using the up-and-down method, with secondary outcomes including model-based EC<inf>50</inf> and EC<inf>95</inf> estimates. Principal findings: We included 22 prospective studies comprising 857 adult participants, and none were assessed as being at a high risk of bias or of low methodologic quality. Based on 28 groups and 653 participants across 17 studies, the pooled mean EC<inf>50</inf> from the up-and-down method was 2.0 ng.mL<sup>-1</sup> (95% confidence interval [CI], 1.8 to 2.3), with considerable heterogeneity (I<sup>2</sup> = 74.5%). Based on 29 groups and 693 participants across 18 studies, the model-based EC<inf>50</inf> was 1.9 ng.mL<sup>-1</sup> (95% CI, 1.6 to 2.1), with considerable heterogeneity (I<sup>2</sup> = 96.1%). Based on 31 groups and 809 participants across 20 studies, the model-based EC<inf>95</inf> was 2.7 ng.mL<sup>-1</sup> (95% CI, 2.5 to 3.0), with considerable heterogeneity (I<sup>2</sup> = 99.5%). Subgroup analyses revealed higher mean EC<inf>50</inf> values in male individuals (2.6 ng.mL<sup>-1</sup>) and the highest mean EC<inf>50</inf> in patients undergoing video-assisted thoracic surgery (2.6 ng.mL<sup>-1</sup>). Using the Grading of Recommendations, Assessment, Development, and Evaluation framework, the certainty of evidence was rated as very low for all outcomes. <br/>Conclusion(s): The identified EC<inf>50</inf> and EC<inf>95</inf> values of remifentanil for suppressing coughing during emergence from general anesthesia in adults were 2.0 and 2.7 ng.mL<sup>-1</sup>, respectively. Patient sex and surgical type may influence the required Ce. Careful dose adjustment is recommended to avoid delayed awakening and hypoventilation, especially in cases requiring higher concentrations. Study registration: PROSPERO (CRD42024623581); first submitted 20 December 2024.<br/>Copyright &#xa9; Canadian Anesthesiologists' Society 2026. <84> Accession Number 2051285659 Title Prior Coronary Artery Bypass Grafting and Its Impact on Lesion Complexity, Procedural Characteristics, and Outcomes in Chronic Total Occlusion Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Source Cardiology in Review. (pp 1-12), 2026. Date of Publication: 2026. Author Azam H.; Alam B.; Javaid S.S.; Janjua H.; Hasan S.U.; Lal R.; Saad R.; Shuja H.; Pandey R.K.; Riaz A.; Pooja L.; Kiani S.S.; Zahid A.; Haq A.; Shah M.N. Institution (Azam) Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan (Alam) Department of Medicine, Rehman Medical College, Peshawar, Pakistan (Javaid) Department of Medicine, University of Mississippi Medical Center, Jackson, MS, United States (Janjua) Department of Medicine, Rhodes College, Memphis, TN, United States (Hasan) Department of Medicine, Dow Medical College, Karachi, Pakistan (Lal) Department of Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, Pakistan (Saad) Department of Medicine, Ziauddin University, Karachi, Pakistan (Shuja) Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan (Pandey) Department of Medicine, Nepalgunj Medical College, Nepalgunj, Nepal (Riaz) Department of Medicine, Sheikh Zayed Medical College, Rahim Yar Khan, Pakistan (Pooja) Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan (Kiani) Department of Medicine, Rawal Institute of Health Sciences, Islamabad, Pakistan (Zahid) Department of Medicine, Windsor University School of Medicine, Cayon, Saint Kitts and Nevis (Haq) Department of Medicine, Ramaiah Medical College, Karnataka, Bengaluru, India (Shah) Al Dhafra Hospitals, SEHA, Abu Dhabi, United Arab Emirates Publisher Lippincott Williams and Wilkins Abstract Prior coronary artery bypass grafting (CABG) is associated with accelerated native vessel atherosclerosis and more complex chronic total occlusion (CTO) anatomy, rendering CTO-percutaneous coronary intervention (PCI) more challenging despite contemporary technical advances. We performed a systematic review and meta-analysis to compare CTO lesion characteristics, procedural demands, and in-hospital outcomes according to prior CABG status. PubMed, the Cochrane Library, and Google Scholar were systematically searched from inception through May 15, 2026, for studies comparing CTO-PCI outcomes in patients with and without prior CABG. Data were pooled using odds ratios (ORs) and standardized mean differences (SMDs). Twelve studies enrolling 47,434 patients, including 10,354 with prior CABG, were included. Compared with patients without prior CABG, those with prior CABG had higher rates of blunt stump morphology (OR 1.51 [1.42-1.61]), proximal cap ambiguity (OR 1.55 [1.45-1.66]), calcification (OR 2.49 [2.22-2.79]), vessel bending (OR 2.27 [1.27-4.05]), distal cap bifurcation (OR 1.73 [1.51-1.98]), and higher Multicenter CTO Registry of Japan scores (SMD 0.48 [0.40-0.56]). Procedural burden was greater, with higher contrast use, longer fluoroscopy time and procedure duration, and greater stent use. Technical success (OR 0.63 [0.43-0.92]) and procedural success (OR 0.60 [0.53-0.69]) were lower in the prior CABG group. In-hospital mortality (OR 2.19), myocardial infarction (OR 2.29), and contrast-induced nephropathy (OR 1.97) were higher, whereas cardiac tamponade was less frequent (OR 0.37). Prior CABG is associated with substantially greater CTO complexity, procedural burden, and in-hospital risk, underscoring the need for careful procedural planning and individualized risk stratification in this population.<br/>Copyright &#xa9; 2026 Wolters Kluwer Health, LLC. All rights reserved. <85> Accession Number 2042477964 Title UK multisociety consensus statement on the emergency management and resuscitation of patients with left-sided Impella support. Source Heart. 112(21) (pp 1171-1178), 2026. Date of Publication: 01 Nov 2026. Author Akhtar W.; Bowles C.T.; Costanzo P.; Deakin C.D.; Elliot P.; Eladawy M.; Gardner R.S.; Govier M.; Handslip R.; Hill J.; Jain A.; Khan S.Q.; Lewis I.; Lim H.S.; Mariathas M.; Mellis C.; Monteagudo-Vela M.; Naldrett I.; Ostermann M.; Perera D.; Pinto S.; Richardson C.; Ranasinghe A.; Gil F.R.; Rosenberg A.; Schueler S.; Sinclair A.; Swanson N.; Wilson S.; Webb I.; Webb S.; Walker C.; Panoulas V. Institution (Akhtar, Perera) St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom (Akhtar, Bowles, Monteagudo-Vela, Pinto, Gil, Rosenberg, Panoulas) Harefield Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom (Akhtar, Elliot) Faculty of Intensive Care Medicine, London, United Kingdom (Costanzo) Royal Papworth Hospital, Cambridge, United Kingdom (Deakin) Resuscitation Council UK, London, United Kingdom (Eladawy, Schueler) Freeman Hospital, Newcastle upon Tyne, United Kingdom (Gardner, Sinclair) Golden Jubilee National Hospital, Clydebank, United Kingdom (Gardner) British Society for Heart Failure, London, United Kingdom (Govier, Mariathas) Bristol Royal Infirmary, University Hospitals Bristol, Bristol, United Kingdom (Handslip, Wilson) St Georges University Hospital, London, United Kingdom (Hill) Royal Brompton Hospital, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom (Jain, Mellis) Barts Health NHS Trust, London, United Kingdom (Khan, Lim, Richardson) University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom (Lewis) University Hospital of Wales, Cardiff, United Kingdom (Naldrett) British Association of Critical Care Nurses, London, United Kingdom (Ostermann, Webb) Intensive Care Society, London, United Kingdom (Ranasinghe) Society for Cardiothoracic Surgery in Great Britain and Ireland, London, United Kingdom (Swanson) British Cardiovascular Society, London, United Kingdom (Webb) King's College Hospital NHS Foundation Trust, London, United Kingdom (Walker) Association of Cardiothoracic Anaesthesia and Critical Care, London, United Kingdom Publisher BMJ Publishing Group Abstract The use of left-sided Impella microaxial flow pumps has expanded rapidly for the management of cardiogenic shock, left ventricular unloading and as a bridge to heart transplantation. However, standard life support and resuscitation algorithms are not directly applicable to patients receiving this therapy due to fundamental alterations in circulatory physiology. To address this gap, eleven UK Impella centres and eight national professional societies collaborated to develop a unified national consensus statement on the emergency management of patients with left-sided Impella support. Using a systematic review of the literature and a modified Delphi process guided by the European Society of Cardiology framework for grading recommendations, expert representatives achieved agreement on key priorities and structured actions to be undertaken in the first few minutes of resuscitation.The consensus outlines early recognition of circulatory inadequacy (mean arterial pressure <30 mm Hg or end-tidal CO2 <2 kPa), prompt activation of multidisciplinary responders, reduction of Impella power to P2 before initiating cardiopulmonary resuscitation and structured division of patient-focused and device-focused teams. Device-specific troubleshooting algorithms are presented for suction, malposition, purge-system failure and mechanical malfunction. This multisociety consensus represents the first national standard for emergency management and resuscitation of patients supported by a left-sided Impella device and is intended to inform structured clinical training and improve patient outcomes through rapid, coordinated and physiologically tailored interventions.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <86> Accession Number 2050437035 Title Acute Kidney Injury After Cardiac Surgery: A Systematic Review of Pharmacological and Non-Pharmacological Interventions. Source Journal of Cardiothoracic and Vascular Anesthesia. 40(12) (pp 3971-3977), 2026. Date of Publication: 01 Dec 2026. Author D'Amico F.; Bonizzoni M.A.; Losiggio R.; Kaufman N.; Oliva F.M.; Vives M.; Bove T.; Redaelli M.B.; Stoppe C.; Zangrillo A.; Monti G.; Landoni G.; Ajello V.; Beretta L.; Chiodi B.; Crusco A.; De Piccoli N.; Facondo A.; Foggia G.D.; Fresilli S.; Fossati L.; Ghezzi M.; Giardina G.; Arina K.; Labanca R.; Lembo R.; Chirojit M.; Mure F.; Nakhnoukh C.; Notarianni L.; Paternoster G.; Pontillo D.; Silvetti S.; Alsa S.; Veneziano M. Institution (D'Amico, Bonizzoni, Losiggio, Kaufman, Oliva, Zangrillo, Monti, Landoni, Beretta) Department of Anaesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy (Vives) Department of Anaesthesia & Critical Care, Clinica Universidad de Navarra, Pamplona, Spain (Vives) IdiSNA, Instituto de Investigacion Sanitaria de Navarra, Pamplona, Spain (Bove) Department of Basic Biotechnological Sciences, Intensive Care Peri-Operative Clinics, Universita Cattolica del Sacro Cuore, Rome, Italy (Bove) Department of Emergency, Anesthesiological and Reanimation Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy (Redaelli) Department of Biotechnologies and Life Science, University of Insubria, Varese, Italy (Redaelli) Azienda Ospedaliera Ospedale di Circolo e Fondazione Macchi di Varese, Varese, Italy (Stoppe) Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Wurzburg, Wurzburg, Germany (Stoppe) Department of Cardiac Anesthesiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Berlin, Germany (Zangrillo, Monti, Landoni, Beretta) School of Medicine, Vita-Salute San Raffaele University, Milan, Italy (Ajello, Chiodi, Crusco, De Piccoli, Facondo, Foggia, Fresilli, Fossati, Ghezzi, Giardina, Arina, Labanca, Lembo, Mure, Nakhnoukh, Notarianni, Pontillo, Alsa, Veneziano) Cardiac Anesthesia Department, Tor Vergata University Hospital, Rome, Italy (Chirojit) Department of Anaesthesia, HELIOS Clinic for Cardiac Surgery Karlsruhe, Karlsruhe, Germany (Paternoster) Department of Health Sciences, University of Basilicata, Potenza, Italy (Paternoster) Anesthesia and ICU, San Carlo Hospital, Potenza, Italy (Silvetti) Department of Cardiac Anaesthesia and Intensive Care, Ospedale Policlinico San Martino IRCCS, IRCCS Publisher W.B. Saunders Abstract Objective: To identify and synthesize all randomized controlled trials (RCTs) evaluating pharmacological and non-pharmacological interventions for the prevention of cardiac surgery-associated acute kidney injury (CSA-AKI). <br/>Design(s): We performed a systematic review of RCTs evaluating pharmacological and non-pharmacological strategies. Interventions were qualitatively synthesized, and meta-analysis was performed when at least 4 RCTs were available. <br/>Setting(s): Hospitals. <br/>Participant(s): Adults undergoing cardiac surgery. <br/>Intervention(s): Pharmacological and non-pharmacological strategies to prevent CSA-AKI. <br/>Measurements and Main Results: A total of 207 RCTs, including 63,785 patients and evaluating 55 interventions, were identified. Most studies were small (median sample size 120) and single-center (76.7%) and reported neutral results (149/206), whereas 49 reported benefit and 8 reported harm. N-Acetylcysteine was the most frequently studied pharmacological intervention (19 RCTs), and remote ischemic preconditioning was the most frequently studied non-pharmacological intervention (34 RCTs). Among interventions evaluated in at least 4 RCTs were the use of dexmedetomidine (odds ratio [OR] 0.48, 95% confidence interval [CI] 0.29-0.80), fenoldopam (OR 0.57, 95% CI 0.33-0.98), nitric oxide (OR 0.61, 95% CI 0.43-0.88), and remote ischemic preconditioning (OR 0.78, 95% CI 0.67-0.90) were associated with lower odds of CSA-AKI. Among interventions evaluated in fewer than 4 RCTs were signals of benefit reported for amino acids, atrial natriuretic peptide, goal-directed perfusion, and KDIGO-based care bundles. <br/>Conclusion(s): Only a limited number of interventions were associated with lower odds of CSA-AKI; these findings require cautious interpretation and confirmation in adequately powered RCTs.<br/>Copyright &#xa9; 2026 Elsevier Inc. <87> Accession Number 2051477163 Title Cardiac lymphatic modulation in myocardial repair: from lymphangiogenesis to microsurgical reconstructive strategies. Source Trends in Cardiovascular Medicine. (no pagination), 2026. Date of Publication: 2026. Author Fabi A.; Melcher S.; Wendelspiess S.R.; Boeddinghaus J.; Salikhanov I.; Kutschka I.; Baraki H.; Mueller C.; Kappos E.A. Institution (Fabi, Melcher, Wendelspiess, Kappos) Department of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital of Basel, Basel, Switzerland (Fabi, Wendelspiess, Kappos) Faculty of Medicine, University of Basel, Basel, Switzerland (Boeddinghaus) BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom (Boeddinghaus, Mueller) Cardiovascular Research Institute Basel and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland (Salikhanov, Kutschka, Baraki) Department of Cardiac Surgery, University Hospital Basel, Basel, Switzerland Publisher Elsevier Inc. Abstract The cardiac lymphatic system is increasingly recognized as a regulator of myocardial fluid homeostasis and tissue remodeling following myocardial injury. Experimental evidence suggests that impaired lymphatic drainage contributes to persistent edema, chronic inflammation and functional deterioration after myocardial infarction and other acute and chronic cardiovascular conditions. However, the translational relevance of pharmacological and microsurgical reconstructive strategies remains largely unexplored. A literature review was performed using PubMed/MEDLINE to identify studies addressing the anatomy, physiology, pathophysiology, and potential therapeutic strategies addressing the cardiac lymphatic system. This study finds that cardiac lymphatics drain myocardial interstitial fluid and immune cells toward mediastinal pathways. Across various disease models, cardiac lymphatic dysfunction contributes to prolonged edema, inflammation, and adverse fibrotic remodeling. In preclinical models, pro-lymphangiogenic strategies have increased lymphatic growth and transport and have been associated with more favorable remodeling. By contrast, lymphovenous anastomosis and vascularized lymph node transfer remain largely untested concepts in cardiac disease; their ability to improve myocardial lymphatic drainage or clinical outcomes has not been demonstrated. Consequently, cardiac lymphatics may become an important therapeutic target in myocardial repair. Preliminary evidence supports the pharmacological promotion of lymphangiogenesis as a promising strategy for myocardial regeneration, but further research is necessary to explore the safety, feasibility and effectiveness of surgical cardiac lymphatic modulation.<br/>Copyright &#xa9; 2026 The Author(s) <88> Accession Number 2050937483 Title Cardiovascular outcomes of oral incretin-based drugs in type 2 diabetes: a GRADE-assessed meta-analysis of 67, 679 patients. Source Frontiers in Cardiovascular Medicine. 13 (no pagination), 2026. Article Number: 1884895. Date of Publication: 29 Sep 2026. Author Ali M.F.; Mohammed O.F.; Suhail A.; Naseer F.; Shafi N.; Arshad M.U.; Shazly O.; Mohmand M.S.; Ahmad H.; Binashikhbubkr N.K.; Maaz M.; Khan M.; Neppala S.; Al-Jarshawi M.; Hemida M.F. Institution (Ali) Department of Internal Medicine, HCA Healthcare Centerpoint Medical Center, Kansas City, MO, United States (Mohammed) Faculty of Medicine, Osmania Medical College, Hyderabad, India (Suhail) Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan (Naseer) Department of Medicine, Nishtar Medical University, Multan, Pakistan (Shafi) Department of Medicine, Arnot Ogden Medical Center, Elmira, NY, United States (Arshad, Ahmad) Department of Medicine, Shalamar Medical and Dental College, Lahore, Pakistan (Shazly) Faculty of Medicine, Ain Shams University, Cairo, Egypt (Mohmand) Department of Medicine, Khyber Medical College, Peshawar, Pakistan (Binashikhbubkr) College of Medicine and Health Science, Hadhramout University, Hadhramout, Yemen (Maaz, Khan) Department of Medicine, Bacha Khan Medical College, Mardan, Pakistan (Neppala) Department of Cardiology, The University of Texas Health Science Center, San Antonio, TX, United States (Al-Jarshawi) NIHR Academy, National Institute for Health & Care Research, Leeds, United Kingdom (Al-Jarshawi) Keele Cardiovascular Research Group, Faculty of Medicine & Health Sciences, Keele University, Stoke-on-Trent, United Kingdom (Al-Jarshawi) Faculty of Biology, Medicine and Health, School of Health Sciences, Division of Informatics, Imaging & Data, University of Manchester, Manchester, United Kingdom (Al-Jarshawi) Cardiology Department, Royal Stoke University Hospitals, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom (Al-Jarshawi) Department of Medicine, Institute of Health Sciences Education, Queen Mary University of London, London, United Kingdom (Hemida) Department of Internal Medicine, Alexandria Main University Hospital, Alexandria, Egypt (Hemida) Department of Internal Medicine, University of Vermont, Burlington, VT, United States (Hemida) Department of Cardiovascular Medicine, American Society for Inclusion, Diversity, Equity in Healthcare (ASIDE), Lewes, DE, United States Publisher Frontiers Media SA Abstract Background - While injectable GLP-1 receptor agonists like semaglutide have demonstrated clear cardiovascular benefits in type 2 diabetes mellitus (T2DM), the role of oral incretin-based therapies, including oral semaglutide and DPP-4 inhibitors-remains less well defined. Comprehensive evaluation of their cardiovascular efficacy is warranted. Research question - What are the cardiovascular outcomes associated with oral incretin-based therapies, specifically oral semaglutide and DPP-4 inhibitors, in patients with T2DM compared to placebo or standard care. Methods - We searched electronic databases for randomized controlled trials (RCTs). Meta-analysis was conducted in R version 4.4.3 using the "meta" and "metasens" packages. Statistical analysis was performed using R software and RStudio (version 4.4.2). We calculated pooled estimates using risk ratios (RR) with 95% confidence intervals (CIs). Results - A total of 9 studies comprising 67, 679 patients were included, of which two evaluated oral semaglutide and the remaining seven assessed DPP-4 inhibitors. There was no significant reduction in all-cause mortality (RR 0.97, 95% CI 0.90-1.04, p = 0.35) or cardiovascular death (RR 0.98, 95% CI 0.91-1.05, p = 0.48). Major adverse cardiovascular events (MACE) showed a non-significant reduction overall (RR 0.95, 95% CI 0.91-1.00, p = 0.06), with oral semaglutide demonstrating a significant benefit (RR 0.86, 95% CI 0.78-0.95, p = 0.003). Non-fatal myocardial infarction (MI) (RR 0.98, 95% CI 0.88-1.09) and non-fatal stroke (RR 0.93, 95% CI 0.83-1.03) were not significantly affected. Hospitalizations due to heart failure (RR 0.98, 95% CI 0.84-1.13) and unstable angina (RR 1.00, 95% CI 0.87-1.15) remained unchanged. Coronary revascularization was slightly reduced with oral semaglutide (RR 0.76, 95% CI 0.64-0.91). Adverse events leading to discontinuation were higher with oral semaglutide (RR 1.51, 95% CI 1.15-1.98), while serious adverse events were significantly reduced (RR 0.96, 95% CI 0.94-0.99, p = 0.003). Sensitivity analyses were conducted due to significant heterogeneity in key outcomes. While omitting certain studies reduced heterogeneity, the overall results remained consistent. Conclusion - Oral incretin-based therapies were not associated with significant reductions in all-cause mortality, cardiovascular death, or MACE overall, though oral semaglutide showed a significant MACE benefit and reduced coronary revascularization on subgroup analysis. Non-fatal MI, fatal or non-fatal MI, non-fatal stroke, fatal or non-fatal stroke and hospitalization due to heart failure or unstable angina were unaffected, and oral semaglutide carried a higher risk of treatment discontinuation. These findings suggest no clear class-wide cardiovascular benefit of oral incretins, with signals specific to oral semaglutide warranting confirmation in dedicated trials. Systematic Review Registration - PROSPERO CRD420251113835.<br/>Copyright &#xa9; 2026 Ali, Mohammed, Suhail, Naseer, Shafi, Arshad, Shazly, Mohmand, Ahmad, Binashikhbubkr, Maaz, Khan, Neppala, Al-Jarshawi and Hemida. <89> Accession Number 2050133833 Title Prognostic value of cardiovascular magnetic resonance in acute myocarditis: a systematic literature review and meta-analysis of late gadolinium enhancement and narrative literature review of parametric mapping. Source BMC Medical Imaging. 26(1) (no pagination), 2026. Article Number: 568. Date of Publication: 01 Dec 2026. Author Gaizauskiene K.; Skorniakov V.; Silinskiene D.; Valeviciene N.; Glaveckaite S. Institution (Gaizauskiene, Valeviciene) Department of Radiology, Nuclear Medicine and Medical Physics, Institute of Biomedical Sciences, Vilnius University Faculty of Medicine, Santariskiu st. 2, Vilnius, Lithuania (Skorniakov) Faculty of Mathematics and Informatics, Institute of Applied Mathematics, Vilnius University, Naugarduko str. 24, Vilnius, Lithuania (Silinskiene) Vilnius University Hospital Santaros Klinikos, Santariskiu st. 2, Vilnius, Lithuania (Glaveckaite) Clinic of Cardiovascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Santariskiu st. 2, Vilnius, Lithuania Publisher BioMed Central Ltd Abstract Background and aims: Limited data exist on the prognostic value of parametric mapping and late gadolinium enhancement (LGE) in patients with acute myocarditis (AM). This meta-analysis aimed to investigate the prognostic value of LGE as assessed by using cardiovascular magnetic resonance (CMR) in patients with AM, including more recent evidence. Additionally, the prognostic value of CMR parametric mapping was narratively reviewed. <br/>Material(s) and Method(s): The systematic search was conducted in the PubMed and Scopus databases from inception to January 17, 2026 (PubMed) and January 20th 2026 (Scopus). 1296 records were found through the search. Finally, sixteen studies were included in this systematic review. Thirteen studies were included in the meta-analysis on association between LGE and clinical outcomes in AM. The composite endpoint was defined as MACE and/or one of the following endpoints: all-cause death, heart failure decompensation requiring hospitalization, heart transplantation, and recurrent AM. MACE was defined as a composite of cardiovascular death (including sudden death), sustained ventricular tachycardia, ventricular fibrillation, complete atrioventricular heart block requiring a pacemaker, and cardiogenic shock. Five studies were reviewed for the prognostic value of parametric mapping parameters. After initial calculations, it appeared that studies using broader composite endpoints than only MACE introduced substantial heterogeneity. Therefore, we have additionally conducted analysis incorporating only eight studies with MACE as the endpoint. <br/>Result(s): The presence of LGE was associated with higher odds of the composite endpoint. The unadjusted pooled OR demonstrated a significant relationship between the presence of LGE and higher chances of the composite endpoint (OR<inf>LGE(+) vs. LGE(-)</inf>[95% CI] = 3.02 [1.40, 6.51], p < 0.001) with high heterogeneity (I<sup>2</sup> = 81.98%, p < 0.0001) On the qualitative level, results obtained in the MACE studies subgroup remained the same (OR<inf>LGE(+) vs. LGE(-)</inf>[95% CI] = 2.88 [2.01, 4.13], p < 0.0001). No clear evidence of publication bias was detected; however, power to detect small-study effects is limited and results should be interpreted cautiously. The prognostic value of parametric mapping parameters did not undergo meta-analysis and was reviewed narratively due to the shortage of the respective data. The data on the prognostic value of native T1, T2, and extracellular volume (ECV) are controversial and limited. <br/>Conclusion(s): Based on the findings, the presence of LGE appears to be associated with an adverse prognosis in patients with AM. However, these findings should be interpreted with caution because of substantial heterogeneity among studies and the unadjusted effect estimations. Evidence regarding the prognostic value of CMR-derived parametric mapping remains limited. Large, prospective, well-designed studies are needed to determine the incremental prognostic value of parametric mapping beyond LGE for risk stratification and outcome prediction in patients with AM.<br/>Copyright &#xa9; The Author(s) 2026. <90> Accession Number 2050141117 Title An Updated Meta-Analysis of Randomized Controlled Trials Comparing the Analgesic Efficacy of Intercostal Nerve Block Versus Erector Spinae Plane Block in Thoracic Surgery. Source Anesthesiology Research and Practice. 2026(1) (no pagination), 2026. Article Number: 7833175. Date of Publication: 2026. Author Faheem M.S.B.; Munir S.U.; Maryam K.U.E.; Abbasi S.U.A.M.; Samadi S. Institution (Faheem) Department of Medicine and Surgery, Karachi Institute of Medical Sciences, Sindh, Karachi, Pakistan (Munir) Department of Medicine, Karachi Medical and Dental College, Sindh, Karachi, Pakistan (Maryam) Department of Medicine, Foundation University Medical College, Islamabad, Pakistan (Abbasi) Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan (Samadi) Department of Medicine, Kabul University of Medical Sciences "Abu Ali Ibn Sina", Kabul, Afghanistan Publisher John Wiley and Sons Ltd Abstract Background: ESPB, an ultrasound-guided fascial plane block, gained considerable attention as a regional anaesthetic because of its longer duration of action, favourable safety profile, and multidermatomal analgesic effect. ICNB, however, is associated with a relatively short duration of action, often requiring repeated dosing and adjunctive systemic analgesics. <br/>Method(s): The methodology of this meta-analysis adhered to the PRISMA 2020 guidelines and included randomized controlled trials comparing ESPB with ICNB in thoracoscopic surgery. A systematic PubMed, Cochrane, and ClinicalTrials.gov search was performed that reviewed the publications available till March 16, 2025. Studies were screened, data were extracted, and two reviewers independently evaluated the risk of bias using the Cochrane ROB 2 tool. Dynamic pain at 48 h was the primary outcome; the secondary outcome was analgesic use. Standardized mean differences (SMDs) or mean differences (MDs), as appropriate, with 95% confidence intervals were computed. Version 5.4 of Review Manager (RevMan) was used to process the statistical analysis, with a random-effects model where necessary. <br/>Result(s): We identified 444 records, out of which 6 randomized controlled trials were part of this meta-analysis, totalling 353 cases: 176 being part of the ESPB group, while the remaining 177 constituted the ICNB group. For the principal outcome of dynamic pain score at 48 h postoperatively, combined analysis from five studies (n = 295) revealed a statistically significant lowered pain score with ESPB in contrast to ICNB (SMD = -0.34, 95% CI: -0.57 to -0.10, p = 0.004; I<sup>2</sup> = 0%). For postoperative analgesic use, all six studies (n = 353) data showed insignificant group difference (MD = 0.14, 95% CI: -1.04 to 1.32, p = 0.81; I<sup>2</sup> = 57%). <br/>Conclusion(s): This study suggests that ESPB contributed to a reduction in pain scores at 48 h after thoracoscopic surgery compared with ICNB, yet both methods exhibited equivalent postoperative analgesic consumption. These findings show that ESPB can be a preferable option for prolonged postoperative analgesia; however, additional well-designed studies are needed to corroborate the evidence base.<br/>Copyright &#xa9; 2026 Muhammad Shaheer Bin Faheem et al. Anesthesiology Research and Practice published by John Wiley & Sons Ltd. <91> Accession Number 2047865156 Title Changes in Free and Total Remimazolam Concentrations During Cardiopulmonary Bypass: A Randomized Dose-Comparison Trial. Source Journal of Cardiothoracic and Vascular Anesthesia. 40(11) (pp 3502-3512), 2026. Date of Publication: 01 Nov 2026. Author Ohno S.; Yoshikawa Y.; Kurihara D.; Sato Y.; Kunigo T.; Takahashi K.; Sato T.; Hirahata T.; Maeda M.; Negishi K.; Ikeshima Y.; Ishida M.; Shimizu H.; Hayashi M.; Takasaki Y.; Chaki T.; Aoyama T.; Toda T.; Yamakage M. Institution (Ohno, Yoshikawa, Sato, Kunigo, Takahashi, Sato, Hirahata, Maeda, Negishi, Ikeshima, Chaki, Yamakage) Department of Anesthesiology, Sapporo Medical University School of Medicine, Hokkaido, Sapporo, Japan (Kurihara, Ishida, Shimizu, Hayashi, Takasaki, Aoyama, Toda) Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Hokkaido, Sapporo, Japan Publisher W.B. Saunders Abstract Objectives: Remimazolam is increasingly used in cardiac surgery for hemodynamic stability; however, during cardiopulmonary bypass (CPB), hemodilution and hypoalbuminemia may increase its pharmacologically active free fraction, raising concern about unrecognized overexposure under constant infusion. Yet, the temporal profile of free remimazolam during CPB has not been fully elucidated. We investigated whether a pragmatic dose adjustment could maintain free remimazolam concentrations within a stable range. <br/>Design(s): Randomized, controlled, parallel-group trial. <br/>Setting(s): A university hospital. <br/>Participant(s): Thirty-six adults undergoing cardiac surgery with CPB. <br/>Intervention(s): Patients were assigned to a normal-dose group (1 mg/kg/h) or a low-dose group in which the infusion rate of remimazolam was reduced to 70% at CPB initiation (0.7 mg/kg/h). <br/>Measurements and Main Results: The primary outcome was free remimazolam concentration. Secondary outcomes included total remimazolam concentration, protein binding, and associations between bispectral index values and drug concentrations. Baseline-adjusted analysis of free remimazolam concentrations showed a significant time-by-group interaction (p<inf>interaction</inf> = 0.001), increasing over time in the normal-dose group but remaining stable in the low-dose group. The largest adjusted between-group difference was observed 30 minutes after CPB termination (mean difference [95% CI], 89 [58-120] ng/mL; p < 0.001). No linear association was observed between bispectral index values and free or total remimazolam concentrations. <br/>Conclusion(s): During CPB, free remimazolam concentrations increased over time under constant infusion without corresponding changes in bispectral index values, whereas reducing the infusion rate to 70% at CPB initiation maintained free remimazolam concentrations within a stable range.<br/>Copyright &#xa9; 2026 Elsevier Inc. <92> Accession Number 2051379345 Title Antithrombotic Therapy After Left Atrial Appendage Occlusion The SIMPLAAFY Randomized Clinical Trial. Source JAMA. (no pagination), 2026. Date of Publication: 2026. Author Reddy V.Y.; Saliba W.I.; Waggoner T.; Nair D.G.; Weiner S.; Evonich R.; Hoskins M.; Dublin A.; Rinaldi M.; Gandhi G.; Dukes J.W.; Reddy M.; DeLurgio D.; Iyer V.R.; Venkataraman G.; Sadhu A.; Yaganti V.; Trulock K.; Gibson D.N.; Alkhouli M.; Shah M.; Doshi S.K.; Natale A.; Coylewright M.; Gibson C.M.; Kolkailah A.A.; Jaber W.A.; Leger K.; Matznick E.; Christen T.; Sutton B.S.; Stein K.M.; Kar S. Institution (Reddy) Helmsley Trust Electrophysiology Center, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, United States (Saliba, Jaber) Cleveland Clinic, Cleveland, OH, United States (Waggoner) US Heart and Vascular, Northwest Medical Center, Tucson, AZ, United States (Nair) St Bernards Healthcare & Arrhythmia Research Group, Jonesboro, AR, United States (Weiner) Christus Trinity Mother Frances Health System, Tyler, TX, United States (Evonich) Emplify Health by Bellin, Green Bay, WI, United States (Hoskins) New Mexico Heart Institute, Lovelace Medical Group, Albuquerque, United States (Dublin) John Muir Medical Center, Walnut Creek, CA, United States (Rinaldi) Sanger Heart and Vascular Institute, Wake Forest School of Medicine, Charlotte, NC, United States (Gandhi) Tri-Health Heart & Vascular Institute, Bethesda North Hospital, Cincinnati, OH, United States (Dukes) Cardiology Associates Medical Group, Ventura, CA, United States (Reddy) University of Kansas Hospital, Kansas City, United States (DeLurgio) Emory St Joseph's Hospital, Atlanta, GA, United States (Iyer) Sentara Healthcare, Norfolk, VA, United States (Venkataraman) Colorado Heart and Vascular, Lakewood, United States (Sadhu) Phoenix Cardiovascular Research Group, Phoenix, AZ, United States (Yaganti) St Mark's Hospital, Salt Lake City, UT, United States (Trulock) Community Heart and Vascular, Indianapolis, IN, United States (Gibson) Scripps Clinic and Prebys Cardiovascular Institute, San Diego, CA, United States (Alkhouli) Mayo Clinic Foundation, Rochester, MN, United States (Shah) Washington Hospital Center, Washington, DC, United States (Doshi) Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, United States (Doshi) Pacific Heart Institute, Santa Monica, CA, United States (Natale) Texas Cardiac Arrhythmia Institute, St David's Medical Center, Austin, United States (Natale) Department of Biomedicine and Prevention, Division of Cardiology, University of Tor Vergata, Rome, Italy (Coylewright) Heart and Vascular Center, Essentia Health, Duluth, MN, United States (Gibson) Baim Institute, Harvard Medical School, Boston, MA, United States (Kolkailah) Structural Heart Disease Center, Henry Ford Health, Detroit, MI, United States (Leger, Matznick, Christen, Sutton, Stein) Boston Scientific Corporation, Marlborough, MA, United States (Kar) Los Robles Hospital and Medical Center, Thousand Oaks, CA, United States Publisher American Medical Association Abstract IMPORTANCE Following a left atrial appendage closure (LAAC) procedure, antithrombotic therapy is administered to safely allow time for device endothelialization. However, the optimal postimplant antithrombotic regimen is unknown. OBJECTIVE To determine if either reduced-dose non-vitamin K oral anticoagulants (NOACs) or aspirin alone are noninferior to dual antiplatelet therapy (DAPT) for the composite clinical end point of death, stroke, systemic embolism, or major bleeding through 6 months post LAAC. DESIGN, SETTING, AND PARTICIPANTS This open-label, 3-group, multicenter clinical trial randomized 1857 patients between October 2024 and December 2025 at 87 US investigational sites, with the final 6-month follow-up in July 2026. Enrolled patients had nonvalvular atrial fibrillation, underwent successful LAAC, and were eligible for all 3 regimens. INTERVENTIONS Patients were randomly allocated 1:1:1 to DAPT for 6 months followed by aspirin (n = 624), a reduced-dose NOAC for 3 months followed by aspirin (n = 620), or aspirin alone for 12 months (n = 613). MAIN OUTCOMES AND MEASURES The primary outcome was the 6-month composite of all-cause death, stroke, systemic embolism, or major bleeding. Noninferiority was tested in the primary analysis population with a 1-sided Farrington-Manning test (alpha = .025). Bleeding and 45-day device-related thrombus rates were exploratory without multiplicity adjustment. RESULTS The cohort had a mean age of 76 (SD, 8) years, 42.9% were female, the mean CHA<inf>2</inf>DS<inf>2</inf>-VASc score was 4.2 (SD, 1.3), and 68.0% had paroxysmal atrial fibrillation. The primary outcome occurred in 41 patients (6.9%) with DAPT vs 31 (5.1%) with a reduced-dose NOAC (risk ratio, 0.75 [95% CI, 0.48-1.18]; risk difference, -1.7 percentage points; 97.5% upper bound, 1.2) and 20 (3.3%) with aspirin alone (risk ratio, 0.49 [95% CI, 0.29-0.82]; risk difference, -3.5 percentage points; 97.5% upper bound, -0.8). Both monotherapy strategies met noninferiority criteria (P < .001 for noninferiority for both). Major bleeding was 4.5% with DAPT, 2.7% with reduced-dose NOACs, and 1.7% with aspirin alone; clinically relevant nonmajor bleeding was 8.7%, 4.8%, and 3.8%, respectively. Device-related thrombus was observed in 3.4%, 0.9%, and 2.7%, respectively. CONCLUSIONS AND RELEVANCE Both reduced-dose NOACs and aspirin alone were noninferior to DAPT for 6-month outcomes after uncomplicated LAAC.<br/>Copyright &#xa9; 2026 American Medical Association. All rights reserved. <93> Accession Number 2049939246 Title Impact of Colloid Cardiopulmonary Bypass Priming Strategy on Perioperative Acid-Base Balance in Coronary Artery Bypass Surgery: Physicochemical Analysis of a Double-Blinded Randomized Controlled Study. Source Journal of Cardiothoracic and Vascular Anesthesia. 40(12) (pp 3930-3937), 2026. Date of Publication: 01 Dec 2026. Author Boer R.; Beukers A.M.; Pols J.M.; Seegers J.C.; van Haasteren N.; Ghantous D.; Nieuwenhuizen R.; Brouwers M.; Bulte C.S.E.; Duska F.; Vonk A.B.A.; Loer S.A.; Heldeweg M.L.A. Institution (Boer, Beukers, Seegers, Bulte, Loer, Heldeweg) Department of Anesthesiology, Amsterdam University Medical Center, Amsterdam, Netherlands (Seegers) Department of Intensive Care Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands (Pols, Seegers, Vonk) Department of Cardiothoracic Surgery, Amsterdam University Medical Center, Amsterdam, Netherlands (van Haasteren, Ghantous, Nieuwenhuizen, Brouwers) Department of Anaesthesiology, University of Amsterdam, Amsterdam, Netherlands (Duska, Heldeweg) Department of Anesthesia and Intensive Care Medicine, The Third Faculty of Medicine, Charles University and FNKV University Hospital, Prague, Czechia Publisher W.B. Saunders Abstract Objective: To determine whether colloid choice within the cardiopulmonary bypass (CPB) priming strategy independently modifies the perioperative acid-base trajectory. <br/>Design(s): Preplanned analysis of a single-center, double-blind, 3-arm randomized controlled trial. <br/>Setting(s): A tertiary academic teaching hospital. <br/>Participant(s): Thirty-four adult patients undergoing elective coronary artery bypass grafting with CPB. <br/>Intervention(s): Patients were randomized 1:1:1 to 3 priming strategies (total 1500 mL): albumin-based, gelofusine-based, and retrograde autologous priming (reference group). <br/>Measurements and Main Results: Acid-base status was characterized using Stewart's physicochemical approach at 5 perioperative time points (postinduction to 24 hours post-intensive care unit admission). A linear mixed model was used to assess the effects of priming strategy, time, and additional crystalloids. Across 170 observations, initiation of CPB induced substantial metabolic acidosis (-0.1 pH, -4.3 mmol/L standard base excess, -6.6 mEq/L effective strong ion difference), driven by reductions in apparent strong ion difference and persisting at 24 hours. pH, standard base excess, and effective strong ion difference did not differ among the priming strategies. Albumin attenuated weak acid-anion dilution (+0.79 mEq/L; p = 0.037), while gelofusine increased the strong ion gap (+2.19 mEq/L; p < 0.001). Each additional liter of crystalloid independently lowered pH (-0.011; p = 0.035), standard base excess (-0.99 mmol/L; p = 0.022), and effective strong ion difference (-1.03 mEq/L; p = 0.025), driven by a rise in strong ion gap (+1.24 mEq/L; p = 0.001). <br/>Conclusion(s): CPB-induced metabolic acidosis is driven predominantly by reductions in apparent strong ion difference and sustained by unbalanced crystalloid load rather than by colloid choice. Acid-base optimization should prioritize balanced, strong ion difference-guided priming fluid and crystalloid strategies over colloid selection.<br/>Copyright &#xa9; 2026 The Author(s) <94> Accession Number 2050135749 Title Differentiated effect of hypothermia versus normothermia after cardiac arrest by neurological status and clinical correlates of ischemic burden. Source Critical Care. 30(1) (no pagination), 2026. Article Number: 561. Date of Publication: 01 Dec 2026. Author Lileikyte G.; Marinho L.L.; Lu Y.; Boileau P.; Moseby-Knappe M.; Spicer A.; Dankiewicz J.; Lilja G.; Wise M.P.; Schrag C.; Aneman A.; Haenggi M.; Grejs A.M.; Horn J.; Stammet P.; Jakobsen J.C.; Kjaergaard J.; Rylander C.; Harhay M.O.; Churpek M.M.; Nielsen N.; Lawler P.R. Institution (Lileikyte) Anesthesiology and Intensive Care, Department of Clinical Sciences Helsingborg, Lund University, Svartbrodragranden 3, Helsingborg, Sweden (Lileikyte) Department of Intensive and Perioperative Care, Skane University Hospital, Malmo, Sweden (Marinho, Lu, Lawler) Cardiology and Critical Care Medicine, McGill University Health Centre, McGill University, Montreal, Canada (Boileau) Departments of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada (Moseby-Knappe) Neurology and Rehabilitation Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden (Moseby-Knappe) Department of Rehabilitation Medicine, Skane University Hospital, Lund, Sweden (Spicer, Churpek) Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Wisconsin, Madison, WI, United States (Dankiewicz) Cardiology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden (Dankiewicz) Department of Cardiology, Skane University Hospital, Lund, Sweden (Lilja) Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden (Lilja) Department of Neurology, Skane University Hospital, Lund, Sweden (Wise) Adult Critical Care Unit, University Hospital of Wales, Cardiff, United Kingdom (Schrag) Division of Intensive Care Medicine, HOCH Cantonal Hospital St. Gallen, St. Gallen, Switzerland (Aneman) Intensive Care Unit, Liverpool Hospital, Sydney, Australia (Aneman) South Western Sydney Clinical School, University of New South Wales, Sydney, Australia (Haenggi) Institute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Grejs) Department of Intensive Care Medicine, Aarhus University Hospital, Aarhus, Denmark (Grejs) Department of Clinical Medicine, Aarhus University, Aarhus, Denmark (Horn) Department of Intensive Care, Amsterdam Neurosciences, Amsterdam University Medical Center, Amsterdam, Netherlands (Stammet) Department of Anesthesia and Intensive Care Medicine, Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg (Stammet) Department of Health, Medicine and Life Sciences, Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg (Jakobsen) Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark (Jakobsen) Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark (Kjaergaard) Department of Cardiology, The Heart Center, Copenhagen University Hospital, Copenhagen, Denmark (Kjaergaard) Department of Clinical Medicine, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark (Rylander) Anesthesia and Intensive Care, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden (Harhay) Department of Biostatistics, Epidemiology and Informatics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States (Nielsen) Anesthesiology and Intensive Care, Department of Clinical Sciences Lund, Lund University, Lund, Sweden (Nielsen) Department of Intensive and Perioperative Care, Skane University Hospital, Lund, Sweden (Lawler) Cardiology and Critical Care Medicine, University of Toronto, Toronto, Canada Publisher BioMed Central Ltd Abstract Introduction: The optimal temperature target after out-of-hospital cardiac arrest (OHCA) remains uncertain, as major randomized trials have not demonstrated a clear benefit of lower-target hypothermia compared with normothermia. Despite this, patients with differing degrees of ischemic burden or early neurological injury may hypothetically respond differently to temperature targets, raising the possibility of heterogeneous treatment effects. This study aimed to determine whether outcomes differ after OHCA with 33 degreeC versus controlled normothermia (36.0-37.7 degreeC) according to correlates of ischemic burden and neurological findings at hospital admission. <br/>Method(s): This secondary analysis of the TTM and TTM2 trials employed effect-based machine learning to probe for heterogeneous treatment effects. Causal forests and Bayesian additive regression trees (BART) estimated individualized treatment effects (ITE) based on ischemia duration, prehospital factors, and neurological examination findings at hospital admission. Treatment effect modifier variable importance parameter (TEM-VIP) analysis ranked the baseline variables most likely to modify effect. The primary outcome was six-month all-cause mortality, and the secondary outcome was poor functional outcome (modified Rankin scale score 4-6). Primary analyses evaluated potential heterogeneity within each trial, while secondary analyses pooled all participants. <br/>Measurements and Main Results: All 2789 adult OHCA patients from the trials' primary analyses were included (median age 65 years (IQR 56-73), 79.9% male). Death occurred in 49.4% of patients in the 33 degreeC group, and in 47.9% in the controlled normothermia group. Variation in six-month mortality ITEs estimated from ischemic burden correlates and initial neurological findings was minimal, and no significant heterogeneity of treatment effect was identified across all methods and analysis populations. In the pooled analysis, estimated conditional mean mortality risk difference ranged from - 1.2% to 2.1% in causal forest (p = 0.99), and from - 0.5% to 1.5% in BART, with posterior probabilities for hypothermia benefit ranging from 42% to 53%. Absolute subgroup estimates in TEM-VIP analysis were small and non-significant. Results were consistent for the six-month functional outcome. <br/>Conclusion(s): Among TTM and TTM2 participants randomized to 33 degreeC versus controlled normothermia post-OHCA, no evidence of detectable heterogeneity of treatment effect based on available clinical correlates of ischemic burden or initial neurological findings was identified, with minimal estimated variation in treatment effect.<br/>Copyright &#xa9; The Author(s) 2026. <95> Accession Number 2050446562 Title Intravenous Immunoglobulin Administration in Cardiac Surgery, Heart Transplantation and Infective Endocarditis: A Scoping Review. Source Journal of Cardiothoracic and Vascular Anesthesia. 40(12) (pp 4157-4165), 2026. Date of Publication: 01 Dec 2026. Author Pilia E.; Derylo K.; Guarnieri M.; Marjanovic S.; Paternoster G.; Finco G.; Landoni G.; Belletti A. Institution (Pilia) Department of Anesthesia and Intensive Care, G. Brotzu Hospital, Cagliari, Italy (Pilia, Finco) Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy (Derylo) Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy (Guarnieri) Department of Anesthesia and Intensive Care, Centro Cardiologico Monzino IRCCS, Milan, Italy (Marjanovic) Faculty of Medicine, University of Belgrade, Belgrade, Serbia (Paternoster) Department of Health Sciences, Anaesthesia and ICU, School of Medicine, University of Basilicata San Carlo Hospital, Potenza, Italy (Landoni, Belletti) Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy (Landoni) School of Medicine, Vita-Salute San Raffaele University, Milan, Italy Publisher W.B. Saunders Abstract Perioperative infections are a common cause of morbidity in cardiac surgery. Intravenous immunoglobulin (IVIG) is increasingly used as a rescue treatment for septic shock. However, data on efficacy and safety in cardiac surgery patients are limited. A scoping review of available literature aimed at identifying studies investigating the use of IVIG in patients undergoing cardiac surgery or with infective endocarditis was performed. Studies reporting data on the use of IVIG in these populations were included, including case reports. Data on study design, population, control group, indications for IVIG therapy, and formulation and dose of IVIG were abstracted. Outcome data from randomized controlled trials (RCTs) were also abstracted. A total of 135 studies were identified, including 7 RCTs and 1 RCT study protocol. Most studies were performed in the setting of heart transplantation, followed by nontransplant cardiac surgery and infective endocarditis. The most common formulation was standard IVIG at a dose of 2 g/kg. Available data on the use of IVIG in cardiac surgery patients are mostly limited to the use of standard IVIG in heart transplantation recipients, and available evidence does not justify the routine use of IVIG in the cardiac surgery setting. However, in light of the strong scientific rationale supporting the use of IVIG, new high-quality RCTs enrolling a larger number of patients and following prospectively registered protocols are needed.<br/>Copyright &#xa9; 2026 Elsevier Inc. <96> Accession Number 2050482190 Title Interpretation and reporting of coronary computed tomographic angiography (2026 update): An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Source Journal of Cardiovascular Computed Tomography. 20(5) (pp 459-482), 2026. Date of Publication: 01 Sep 2026. Author Rajiah P.S.; Alkadhi H.; Andreini D.; Bullock-Palmer R.P.; Chinnaiyan K.M.; Chow B.J.W.; Cury R.C.; Hedgire S.; Hurwitz Koweek L.M.; Nieman K.; Sucha D.; Williams M.C.; Woodard P.K.; Truong Q.A. Institution (Rajiah) Department of Radiology, Mayo Clinic, Rochester, MN, United States (Alkadhi) Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Andreini) Division of University Cardiology and Cardiac Imaging, IRCCS Galeazzi Sant'Ambrogio Hospital, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy (Bullock-Palmer) Department of Cardiology, Deborah Heart and Lung Center, Browns Hills, NJ, United States (Bullock-Palmer) Department of Medicine, Division of Cardiology, Thomas Jefferson University, Philadelphia, PA, United States (Chinnaiyan) Department of Cardiovascular Medicine, Oakland University William Beaumont School of Medicine, Royal Oak, MI, United States (Chow) Departments of Medicine (Cardiology) and Radiology, University of Ottawa, Canada (Cury) Department of Radiology, Florida International University, Baptist Health Heart and Vascular Institute and Baptist Health of South Florida, Miami, FL, United States (Hedgire) Department of Radiology, Center for Cardiovascular Imaging, Mass General Brigham, Boston, MA, United States (Hurwitz Koweek) Department of Radiology, Duke University School of Medicine, Durham, NC, United States (Nieman) Department of Cardiovascular Medicine, Stanford University, CA, United States (Sucha) Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, Netherlands (Williams) British Heart Foundation Centre for Research Excellence, Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, United Kingdom (Woodard) Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States (Truong) Department of Radiology and Medicine, Weill Cornell Medicine, New York, United States Publisher Elsevier Inc. <97> Accession Number 2051065866 Title Management strategies for right-to-left intraatrial shunt with thrombus in transit: a systematic review of 297 patients and associated mortality outcomes. Source Therapeutic Advances in Cardiovascular Disease. 20 (no pagination), 2026. Date of Publication: 01 Jan 2026. Author Alkhawam M.; Simmons J.; Ray T.; Wong R.W.; Cooke B.J.; Sghayyer M.; Ahmad Y.; Nguyen S.; Pridemore A.; Ebrahimi A.J.; Bakradze E.; Ahmed M.I. Institution (Alkhawam, Nguyen, Pridemore, Ebrahimi) Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States (Simmons, Ray, Wong, Cooke, Sghayyer, Ahmad) University of Alabama at Birmingham, AL, United States (Bakradze) Department of Neurology, Division of Cerebrovascular Disease/Comprehensive Stroke Center, University of Alabama at Birmingham, Birmingham, AL, United States (Ahmed) Cardiac Network and Interventional Cardiology, Division of Cardiovascular Disease, University of Alabama at Birmingham (UAB), 619 19th Street South, Birmingham, AL, United States Publisher SAGE Publications Ltd Abstract Background: Thrombus in transit (TIT) through a patent foramen ovale (PFO) or atrial septal defect (ASD) is a rare but potentially life-threatening condition associated with paradoxical embolism. Despite advances in imaging and interventional techniques, optimal management strategies remain poorly defined. <br/>Objective(s): To systematically characterize the clinical presentation, diagnostic approaches, management strategies, and outcomes of adult patients with TIT across right-to-left intra-atrial shunts. <br/>Design(s): Systematic review of published cases. Data sources and methods: Following PRISMA guidelines, PubMed, Embase, and Scopus were searched from inception through March 2025 for case reports, case series, and letters describing adult patients with TIT visualized by transthoracic or transesophageal echocardiography. After screening 1736 records, 278 studies reporting 297 patients were included. Two independent reviewers extracted demographic, clinical, imaging, treatment, and outcome data. Descriptive statistics were summarized, and treatment groups were compared using chi-square and Mann-Whitney U tests. Kaplan-Meier survival curves with log-rank testing assessed 120-day survival, and multivariable Cox regression was used to evaluate potential predictors of mortality. <br/>Result(s): A total of 297 patients from 278 studies were included. The mean age was 58.5 +/- 15.8 years, and 50.2% were male. Respiratory symptoms predominated (77.7%), followed by cardiac (29.7%) and neurological (23.0%) manifestations. Provoked events accounted for 70.3% of cases, most commonly in the postoperative setting. Thrombi were detected by transthoracic echocardiography in 92.1% of cases and by transesophageal echocardiography in 100%. Management strategies included surgical embolectomy (57.8%), anticoagulation (36.5%), thrombolysis (13.5%), and percutaneous aspiration (2.7%); 61.1% underwent PFO/ASD closure. Overall mortality was 8.3%. Surgical management was associated with the lowest mortality (3.0%) and the highest short-term clinical improvement (90.5%; p < 0.001). Thrombolysis and percutaneous aspiration were associated with higher mortality (16.6% and 25.0%, respectively). Kaplan-Meier analysis demonstrated superior 120-day survival with surgical management compared with other treatment strategies (log-rank p < 0.001). In multivariable Cox models, no independent predictors of mortality were identified. <br/>Conclusion(s): In this largest synthesis of TIT cases to date, surgical management and PFO/ASD closure were associated with favorable short-term outcomes. Surgical intervention demonstrated the lowest observed mortality, while anticoagulation provided acceptable outcomes in selected patients. Thrombolysis and percutaneous aspiration were associated with higher mortality. These findings support the role of definitive management and shunt closure in selected patients, although prospective studies are needed to establish standardized treatment strategies. Trial registration: This study was registered in the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY) (Registration number: INPLASY202630021).<br/>Copyright &#xa9; The Author(s), 2026. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). <98> Accession Number 2048980694 Title Factor Concentrates for the Treatment of Acquired Coagulopathy in Patients With Left Ventricular Assist Devices: A Systematic Review. Source Journal of Cardiothoracic and Vascular Anesthesia. 40(12) (pp 4166-4186), 2026. Date of Publication: 01 Dec 2026. Author Kojundzic I.; Lam A.; Holmes M.; Dvirnik N.; Janda A.; Petricevic M.; Englesakis M.; Karkouti K.; Bartoszko J. Institution (Kojundzic, Holmes, Karkouti, Bartoszko) Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Toronto, ON, Canada (Kojundzic, Lam) University of Ottawa, Ottawa, ON, Canada (Lam, Holmes, Karkouti, Bartoszko) University of Toronto, Toronto, ON, Canada (Holmes, Karkouti, Bartoszko) Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, ON, Canada (Dvirnik) Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada (Dvirnik) Division of Cardiothoracic Surgery, Department of Surgery, University Health Network, Toronto, ON, Canada (Janda) Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, United States (Petricevic) Department of Cardiac Surgery, University Hospital Center Split, Split, Croatia (Petricevic) University Department of Health Studies, University of Split, Split, Croatia (Englesakis) Library & Information Services, University Health Network, Toronto, ON, Canada Publisher W.B. Saunders Abstract Patients with left ventricular assist devices (LVADs) represent a high-risk population at risk of both bleeding and thrombotic complications. A review of the available literature on nonfibrinogen factor concentrate use in LVAD patients up to June 1, 2026, was conducted by searching MEDLINE, Embase, and clinical trial and review registries. A total of 2,355 studies were identified, and 14 retrospective studies were included. Seven studies used factors to treat bleeding during LVAD implant or exchange. In this context, 134 patients received prothrombin complex concentrate (PCC), 487 received usual management or frozen plasma, 82 received factor eight inhibitor bypassing activity (FEIBA), 78 received recombinant activated factor VII (rVIIa), and 5 received isolated factor IX complex/3F-PCC. Given the limited and heterogeneous evidence, this review provides a descriptive summary of eligible studies rather than a formal evidence synthesis. When used first-line and protocolized, PCC is likely safe and effective. rFVIIa appears effective, but higher doses are associated with thrombosis and mortality. Evidence for FEIBA is limited to one small nonrandomized study. Seven studies used factors for emergency anticoagulation reversal, with 139 individual PCC exposures, 47 frozen plasma exposures, and 3 rVIIa exposures. PCC was associated with more rapid International Normalized Ratio normalization, no excess harm, and, in one study, improved survival and progression to transplant. In this context, rFVIIa was associated with a dose-dependent risk of thrombosis. Overall, PCC-based hemostatic management in LVAD patients appears reasonable; however, it is not currently possible to judge the safety of low-dose rVIIa or FEIBA.<br/>Copyright &#xa9; 2026 Elsevier Inc. <99> Accession Number 2050124031 Title Residual physiological profiles in patients with CABG- or PCI-Favored coronary anatomy: A post hoc analysis of the PANDA III randomized clinical trial. Source Progress in Cardiovascular Diseases. (no pagination), 2026. Date of Publication: 2026. Author Hu K.; Xu H.; Li B.; Yuan S.; Wu S.; Guan C.; Song C.; Gao G.; Yang M.; An T.; Zhao Z.; Zhao Y.; Liu W.; Jia L.; Liu Q.; Wang C.; Wu C.; Song W.; Wang H.; Song L.; Feng L.; Zhu C.; Yin D.; Zhang R.; Dou K. Institution (Hu, Li, Wang, Yuan, Song, Zhang, Dou) Cardiometabolic Medicine Center, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Hu, Xu, Li, Wang, Yuan, Guan, Song, Gao, Yang, An, Zhao, Wang, Jia, Liu, Wang, Wu, Song, Wang, Song, Feng, Zhu, Yin, Zhang, Dou) Department of Cardiology, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Hu, Xu, Li, Wang, Yuan, Guan, Song, Gao, Yang, An, Zhao, Wang, Jia, Liu, Wang, Wu, Song, Wang, Song, Feng, Zhu, Yin, Zhang, Dou) Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Hu, Li, Wang, Yuan, Song, Zhang, Dou) State Key Laboratory of Cardiovascular Disease, Beijing, China (Wu) Department of Cardiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China (Zhao) Medical Research and Biometrics Centre, National Centre for Cardiovascular Diseases, Beijing, China (Liu) State Key Laboratory for Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China (Song) Catheterization Laboratories, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China Publisher W.B. Saunders Abstract Background and aims Patients with anatomically complex coronary artery disease may be considered more suitable for coronary artery bypass grafting (CABG) than percutaneous coronary intervention (PCI), but some undergo PCI because of clinical constraints and experience higher long-term cardiovascular risk. The physiological rationale underlying this excess post-PCI risk remains unclear. From the perspective of post-PCI revascularization completeness and physiological results, we sought to explain the drivers of excess long-term adverse risk among patients with Favor CABG anatomy undergoing PCI. Methods Coronary physiology based on quantitative flow ratio (QFR) was retrospectively evaluated in the randomized PANDA III trial in which all patients underwent PCI. Patients were stratified into 2 predefined groups by baseline SYNTAX score: Favor PCI or Favor CABG. Functional revascularization completeness was assessed using classic residual functional SYNTAX score (c-rFSS). Final physiological results were quantified by post-PCI QFR. Causal mediation analyses used 2-year major adverse cardiovascular events (MACE) excluding periprocedural MI as the outcome to estimate the proportion of the group-outcome association statistically accounted for by residual coronary physiological profiles. The primary endpoint was 2-year MACE, defined as the composite of all-cause death, all MI, or any ischemia-driven revascularization. Results A total of 1555 patients with complete post-PCI physiological assessment constituted the final study cohort, among whom 269 (17.3%) individuals were stratified to Favor CABG group by baseline SYNTAX score. The 2-year MACE rate was significantly higher in the Favor CABG than the Favor PCI group (18.6% vs 9.2%; adjusted HR: 1.78; 95% CI: 1.27-2.50). Functional incomplete revascularization (c-rFSS >0) was substantially more prevalent among patients in the Favor CABG group (53.2% vs. 15.1%, P < 0.001). Suboptimal post-PCI physiology defined by QFR <0.90 was more frequent in Favor CABG cohort (32.0% vs 11.8%, P < 0.001). In analyses using MACE excluding periprocedural MI, the estimated proportions mediated by functional incomplete revascularization and suboptimal post-PCI physiology were 49.4% and 47.8%, respectively, and their estimated joint proportion mediated was 79.8%. Integrating c-rFSS or post-PCI QFR into clinical-anatomic risk models significantly improved discrimination and reclassification capacity for 2-year MACE (all P < 0.05). Conclusions In this post hoc analysis of an all-comers PCI trial, approximately one-fifth of patients presented with anatomic complexity warranting CABG as the preferred revascularization strategy. Favor CABG anatomy was associated with higher 2-year MACE than Favor PCI anatomy. This association may be partly explained by the higher prevalence of residual functional incomplete revascularization and suboptimal post-PCI physiology. These findings between Favor CABG and Favor PCI anatomy do not represent a head-to-head comparison and should not be interpreted as a direct comparison of revascularization modalities. Trial registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT02017275 .<br/>Copyright &#xa9; 2026 Elsevier Inc. <100> Accession Number 2050133233 Title Transcutaneous low-level vagus nerve stimulation for the prevention of postoperative atrial fibrillation after cardiac valve surgery with cardiopulmonary bypass: protocol for a randomized controlled trial. Source BMC Complementary Medicine and Therapies. 26(1) (no pagination), 2026. Article Number: 333. Date of Publication: 01 Dec 2026. Author Bian L.; Shi Y.; Liu T.; Zhang Y.; Li J.; Zhang J. Institution (Bian, Liu, Zhang, Zhang) Department of Anesthesiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 Qingchun East Road, Zhejiang, Hangzhou, China (Shi) Department of Nutrition and Food Hygiene, School of Public Health, Zhejiang University, Zhejiang, Hangzhou, China (Li) Department of Cardiac Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 Qingchun East Road, Zhejiang, Hangzhou, China Publisher BioMed Central Ltd Abstract Background: Atrial fibrillation (AF) is one of the most common complications following cardiac surgery, with reported incidence rates reaching up to 44%. Transcutaneous low-level vagus nerve stimulation (TLL-VNS) has shown potential in reducing the risk of postoperative AF by modulating autonomic nervous system activity, suppressing inflammation, and regulating atrial ganglionic function. <br/>Method(s): The Vagus-Heart Trial is a prospective, randomized, double-blind, sham-controlled study designed to evaluate the efficacy of TLL-VNS in preventing postoperative AF. A total of 140 patients undergoing elective cardiac valve surgery with cardiopulmonary bypass (CPB) are randomly assigned to receive either active TLL-VNS or sham stimulation. The primary endpoint is the incidence of AF within the first week after surgery. Secondary endpoints include the duration of AF within the first week after surgery, surgical parameters, vital signs, inflammatory markers, renal function, surgical prognosis, and stress response biomarkers. <br/>Discussion(s): This trial is the first large-scale, randomized, sham-controlled study to evaluate TLL-VNS for the prevention of postoperative AF in patients undergoing cardiac valve surgery with CPB. If proven effective, TLL-VNS could represent a novel, non-invasive, and cost-effective strategy to enhance postoperative recovery and reduce the burden of AF in this high-risk population. Trial registration: Chictr.org.cn Identifer: ChiCTR2400080750. Registered on 6 February 2024.<br/>Copyright &#xa9; The Author(s) 2026. <101> Accession Number 2044725627 Title Upfront Aspirin-Free Antiplatelet Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Safety and Efficacy. Source Indian Heart Journal. 78(5) (pp 238-245), 2026. Date of Publication: 01 Sep 2026. Author Mahajan K.; Dutta D.; Kamrul-Hasan A.B.M.; Pradhan A.; Vohra S.; Mahajan N. Institution (Mahajan) Department of Cardiology, Himachal Heart Institute, Himachal Pradesh, Mandi, India (Dutta) Department of Endocrinology, Center for Endocrinology Diabetes Arthritis & Rheumatism (CEDAR) Superspeciality Healthcare, Dwarka, New Delhi, India (Kamrul-Hasan) Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh (Pradhan) Department of Cardiology, King George Medical College, Uttar Pradesh, Lucknow, India (Vohra) Mount Sinai Morningside, Icahn School of Medicine at Mount Sinai, New York, United States (Mahajan) Translational Research and Data Science Consultant, United States Publisher Elsevier B.V. Abstract Background: Evidence comparing non-aspirin single antiplatelet therapy (SAPT) with aspirin-containing dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is limited. We performed a systematic review and meta-analysis to evaluate the safety and efficacy of non-aspirin SAPT with a P2Y12 inhibitor started at or within one week of PCI. <br/>Method(s): Electronic databases were searched for studies evaluating non-aspirin SAPT after PCI. Primary outcomes were bleeding defined by Bleeding Academic Research Consortium (BARC) criteria [BARC 1-5 (any bleeding) and BARC 3-5 (major bleeding)], all-cause mortality (ACM), and cardiovascular mortality. Secondary outcomes were stroke, myocardial infarction (MI), need for revascularization, and stent thrombosis (STS). <br/>Result(s): Seven studies (2 randomized controlled trials and 5 observational studies) including 5468 patients on non-aspirin SAPT were analyzed. In the single-arm meta-analysis of non-aspirin SAPT, pooled prevalence was 5% (95% CI 3-11; I<sup>2</sup> = 92%) for any BARC 1-5 bleeding, 3% (95% CI 1-7; I<sup>2</sup> = 92.5%) for major BARC 3-5 bleeding, 2% (95% CI 1-3; I<sup>2</sup> = 65.4%) for ACM, 2% (95% CI 2-3; I<sup>2</sup> = 31%) for cardiovascular mortality, 1% (95% CI 1-1; I<sup>2</sup> = 0%) for STS, 1% (95% CI 0-1; I<sup>2</sup> = 40.1%) for stroke, 2% (95% CI 1-3; I<sup>2</sup> = 66.6%) for MI, and 2% (95% CI 1-4; I<sup>2</sup> = 75.9%) for revascularization. In pairwise analyses of the two trials, non-aspirin SAPT versus aspirin-based DAPT showed similar risks of all-cause mortality, cardiovascular mortality, bleeding, and stroke but higher risks of MI (odds ratio [OR]1.41; 95% CI 1.01-1.97; P = 0.05; I<sup>2</sup> = 0%) and revascularization (OR1.73; 95% CI 1.18-2.52; P = 0.005; I<sup>2</sup> = 0%). <br/>Conclusion(s): Upfront aspirin-free SAPT after PCI was associated with increased risks of MI and revascularization without a reduction in bleeding compared with aspirin-based DAPT.<br/>Copyright &#xa9; 2026 Cardiological Society of India <102> Accession Number 652650784 Title Prosthesis-Patient Mismatch and Patient-Centered Outcomes After TAVR. Source JACC. Cardiovascular interventions. 19(21) (pp 2857-2871), 2026. Date of Publication: 09 Nov 2026. Author Cozzi O.; Tomii D.; Lanz J.; Thiele H.; Heg D.; Joner M.; Mollmann H.; Linke A.; Conradi L.; Toggweiler S.; Thilo C.; Prendergast B.; Windecker S.; Pilgrim T. Institution (Cozzi) Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland; Cardio Center, IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy (Tomii, Lanz, Windecker, Pilgrim) Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland (Thiele) Heart Centre Leipzig at Leipzig University, Leipzig, Germany (Heg) Department of Clinical Research, University of Bern, Bern, Switzerland (Joner) German Heart Centre, Technical University of Munich, Munich, Germany (Mollmann) Department of Internal Medicine I, St-Johannes-Hospital, Dortmund, Germany (Linke) Department of Internal Medicine and Cardiology, Heart Centre Dresden, Technische Universitat Dresden, Dresden, Germany (Conradi) Department of Cardiovascular Surgery, University Heart Centre Hamburg, Hamburg, Germany (Toggweiler) Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland (Thilo) Department of Internal Medicine I, RoMed Klinikum Rosenheim, Rosenheim, Germany (Prendergast) Department of Cardiology, St Thomas' Hospital & Cleveland Clinic London, London, United Kingdom Abstract BACKGROUND: Prosthesis-patient mismatch (PPM) after transcatheter aortic valve replacement has been widely studied for its association with clinical outcomes, but its effect on patient-reported health status remains less defined. <br/>OBJECTIVE(S): This study sought to evaluate the association between PPM severity and health status through 3-year follow-up after transcatheter aortic valve replacement. <br/>METHOD(S): This post hoc analysis of the SCOPE I (Safety and Efficacy of the ACURATE Neo/TF Compared to the SAPIEN 3 Bioprosthesis) randomized trial categorized patients according to PPM severity using Valve Academic Research Consortium-3 criteria. Endpoints included survival and patient-reported health status, with an integrated outcome defined as being alive with good health status (Kansas City Cardiomyopathy Questionnaire Overall Summary score >=75 without a decline of >10 points from baseline). <br/>RESULT(S): Among 662 patients, moderate and severe PPM occurred in 184 (27.8%) and 69 (10.4%), respectively. All-cause mortality at 1 and 3 years was 7.0% and 20.5%, with no differences across PPM categories. Kansas City Cardiomyopathy Questionnaire Overall Summary score was similar through 1 year but lower at 3 years in patients with severe vs no PPM (median 71.1 vs 83.9; P = 0.027). Fewer patients with severe PPM were alive with good health status at 3 years (30.6% vs 49.4%; P = 0.021). In multivariable analysis, severe PPM was associated with a lower likelihood of the integrated outcome (OR: 0.51; 95% CI: 0.27-0.96; P = 0.036), but this association was no longer statistically significant after adjustment for 30-day mitral regurgitation (OR: 0.59; 95% CI: 0.30-1.15; P = 0.121). <br/>CONCLUSION(S): Among survivors, severe PPM was associated with a lower likelihood of good health status at 3 years. This association was attenuated after accounting for 30-day residual mitral regurgitation, suggesting a possible contributory role. Given the post hoc design, the findings are hypothesis-generating.<br/>Copyright &#xa9; 2026 The Authors. Published by Elsevier Inc. All rights reserved. <103> Accession Number 652654590 Title Prevalence and Consequences of Guideline-Directed Indications for Aortic Valve Replacement in the EARLY TAVR Trial. Source JACC. Cardiovascular interventions. 19(21) (pp 2876-2888), 2026. Date of Publication: 09 Nov 2026. Author Madhavan M.V.; Schwartz A.; Lindman B.R.; Pibarot P.; Cohen D.J.; Oldemeyer J.B.; Babaliaros V.; Fearon W.F.; Daniels D.; Chhatriwalla A.; Kavinsky C.J.; Shah P.; Szerlip M.; Dahle T.; Goel K.; O'Neill W.; Makkar R.; Davidson C.; Sheth T.; Sorajja P.; DeVries J.; Southard J.; Depta J.P.; Pop A.; Hahn R.T.; Zhao Y.; Leon M.B.; Genereux P. Institution (Madhavan) NewYork Presbyterian Hospital and Weill Cornell Medicine, New York, New York, USA; Cardiovascular Research Foundation, New York, New York, USA (Schwartz) NewYork Presbyterian Hospital and Columbia University Irving Medical Center, NY, United States (Lindman, Goel) Structural Heart and Valve Center, Vanderbilt University Medical Center, Nashville, TN, United States (Pibarot) Institut universitaire de cardiologie et de pneumologie de Quebec, Universite Laval, QC, Canada (Cohen) Cardiovascular Research Foundation, New York, New York, USA; St Francis Hospital and Heart Center, Roslyn, New York, USA (Oldemeyer) UC Health Northen Colorado, Loveland, CO, United States (Babaliaros) Emory University, Atlanta, GA, United States (Fearon) Stanford University Medical Center, Palo Alto, CA, United States (Daniels) Bay Area Structural Heart at Sutter Health, Burlingame, CA, United States (Chhatriwalla) Saint Luke's Mid America Heart Institute, Kansas City, MO, United States (Kavinsky) Rush University Medical Center, Chicago, IL, United States (Shah) Brigham and Women's Hospital, Boston, MA, United States (Szerlip) Baylor Scott and White the Heart Hospital Plano, Plano, TX, United States (Dahle) CentraCare Heart and Vascular Center, St Cloud, MN, United States (O'Neill) Henry Ford Hospital, Detroit, MI, United States (Makkar) Cedars Sinai Medical Center, Los Angeles, CA, United States (Davidson) Northwestern Feinberg University School of Medicine, Chicago, IL, United States (Sheth) Hamilton Health Sciences, Hamilton, ON, Canada (Sorajja) Minneapolis Heart Institute Foundation, Minneapolis, MN, United States (DeVries) Dartmouth-Hitchcock Medical Center, Hanover, NH, United States (Southard) University of California Davis Medical Center, Sacramento, CA, United States (Depta) Rochester General Hospital, Rochester, NY, United States (Pop) Ascension Alexian Brothers Hospital, Elk Grove Village, IL, United States (Hahn, Leon) Cardiovascular Research Foundation, New York, New York, USA; NewYork Presbyterian Hospital and Columbia University Irving Medical Center, New York, New York, USA (Zhao) Edwards Lifesciences, Irvine, CA, United States (Genereux) Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, NJ, United States Abstract BACKGROUND: The current American College of Cardiology/American Heart Association valvular heart disease guidelines were published before several recent trials that provide greater support for early intervention in patients with asymptomatic severe aortic stenosis (AS). <br/>OBJECTIVE(S): This study sought to investigate the prevalence and clinical impact of American College of Cardiology/American Heart Association Class II recommendations for AVR in the EARLY TAVR trial. <br/>METHOD(S): The EARLY TAVR trial randomized patients with asymptomatic severe AS to transfemoral transcatheter aortic valve replacement (TAVR) with a balloon-expandable valve or clinical surveillance (CS) with conversion to TAVR based on development of ACC/AHA Class I indications. Patients in the intention-to-treat cohort were stratified by presence of a Class II indication for AVR at randomization. The primary endpoint of the present analysis was the composite of all-cause death, stroke, or heart failure hospitalization. Interaction tests were performed to assess whether the treatment effect differed by level of guideline recommendation. Timing of conversion to AVR in the CS group according to the presence/absence of Class II indications was also assessed. <br/>RESULT(S): Of the 901 patients randomized to TAVR (N = 445) and CS (N = 446), 636 (70.6%) patients had no guideline recommendation, and 265 (29.4%) had at least1 1 Class II recommendation for AVR at the time of randomization. At a median follow-up of 3.8 years, patients with a Class II indication for AVR experienced higher rates of the primary endpoint (Class II: 24.5% vs no recommendation: 14.5%; HR = 1.78; 95% CI: 1.30-2.44; P < 0.001) and were more likely to have acute valve syndrome at the time of conversion. Compared with CS, the relative benefit of early TAVR on the primary endpoint was similar regardless of the presence or absence of a Class II guideline recommendation (HR = 0.62; 95% CI: 0.37-1.02 vs 0.61; 95% CI: 0.40-0.92; Pinteraction = 0.96). <br/>CONCLUSION(S): Among patients in the EARLY TAVR trial, Class II indications for AVR were present in almost one-third of patients at baseline. The benefit of early TAVR was consistent regardless of the presence or absence of Class II indications. These findings support the strategy of early TAVR over CS in asymptomatic patients with severe AS, independent of guideline indications. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT03042104; Unique Identifier: NCT03042104.<br/>Copyright &#xa9; 2026 The Authors. Published by Elsevier Inc. All rights reserved. <104> Accession Number 2051257061 Title Direct Oral Anticoagulants Versus Vitamin K Antagonists for Atrial Fibrillation After Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Source Cardiology in Review. (no pagination), 2026. Date of Publication: 2026. Author Al-Harrasi A.; Almutairi A.; Alghazali R.A.; Alrefaei N.; Rusheidi R.S.A.; Zuhair S.A.; Alfailakawi A.K.E.A.E.A.; Zamzamy D.A.; Mousa H.A.; Elkasaby M.H.; Frishman W.H.; Aronow W.S. Institution (Al-Harrasi) Department of Medicine, Arabian Gulf University, Manama, Bahrain (Almutairi, Alghazali, Rusheidi) Department of Medicine, Royal College of Surgeons in Ireland, Busaiteen, Bahrain (Alrefaei) Department of Medicine, University of Sharjah, Sharjah, United Arab Emirates (Zuhair) Department of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia (Alfailakawi) Department of Medicine, Alexandria University, Alexandria, Egypt (Zamzamy) Department of Medicine, Hera General Hospital, Makkah, Saudi Arabia (Mousa) Department of Internal Medicine, Kingdom Medical Center, Makkah, Saudi Arabia (Elkasaby) Department of Medicine, Faculty of Medicine, Al-Azhar University, Cairo, Egypt (Frishman, Aronow) Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, United States Publisher Lippincott Williams and Wilkins Abstract Atrial fibrillation after cardiac surgery is common and is associated with stroke, prolonged hospitalization, and mortality; yet, the optimal oral anticoagulant in this setting remains uncertain. We performed a systematic review and meta-analysis comparing direct oral anticoagulants (DOACs) with vitamin K antagonists (VKAs) in adults requiring oral anticoagulation for atrial fibrillation after cardiac surgery. PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials were searched from inception through August 2026 for randomized controlled trials. The primary outcome was any bleeding; secondary outcomes were stroke or transient ischemic attack, systemic embolism, major bleeding, intracranial hemorrhage, reoperation, and length of hospital stay. Odds ratios (ORs) and mean differences (MDs) were pooled with random-effects models, risk of bias was assessed with the Cochrane Risk of Bias 2 tool, and certainty of evidence was rated with GRADE. Five randomized trials including 302 patients (153 DOACs and 149 warfarin) were included; rivaroxaban was tested in 3 trials, and apixaban and dabigatran in 1 trial each. Any bleeding did not differ significantly between DOACs and VKAs (9.2% vs 8.1%; OR, 1.24; 95% confidence interval [CI], 0.39-3.99).<br/>Copyright &#xa9; 2026 Wolters Kluwer Health, LLC. All rights reserved. <105> Accession Number 2050355631 Title Native Coronary Artery Versus Saphenous Vein Graft Percutaneous Coronary Intervention in Patients with Prior Coronary Artery Bypass Grafting: An Updated Systematic Review and Meta-Analysis. Source Journal of Clinical Medicine. 15(21) (no pagination), 2026. Article Number: 8672. Date of Publication: 01 Nov 2026. Author Patel V.; Al-Ghazawy A.; Patel J.; Akele O.; Englander R.; Singh A.; Ingrassia J.; Dahal K. Institution (Patel, Al-Ghazawy, Patel, Akele, Englander, Singh) Department of Internal Medicine, University of Connecticut Health, Farmington, CT, United States (Ingrassia) Department of Cardiology, Hartford Hospital, Hartford, CT, United States (Dahal) Division of Cardiology, University of Connecticut Health, Farmington, CT, United States Publisher Multidisciplinary Digital Publishing Institute (MDPI) Abstract Background/Objectives: Patients with prior coronary artery bypass grafting (CABG) frequently require repeat percutaneous coronary intervention (PCI), but the optimal target-native coronary artery or saphenous vein graft (SVG)-remains uncertain. We performed an updated systematic review and random-effects meta-analysis comparing clinical and procedural outcomes of native coronary artery PCI versus SVG PCI. <br/>Method(s): PubMed, Embase, and the Cochrane Library (Cochrane Central Register of Controlled Trials) were searched from inception through May 2026. <br/>Result(s): Twenty-five studies (343,524 patients) were included, with 21 contributing to the MACE and/or all-cause mortality analyses. Compared with native-vessel PCI, SVG PCI was associated with higher rates of major adverse cardiovascular events (MACE) (risk ratio [RR] 1.30, 95% confidence interval [CI] 1.05-1.60; p = 0.017), all-cause mortality (RR 1.47, 95% CI 1.19-1.81; p < 0.001), myocardial infarction (RR 1.64, 95% CI 1.31-2.05; p < 0.001), in-stent restenosis (RR 1.71, 95% CI 1.19-2.44; p = 0.004), and target lesion revascularization (RR 1.70, 95% CI 1.16-2.47; p = 0.006). After exclusion of the single randomized trial, associations for MACE (RR 1.38, 95% CI 1.12-1.71) and all-cause mortality (RR 1.50, 95% CI 1.21-1.85) were slightly stronger. Cardiac death, stroke, and bleeding did not differ significantly. Findings for MACE and target lesion revascularization were sensitive to the omission of single studies. In the exploratory drug-eluting stent-predominant subgroup, effect directions were generally consistent. Despite these associations, most included studies were observational, and substantial heterogeneity and residual confounding remain important limitations (95% prediction intervals for MACE and mortality included the null), and the certainty of evidence (GRADE) was low to very low. <br/>Conclusion(s): SVG PCI was associated with less favorable long-term outcomes than native coronary artery PCI, although these findings do not establish causality and should be interpreted alongside randomized evidence supporting individualized, anatomy-based target selection. Adequately powered randomized trials with extended follow-up are needed to define the optimal revascularization strategy across the spectrum of post-CABG anatomy.<br/>Copyright &#xa9; 2026 by the authors. <106> Accession Number 2050355097 Title Anesthetic Considerations in Off-Pump Coronary Artery Bypass Grafting: A Narrative Review. Source Journal of Clinical Medicine. 15(21) (no pagination), 2026. Article Number: 8499. Date of Publication: 01 Nov 2026. Author Huti G.; Jahollari A.; Abdyli A.; Domi R.; Hoxha D.; Filaj B.; Demiri O.; Abdyli E.; Biasucci D.; Coniglione F.; Guarracino F.; Neskovic V.; Matot I.; Lilaj K.; Eljezi V.; Camilleri-Podesta A.-M. Institution (Huti, Abdyli, Domi, Hoxha, Filaj, Demiri, Abdyli) Department of Anesthesia and Intensive Care Medicine, American Hospital 3, Tirana, Albania (Jahollari) Department of Cardiovascular Surgery, American Hospital 3, Tirana, Albania (Domi, Lilaj) Department of Surgery, University of Medicine, Tirana, Albania (Biasucci, Coniglione) Department of Clinical Science and Translational Medicine, 'Tor Vergata' University of Rome, Rome, Italy (Guarracino) Department of Medical, Dental and Biotechnological Sciences, University Gabriele d'Annunzio Chieti-Pescara, Anesthesia, Resuscitation and Intensive Care, University Hospital of Chieti, Chieti, Italy (Neskovic) Clinic for Anesthesia and Critical Care, Military Medical Academy, Faculty of Medicine MMA, Belgrade, Serbia (Matot) Division of Anesthesiology, Intensive Care and Pain, Tel Aviv Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Eljezi) Department of Perioperative Medicine, CHU Gabriel-Montpied, Clermont-Ferrand, France (Camilleri-Podesta) Department of Anesthesia and Intensive Care, Mater Dei Hospital, Msida, Malta Publisher Multidisciplinary Digital Publishing Institute (MDPI) Abstract Background: Off-pump coronary artery bypass grafting (OPCAB) avoids cardiopulmonary bypass (CPB) and may reduce selected perioperative complications, but its technical and hemodynamic demands remain important limitations. <br/>Method(s): We narratively reviewed the literature indexed in PubMed/MEDLINE and Scopus, supplemented by Google Scholar and reference-list screening, covering January 2000 to August 2026. Priority was given to systematic reviews, meta-analyses, randomized trials, prospective studies, guidelines, and relevant landmark reports. <br/>Result(s): OPCAB may be particularly useful in selected patients at increased risk from CPB or aortic manipulation. Cardiac displacement and coronary stabilization can cause rapid changes in preload, ventricular function, myocardial perfusion, and cardiac output, making invasive monitoring, transesophageal echocardiography, and coordinated hemodynamic management central to anesthetic care. Current evidence does not establish the superiority of volatile anesthesia or total intravenous anesthesia. Comparative studies suggest potential reductions in perioperative stroke, transfusion, renal complications, and hospital stay, although potential stroke benefits depend on the aortic-handling strategy and should not be attributed to avoidance of CPB alone. Concerns remain regarding completeness of revascularization, graft durability, repeat revascularization, and long-term survival. <br/>Conclusion(s): OPCAB should be considered an individualized strategy rather than a universal alternative to on-pump CABG. Optimal outcomes depend on patient selection, surgical expertise, vigilant monitoring, and timely correction of hemodynamic compromise. Potential neurological benefits should be interpreted in relation to the aortic-handling strategy, particularly when an anaortic/no-touch technique is used.<br/>Copyright &#xa9; 2026 by the authors. <107> Accession Number 2050223038 Title Differential Effects of Sevoflurane and Propofol on Perioperative Glomerular Permselectivity During Cardiopulmonary Bypass: A Randomized Trial. Source Drug Design, Development and Therapy. 20 (no pagination), 2026. Article Number: 651212. Date of Publication: 2026. Author Feng L.; Lin Y.; Xi W.; Wu Q.; Wu F.; Mao J.; Gao W.; Wang W. Institution (Feng, Lin, Wu, Wu, Gao, Wang) Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, Wenzhou, China (Xi) Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, Wenzhou, China (Mao) Operating Room, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, Wenzhou, China Publisher Dove Medical Press Ltd Abstract Background: Creatinine-defined acute kidney injury does not capture early, compartment-specific renal responses to cardiopulmonary bypass (CPB). Whether anesthetic choice modulates the charge and size selectivity of the glomerular filtration barrier (GFB) remains unknown. <br/>Method(s): In this single-center randomized trial, 106 adults undergoing elective cardiac surgery with CPB were assigned 1:1 to sevoflurane-based anesthesia or propofol-based total intravenous anesthesia. The primary outcome was longitudinal urinary albumin-to-creatinine ratio (UACR). Secondary outcomes included plasma heparan sulfate (HS), syndecan-1, clearance-derived charge and size selectivity indices, and postoperative acute kidney injury. <br/>Result(s): The UACR group-by-time interaction was significant (P = 0.001). Sevoflurane-to-propofol ratios were 0.785 (95% CI 0.714-0.863) 10 min after aortic unclamping, 0.826 (0.751-0.908) 1 h after surgery, and 0.779 (0.708-0.856) 24 h after surgery (all Holm-adjusted P < 0.001). Coordinated separation was also observed for HS (interaction P = 0.001), charge selectivity (P = 0.013), and size selectivity (P = 0.011). HS was associated with UACR and both selectivity indices. Postoperative acute kidney injury occurred in 13/53 (24.5%) participants receiving sevoflurane and 17/53 (32.1%) receiving propofol. <br/>Conclusion(s): Sevoflurane attenuated a coordinated perioperative GFB phenotype characterized by albumin leakage, HS release, and deterioration of charge and size selectivity. Functionally resolved glomerular permselectivity may provide exploratory pharmacodynamic measures for studying renal effects of anesthetic regimens during CPB, but their measurement properties and clinical utility require further validation. Outcomes-powered trials are required to determine whether modulation of this early phenotype improves renal recovery.<br/>Copyright &#xa9; 2026 Feng et al. <108> Accession Number 2051535469 Title Efficacy and safety of haemostatic agents for patients receiving antiplatelet therapy before coronary artery bypass grafting: a protocol for a systematic review and network meta-analysis of randomised controlled trials. Source BMJ Open. 16(7) (no pagination), 2026. Article Number: e120125. Date of Publication: 09 Jul 2026. Author Chen C.; Wei X.; Han Y.; Ren X.; Xiao Q.; Xiong Y.; Mao R.; Liu Y. Institution (Chen, Wei, Han, Ren, Xiao, Xiong, Liu) Department of Cardiopulmonary Bypass, Wuhan Asia Heart Hospital Affiliated to Wuhan University of Science and Technology, Hubei, Wuhan, China (Wei, Mao, Liu) School of Medicine, Wuhan University of Science and Technology, Hubei, Wuhan, China Publisher BMJ Publishing Group Abstract Introduction: Most patients undergoing coronary artery bypass grafting (CABG) receive preoperative antiplatelet therapy to reduce ischaemic events but this increases perioperative bleeding and transfusion risk. Tranexamic acid, aminocaproic acid, aprotinin and desmopressin are commonly employed to reduce such risk; however, robust direct head-to-head comparative evidence remains limited in this specific population. Therefore, we will conduct a network meta-analysis (NMA) of randomised controlled trials (RCTs) to compare their relative efficacy and safety. Methods and analysis: We will systematically search PubMed, Embase, Web of Science, Scopus and Cochrane Central Register of Controlled Trials from inception to 24 March 2026 for RCTs that compare these four agents versus placebo/standard care or head-to-head in adults receiving preoperative antiplatelet therapy for CABG. Two reviewers will independently screen studies, extract data and assess the risk of bias using the Risk of Bias Instrument for Use in SysTematic reviews-for Randomised Controlled Trials tool. Primary outcomes will be the total perioperative volume of blood loss and the proportion of patients receiving red blood cell transfusions. Secondary outcomes will include blood product transfusion volumes, reoperation rates for bleeding or cardiac tamponade, rates of composite thromboembolic events, all-cause mortality and incidence of acute kidney injury. Pairwise random-effects meta-analyses will be performed first followed by Bayesian NMA. Surface under the cumulative ranking curve for the outcomes of interest will be used to rank the competing interventions. The Confidence in Network Meta-Analysis framework will be used to assess the quality of evidence. Ethics and dissemination: Ethical approval is not required. Findings will be submitted to a peer-reviewed journal and disseminated to support clinical decision-making. PROSPERO registration number: CRD420251235248.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <109> Accession Number 2050363019 Title Net Clinical Benefit of Left Atrial Appendage Occlusion After Intracerebral Hemorrhage in Atrial Fibrillation: A Focused Review and Benchmark-Adjusted Secondary Analysis. Source Journal of Clinical Medicine. 15(21) (no pagination), 2026. Article Number: 8612. Date of Publication: 01 Nov 2026. Author Kourek C.; Sicouri S.; Briasoulis A.; Magouliotis D.E.; Xanthopoulos A.; Paraskevaidis I.; Ramlawi B. Institution (Kourek, Sicouri, Magouliotis, Ramlawi) Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Wynnewood, PA, United States (Briasoulis) Amyloidosis Center of Excellence, Department of Therapeutics, National and Kapodistrian University of Athens, Athens, Greece (Xanthopoulos) Department of Cardiology, University Hospital of Larissa, Larissa, Greece (Paraskevaidis) Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece (Ramlawi) Department of Cardiac Surgery, Lankenau Medical Center, Wynnewood, PA, United States Publisher Multidisciplinary Digital Publishing Institute (MDPI) Abstract Background/Objectives: Atrial fibrillation (AF) after intracerebral hemorrhage (ICH) creates a therapeutic conflict: withholding oral anticoagulation may increase ischemic stroke risk, whereas resumption of anticoagulation may increase recurrent ICH. Left atrial appendage occlusion (LAAO) offers a nonpharmacologic alternative, but isolated stroke or bleeding rates do not describe the overall benefit-harm balance. This focused review examines net clinical benefit (NCB) as a decision framework for LAAO after ICH and presents a secondary benchmark-adjusted analysis derived from our prior systemaatic review and meta-analysis. <br/>Method(s): Thirteen endocardial LAAO cohorts with complete data for ischemic stroke, recurrent ICH, major bleeding, and all-cause death contributed to the analysis. The component event data and prespecified severity weights were carried forward from the prior meta-analysis; the external benchmark comparison, study-level benchmark-adjusted NCB synthesis, and benchmark-sensitivity analyses were not part of that report and constitute the distinct secondary analysis presented here. <br/>Result(s): Prespecified external benchmark rates were 8.0, 2.0, 3.0, and 6.0 events per 100 patient-years, respectively. Unweighted and severity-weighted NCB were evaluated using both pooled-rate and study-level Hartung-Knapp random-effects approaches. Study-level pooled NCB was 12.20 events per 100 patient-years (95% CI, 8.61-15.79; I<sup>2</sup> = 96%), and weighted NCB was 14.39 (95% CI, 8.84-19.94; I<sup>2</sup> = 94%). Additional two-component analyses using PRESTIGE-AF reference rates yielded unweighted NCB estimates of 5.65 and 2.06 events per 100 patient-years for no-OAC and DOAC comparator scenarios, respectively. Excluding all-cause mortality from the original model yielded an unweighted NCB of 8.41. These exploratory results highlight the sensitivity of NCB estimates to comparator selection and endpoint composition. <br/>Conclusion(s): Contemporary randomized evidence, including PRESTIGE-AF, CLOSURE-AF, and CHAMPION-AF, reinforces that benefit-harm balance is population-, comparator-, endpoint-, and time-horizon-dependent. Accordingly, these NCB estimates should be interpreted as decision-analytic and hypothesis-generating rather than causal treatment effects. ICH-specific randomized comparisons remain essential.<br/>Copyright &#xa9; 2026 by the authors. <110> Accession Number 2051244419 Title Left atrial appendage occlusion: an alternative to anticoagulation in atrial fibrillation. Source Frontiers in Cardiovascular Medicine. 13 (no pagination), 2026. Article Number: 1889918. Date of Publication: 2026. Author Messaoudi Y.; Roux O.; Monney P.; Muller O.; Nietlispach F. Institution (Messaoudi) Faculte de Medecine de Sousse, Universite de Sousse, Sousse, Tunisia (Messaoudi) Department of Cardiology, Ibn El Jazzar Hospital, Kairouan, Tunisia (Roux, Nietlispach) University Heart Center, University Hospital Zurich, Zurich, Switzerland (Monney, Muller) Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland (Monney, Muller) Department of Cardiology, University of Lausanne, Lausanne, Switzerland Publisher Frontiers Media SA Abstract Atrial fibrillation (AF) is the most common sustained arrhythmia. Global Burden of Disease estimates indicate that 52.6 million individuals were living with AF or atrial flutter in 2021, and one in three to one in five persons are expected to develop AF during their lifetime. AF is associated with an increased risk of stroke, systemic thromboembolism, and death. Oral anticoagulation (OAC) is the first-line strategy for preventing AF-associated embolism. However, embolic events still occur in 1%-4% of anticoagulated patients per year, major bleeding occurs in 2%-4% per year, and long-term adherence to direct oral anticoagulants (DOAC) is incomplete. Left atrial appendage occlusion (LAAO) was developed as a mechanical alternative to address these unmet needs. The evidence base has changed substantially over the last 2 years: three randomized controlled trials comparing LAAO with DOAC-OPTION, CHAMPION-AF, and CLOSURE-AF-have now reported. In this update, we summarize the pathophysiological rationale, the technical aspects of the procedure, and the totality of the randomized and observational evidence, including a 2026 meta-analysis of 5,890 randomized patients. Taken together, these data indicate that LAAO reduces non-procedure-related bleeding but does not decrease all-cause major bleeding, intracranial haemorrhage, or mortality, and may carry a higher risk of ischaemic stroke than DOAC. LAAO remains an established option for patients with contraindications to or intolerance of long-term OAC. In DOAC-eligible patients, it has become a randomized-tested alternative, but current evidence supports an individualized, shared decision rather than a universal offer. We outline the remaining controversies-patient selection, device-related thrombus, peri-device leak, post-procedural antithrombotic therapy, and the interpretation of observational data-and the trials designed to resolve them.<br/>Copyright &#xa9; 2026 Messaoudi, Roux, Monney, Muller and Nietlispach. <111> Accession Number 2051534711 Title Coronary artery fistulas: a systematic review and pooled analysis of anatomy, risk stratification and contemporary management. Source Open Heart. 13(2) (no pagination), 2026. Article Number: e004055. Date of Publication: 01 Jul 2026. Author Vinciguerra M.; Pisani A.; Caldaroni F.; Garofalo G.; Tennyson C.; Karuppannan M.; Garg S.; D'Ambrosio L.; Saltarocchi S.; Galli M.; Schirone L.; Greco E.; Spadaccio C.; Rose D. Institution (Vinciguerra, Pisani) Department of Clinical, Anaesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy (Vinciguerra, Schirone, Greco) Department of Health and Life Sciences, European University of Rome, Rome, Italy (Caldaroni) Department of Cardiothoracic Surgery, Royal Melbourne Hospital, Melbourne, VIC, Australia (Garofalo) Department of Cardiac Surgery, S. G. Moscati Hospital, Avellino, Italy (Tennyson) Division of Cardiothoracic Surgery, Department of Surgery, University of Washington Medical Center, Seattle, Washington DC, United States (Karuppannan, Rose) Department of Cardiothoracic Surgery, Lancashire Cardiac Centre, Blackpool Victoria Hospital, Blackpool, United Kingdom (Garg) Department of Cardiology, Royal Blackburn Teaching Hospital, Blackburn, United Kingdom (D'Ambrosio, Schirone) Department of Angiocardioneurology, IRCCS Neuromed, IS, Pozzilli, Italy (Saltarocchi) Department of General Surgery, Surgical Specialty and Anesthesiology "Paride Stefanini", Sapienza University of Rome, Rome, Italy (Galli) Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (Galli) IRCCS Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy (Spadaccio) Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, United States (Rose) Lancaster University, Lancaster, United Kingdom Publisher BMJ Publishing Group Abstract Objective: Coronary artery fistulas (CAFs) are rare congenital or acquired anomalies characterised by abnormal coronary communications, with variable natural history and no consensus on optimal management. <br/>Method(s): A comprehensive state-of-the-art review and pooled analysis of published literature was conducted, integrating clinical, anatomical, imaging, management and outcome data from 1966 patients with 1986 CAFs. Comparative descriptive analyses between complicated and uncomplicated cases were performed to identify recurring features associated with adverse clinical outcomes. <br/>Result(s): Specific anatomical and clinical patterns were more frequently observed in patients with complications, including fistulas originating from the right coronary artery or left main coronary artery, drainage into venous or left-sided structures, large-calibre fistulas and reduced ventricular function. Based on these recurring patterns, two pragmatic phenotypes of CAFs (higher-risk and lower-risk) were identified. Given the descriptive nature of the available evidence and the absence of formal multivariable modelling, these findings should be considered hypothesis-generating rather than indicative of independent predictors. <br/>Conclusion(s): CAFs are heterogeneous vascular anomalies with variable clinical presentation and substantial potential for complications. An integrated assessment of anatomical configuration, fistula size, drainage pattern and ventricular function may support structured clinical evaluation and individualised management. We propose a practical anatomy- and risk-informed framework to guide multidisciplinary decision-making and follow-up strategies.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <112> Accession Number 2050353755 Title Esophageal Injury During Transesophageal Echocardiography-Guided Left Atrial Appendage Occlusion: A Narrative Review. Source Diagnostics. 16(21) (no pagination), 2026. Article Number: 3631. Date of Publication: 01 Nov 2026. Author Vukovic J.; Becic T.; Radic J.; Radic M.; Fabijanic D.; Jukic I. Institution (Vukovic, Jukic) Department of Internal Medicine, Division of Gastroenterology, University Hospital of Split, Split, Croatia (Vukovic, Radic, Radic) Department of Internal Medicine, School of Medicine, University of Split, Split, Croatia (Becic, Fabijanic) Department of Cardiovascular Diseases, University Hospital of Split, Split, Croatia (Radic) Department of Internal Medicine, Division of Nephrology and Haemodialysis, University Hospital of Split, Split, Croatia (Radic) Department of Internal Medicine, Division of Rheumatology, Allergology and Clinical Immunology, University Hospital of Split, Split, Croatia (Fabijanic) Department of Clinical Propedeutics, School of Medicine, University of Split, Split, Croatia (Jukic) Faculty of Health Sciences, University of Split, Split, Croatia Publisher Multidisciplinary Digital Publishing Institute (MDPI) Abstract Transesophageal echocardiography (TEE) remains an established imaging modality for guiding percutaneous left atrial appendage occlusion (LAAO), providing real-time visualization during transseptal puncture, device deployment, and procedural assessment. However, esophageal instrumentation and prolonged probe manipulation may result in gastrointestinal injury, particularly in patients with pre-existing esophageal abnormalities or increased bleeding risk. This narrative review summarizes the available evidence regarding the mechanisms, risk factors, clinical manifestations, diagnosis, management, and prevention of TEE-associated esophageal injury during LAAO while examining alternative imaging strategies. A literature search was conducted in PubMed, Scopus, Web of Science, and the Cochrane Library, supplemented by targeted searches of broader structural heart intervention literature. Although clinically recognized TEE-associated gastrointestinal complications are uncommon, studies employing systematic endoscopic surveillance have identified substantially higher rates of subclinical mucosal injury. Reported manifestations range from transient dysphagia and superficial mucosal lesions to gastrointestinal bleeding, intramural esophageal hematoma, perforation, and fistula formation. LAAO-specific registry and administrative datasets report gastrointestinal bleeding rates ranging from approximately 0.2% to 8.2%, but heterogeneous outcome definitions, ascertainment methods, and the absence of systematic endoscopic verification prevent these findings from being interpreted as rates of TEE-associated esophageal injury. Nevertheless, limited LAAO-specific evidence, heterogeneous outcome definitions, and differences in surveillance strategies preclude reliable estimation of procedure-specific esophageal injury incidence. Intracardiac echocardiography eliminates esophageal instrumentation but carries a distinct procedural risk profile, whereas cardiac computed tomography (CCT) provides complementary opportunities for preprocedural planning and postprocedural surveillance. Careful preprocedural assessment, judicious probe manipulation, early recognition of complications, and individualized imaging selection are important considerations. Prospective studies incorporating standardized esophageal injury endpoints are needed to establish the true clinical burden and guide preventive strategies.<br/>Copyright &#xa9; 2026 by the authors. <113> [Use Link to view the full text] Accession Number 2051519784 Title Causal Factors of Nonischemic Cardiomyopathy: A Contemporary Review of Mendelian Randomization Studies. Source Cardiology in Review. (no pagination), 2025. Date of Publication: 2025. Author Dhabuwala A.; Senapati S.G.; Lapsiwala B.; Wala L.; Madhavaram N.J.; Kolli D.; Desai R. Institution (Dhabuwala) From the Department of Internal Medicine, Government Medical College, Surat, India (Senapati) Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, United States (Lapsiwala) Department of Internal Medicine, HCA Medical City, Arlington, TX, United States (Wala) Department of Internal Medicine, Shantabaa Medical College, Amreli, India (Madhavaram) Department of Internal Medicine, BLDE University, Bijapur, India (Kolli) Department of Internal Medicine, Kasturba Medical College, Manipal, India (Desai) Independent Outcome Researcher, Atlanta, GA, United States Publisher Lippincott Williams and Wilkins Abstract Nonischemic cardiomyopathies (NICMs), encompassing hypertrophic (HCM), dilated (DCM), restrictive, arrhythmogenic right ventricular cardiomyopathy/dysplasia, and nondilated left ventricular cardiomyopathies, contribute significantly to cardiovascular morbidity, representing nearly 50% of cardiac transplants. Despite improved genetic and imaging techniques, underdiagnosis persists, particularly for HCM. Mendelian randomization (MR) studies provide a powerful method to identify causal risk factors, overcoming limitations of observational studies and randomized controlled trials. This manuscript reviews MR studies to identify causal factors for NICM, including endocrine, neurological, psychological, musculoskeletal, and microbial influences, and evaluates their implications for diagnostics and therapeutics. We reviewed MR studies using genetic variants as instrumental variables to establish causality. Studies employed one-sample and 2-sample MR, univariable and multivariable analyses, and large-scale genome-wide association study data. Causal relationships between exposures (eg, thyroid dysfunction, type-1 diabetes, iron overload, gut microbiome) and NICM subtypes were assessed, focusing on mediators such as inflammatory biomarkers. MR studies confirmed causal links between NICM and autoimmune endocrinopathies (eg, Hashimoto's thyroiditis and type-1 diabetes), iron overload, obesity, smoking, stress/irritability, and gut microbial taxa. Inflammatory biomarkers, such as monokine induced by interferon-gamma, mediated endocrine pathways. Alzheimer's disease showed a protective effect, while bone mineral density and homocysteine lacked causality. Genetic loci (eg, SVIL and RBM20) were implicated in HCM and DCM. Population stratification biased results, limiting generalizability. MR studies reveal diverse NICM causal factors, supporting precision medicine via enhanced screening and therapies targeting inflammatory mediators and microbial influences. Future research should improve population diversity, validate causal pathways, and explore the cardiac-gut-microbiome axis.<br/>Copyright &#xa9; 2025 Wolters Kluwer Health, Inc. All rights reserved. <114> Accession Number 2050352272 Title Artificial Intelligence in Thoracic Surgical Oncology: Technical Foundations and Applications in Lung and Esophageal Cancer Surgery. Source Cancers. 18(21) (no pagination), 2026. Article Number: 3438. Date of Publication: 01 Nov 2026. Author Cassidy R.; Razzaq S.; Howell A.; Leiva-Juarez M.; Schumacher L. Institution (Cassidy, Razzaq, Leiva-Juarez) Tufts Medical Center, Boston, MA, United States (Howell) Boston Medical Center Brighton, Brighton, MA, United States (Schumacher) Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, United States Publisher Multidisciplinary Digital Publishing Institute (MDPI) Abstract Background/Objectives: Artificial intelligence (AI) is increasingly being investigated in lung and esophageal cancer surgery, where treatment decisions require integrating imaging, clinical risk, and operative findings. This narrative review describes the technical foundations of surgical AI and examines its applications in thoracic surgical oncology, with particular emphasis on robotic surgery and the evidence supporting clinical use. <br/>Method(s): PubMed/MEDLINE was searched for English-language publications addressing AI, machine learning, deep learning, computer vision, and robotic thoracic surgery. Targeted searches and examination of reference lists identified additional studies. Publications were selected for clinical and technical relevance, prioritizing original investigations, external or prospective validation studies, and reporting guidelines. Applications were examined across preoperative assessment, intraoperative assistance, and postoperative care. <br/>Result(s): Preoperative applications include pulmonary nodule characterization, prediction of nodal disease and invasive tumor features, anatomical reconstruction, and assessment of response to neoadjuvant therapy. Intraoperative systems have demonstrated anatomical segmentation, surgical-phase recognition, and augmented reality guidance. Other models address technical performance, postoperative complications, recurrence, and survival. Selected studies report improved predictive performance or earlier recognition of critical structures; however, much of the evidence remains retrospective and institution-specific. External validation is limited, and evidence that AI assistance reduces complications or improves oncologic outcomes remains insufficient. <br/>Conclusion(s): AI offers tools for interpreting information relevant to thoracic cancer surgery, but technical accuracy alone does not establish clinical benefit. Prospective, multicenter evaluations should determine whether AI changes consequential surgical decisions and improves patient outcomes. Reliable performance under difficult operative conditions, integration into clinical workflow, and surgeon oversight remain essential to adoption.<br/>Copyright &#xa9; 2026 by the authors. <115> Accession Number 2050249003 Title Continuous Regional Anesthesia: A Practical Review of Perineural and Fascial Plane Catheters, Clinical Evidence, and Troubleshooting. Source Pain and Therapy. (no pagination), 2026. Date of Publication: 2026. Author Dost B.; Narayanan M.; Kaya C.; Wand R.; Yayik A.M.; John Martin Alexis R.; Bugada D.; Turunc E.; De Cassai A. Institution (Dost, Kaya, Turunc) Department of Anesthesiology and Reanimation, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey (Narayanan) Frimley Park Hospital, NHS Frimley Health Foundation Trust, Camberley, United Kingdom (Wand) Wexham Park Hospital, NHS Frimley Health Foundation Trust, Slough, United Kingdom (Yayik) Department of Anesthesiology and Reanimation, Ataturk University School of Medicine, Erzurum, Turkey (John Martin Alexis) North Hampshire Hospital, HHFT, Basingstoke, United Kingdom (Bugada) Department of Emergency and Critical Care, ASST Papa Giovanni XXIII, Bergamo, Italy (De Cassai) Department of Medicine (DIMED), University of Padua, Padua, Italy (De Cassai) Institute of Anesthesia and Intensive Care Unit, University Hospital of Padua, Padua, Italy Publisher Adis Abstract Continuous regional anesthesia (CRA) can extend postoperative analgesia beyond the duration of single-injection blocks and may reduce reliance on systemic opioids. The expanding use of perineural and fascial plane catheters has broadened the clinical applications of catheter-based regional analgesia across a wide range of surgical settings. However, successful CRA requires appropriate patient and catheter selection, accurate catheter placement, effective local anesthetic delivery, securement, monitoring, and timely recognition of catheter failure or complications. This review provides a practical overview of contemporary perineural and fascial plane catheter techniques and summarizes the available clinical evidence for their use in upper- and lower-limb, thoracic, cardiac, and abdominal surgery. Catheter-through-needle and catheter-over-needle systems, catheter tip configurations, pumps and delivery systems, and continuous, programmed intermittent, and patient-controlled infusion strategies are discussed. Practical aspects of ultrasound-guided catheter insertion, catheter-tip confirmation, fixation, and prevention of catheter migration are also reviewed. Current evidence suggests that continuous catheter techniques can improve postoperative analgesia and reduce opioid requirements in selected procedures, although the magnitude and consistency of benefit vary according to the surgical population, anatomical target, catheter technique, and comparator. Local anesthetic selection, concentration, infusion rate, cumulative dose, catheter location, and patient-specific risk factors should be considered to balance analgesic efficacy against motor impairment and local anesthetic systemic toxicity. Particular attention is required in patients with increased susceptibility to toxicity and when bilateral or multiple catheters are used. Catheter failure may result from inadequate dosing or spread, catheter malposition or migration, mechanical dysfunction, or pain outside the expected block distribution. A structured approach incorporating clinical assessment, catheter-site inspection, delivery-system evaluation, and ultrasound-guided assessment of injectate spread may identify reversible causes of inadequate analgesia. A stepwise troubleshooting algorithm is presented to guide catheter optimization, rescue interventions, replacement, or removal. In conclusion, effective CRA requires integration of appropriate catheter technology, individualized dosing, secure fixation, systematic monitoring, and structured troubleshooting.<br/>Copyright &#xa9; The Author(s) 2026. <116> Accession Number 652619693 Title Transcatheter Left Atrial Appendage Closure Versus Oral Anticoagulation in Patients with Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. Source American journal of therapeutics. 33(6) (pp e524-e526), 2026. Date of Publication: 01 Nov 2026. Author Bin Abdulhak A.A.; Mahmoud A.N.; Baqi A.; Hadi K.A.; Mohsen A.; Noman A.; Rahbi H.; Ekanem E.; Bahurmuz R.; Alasnag M.; Fanari Z. Institution (Bin Abdulhak, Ekanem) Winchester Medical Center, Winchester Cardiology and Vascular Medicine, Winchester, VA, United States (Mahmoud) Department of Cardiovascular Medicine, Florida Heart and Vascular, Orlando Health, Leesburg, FL, United States (Baqi, Noman) Department of Internal Medicine, Mercy St. Vincent Medical Center, Toledo, OH (Hadi) RiyadhSaudi Arabia (Mohsen) Division of Cardiology, Loma Linda University Medical Center, Loma Linda, CA, United States (Mohsen) Department of Cardiology, East Jefferson General Hospital, LCMC Health, Metairie, LA, United States (Rahbi) King Saud Medical City, Riyadh, Saudi Arabia (Bahurmuz) King Salman Heart Center, King Fahad Medical City, Riyadh, Saudi Arabia (Alasnag) Cardiac Center, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia; and (Fanari) Division of Cardiology, UCSF Fresno, University of California San Francisco, Fresno, CA, United States <117> Accession Number 2051585767 Title Effects of remimazolam versus propofol on cerebral oxygenation in elderly patients undergoing prone spine surgery: study protocol for a randomised controlled trial. Source BMJ Open. 16(10) (no pagination), 2026. Article Number: e123988. Date of Publication: 01 Oct 2026. Author Lazaro B.; Jin Z.; Sugaya Y.; Ueda K. Institution (Lazaro, Jin, Ueda) Department of Anesthesiology, Kameda Medical Center, Chiba, Kamogawa, Japan (Jin) Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, Portland, OR, United States (Jin) Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan (Sugaya) Advanced Clinical Specialist Center, Kameda Medical Center, Chiba, Kamogawa, Japan (Ueda) Department of Anesthesiology, University of Iowa Hospitals and Clinics, Iowa City, IA, United States Publisher BMJ Publishing Group Abstract Introduction: Prone spine surgery may increase the risk of cerebral hypoperfusion and postoperative neurological adverse events, particularly in elderly patients. Remimazolam is a novel ultra-short-acting benzodiazepine anaesthetic that may provide greater haemodynamic stability than propofol. However, its effects on cerebral oxygenation during prone spine surgery remain unclear, indicating clinical equipoise between remimazolam and propofol. This study compares the effects of remimazolam and propofol on cerebral oxygenation in elderly patients undergoing thoracic or lumbar spine surgery in the prone position under general anaesthesia. Methods and analysis: This prospective randomised controlled trial will be conducted at a single tertiary medical centre. Sixty patients scheduled for elective lumbar or thoracic spine surgery in prone position will be randomly assigned in a 1:1 ratio to receive either remimazolam or propofol-based total intravenous anaesthesia. Regional cerebral oxygen saturation (rScO<inf>2</inf>) will be continuously monitored using near-infrared spectroscopy. The primary outcome is the between-group difference in time-weighted average change in rScO<inf>2</inf> (DELTArScO<inf>2</inf>) in the prone position relative to baseline values in the supine position prior to the induction of anaesthesia. Secondary outcomes include cerebral desaturation events, intraoperative haemodynamic changes, vasopressor requirements, intraoperative complications and postoperative neurocognitive disorder assessed using Mini-Cog and Ultra-Brief Confusion Assessment Method. Ethics and dissemination: The study was approved by the Clinical Research Review Board of Kameda Medical Center (approval number 25-130; approval date: 5 February 2026). Written informed consent will be obtained from all participants before enrolment. The findings will be disseminated through publication in peer-reviewed journals and presentation at academic conferences. Trial registration number: Japan Registry of Clinical Trials, jRCT1031250782, first registered on 6 March 2026.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <118> Accession Number 2051610380 Title Nurse-coordinated multidisciplinary prehabilitation for older adults with frailty undergoing elective transcatheter aortic valve replacement: protocol for a randomised controlled trial. Source BMJ Open. 16(11) (no pagination), 2026. Article Number: e127667. Date of Publication: 01 Nov 2026. Author Luo Z.; Li Y.; Zhang X.; Wang Y.; Liu X.; Yu P.; Miao C. Institution (Luo, Zhang, Yu) Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, Sichuan University West China Hospital, Sichuan, Chengdu, China (Luo, Zhang, Yu) Key Laboratory of Rehabilitation Medicine in Sichuan Province, Sichuan University West China Hospital, Sichuan, Chengdu, China (Li) Department of Nursing, Sichuan University West China Second University Hospital, Sichuan, Chengdu, China (Li) Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Sichuan, Chengdu, China (Wang, Miao) Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, Sichuan University West China Hospital, Sichuan, Chengdu, China (Wang, Miao) Department of Cardiovascular Surgery, Institute of Cardiovascular Surgery, Sichuan University West China Hospital, Sichuan, Chengdu, China (Liu) Information Technology Center, Sichuan University West China Hospital, Sichuan, Chengdu, China Publisher BMJ Publishing Group Abstract Introduction: Frailty assessment can identify older adults undergoing transcatheter aortic valve replacement (TAVR) who are at increased risk of disability and poor functional recovery despite procedural success. A nurse-coordinated, multidisciplinary prehabilitation model may integrate the physical, nutritional, educational and psychological components needed to address these vulnerabilities, but randomised evidence in this population remains limited. Methods and analysis: This investigator-initiated, single-centre, assessor-blinded, parallel-group randomised controlled trial will enrol 96 adults aged 65-90 years with an Essential Frailty Toolset score of 3 or greater who are scheduled for elective TAVR. Participants will be randomised 1:1 to usual perioperative care alone or usual care plus a nurse-coordinated prehabilitation programme. The intervention combines supervised aerobic and functional exercise, respiratory training, individualised nutritional optimisation, structured education and psychological support from the day after admission until the day before TAVR. The primary outcomes are 6-minute walk distance within 48 hours before hospital discharge and health-related quality of life assessed using the EuroQol 5-Dimension 5-Level at 1 and 3 months after discharge. Secondary outcomes are hospital-associated disability and post-TAVR complications. Additional exploratory and process outcomes include anxiety and depressive symptoms, functional capacity at other time points, hospital costs, feasibility, adherence, acceptability and safety. The primary analysis will follow the intention-to-treat principle. Ethics and dissemination: The Biomedical Ethics Review Committee of West China Hospital, Sichuan University, approved the protocol (approval no. 2025 Review (2324)). The trial was prospectively registered in the Chinese Clinical Trial Registry on 22 May 2026 (ChiCTR2600125252). Results will be submitted to a peer-reviewed journal and presented at scientific conferences. Trial registration number: ChiCTR2600125252.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <119> Accession Number 2051589485 Title Comparison of ultrasound-guided intertransverse process block versus paravertebral block for postoperative quality of recovery in elderly patients undergoing minimally invasive thoracic surgery: protocol for a randomised controlled trial. Source BMJ Open. 16(7) (no pagination), 2026. Article Number: e118794. Date of Publication: 01 Jul 2026. Author Su Y.; Li X.; He X.; Li Y.; Cai Y.; Lu D.; Wang R. Institution (Su, Li, Li, Cai, Lu, Wang) Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China (He) Department of Anaesthesiology, The People's Hospital of Dazu, South Second Ring Road, Dazu District, Chongqing, China Publisher BMJ Publishing Group Abstract Introduction: Thoracic paravertebral block (PVB) is widely used for analgesia but carries risks such as pneumothorax and hypotension. Intertransverse process block (ITPB) is a newer alternative that may offer comparable analgesia with a potentially improved safety profile. However, few studies have compared the two from the patient's perspective, and none have assessed ultrasound-guided ITPB against PVB for postoperative recovery quality in elderly patients. Methods and analysis: This two-centre, double-blind, parallel-group, randomised controlled trial will enrol 152 elderly patients (age >=65 years) undergoing video-assisted thoracoscopic surgery (VATS) at West China Hospital and Shangjin Branch of West China Hospital, Sichuan University in China. Participants will be randomly assigned in a 1:1 ratio to receive either ultrasound-guided ITPB (n=76) or PVB (n=76). The primary outcome is the Quality of Recovery-15 (QoR-15) score on postoperative day 1. Secondary outcomes will include (1) QoR-15 scores measured on postoperative days 2, 3, 7 and 30; (2) pain scores at rest and during movement assessed on postoperative days 1, 2 and 3 using the Numerical Rating Scale (NRS); (3) worst NRS resting pain score within 30 min of post-anaesthesia care unit (PACU) admission; (4) proportion of patients requiring rescue analgesia within 24 hours after surgery; (5) patient satisfaction with analgesia within 24 hours after surgery; (6) total opioid consumption within 24 hours after surgery; (7) incidence of major complications of surgery within 7 days after surgery; (8) length of postoperative hospital stay; and (9) number of days at home within 30 days after surgery. Ethics and dissemination: The study protocol has received approval from the Ethics Committee of West China Hospital, Sichuan University (approval no. 2603), and the Ethics Committee of Shangjin Branch of West China Hospital, Sichuan University (approval no. 2613). Written informed consent will be obtained from all participants. Study results will be disseminated through publication in peer-reviewed journals. Trial registration number: ChiCTR2600116524.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <120> Accession Number 2051636847 Title Angiography-Derived vs Wire-Based Fractional Flow Reserve to Guide Revascularization: The Randomized LIPSIA-STRATEGY Trial. Source Journal of the American College of Cardiology. (no pagination), 2026. Date of Publication: 2026. Author Majunke N.; Desch S.; Kister T.; Buske M.; Poss J.; Feistritzer H.-J.; Erbs S.; Hosler N.; Wolff J.; Schneider S.; Zeymer U.; Woitek F.; Crusius L.; Lenk K.; Antoniadis M.; Nef H.; Dorr O.; Sossalla S.; Achenbach S.; Marwan M.; Barlagiannis D.; Haude M.; Thevathasan T.; Mahabadi A.A.; Rassaf T.; Ouarrak T.; Thiele H. Institution (Majunke, Desch, Kister, Buske, Poss, Feistritzer, Erbs, Thiele) Heart Center Leipzig at Leipzig University, Leipzig, Germany (Hosler, Wolff) Leipzig Heart Science, Leipzig, Germany (Schneider, Zeymer, Ouarrak) Stiftung Institut fur Herzinfarktforschung, Ludwigshafen am Rhein, Germany (Woitek, Crusius) Heart Center Dresden - Technische Universitat Dresden, Dresden, Germany (Lenk, Antoniadis) University Clinic Leipzig, Klinik und Poliklinik fur Kardiologie, Leipzig, Germany (Nef) Heart Center, Segeberger Kliniken GmbH, Department of Cardiology, Bad Segeberg, Germany (Dorr) CCB Am Markuskrankenhaus, Med. Klinik III, Agaplesion Markuskrankenhaus, Frankfurt am Main, Germany (Sossalla) University Clinic Giesen, Department of Internal Medicine/Cardiology, Giesen, Germany (Achenbach, Marwan) Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Department of Cardiology, Erlangen-Nurnberg, Germany (Barlagiannis, Haude) Rheinland Klinikum Neuss GmbH, Medical Clinic I, Lukaskrankenhaus, Neuss, Germany (Thevathasan) Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite (DHZC), Campus Benjamin Franklin, Berlin, Germany (Thevathasan) Berlin Institute of Health (BIH), Charite - Universitatsmedizin Berlin, Berlin, Germany (Thevathasan) DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany (Mahabadi, Rassaf) West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, Essen, Germany Publisher Elsevier Inc. Abstract Background: Wire-based physiological assessment is recommended to guide coronary revascularization but remains underused. Angiography-derived physiology offers a wire-free alternative; however, randomized comparisons with pressure wire fractional flow reserve (FFR) have yielded inconsistent findings. <br/>Objective(s): This study sought to determine whether angiography-derived vessel fractional flow reserve (vFFR)-guided revascularization is noninferior to pressure wire FFR guidance for intermediate coronary stenoses. <br/>Method(s): The multicenter, investigator-initiated, randomized LIPSIA-STRATEGY trial included patients with acute or chronic coronary syndromes and at least 1 intermediate coronary stenosis at 8 German centers. Patients were randomized 1:1 to undergo revascularization based on vFFR or FFR. The primary outcome was major adverse cardiac events, defined as a composite of cardiac death, nonfatal myocardial infarction, or unplanned clinically driven revascularization within 1 year, analyzed by modified intention to treat against a noninferiority margin of 3.5 percentage points. <br/>Result(s): Between June 2020 and February 2025, 1,053 patients (median age: 69 years) underwent randomization (vFFR, n = 528; FFR, n = 525). At 1 year, major adverse cardiac events occurred in 15 of 493 patients (3.0%) in the vFFR group and in 20 of 493 (4.1%) in the FFR group (risk difference: -1.01 percentage points; P for noninferiority <0.001); the primary outcome was ascertainable in 986 of the 1,053 randomized patients. The upper boundary of the 1-sided 97.5% CI for the risk difference was 1.29 percentage points, below the prespecified margin (relative risk: 0.75; 95% CI: 0.39-1.45). Physiological values of 0.80 or less occurred in 43.1% vs 35.9% of patients, and the study lesion was revascularized in 41.2% vs 35.5%, respectively. <br/>Conclusion(s): In patients with intermediate coronary stenoses requiring physiological assessment, a vFFR-guided revascularization strategy met the prespecified absolute criterion for noninferiority to wire-based FFR at 1 year. Because the observed event rate was lower than anticipated, the margin was less conservative on a relative scale than intended. In a post hoc sensitivity analysis using the relative margin of 1.44 implied by the original assumptions, noninferiority was not met in the primary modified intention-to-treat population. In the corresponding post hoc per-protocol sensitivity analysis, noninferiority was met using this relative margin. Whether that additional revascularization is beneficial is not answered by similar 1-year event rates. (Comparison of Vessel-FFR Versus FFR in Intermediate Coronary Stenoses; NCT03497637; Protocol ID HRC045277.)<br/>Copyright &#xa9; 2026 by the American College of Cardiology Foundation. Published by Elsevier Inc <121> Accession Number 2051585243 Title Use, physiological effects and safety of pulmonary vasodilator therapy in thoracic surgical patients: a scoping review protocol. Source BMJ Open. 16(10) (no pagination), 2026. Article Number: e123437. Date of Publication: 01 Oct 2026. Author Lipton G.; McCall P.; Burden A.; Shelley B. Institution (Lipton) Clinical Research Fellow in Anaesthesia, University of Glasgow School of Medicine Dentistry and Nursing, Glasgow, United Kingdom (Lipton, McCall, Shelley) Cardiothoracic Anaesthesia & Critical Care, Golden Jubilee National Hospital West of Scotland Regional Heart and Lung Centre, Glasgow, United Kingdom (McCall) School of Medicine Dentistry and Nursing, University of Glasgow, Glasgow, United Kingdom (Burden) Anaesthesia, Queen Elizabeth University Hospital, Glasgow, United Kingdom (Shelley) School of Medicine Dentistry and Nursing, University of Glasgow, New Lister Building, Glasgow, United Kingdom Publisher BMJ Publishing Group Abstract Introduction: Thoracic surgery requiring one-lung ventilation is associated with acute increases in right ventricular (RV) afterload, which may contribute to perioperative RV dysfunction and long-term functional limitation. Pulmonary vasodilator therapy represents a potential strategy to attenuate these effects however, the breadth, characteristics and implications of pulmonary vasodilator therapy in the thoracic surgical population have not been comprehensively synthesised. This scoping review aims to map the existing evidence base on the use, physiological effects and safety of pulmonary vasodilator therapy in adult thoracic surgery. Methods and analysis: This protocol has been developed in accordance with Joanna Briggs Institute (JBI) methodology and reported in line with the PRISMA Extension for Scoping Reviews (PRISMA-ScR). A comprehensive search of Ovid MEDLINE and Embase will be conducted from 1946 to 2026. Eligible studies will include original research (including case reports and case series) involving adult patients (>=18 years) undergoing thoracic surgery with perioperative administration of pulmonary vasodilator or inodilator therapy. Cardiac surgery, transplantation, non-surgical populations and paediatric studies will be excluded. Two independent reviewers will perform study selection, with disagreements resolved by consensus or third reviewer adjudication. Data extraction will be conducted by one reviewer and independently verified by a second. Extracted data will include study characteristics, patient population, surgical context, pharmacological interventions and reported physiological and safety outcomes. Data will be summarised descriptively using tabulated and narrative synthesis. Consistent with scoping review objectives, formal critical appraisal will not be undertaken, as the aim is to map the evidence rather than assess effect size or certainty. Methodological characteristics will be described to contextualise interpretation of results. Ethics and dissemination: Ethical approval is not required. Findings will be disseminated through peer-reviewed publication and conference presentation, informing future clinical trial design.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. <122> Accession Number 2051576474 Title Fast-track cardiac anaesthesia and early extubation pathway versus usual care for adults undergoing coronary artery bypass graft surgery: a two-centre pilot randomised controlled feasibility trial in Victoria, Australia. Source BMJ Open. 16(11) (no pagination), 2026. Article Number: e125544. Date of Publication: 01 Nov 2026. Author Weinberg L.; Raykateeraroj N.; Pillai P.; Lee W.; Le V.; Caragata R.; Suh J.; Williams K.; Koshy A.N.; Bhaskar J.; Matalanis G.; Seevanayagam S.; Warrillow S.; Ansari Z.; Lee D.-K.; Yii M. Institution (Weinberg, Pillai, Lee, Le, Caragata, Suh, Williams) Department of Anaesthesia, Austin Health, Heidelberg, VIC, Australia (Weinberg) Department of Critical Care, The University of Melbourne, Melbourne, VIC, Australia (Raykateeraroj) Department of Anesthesiology, Mahidol University Faculty of Medicine Siriraj Hospital, Bangkok, Thailand (Koshy) Department of Cardiology, Austin Health, Heidelberg, VIC, Australia (Bhaskar, Matalanis, Seevanayagam) Department of Cardiac Surgery, Austin Health, Heidelberg, VIC, Australia (Seevanayagam) Department of Thoracic Surgery, Austin Health, Heidelberg, VIC, Australia (Warrillow) Intensive Care, Austin Health, Heidelberg, VIC, Australia (Ansari) Department of Intensive Care, Epworth Eastern Hospital, Box Hill, VIC, Australia (Lee) Department of Anesthesiology and Pain Medicine, Dongguk University Ilsan Hospital, Goyang, South Korea (Yii) Department of Cardiac Surgery, Epworth Eastern Hospital, Box Hill, VIC, Australia Publisher BMJ Publishing Group Abstract Objectives: To assess feasibility and preliminary clinical outcomes of a fast-track cardiac anaesthesia (FTCA) pathway for scheduled coronary artery bypass grafting (CABG). <br/>Design(s): Two-centre, open-label, blinded-endpoint, pilot randomised controlled trial. <br/>Setting(s): One public and one private hospital in Victoria, Australia. <br/>Participant(s): Adults undergoing scheduled isolated CABG with cardiopulmonary bypass, preserved left ventricular systolic function and low-to-moderate operative risk. <br/>Intervention(s): Participants were randomised 1:1 to usual care or an FTCA pathway comprising methadone, dexmedetomidine, remifentanil, magnesium, lignocaine, sugammadex-based reversal and structured early extubation. Primary and secondary outcome measures: Feasibility comprised five prespecified criteria: recruitment capacity, consent, study drug administration, absence of administration errors and retention. The primary clinical endpoint was extubation within 4 hours of intensive care unit admission, with operating-room extubation assigned zero hours. Secondary outcomes included extubation time, opioid requirements, pain, length of stay and safety. Analyses used Fisher's exact, Wilcoxon rank-sum and Kaplan-Meier/Cox methods; efficacy comparisons were exploratory. <br/>Result(s): Of 374 patients screened, 102 were eligible and 100 were randomised. Four of the five feasibility criteria were met at both centres. Recruitment capacity was 1.28 eligible patients per week at Hospital A and 2.07 at Hospital B; only Hospital B exceeded the threshold of two. Consent was 98.0%, study drug administration 100% without errors, and dropout 0%. Early extubation occurred in 27/50 FTCA vs 3/50 usual-care participants (risk difference 0.48, 95% CI 0.31 to 0.62). Median extubation times were 3.9 versus 10.8 hours (location shift -5.0 hours, 95% CI -7.2 to -3.2). Opioid requirements in the first 24 hours and severe pain were lower with FTCA. Length of stay was not clearly reduced; uncommon harms could not be excluded. <br/>Conclusion(s): Pathway delivery and retention were achievable, but recruitment feasibility was not established at both centres. Preliminary clinical findings support a definitive trial with centre-specific recruitment planning. Trial registration number: ACTRN12625001245482.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <123> Accession Number 2051585541 Title Effect of auricular acupressure as an adjunct to standard postoperative care on physical and psychological outcomes following coronary artery bypass graft surgery: protocol for a randomised, single-blind, sham-controlled trial. Source BMJ Open. 16(10) (no pagination), 2026. Article Number: e126650. Date of Publication: 01 Oct 2026. Author Allahbakhshian A.; Farshbaf-Khalili A.; Ghasemi K.; Rahimi H.; Babaei L.; Radimaher F. Institution (Allahbakhshian) Department of Medical Surgical Nursing, Tabriz University of Medical Sciences, Tabriz, Iran, Islamic Republic of (Farshbaf-Khalili) Physical Medicine and Rehabilitation Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Islamic Republic of (Ghasemi, Rahimi, Babaei, Radimaher) Tabriz University of Medical Sciences, Tabriz, Iran, Islamic Republic of Publisher BMJ Publishing Group Abstract Introduction: Patients undergoing coronary artery bypass graft (CABG) surgery frequently experience postoperative pain, anxiety, depression, sleep disturbance and physiological instability during recovery in the cardiac intensive care unit. Although auricular acupressure (AA) has been investigated as a non-pharmacological adjunct for symptom management, existing studies are limited by methodological shortcomings, including inadequate blinding, absence of appropriate sham controls and heterogeneous surgical populations. This study aims to evaluate whether AA, as an adjunct to standard postoperative care, improves physical and psychological outcomes following CABG surgery. Methods and analysis: This is a prospective, randomised, single-blind, sham-controlled, three-arm parallel-group superiority trial. Ninety-six adults undergoing elective on-pump CABG surgery will be randomly allocated (1:1:1) to active AA, sham AA or usual postoperative care. The intervention will be delivered two times per day on postoperative days 2 through 7 (six consecutive days). The primary outcomes are pain intensity assessed using the Visual Analogue Scale and anxiety and depression assessed using the Hospital Anxiety and Depression Scale. Secondary outcomes include sleep quality, fatigue, delirium severity, physiological parameters, analgesic consumption and intensive care unit and hospital length of stay. Outcome assessments will be conducted at baseline, throughout the intervention period, at hospital discharge and 1 month after surgery. Analyses will follow the intention-to-treat principle using linear mixed-effects models to evaluate between-group differences over time. Ethics and dissemination: Ethical approval has been obtained from the Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.REC.1404.249). Written informed consent will be obtained from all participants before enrolment. Study findings will be disseminated through peer-reviewed publications, presentations at scientific conferences and updates to the trial registry. Trial registration: Iranian Registry of Clinical Trials (IRCT20160110025937N9), registered on 4 September 2025 (https://irct.behdasht.gov.ir/user/trial/84266/view).<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <124> Accession Number 2051583170 Title Sex-based differences in outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis of randomised trials. Source Open Heart. 13(1) (no pagination), 2026. Article Number: e003642. Date of Publication: 01 Jan 2026. Author Ferraz-Costa G.N.; Almeida M.D.J.; Delgado Silva J.; Goncalves L. Institution (Ferraz-Costa, Delgado Silva, Goncalves) ULS Coimbra, Coimbra District, Coimbra, Portugal (Ferraz-Costa, Delgado Silva, Goncalves) Institute for Clinical and Biomedical Research, University of Coimbra, Coimbra District, Coimbra, Portugal (Ferraz-Costa, Almeida, Delgado Silva, Goncalves) Faculty of Medicine, Universidade de Coimbra Faculdade de Medicina, Coimbra District, Coimbra, Portugal Publisher BMJ Publishing Group Abstract Background: While female sex has historically been associated with worse outcomes following surgical aortic valve replacement, the evidence regarding sex-related differences after transcatheter aortic valve implantation (TAVI) remains inconclusive. Given that women are more frequently referred for TAVI, clarifying the role of sex in procedural outcomes is clinically relevant. <br/>Objective(s): To systematically evaluate and summarise randomised clinical trial (RCT) evidence comparing TAVI outcomes between women and men. <br/>Method(s): A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and registered in PROSPERO (CRD42024510202). PubMed, EMBASE and Web of Science were searched for English-language RCTs up to 1 July 2024. Studies comparing TAVI outcomes by sex were included. The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular mortality, stroke or transient ischaemic attack (TIA), major bleeding and permanent pacemaker implantation (PPI). Pooled ORs were calculated using Mantel-Haenszel random-effects models. <br/>Result(s): 14 RCTs with a total of 15 225 participants were included. No overall difference in all-cause mortality was observed between sexes (OR: 0.83; 95% CI 0.65 to 1.06), though a significant protective effect for female sex was found among intermediate-risk patients (OR: 0.64; 95% CI 0.49 to 0.84; I2=0%). Women had a significantly higher risk of major bleeding (OR: 1.35; 95% CI 1.21 to 1.52; I2=15%). No significant sex-based differences were identified in cardiovascular mortality (OR: 0.98), stroke/TIA (OR: 0.96) or PPI (OR: 1.05). <br/>Conclusion(s): Female sex was associated with a lower all-cause mortality among intermediate-risk patients undergoing TAVI, but also with a higher overall risk of major bleeding. These findings suggest the need for further investigation into sex-related anatomical and procedural factors. PROSPERO registration number: CRD42024510202.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <125> Accession Number 2051590040 Title Intravenous iron to treat anaemia before cardiac surgery (ITACS): international, double blind, placebo controlled randomised trial. Source BMJ. 394(8495) (no pagination), 2026. Article Number: e100407. Date of Publication: 22 Aug 2026. Author Myles P.S.; Klein A.A.; Smith J.A.; Wallace S.; Forbes A.; Zavarsek S.; Symons J.A.; Baker R.A.; Wood E.M.; McQuilten Z.; McGiffin D.; Christie-Taylor G.; Soon C.K.; Chan M.T.V.; Martin C.; Richards T. Institution (Myles, Wallace, Symons, McQuilten, McGiffin) Alfred Hospital, Melbourne, VIC, Australia (Myles, Smith, Wallace, Forbes, Wood, McQuilten, Martin) Monash University, Melbourne, VIC, Australia (Klein) Royal Papworth Hospital, Cambridge, United Kingdom (Smith, Wood) Monash Health, Clayton, VIC, Australia (Zavarsek) Deakin University, Burwood, VIC, Australia (Symons) University of Melbourne, Melbourne, VIC, Australia (Baker) Flinders Medical Centre, Flinders University, Adelaide, SA, Australia (Christie-Taylor) Royal Adelaide Hospital, Adelaide, SA, Australia (Soon) Institut Jantung Negara, Kuala Lumpur, Malaysia (Chan) Chinese University of Hong Kong, Hong Kong (Richards) School of Health, Sport & Bioscience, University of East London, London, United Kingdom Publisher BMJ Publishing Group Abstract Objective: To evaluate the effects of intravenous iron on red cell transfusion and recovery after cardiac surgery. <br/>Design(s): International, multicentre, double blind, placebo controlled randomised trial (ITACS). <br/>Setting(s): 33 hospitals across 10 countries. Participants were enrolled between July 2016 and December 2023. <br/>Participant(s): 955 adults with anaemia undergoing elective cardiac surgery. Exclusion criteria included haemoglobinopathy or iron storage disorder, renal dialysis, and erythropoietin or intravenous iron given in the previous four weeks. <br/>Intervention(s): A computer generated program randomised participants to intravenous iron 1000 mg or placebo 1-26 weeks before surgery. Participants, clinicians, and data collectors were masked to the intervention. <br/>Main Outcome Measure(s): The number of days alive and at home up to 90 days after surgery (primary outcome), red cell transfusion requirements and complications (secondary outcomes). <br/>Result(s): Of 2993 screened participants, 955 were enrolled and 921 of the eligible 939 modified intention-to-treat participants were assessed for the primary outcome. The median number of days alive and at home up to 90 days after surgery was 81.1 (interquartile range 74.8-83.7) in patients assigned to intravenous iron and 80.0 (69.5-83.6) in those receiving placebo (adjusted median difference 1.0 day, 95.4% confidence interval 0.0 to 2.1 days, P=0.041). Red cell transfusions were given to 262 patients (61.1%) in the iron group and 302 (68.2%) in the placebo group during their hospital stay (relative risk 0.90, 95% confidence interval 0.82 to 0.99, P=0.027). No differences were observed for major complications or length of hospital stay. <br/>Conclusion(s): Among patients with anaemia undergoing elective cardiac surgery, preoperative intravenous iron was associated with a reduction in red cell transfusion and a small improvement in the number of days alive and at home in the first 90 days after surgery. Intravenous iron is an effective component of patient blood management in this setting. Trial registration: ClinicalTrials.gov NCT02632760.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. <126> Accession Number 2051585540 Title One-stage versus two-stage video-assisted thoracic surgery for synchronous bilateral pulmonary nodules: protocol for a prospective, multicentre, randomised controlled clinical trial in China (OTVATS-2). Source BMJ Open. 16(9) (no pagination), 2026. Article Number: e115819. Date of Publication: 01 Sep 2026. Author Han Y.; Wang J.; Yang X.; He H.; Li D.; Liu X.; Huang C.; Qiang G.; Liang C. Institution (Han, Wang, Liang) Department of General Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China (Yang) Peking University Health Science Centre, Beijing, China (He, Qiang) Department of Thoracic Surgery, Peking University Third Hospital, Beijing, China (Li, Huang) Department of General Thoracic Surgery, Beijing Hospital, Beijing, China (Liu) Institute of Medical Information, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Publisher BMJ Publishing Group Abstract Introduction: With the increasing detection of synchronous bilateral pulmonary nodules in clinical practice, both one-stage and two-stage video-assisted thoracic surgery (VATS) have been widely applied. This study protocol describes the OTVATS-2 trial, which aims to compare perioperative complications and long-term outcomes between these two surgical strategies. Methods and analysis: A prospective, multicentre, randomised controlled clinical trial will be conducted to compare the surgical outcomes of one-stage versus two-stage VATS in patients with synchronous bilateral pulmonary nodules. A total of 256 patients will be enrolled from three academic institutions in China. This trial is expected to last for 2 years, with patient recruitment starting in July 2025. The primary outcome is perioperative complication rate within 30 days. Secondary outcomes including 5-year overall survival, 5-year disease-free survival, surgical time, blood loss, duration of chest tube, length of stay, postoperative pain scores, quality of life scores as well as anxiety and depression scores. Ethics and dissemination: This study has been approved by the Ethics Committee of China-Japan Friendship Hospital (No. 2025-KY-150) and the institutional review boards of all participating centres, including the Ethics Committees of Peking University Third Hospital and Beijing Hospital. Written informed consent will be obtained from all enrolled participants. Results of the research will be published in a peer-reviewed journal. Trial registration number: ChiCTR 2500106215.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <127> Accession Number 2051605351 Title Risk factors associated with in-hospital mortality and a composite of major complications following paediatric congenital cardiac surgery: A systematic review protocol. Source PLOS One. 21(11 November) (no pagination), 2026. Article Number: e0360693. Date of Publication: 01 Nov 2026. Author Mogane P.; Kebalepile M.; Motshabi Chakane P. Institution (Mogane, Kebalepile, Motshabi Chakane) Department of Anaesthesiology, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Parktown, Johannesburg, South Africa Publisher Public Library of Science Abstract Background: Approximately 70% of patients born with congenital heart disease (CHD) require medical or surgical treatment in their first year of life. A reported 90-95% will survive to adulthood due to advances in paediatric cardiology, cardiac surgery and anaesthesia. These reported advances are still not available for over 90% of the children born with CHD in low-and middle-income countries (LMIC). The objectives of this study are to determine the pooled incidence of in-hospital all-cause mortality; identify risk factors associated with in-hospital all-cause mortality and a composite of major complications in paediatric patients undergoing congenital cardiac surgery; and to compare these risk factors between LMICs and high-income countries (HICs). <br/>Method(s): A systematic review will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines; this has been registered with PROSPERO 2024 (CRD42024618297). The Population, Exposure and Outcome (PEO) framework will guide the search strategy. Eligible studies will include prospective and retrospective cohort studies, case-control studies, interventional studies and registry/database studies reporting risk factors for in-hospital all-cause mortality and/or major postoperative complications in paediatric patients (<=18 years) undergoing cardiac surgery for CHD. A comprehensive electronic search of PubMed, Scopus, CINAHL, Cochrane Library and Web of Science will identify peer-reviewed English-language studies published from January 2000-2026. Two reviewers will independently screen studies, extract data using a standardised data extraction form, and assess risk of bias using the Newcastle-Ottawa Scale or ROBINS-I, as appropriate to study design. Where appropriate, we will perform random-effects meta-analysis to estimate pooled effect measures and 95% confidence intervals. Statistical heterogeneity will be assessed using the I2 statistic, and results will otherwise be synthesised narratively. Where sufficient data are available, risk factors will be compared between LMICs and HICs. <br/>Discussion(s): In-hospital mortality and major complications following paediatric congenital cardiac surgery are associated with a combination of patient-, surgical- and perioperative risk factors. Identifying these facilitates early risk stratification and optimisation of modifiable risk factors to support targeted perioperative interventions and resource allocation, particularly in LMICs where evidence remains limited. A meta-analysis is not anticipated because of substantial heterogeneity in the study population.<br/>Copyright &#xa9; 2026, Mogane et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. http://creativecommons.org/licenses/by/4.0/ <128> Accession Number 652622051 Title SGLT2 Inhibitors as Potential Agents for Prevention, Treatment, and/or Improved Recovery from Acute Kidney Injury. Source Handbook of experimental pharmacology. (no pagination), 2026. Date of Publication: 13 Sep 2026. Author Sanchez-Vega D.; Oskoui E.P.; Siskind L.J. Institution (Sanchez-Vega, Siskind) Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, United States (Sanchez-Vega, Siskind) Department of Medicine, University of Louisville School of Medicine, Louisville, KY, United States (Oskoui, Siskind) University of Louisville School of Medicine, University of Louisville Health Brown Cancer Center, Louisville, KY, United States Abstract Acute kidney injury (AKI) results in rapid loss of blood filtration, reabsorption, and excretion of metabolic waste. AKI can progress to chronic kidney disease or even lead to premature death. AKI significantly worsens mortality in several of the top 20 leading causes of death as well as in populations of hospitalized patients postcoronary intervention or cardiac surgery or with sepsis. Experimental rodent models of AKI have been used to investigate the pathophysiology of the different AKI etiologies and their subtypes due to challenges of mechanistic studies and risks of acquiring kidney biopsies in human patients. The sodium-glucose cotransporter 2 (SGLT2), located on the apical membrane of early proximal tubules, is responsible for reabsorbing more than 90% of the filtered glucose back into the bloodstream. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduced AKI severity and/or improved recovery when tested in rodent models of AKI. While SGLT2i are not currently approved by the FDA to treat AKI, there is clinical evidence to support their use as preventative agents. Of note, most clinical evidence for the use of SGLT2 inhibitors for AKI comes from studies in which AKI was not the primary end point. Data obtained from retrospective studies and animal models of AKI provide rationale for randomized clinical trials on SGLT2 inhibitors to prevent or improve recovery from AKI.<br/>Copyright &#xa9; 2026. The Author(s), under exclusive license to Springer Nature Switzerland AG. <129> Accession Number 652617386 Title Pharmacological Prevention of Cardiac Surgery-Associated Acute Kidney Injury: Why Trials Failed and a Reimagined Endpoint Framework. Source The Annals of thoracic surgery. (no pagination), 2026. Date of Publication: 05 Nov 2026. Author Engelman D.T.; Zarbock A.; Corteville D.C.; Lamy A.; Mehta R.L.; Ostermann M.; Parikh C.R.; Kellum J.A. Institution (Engelman) Department of Surgery, Division of Cardiac Surgery, Baystate Medical Center, University of Massachusetts Chan Medical School-Baystate, Springfield, MA, United States (Zarbock) Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital Munster, Munster, Germany (Corteville) Division of Cardiology, Rochester Regional Health, Rochester, NY, United States (Lamy) Division of Cardiac Surgery, Department of Surgery, McMaster University, Population Health Research Institute, Hamilton, ON, Canada (Mehta) Division of Nephrology-Hypertension, Department of Medicine, University of California San Diego, San Diego, CA, United States (Ostermann) Department of Critical Care, King's College London, Guy's and St Thomas' Hospital, London, United Kingdom (Parikh) Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States (Kellum) Department of Critical Care Medicine and Center for Critical Care Nephrology, University of Pittsburgh, Pittsburgh, PA, United States Abstract BACKGROUND: Cardiac surgery-associated acute kidney injury affects approximately one in four adults and is independently associated with perioperative mortality and progression to chronic kidney disease. Despite more than two decades of randomized pharmacological trials, few have met their primary endpoint. <br/>METHOD(S): This invited narrative review examined 33 pivotal randomized trials of pharmacological prevention published from 2004 to 2026, grouped by mechanism, and related population, intervention timing, and endpoint selection to trial outcome. <br/>RESULT(S): Trials using short-term creatinine-based kidney injury endpoints produced the positive signals, whereas trials using major adverse kidney events at 90 days as the primary endpoint were negative. This divergence reflects both the low power of that composite for detecting injury prevention and unresolved biology, since no agent has shown benefit on both types of endpoint. Positive trials shared a matched mechanism, a defined population, and an aligned endpoint. Recurrent failure modes were endpoint misalignment, mismatch between population and the timing of injury, confounding by postoperative cardiac recovery, and direct drug effects on creatinine or urine output that mimic or mask injury. <br/>CONCLUSION(S): We propose a trial framework with persistent stage 2 or 3 acute kidney disease at 30 days, by Kidney Disease: Improving Global Outcomes criteria, as the primary endpoint; preoperative albuminuria as an enrichment criterion; and attenuation of the postoperative rise in albuminuria at 30 and 90 days as a key secondary endpoint. Platform designs with biomarker-enriched enrollment could convert the next generation of trials into interpretable tests of kidney protection.<br/>Copyright &#xa9; 2026 The Author(s). Published by Elsevier Inc. All rights reserved. <130> Accession Number 652619684 Title Safety and efficacy of cerebral embolic protection devices during TAVI: a meta-analysis and sequence analysis of trials. Source Arquivos de neuro-psiquiatria. 84(11) (pp 1-12), 2026. Date of Publication: 01 Nov 2026. Author Costa A.J.S.C.; Fernandes M.V.C.; Batista T.C.; Felix A.V.J.; Barbosa T.L.S.; Cruz I.M.L.; Noleto G.S. Institution (Costa, Fernandes, Batista, Felix, Barbosa, Cruz) Universidade Federal do Piaui, Faculdade de Medicina, Brazil (Noleto) Universidade Federal do Piaui, Faculdade de Medicina, Hospital Universitario, Brazil Abstract Background: Cerebral embolic protection (CEP) devices have been developed to reduce postoperative neurological outcomes after transcatheter aortic valve implantation (TAVI); however, their effectiveness remains controversial. <br/>Objective(s): To evaluate the impact of CEP use during TAVI on the occurrence in clinical outcomes. <br/>Method(s): Databases were used to search for randomized clinical trials. The occurrence of all strokes, of disabling strokes specifically, transient ischemic attacks (TIAs), all-cause mortality, and vascular complications were analyzed. Conventional meta-analysis was conducted using fixed-effects modeling and trial sequential analysis (TSA: type I error of 5%, power of 90%). The systematic review protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO; CRD420251081075). <br/>Result(s): In total, eight clinical trials were included, gathering 11,589 patients randomized between those who used the devices (5,943) and those who did not (5,646). The meta-analysis demonstrated no significant association between CEP use and reduced odds of all-cause stroke (OR = 0.92, 95% CI: 0.73-1.15, p = 0.46) and disabling stroke (OR = 0.80, 95% CI: 0.57-1.13, p = 0.20). The sequential analysis identified a lack of evidence for all strokes (required sample size [rSS] = 38,626; 10.53%), disabling strokes (rSS = 59,732; 17.05%). In terms of mortality, there was no significance in the use of devices (OR = 1.09, 95% CI: 0.71-1.69, p = 0.69), reaching evidence for support (rSS = 7,053; 42.25%). <br/>Conclusion(s): The data on the use of CEP is insufficient to support meta-analytic conclusions regarding cerebrovascular outcomes. Nevertheless, TSA demonstrated evidence supporting futility regarding mortality reduction.<br/>Copyright The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/). <131> Accession Number 2038854208 Title The effect of vitamin C supplementation additive to the priming solution on postoperative bleeding in coronary artery bypass grafting: A randomized controlled trial. Source ARYA Atherosclerosis. 22(4) (pp 53-61), 2026. Date of Publication: 01 Jul 2026. Author Hosseini A.; Shahzamani M.; Maghami-Mehr A.; Moshgelgosha M. Institution (Hosseini, Shahzamani) Department of Cardiovascular Surgery, Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of (Maghami-Mehr) Department of Statistics, Yazd University, Yazd, Iran, Islamic Republic of (Maghami-Mehr) Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of (Moshgelgosha) Department of Circulation Technology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of Publisher Isfahan University of Medical Sciences(IUMS) Abstract BACKGROUND: Patients undergoing cardiac surgery often experience bleeding during and after the procedure. Antioxidants such as Vitamin C (VC) are used to manage postoperative bleeding and inflammation after cardiac surgery. <br/>METHOD(S): A total of 110 patients undergoing elective coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB) were enrolled. Patients were randomly assigned into two groups of 55 participants each. In the intervention group, 25 mg/ kg of VC was added to the CPB priming solution. In the control group, 25 mg/kg of normal saline was added instead. Nurse recorded the amount of chest tube drainage on intensive care unit (ICU) entry, and 2, 4, 6, 12, and 24 hours. They also documented the amount of blood product transfusion required during surgery and in the ICU. <br/>RESULT(S): The amount of chest tube drainage in the control group was higher than the intervention group, but this difference was not statistically significant between the two groups (P > 0.05). The amount transfused blood in the operating room and in the ICU in the intervention group was 1.64+/-0.79 and 2.14+/-1.17 ml, respectively, and in the control group it was 1.69+/-0.84 and 2.52+/-1.68 ml, which was not statistically significant between the two groups (P > 0.05). There was no significant difference in duration of ICU and hospital stay between the two groups (P > 0.05). <br/>CONCLUSION(S): Adding VC to the CPB prime showed a non-significant trend toward reduced postoperative bleeding after CABG. Current evidence from this study is insufficient to recommend routine use; further larger trials are needed.<br/>Copyright &#xa9; 2026, Isfahan University of Medical Sciences(IUMS). All rights reserved. <132> Accession Number 2051365472 Title Artificial intelligence in esophageal cancer: a narrative review from a thoracic surgical perspective. Source Frontiers in Oncology. 16 (no pagination), 2026. Article Number: 1917622. Date of Publication: 2026. Author Peng D.; Liu W.; Zhang B. Institution (Peng, Liu, Zhang) Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China (Liu) Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China Publisher Frontiers Media SA Abstract Background - Artificial intelligence (AI) has potential applications across the esophageal cancer (EC) care pathway, but reported retrospective performance often has not translated into clinically validated decision support. We review the evidence through the lens of thoracic surgical decisions, where the consequences of prediction errors are asymmetric. Scope - This narrative review examines AI studies relevant to thoracic surgical decisions, with an emphasis on esophageal squamous cell carcinoma (ESCC). Selected reports were mapped to clinical tasks, analysis units, and validation settings. Supplementary PubMed and Web of Science searches informed the review; studies were selected purposively to illustrate clinical tasks and validation problems, not to represent the entire field. Key observations - A randomized endoscopy trial supports improved lesion detection in its study setting. Selected retrospective studies report external testing for nodal risk or pathological response, whereas surgical video and complication models mainly provide internal evaluation. Image-level results, patient-level predictions, and clinical outcomes are distinct. Calibration and prospective pathway evaluation remain necessary before treatment allocation can be based on model output. Conclusions - AI in EC should presently be considered an investigational decision-support layer rather than a replacement for endoscopic, imaging-based, or multidisciplinary assessment. Translation requires patient-level data partitioning, transparent reporting of calibration and clinical utility, independent external validation, and prospective studies using prespecified decision thresholds.<br/>Copyright &#xa9; 2026 Peng, Liu and Zhang. <133> Accession Number 2051536290 Title Development and real-world cohort validation of a meta-analysis-derived simplified scoring model for cardiac resynchronisation therapy response: a study protocol. Source BMJ Open. 16(4) (no pagination), 2026. Article Number: e117565. Date of Publication: 01 Apr 2026. Author Liu X.; Wang Y.; Wei M.; Tuerhong Z.; Lu Y. Institution (Liu, Wei, Tuerhong, Lu) Department of Cardiac Pacing and Electrophysiology, The first Affiliated Hospital of Xinjiang Medical University, Urumqi, China (Liu, Wei, Tuerhong) Department of Cardiac Electrophysiology and Remodeling, The first Affiliated Hospital of Xinjiang Medical University, Xinjiang, Urumqi, China (Wang) Department of Pharmacy, The first Affiliated Hospital of Xinjiang Medical University, Xinjiang, Urumqi, China Publisher BMJ Publishing Group Abstract Background: Cardiac resynchronisation therapy (CRT) is a cornerstone device-based treatment for patients with heart failure with ventricular dyssynchrony. However, approximately 30-40% of recipients fail to achieve clinical response. Despite extensive research, validated prediction tools grounded in high-level evidence and readily applicable in clinical practice remain lacking. This study protocol describes the development and real-world validation of a simplified clinical scoring model for CRT response derived from systematic review and meta-analysis. Methods and analysis: This study will develop a CRT response prediction model via meta-analysis and preliminarily validates it in a single-centre retrospective cohort. Initially, systematic searches of multiple databases up to 31 January 2026 and meta-analysis will synthesise effect estimates for candidate predictors, creating an evidence-based foundation that conceptually functions as a 'training dataset'. Predictor selection and prioritisation will be guided by study frequency, effect magnitude and clinical accessibility, with factor weights derived directly from pooled random-effects meta-analytic estimates. Log relative risks will be converted to integer scores to establish a series of nested prediction models. Model performance will then be comprehensively assessed in an independent 'validation dataset' comprising a single-centre cohort from Xinjiang Medical University, evaluating discrimination (area under the receiver operating characteristic curve), calibration (calibration plots and Hosmer-Lemeshow test) and clinical utility (decision curve analysis). The final scoring system will be identified through comparative model evaluation guided by parsimony principles. Ethics and dissemination: This meta-analysis exclusively uses published, de-identified data and therefore does not require ethical approval. The validation cohort employs retrospectively anonymised patient data in strict adherence to the ethical principles of the Declaration of Helsinki. The study protocol has been approved by the Institutional Review Board of the First Affiliated Hospital of Xinjiang Medical University (Approval No.: K202403-48-2503A-Y1). As this constitutes a retrospective analysis of existing data, individual informed consent will be waived. Comprehensive measures to protect participant privacy and ensure data integrity will be implemented throughout all research procedures. The findings will be presented at academic gatherings or published in scholarly, peer-reviewed journals. PROSPERO registration number: CRD42024572313.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. <134> [Use Link to view the full text] Accession Number 2051469367 Title Vasopressor use in cardiogenic shock. Source Current Opinion in Critical Care. 26(4) (pp 411-416), 2020. Date of Publication: 01 Aug 2020. Author Levy B.; Klein T.; Kimmoun A. Institution (Levy, Klein, Kimmoun) Service de Reanimation Medicale Brabois, CHRU Nancy, Pole Cardio-Medico-Chirurgical, France (Levy, Klein, Kimmoun) INSERM U1116, Faculte de Medecine, Vandoeuvre-les-Nancy, France (Levy, Klein, Kimmoun) Universite de Lorraine, Nancy, France Publisher Lippincott Williams and Wilkins Abstract Purpose of review - Data and interventional trials on vasopressor use during cardiogenic shock are scarce. Their use is limited by their side-effects and the lack of solid evidence regarding their effectiveness in improving outcomes. In the present article, we review the current use of vasopressor therapy during cardiogenic shock. Recent findings - Two recent Cochrane analyses concluded that there was insufficient evidence to prove that any one vasopressor was superior to others in terms of mortality. A recent RCT and a meta-analysis on individual data suggested that norepinephrine may be preferred over epinephrine in patients with cardiogenic shock, in particular, after myocardial infarction. In patients with right ventricular failure and pulmonary hypertension, the use of vasopressin may be advocated under advanced monitoring. Summary - When blood pressure needs to be restored, norepinephrine is a reasonable first-line agent. Information regarding comparative effective outcomes is sparse and their use should be limited to a temporary measure as a bridge to recovery, mechanical circulatory support or heart transplantation.<br/>Copyright &#xa9; 2020 Wolters Kluwer Health, Inc. All rights reserved. <135> Accession Number 2051515881 Title Effect of adding preoperative serratus anterior plane block to intercostal nerve block with liposomal bupivacaine on postoperative pain in patients undergoing video-assisted thoracoscopic lung resection: study protocol for a prospective randomized controlled trial. Source Frontiers in Medicine. 13 (pp 1-8), 2026. Article Number: 1948798. Date of Publication: 13 Oct 2026. Author Liang H.; Cui Q.; Wang Q.; Ding H.; Zhou Y.; Ling Z.; Ran M.; Tang L. Institution (Liang) Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (Cui, Wang, Ding, Zhou, Ling, Ran, Tang) Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Publisher Frontiers Media SA Abstract Background - Effective postoperative pain management is fundamental to enhanced recovery after video-assisted thoracoscopic surgery (VATS). Previous studies have demonstrated that both serratus anterior plane block (SAPB) and intercostal nerve block (ICNB) effectively alleviate postoperative pain. However, data on the combination of these two techniques using liposomal bupivacaine, a sustained-release local anesthetic formulation, remain limited. Accordingly, this randomized controlled trial aims to compare the postoperative analgesic efficacy of combined preoperative SAPB and intraoperative ICNB vs. sham SAPB plus active ICNB in patients undergoing VATS lung resection, with liposomal bupivacaine administered for both blocks. Methods - This single-center randomized controlled trial will enroll 98 patients scheduled for video-assisted thoracoscopic lung resection to compare the postoperative analgesic efficacy of combined preoperative SAPB and intraoperative ICNB vs. sham SAPB plus intraoperative ICNB, with liposomal bupivacaine administered for both nerve blocks. The primary outcome is the VAS (0-10) pain score with movement at 24 h postoperatively; secondary outcomes include cumulative sufentanil consumption within 48 h and the number of patient-controlled intravenous analgesia (PCIA) demands. Discussion - This trial will provide the first head-to-head evidence comparing the analgesic efficacy of combined SAPB and ICNB vs. sham SAPB plus ICNB using liposomal bupivacaine in VATS lung resection. If the combination strategy demonstrates superior analgesic efficacy, it may establish a more effective multimodal analgesic regimen for postoperative pain management in thoracic surgery. These findings are expected to inform clinical practice and guide the development of future perioperative analgesic protocols. Clinical Trial Registration:https://www.chictr.org.cn/showproj.html?proj=295245, identifier ChiCTR2500112224.<br/>Copyright &#xa9; 2026 Liang, Cui, Wang, Ding, Zhou, Ling, Ran and Tang. <136> Accession Number 652617539 Title Prevalence of Burnout in Cardiothoracic Surgery From Training to Consultancy: A Meta-Analysis. Source The Journal of surgical research. 328 (pp 591-600), 2026. Date of Publication: 05 Nov 2026. Author Santos K.; Cetinel E.; Scremin G.M.; Pereira H.; Lim C.J.; Shamaz H.; Plonek T. Institution (Santos) New Vision University School of Medicine, Tbilisi, Georgia; Department of Cardiothoracic Surgery, Medisch Spectrum Twente, Enschede, Netherlands (Cetinel) Vita-Salute San Raffaele University, Milan, Italy (Scremin) Pontifical Catholic University of Parana, Curitiba, Brazil (Pereira) University of Messina, Messina, Italy (Lim) University of Sheffield Medical School, Sheffield, United Kingdom (Shamaz) University of Edinburgh, Edinburgh, United Kingdom (Plonek) Department of Cardiothoracic Surgery, Medisch Spectrum Twente, Enschede, Netherlands; Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland Abstract INTRODUCTION: Burnout is a psychological syndrome marked by emotional exhaustion, depersonalization, and a reduced sense of personal accomplishment. Cardiothoracic surgeons are especially vulnerable due to long hours, high-stakes decision-making, and limited recovery time. However, the global burden of burnout in this field remains poorly defined. Our study provides the first meta-analysis of burnout prevalence among cardiothoracic surgery trainees and consultants, with subgroup analysis by career stage, geographical region, and burnout domains. <br/>METHOD(S): A systematic search was conducted to identify studies reporting quantitative burnout prevalence in cardiothoracic surgery using validated tools. Studies were included if they stratified results by career stage or reported Maslach Burnout Inventory (MBI) subscale data. Pooled prevalence estimates were calculated using a random-effects model. Subgroup analyses were conducted by training level, geographic region (US-based versus European-based cohorts), and MBI domains. <br/>RESULT(S): Six studies met the inclusion criteria, encompassing 603 trainees and 394 consultants. The pooled burnout prevalence was 50.8% [95% confidence interval: 38.8-62.8%]. Burnout rates were comparable between consultants (52.9%) and trainees (51.3%). Regionally, burnout prevalence was numerically higher in US-based studies (57.9%) than in European cohorts (40.2%) although the subgroup difference was not statistically significant. MBI subscale analysis revealed high rates of emotional exhaustion (45.4%) and depersonalization (39.9%), with low personal accomplishment reported in 24.2% of participants. <br/>CONCLUSION(S): Burnout is highly prevalent across all stages of a cardiothoracic surgical career. The observed geographic variation warrants further investigation into whether systemic and cultural factors may contribute to burnout.<br/>Copyright &#xa9; 2026 Elsevier Inc. All rights reserved. <137> Accession Number 2050215584 Title Influence of diabetes mellitus on dapagliflozin response after transcatheter aortic valve replacement (TAVR): insights from the DAPA-TAVI trial. Source Cardiovascular Diabetology. 25(1) (no pagination), 2026. Article Number: 325. Date of Publication: 01 Dec 2026. Author Parraga R.; Real C.; Nombela-Franco L.; Amat-Santos I.; Jimenez-Quevedo P.; Otero D.L.; Gheorghe L.; Sanz-Sanchez J.; Zorita C.B.; Ojeda S.; Ferreiro R.G.; Garcia A.J.M.; Vilalta V.; Fernandez G.V.; Soriano J.G.C.; Cepas-Guillen P.; Rollan M.S.; Rios X.F.; Palma-Carbajal R.; Reyes R.M.; Romaguera R.; Avanzas P.; Blas S.G.; Franco-Pelaez J.A.; Moreiras J.M.; Gonzalez-Juanatey J.R.; Calle G.; Diez J.L.; Santos-Martinez S.; Erquicia P.D.; Garcia E.M.; Fernandez-Nofrerias E.; Sanmartin X.; Barrios A.G.; Bermudez I.G.; Fuster V.; Ibanez B.; Roubin S.R. Institution (Parraga, Real, Nombela-Franco, Jimenez-Quevedo) Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Profesor Martin Lagos, Madrid, Spain (Parraga, Real, Fuster, Ibanez, Roubin) Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (Amat-Santos, Zorita, Santos-Martinez) Cardiology Department, University Clinical Hospital of Valladolid, Valladolid, Spain (Amat-Santos, Zorita, Avanzas, Santos-Martinez, Ibanez) Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain (Otero, Sanmartin) Cardiology Department, University Hospital Montecelo, Pontevedra, Spain (Gheorghe, Calle, Barrios) Cardiology Department, University Hospital Puerta del Mar, Cadiz, Spain (Sanz-Sanchez, Diez) Cardiology Department, University Hospital La Fe, Valencia, Spain (Ojeda) Department of Cardiology, Reina Sofia University Hospital, Cordoba, Spain (Ojeda) Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain (Ojeda) Department of Medicine, University of Cordoba, Cordoba, Spain (Ferreiro, Erquicia, Bermudez, Roubin) Cardiology Department, University Hospital Alvaro Cunqueiro, Estrada de Clara Campoamor 341, Pontevedra, Vigo, Spain (Ferreiro, Erquicia, Bermudez, Roubin) Instituto de Investigacion Sanitaria Galicia Sur, Vigo, Spain (Garcia, Garcia) Cardiology Department, University Hospital Virgen de la Victoria, Malaga, Spain (Vilalta, Fernandez-Nofrerias) Cardiology Department, University Hospital German Trias i Pujol, Badalona, Spain (Fernandez) Cardiology Department, University Hospital Marques de Valdecilla, Santander, Spain (Fernandez) Instituto de Investigacion Valdecilla, Santander, Spain (Soriano) Cardiology Department, University Hospital of Albacete, Albacete, Spain (Cepas-Guillen) Cardiology Department, University Clinical Hospital. Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (Rollan) Cardiology Department, Dr. Balmis University General Hospital, Alicante, Spain (Rios) Cardiology Department, University Hospital Juan Canalejo, A Coruna, Spain (Palma-Carbajal) Cardiology Department, University Hospital Vall D'Hebron, Barcelona, Spain (Reyes) Cardiology Department, University Hospital Quiron Salud La Luz, Madrid, Spain (Romaguera) Cardiology Department, Hospital Universitari de Bellvitge; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigacio Biomedica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain (Avanzas) Cardiology Department, Hospital Universitario Central Asturias, Oviedo, Spain (Avanzas) Health Research Institute of the Principality of Asturias (ISPA), Oviedo, Spain (Avanzas) Medicine Department, University of Oviedo, Oviedo, Spain (Blas) Cardiology Department, Clinic University Hospital of Valencia, Valencia, Spain (Blas) INCLIVA Biomedical Research Institute, Valencia, Spain (Franco-Pelaez, Ibanez) Cardiology Department, University Hospital Fundacion Jimenez Diaz, Madrid, Spain (Moreiras) Cardiology Department, University Clinical Hospital of Salamanca, Salamanca, Spain (Gonzalez-Juanatey) Cardiology Department, University Clinical Hospital of Santiago de Compostela, Compostela, Spain (Fuster) Mount Sinai Fuster Heart, New York, NY, United States (Roubin) University of Santiago de Compostela, Compostela, Spain (Ojeda, Blas) Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain Publisher BioMed Central Ltd Abstract Background: The DAPA-TAVI trial demonstrated that dapagliflozin reduced the composite of all-cause mortality or worsening heart failure (HF) at 1 year in patients undergoing transcatheter aortic valve replacement (TAVR) with prior HF. Whether the magnitude of this benefit differs according to diabetes mellitus (DM) status remains uncertain. <br/>Method(s): This pre-specified subgroup analysis of the multicenter randomized DAPA-TAVI trial conducted at 39 centers in Spain, which enrolled 1222 patients with severe aortic stenosis undergoing TAVR with prior HF and at least one high-risk condition. Patients were stratified by the presence or absence of DM. The primary endpoint was a composite of all-cause mortality or worsening HF at 12 months. Secondary endpoints included the individual components of the primary endpoint, cardiovascular death, and safety outcomes. Cox proportional-hazards models adjusted for age, sex, coronary artery disease, baseline ejection fraction and baseline estimated glomerular filtration rate were used to estimate treatment effects. <br/>Result(s): Among 1222 patients, 537 (43.9%) had DM. In patients with DM, dapagliflozin significantly reduced the primary endpoint compared with standard care (15.2% vs. 22.7%; HR 0.580; 95% CI 0.389-0.866; p = 0.008; number needed to treat [NNT] = 11), driven primarily by fewer worsening HF events. In patients without DM, the reduction was numerically lower and non-significant (15.0% vs. 18.0%; HR 0.814; 95% CI 0.560-1.183; p = 0.280; NNT = 32). Genital infections were more frequent with dapagliflozin in patients with DM, whereas symptomatic hypotension was more common in those without DM. No significant differences in serious adverse events were observed in either subgroup. No statistically significant interactions between DM status and treatment effect were observed for the primary or secondary endpoints. <br/>Conclusion(s): In this pre-specified subanalysis of the DAPA-TAVI trial, dapagliflozin significantly reduced the risk of death or worsening HF in patients with DM undergoing TAVR, with a favorable benefit-risk profile, whereas a more modest and non-significant effect was observed in non-DM patients. Although no statistically significant interaction according to diabetes status was observed, the apparently greater benefit among patients with DM warrants further investigation.<br/>Copyright &#xa9; The Author(s) 2026. <138> Accession Number 2051500181 Title Successful Management of Ischaemic Large Vessel Occlusion and 'Double' Prosthetic Valve Thrombosis: Short Report with Systematic Review of Literature. Source Journal of Stroke Medicine. (no pagination), 2026. Date of Publication: 2026. Author Angel Miraclin A.M.; Mampilly A.; Daniel E.; K. B. S.B.; Arullselvam S.M.; Davis J.; Nair A.V.; Jose J.; Nair S.; Keshava S.N.; Mathew V.; Aaron S. Institution (Angel Miraclin, Arullselvam, Davis, Nair, Mathew, Aaron) Department of Neurological Sciences, Christian Medical College, Tamil Nadu, Vellore, India (Mampilly, Nair) Department of Neuro-critical Care, Christian Medical College, Tamil Nadu, Vellore, India (Daniel, Jose) Department of Cardiology, Christian Medical College, Tamil Nadu, Vellore, India (K. B., Keshava) Department of Interventional Radiology, Christian Medical College, Tamil Nadu, Vellore, India Publisher SAGE Publications Inc. Abstract Background: Treatment of embolic events, especially ischaemic stroke with large vessel occlusions (LVOs) in the context of prosthetic valve dysfunction, is a management challenge. Stroke might be the harbinger of prosthetic valve thrombosis. Timely management of ischaemic stroke and prosthetic valve thrombosis is essential to offer optimal outcomes. <br/>Method(s): We report our experience in the management of a young woman, a known patient with rheumatic heart disease, status post double valve replacement (St Jude mechanical valves) on anticoagulation, who presented with acute right middle cerebral artery occlusion and 'double prosthetic valve' thrombosis. We present a systematic review of the utility of thrombolysis in the management of prosthetic valve thrombosis. <br/>Result(s): The patient presented within the 'window period' with left hemiparesis and hemineglect. Imaging revealed a right striatocapsular infarct with occlusion of the right middle cerebral artery stem. She underwent mechanical thrombectomy, which resulted in successful reperfusion. Post-procedure, she developed acute pulmonary oedema, and echocardiography (ECHO) revealed severe biventricular dysfunction with mitral and aortic valve thrombosis. As she was critically ill, she was immediately thrombolysed with two doses of reteplase. Her pulmonary oedema subsequently improved, with repeat ECHO showing normal prosthetic valve function. She was discharged on day 3 with no neurological deficits. <br/>Conclusion(s): Coordinated input from a multidisciplinary team guided the choice of treatment strategy and was central to the favourable outcome achieved. Our findings support thrombolysis as a reasonably safe therapeutic choice for critically ill patients with prosthetic valve dysfunction.<br/>Copyright &#xa9; The Author(s) 2026 <139> Accession Number 2050206387 Title Coronary Complications During PCI: Contemporary Management and Recent Advances. Source Current Treatment Options in Cardiovascular Medicine. 28(1) (no pagination), 2026. Article Number: 35. Date of Publication: 01 Dec 2026. Author Desai P.V.; Williford N.N.; Sandoval Y.; Brilakis E.S. Institution (Desai, Sandoval, Brilakis) Center for Coronary Artery Disease, Allina Health Minneapolis Heart Institute Foundation, 920 E 28th Street #100, Minneapolis, MN, United States (Williford) Oklahoma Heart Institute, Tulsa, OK, United States Publisher Springer Abstract Purpose of Review: Coronary complications during percutaneous coronary intervention (PCI) are uncommon but may lead to abrupt hemodynamic deterioration, myocardial infarction, cardiac tamponade, emergency surgery, other adverse clinical outcomes, or death. As contemporary PCI is increasingly performed in patients with complex coronary anatomy and greater clinical risk, prompt recognition and familiarity with complication-management strategies remain essential. This focused review summarizes contemporary management of coronary perforation, acute vessel closure, and equipment loss or entrapment, with emphasis on recent advances. Recent Findings: Recent developments in coronary perforation management include flow-preserving perfusion balloons, improved deliverability and optimization of covered stents, covered-stent fenestration for bifurcation perforations, contemporary embolization strategies, and emerging data regarding anticoagulation reversal. For acute vessel closure, intravascular imaging and chronic total occlusion-derived dissection and re-entry techniques can facilitate restoration of true-lumen flow when conventional rewiring fails, while intracoronary epinephrine and other adjunctive therapies have expanded treatment options for refractory no-reflow. Recent advances in equipment loss and entrapment include novel guidewire-retrieval techniques and percutaneous bailout strategies for entrapped atherectomy devices. <br/>Summary: Most coronary complications can be managed percutaneously when recognized early and treated with a stepwise approach. A systematic approach incorporating pre-procedural preparation, intraprocedural vigilance and escalation, and structured post-procedural follow-up may further improve outcomes.<br/>Copyright &#xa9; The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2026. <140> Accession Number 2051388121 Title Clinical Impact of Medical Therapy Versus Revascularization in Patients With Chronic Coronary Total Occlusions. Source Journal of Invasive Cardiology. 33(1) (no pagination), 2021. Date of Publication: 01 Jan 2021. Author Alvarez-Contreras L.; Flores-Umanzor E.; Cepas-Guillen P.; Ferreira-Gonzalez I.; Freixa X.; Regueiro A.; Brugaletta S.; Sabate M.; Martin-Yuste V. Institution (Alvarez-Contreras, Flores-Umanzor, Cepas-Guillen, Ferreira-Gonzalez, Freixa, Regueiro, Brugaletta, Sabate, Martin-Yuste) Cardiology Department, Clinic Cardiovascular Institute, Hospital Clinic, IDIBAPS, Barcelona, Spain (Ferreira-Gonzalez) Cardiology Department, Vall d'Hebron Hospital, Barcelona, Spain (Martin-Yuste) Service de Cardiologie, Centre Hospitalier de Saintonge, Saintes, France Publisher Cliggott Publishing Co. Abstract Background. Chronic total occlusions (CTOs) are prevalent angiographic findings in patients with suspected coronary artery disease. Conflicting results of randomized controlled trials and registries have not clarified the therapeutic approach for patients with CTO in clinical practice. Therefore, we sought to analyze variables influencing the decision-making process and their relationship with clinical outcomes according to the type of selected therapy. Methods. A total of 1248 consecutive patients with at least 1 CTO were identified between 2010 and 2014 at our institution. Clinical and angiographic variables were collected to allow the calculation of several predictive scores. Primary outcome was all-cause death at the longest follow-up available. Other endpoints of interest included cardiac mortality and myocardial infarction. Medical therapy (MT) alone was indicated in 719 patients (58%), whereas percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) were used in 240 (19%) and 298 (24%), respectively. Age, acute myocardial infarction, previous CABG, and age, creatinine, ejection fraction (ACEF) score were independently associated with the decision for MT alone. Conversely, the presence of multivessel disease, left main coronary artery involvement, and high Syntax score favored the decision for CABG. At a median follow-up of 4.3 years, revascularization strategies were independently associated with all-cause mortality and cardiac mortality (hazard ratio [HR], 0.42; 95% confidence interval [CI] 0.27-0.65; P<.001 and HR, 0.32; 95% CI, 0.17-0.60; P<.001, respectively) for PCI and (HR, 0.39; 95% CI, 0.26-0.58 and HR, 0.51; 95% CI, 0.32-0.81; P<.01, respectively) for CABG. Conclusion. Several clinical and angiographic parameters influence the decision-making process of patients with CTO. CTO revascularization with either PCI or CABG appeared to be associated with improved clinical outcomes at long-term follow-up as compared with MT alone.<br/>Copyright &#xa9; (2021), (Cliggott Publishing Co.). All rights reserved. <141> Accession Number 652611790 Title Hydralazine-isosorbide dinitrate in chronic heart failure with reduced ejection fraction: the H-HeFT trial. Source European heart journal. (no pagination), 2026. Date of Publication: 04 Nov 2026. Author Kober L.; Skak-Hansen K.W.; Larsen A.H.; Vraa S.; Schou M.; Hofsten D.E.; Refsgaard J.; Steffensen F.; Hassager C.; Parner E.; Moller J.; Eiskjaer H.; Botker H.E.; Serup-Hansen K.; Madsen J.S.; Kristensen S.L.; Poulsen M.K.; Holst-Hansen C.; Hollingdal M.; Hove J.D.; Barasa A.; Wolsk E.; Buch N.P.G.; Bruun N.E.; Bottcher M.; Dodt K.; Brogaard V.; Nielsen G.; Ryde H.; Mikkelsen K.V.; Wang Y.; Madsen E.H.; Poenaru M.P.; Raymond I.; Mahboubi K.; Petersen M.; Tonder N.; Gislason G.; Mellemkjaer S.; Gustafsson F.; Wiggers H. Institution (Kober, Skak-Hansen, Hofsten, Hassager, Moller, Kristensen, Gustafsson) Department of Cardiology, Rigshospitalet and Herlev-Gentofte Hospital, University of Copenhagen, Blegdamsvej 9, Denmark (Kober, Skak-Hansen, Schou, Madsen, Wolsk, Gislason) Department of Cardiology, Herlev-Gentofte Hospital, Copenhagen, Denmark (Kober, Schou, Hassager, Gislason) Department of Clinical Medicine, University of Copenhagen 2100 Panum, Copenhagen, Denmark (Larsen, Eiskjaer, Botker, Serup-Hansen, Mellemkjaer, Wiggers) Department of Cardiology, Aarhus University Hospital, Denmark (Larsen, Bottcher) Department of Cardiology, Godstrup Hospital, Denmark (Vraa, Holst-Hansen) Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark (Refsgaard, Hollingdal) Department of Cardiology, Viborg Hospital, Viborg, Denmark (Steffensen, Brogaard) Department of Cardiology, Sygehus Lillebaelt, Vejle, Denmark (Steffensen, Poenaru) Department of Cardiology, Sygehus Lillebaelt, 6000 Kolding, Denmark (Parner) Department of Biostatistics, Aarhus University, Denmark (Moller, Poulsen) Department of Cardiology, Odense University Hospital, Odense, Denmark (Hove, Barasa, Petersen) Department of Cardiology, Amager-Hvidovre Hospital, Copenhagen, Denmark (Buch) Department of Cardiology, Bispebjerg Hospital, Copenhagen, Denmark (Bruun) Department of Cardiology, Roskilde Hospital, Roskilde, Denmark (Dodt) Department of Cardiology, Horsens Hospital, Horsens, Denmark (Nielsen) Department of Cardiology, Hjorring Hospital, Denmark (Ryde) Department of Cardiology, Slagelse Hospital, Slagelse, Denmark (Mikkelsen) Department of Cardiology, Sydvestjysk Sygehus, Esbjerg, Denmark (Wang) Department of Cardiology, Sygehus Sonderjylland, Denmark (Madsen) Department of Cardiology, Silkeborg Hospital, Silkeborg, Denmark (Raymond) Department of Cardiology, Holbaek Hospital, Denmark (Mahboubi) Department of Cardiology, Randers Hospital, Randers, Denmark (Tonder) Department of Cardiology, Nordsjaellands Hospital, Denmark (Gislason) Danish Heart Foundation, Copenhagen, Denmark (Wiggers) Department of Clinical Medicine, Aarhus University, Denmark Abstract BACKGROUND AND AIMS: Hydralazine-isosorbide dinitrate (H-ISDN) has shown benefit in earlier randomized trials of patients with reduced left ventricular ejection fraction (LVEF) and chronic heart failure. This trial tested if H-ISDN could reduce worsening heart failure or mortality in patients with chronic heart failure with reduced ejection fraction (HFrEF) receiving contemporary treatment. <br/>METHOD(S): The Hydralazine-Isosorbide Dinitrate in Patients With Chronic Heart Failure Trial (H-HeFT) was a multicentre, randomized (1:1), double-blind, placebo-controlled trial in patients with HFrEF at 23 Danish hospitals (New York Heart Association class II-IV, elevated N-terminal pro-B-type natriuretic peptide and LVEF <=40%). Target treatment was hydralazine 75 mg/isosorbide dinitrate 40 mg three times a day (t.i.d). The primary endpoint was a composite of hospitalization with worsening heart failure, an urgent outpatient visit resulting in intravenous/metolazone therapy for heart failure, heart transplantation, left ventricular assist device implantation, or death. Secondary endpoints included components of the primary outcome. <br/>RESULT(S): Overall, 592 predominantly White patients (median age 72 years, 18% women) were randomized with a mean follow-up of 3.7 years. The primary outcome occurred in 90 of 294 patients (30.6%) in the H-ISDN group and in 91 of 298 patients (30.5%) in the placebo group [hazard ratio (HR) 0.90; 95% confidence interval (CI) 0.67-1.21; P = .48]. There were 57 deaths in the H-ISDN group vs 72 in the placebo group (HR 0.72; 95% CI 0.51-1.02); worsening heart failure events occurred in 52 vs 47 patients (HR 1.01; 95% CI 0.68-1.50). <br/>CONCLUSION(S): Hydralazine-isosorbide dinitrate did not change the incidence of the composite endpoint of heart failure events or death in patients with heart failure and LVEF <=40%.<br/>Copyright &#xa9; The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact <142> Accession Number 652605287 Title Single vs Double ProGlide Devices for Access Site Closure after Transfemoral Aortic Valve Replacement: The SINGLE-CLOSURE Trial. Source Journal of the American College of Cardiology. (no pagination), 2026. Date of Publication: 03 Nov 2026. Author Liu X.; Song G.; Chen T.; An G.; Guo Y.; Zhou H.; Jiang L.; Chen X.; Cheng B.; Niu G.; Xu K.; Shao Y.; Chen Z.; Yang Y.; Fang Z.; Liu J.; Xiu J.; Chen J.; Bai Y.; Zhuang X.; Cheng Z.; Wang L.; Xu J.; Liang X.; Han K.; Hu H.; Liu Q.; Leon M.B.; Wang J. Institution (Liu, Guo, Wang, Hu, Liu, Wang) Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China; Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Hangzhou, China; Transvascular Implantation Devices Research Institute, Hangzhou, China (Song) Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China (Chen) Department of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, China (An) State Key Laboratory for Innovation and Transformation of Luobing Theory, Jinan, China; Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Jinan, China; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China (Guo) Department of Cardiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China (Zhou) Department of Cardiology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China (Jiang) Department of Cardiac Surgery, Affiliated Hospital of Qingdao University, Qingdao, China (Chen) Department of Cardiology, First Affiliated Hospital of Ningbo University, Ningbo, China (Cheng) Department of Cardiovascular Disease, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China (Niu) Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Xu) Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China (Shao) Department of Cardiology, Qingdao Municipal Hospital (Qingdao Hospital of Rehabilitation University), Qingdao, China (Chen) Department of Cardiology, Affiliated Lihuili Hospital of Ningbo University, Ningbo University, Ningbo, China (Yang) Department of Cardiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China (Fang) Department of Cardiology, Second Xiangya Hospital of Central South University, Changsha, China (Liu) Department of Cardiology, First Affiliated Hospital of Bengbu Medical University, Bengbu, China (Xiu) Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China (Chen) Department of Structural Heart Disease, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China (Bai) Department of Cardiovascular Medicine, Center of Coronary Circulation, National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Department of Geriatric Medicine, Xiangya Hospital, Central South University, Hunan, China (Zhuang) Department of Cardiology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China (Cheng) Department of Cardiology, Huzhou Central Hospital, Huzhou, China (Wang) Department of Cardiology, Henan Provincial Chest Hospital, Zhengzhou, China (Xu) Department of Cardiology, First Hospital of Lanzhou University, Lanzhou, China (Liang) Department of Cardiology, First People's Hospital of Yulin, Yulin, China (Han) Department of Cardiology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China (Leon) Columbia University Irving Medical Center, New York, New York, USA; NewYork-Presbyterian Hospital, New York, New York, USA Abstract BACKGROUND: Despite advances in transcatheter aortic valve replacement (TAVR), access-site vascular complications remain an important source of procedural morbidity. The conventional double-ProGlide strategy may increase the risk of access-site stenosis and other vascular complications, particularly in patients with challenging iliofemoral anatomy. Retrospective studies have suggested that a single-ProGlide strategy may offer an effective alternative, but this strategy has not yet been evaluated in a randomized trial. <br/>OBJECTIVE(S): This trial aimed to determine whether a single-ProGlide strategy could offer a simpler alternative to the conventional double-ProGlide strategy without increasing vascular complications. <br/>METHOD(S): The SINGLE-CLOSURE trial was a prospective, multicenter, open-label, randomized trial conducted at 25 centers in China. Patients aged >=65 years scheduled for transfemoral TAVR were assigned 1:1 to single-ProGlide or double-ProGlide closure for the main access site. The primary endpoint was the in-hospital composite of Valve Academic Research Consortium (VARC)-3-defined access-site or access-related major and minor vascular complications. <br/>RESULT(S): A total of 876 patients were randomized. In the modified intention-to-treat population, the primary endpoint occurred in 57 of 436 patients (13.1%) in the single-ProGlide group and 65 of 430 patients (15.1%) in the double-ProGlide group, meeting the prespecified criterion for noninferiority (risk difference: -2.2%; 95%: -7.0% to 2.6%; P = 0.013; noninferiority margin: 3.19%). Access-related major vascular complications occurred in 2 patients (0.5%) in the single-ProGlide group and 6 patients (1.4%) in the double-ProGlide group. Among the secondary endpoints, individual components of the primary endpoint, access-related bleeding, time to hemostasis, and all-cause mortality were similar between groups. Access-site stenosis was numerically less frequent with the single-ProGlide strategy (5.0% vs 7.9%), whereas additional closure devices might be used more often (2.5% vs 0.9%). <br/>CONCLUSION(S): A single-ProGlide strategy was noninferior to conventional double-ProGlide closure for the composite of VARC-3-defined access-site or access-related vascular complications after transfemoral TAVR. Primary endpoint events were predominantly minor vascular complications.<br/>Copyright &#xa9; 2026. Published by Elsevier Inc. <143> Accession Number 652611640 Title The Effect of Adding Dexmedetomidine to Modified Del Nido Cardioplegia Solution on Myocardial Protection in Children Undergoing Congenital Heart Defect Surgery - A Prospective, Randomized, Triple-Blind, Controlled Trial. Source Brazilian journal of cardiovascular surgery. 41(4) (no pagination), 2026. Date of Publication: 01 Jul 2026. Author Samadieh F.; Maleki M.H.; Razeghian M.; Izanlou T.; Sistani M.N.; Fazli B.; Yaghubi M. Institution (Samadieh, Izanlou) Mashhad University of Medical Sciences Imam Reza Hospital Department of Extra-Corporeal Circulation Mashhad Iran Department of Extra-Corporeal Circulation (ECC), Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of (Maleki) Mashhad University of Medical Sciences Imam Reza Hospital Department of Cardiac Surgery Mashhad Iran Department of Cardiac Surgery, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of (Razeghian) Torbat Heydariyeh University of Medical Sciences School of Medicine Department of General Surgery Torbat Heydariyeh Iran Department of General Surgery, School of Medicine, Torbat Heydariyeh University of Medical Sciences, Iran, Islamic Republic of (Sistani) Mashhad University of Medical Sciences Faculty of Medicine Department of Pediatrics Mashhad Iran Pediatric and Congenital Cardiology Division, Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of (Fazli) Mashhad University of Medical Sciences Faculty of Medicine Department of Anesthesiology Mashhad Iran Department of Anesthesiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of (Yaghubi) Imam Reza International University Razavi Hospital Department of Extra-Corporeal Circulation Mashhad Iran Department of Extra-Corporeal Circulation (ECC), Razavi Hospital, Imam Reza International University, Mashhad, Iran, Islamic Republic of Abstract INTRODUCTION: The myocardial ischemia-reperfusion injury (IRI) is an indispensable factor in pediatric congenital heart defect (CHD) surgery. Although effective myocardial protection strategies are crucial, the issue remains a dilemma. This study aimed to evaluate the effect of adding dexmedetomidine to modified Del Nido cardioplegia on myocardial protection in children undergoing CHD surgery. <br/>METHOD(S): This was a prospective, randomized, triple-blind, controlled clinical trial. A total of 60 pediatric patients were enrolled and randomized 1:1 into two groups - an intervention group that received dexmedetomidine-enriched modified Del Nido cardioplegia and a control group that received standard modified Del Nido cardioplegia with normal saline. Primary outcomes included serum troponin I and creatine kinase-MB levels, as well as coronary sinus lactate levels. Secondary outcomes were the vasoactive-inotropic score, weaning time from mechanical ventilation, and intensive care unit length of stay. <br/>RESULT(S): Adding dexmedetomidine to modified Del Nido cardioplegia significantly improved myocardial protection in children undergoing CHD surgery. The intervention group showed significantly lower troponin I levels at all postoperative time points compared to the control group (P < 0.001). Similarly, the dexmedetomidine group had significantly lower vasoactive-inotropic score at all time points (P < 0.001). Patients in the intervention group also experienced a significantly shorter mean ventilator weaning time (P < 0.001) and intensive care unit stay duration (P < 0.001). The overall distribution of postoperative morbidities did not differ significantly between the groups (P = 0.059). <br/>CONCLUSION(S): Adding dexmedetomidine to modified Del Nido cardioplegia significantly improved myocardial protection in children undergoing corrective CHD surgery. <144> Accession Number 652601473 Title Effect of Continuous Positive Airway Pressure Adherence on Cardiovascular Outcomes in Obstructive Sleep Apnea: A Real-World Weighted Cohort Analysis. Source Journal of Sleep Research. Conference: 28th Congress of the European Sleep Research Society. Maastricht Netherlands. 35(Supplement 1) (no pagination), 2026. Article Number: e70435. Date of Publication: 01 Oct 2026. Author Na J.O.; Yoo H.; Yun Y.; Choi Y.; Gwak S.-Y.; Lee J.E.; Bak M. Institution (Na, Gwak, Lee) Korea University Guro Hospital, Seoul, South Korea (Yoo, Yun, Choi) Korea University Medicine, Seoul, South Korea (Bak) Seoul National University Bundang Hospital, Sungnam, South Korea Publisher John Wiley and Sons Inc Abstract Background and aims: Obstructive sleep apnea (OSA) is a prevalent disorder increasingly recognized as a major contributor to cardiovascular morbidity and mortality. Continuous positive airway pressure (CPAP) is the first-line therapy; however, its effectiveness in preventing major adverse cardiac and cerebrovascular events (MACCE) remains debated. Emerging evidence suggests that adherence is a critical determinant of therapeutic efficacy, yet real-world data comprehensively accounting for healthy user bias and confounding factors are limited, particularly in Asian populations. This study aimed to evaluate the association between CPAP adherence and the risk of MACCE in a real-world cohort of patients with OSA. <br/>Method(s): We conducted a retrospective cohort study involving patients who underwent polysomnography at a tertiary academic medical center between December, 2011 and September, 2025. A total of 636 eligible patients were analyzed. Patients with a clinical indication for CPAP (n = 334) were categorized into three groups based on objective usage data: Adherent (usage >= 4 h/day on >= 70% of days for >= 90 days; n = 113), Non-adherent (did not meet criteria; n = 123), and Non-users (prescribed but never used; n = 98). A control group of patients with mild or non-indicated OSA (n = 302) was included for reference. The primary endpoint was composite MACCE, defined as all-cause mortality, myocardial infarction, stroke, or coronary revascularization. <br/>Result(s): After applying inverse probability of treatment weighting, baseline characteristics were well-balanced across groups (standardized mean differences < 0.1). During follow-up period, KM analysis demonstrated significant differences in MACCE-free survival (log-rank p = 0.008), with the Adherent group exhibiting the highest event-free survival rate. In the weighted Adherent CPAP use was associated with a significant reduction in the risk of composite MACCE compared with non-users (HR 0.18; 95% CI 0.04-0.81; p = 0.038). A pooled analysis comparing all CPAP users (regardless of adherence) versus nonusers also showed a protective effect (HR 0.33; 95% CI 0.14-0.80; p = 0.023). <br/>Conclusion(s): In this rigorously adjusted real-world analysis, high adherence to CPAP therapy was associated with a significantly reduced risk of MACCE in patients with OSA. Conversely, non-use or suboptimal adherence was linked to poorer outcomes. These findings support the hypothesis that the neutral results of previous RCTs may reflect inadequate therapeutic exposure rather than a lack of efficacy. <145> Accession Number 652592851 Title From liberal to restrictive and beyond: a narrative review of red blood cell transfusion strategies in the modern era. Source Blood transfusion = Trasfusione del sangue. (no pagination), 2026. Date of Publication: 14 Oct 2026. Author Koutoulogeni A.; Tsalas S.; Kyriakou E.; Kokoris S.I.; Tsante A.; Loukopoulou E.; Tsantes E.A.; Petrou E.; Nikolopoulos G.K.; Bonovas S.; Tsantes A.E. Institution (Koutoulogeni, Tsalas, Kyriakou, Kokoris, Tsante, Loukopoulou, Tsantes, Petrou, Tsantes) Laboratory of Hematology and Blood Bank Unit, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece (Nikolopoulos) Medical School, University of Cyprus, Nicosia, Cyprus (Bonovas) Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy (Bonovas) IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy Abstract BACKGROUND: Red blood cell (RBC) transfusion remains a cornerstone of modern medicine, yet optimal transfusion thresholds continue to be debated. Historically, liberal strategies -maintaining hemoglobin (Hb) concentration above 10 g/dL- predominated, but evidence from the 1990s onward has favored restrictive approaches (Hb threshold 7-8 g/dL). This narrative review synthesizes contemporary evidence on restrictive versus liberal transfusion strategies published between 2021 and 2026, evaluates population-specific considerations, and explores emerging ultra-restrictive thresholds. MATERIALS AND METHODS: A structured narrative literature search was conducted in PubMed and Google Scholar with particular emphasis on evidence published between 2021 and 2026. Evidence from randomized controlled trials, systematic reviews, meta-analyses, and clinical practice guidelines is critically discussed. <br/>RESULT(S): The 2025 Cochrane update (48 trials, >20,000 participants) provided high-certainty evidence that restrictive strategies induce a reduction in the risk or proportion of patients receiving at least one RBC transfusion by 41% without increasing 30-day mortality or major morbidity. Restrictive thresholds are safe in stable critically ill patients, in those undergoing non-cardiac surgery, and in patients with acute gastrointestinal bleeding. However, important exceptions include: acute myocardial infarction (in which liberal strategies may reduce cardiac events), neurocritical care (conflicting evidence on neurological outcomes), chronic transfusion-dependent conditions such as thalassemia (liberal strategies are disease-modifying), and hematologic malignancies (individualized approach required). Ultra-restrictive thresholds (Hb <6-7 g/dL) have emerged as a potential blood conservation tool during shortages but require further safety validation. <br/>DISCUSSION(S): Restrictive transfusion strategies are safe and effective for many stable adult hospitalized patients, reducing blood product utilization without compromising outcomes. However, individualized approaches remain essential for specific high-risk populations. Ultra-restrictive strategies are promising, but these approaches should currently be considered only in selected contexts pending further safety validation. <146> Accession Number 2051443667 Title Valvular surgery for rheumatic heart disease in Africa: a scoping review protocol. Source International Journal of Surgery Protocols. 29(2) (pp 26-29), 2025. Date of Publication: 01 Jun 2025. Author Femi-Lawal .O.; Effiom V.B.; James Michael A.; Bill-Smith Anyinkeng A.; Ekpenyong J.N.; Nwajei E.; Patel S.K.; An K.R.; Okonta K.E. Institution (Femi-Lawal, James Michael) Department of Medicine and Surgery, College of Medicine, University of Ibadan, Oyo State, Ibadan, Nigeria (Femi-Lawal, Effiom, James Michael, Bill-Smith Anyinkeng, Ekpenyong) Research Division, Association of Future African Cardiothoracic Surgeons, Yaounde, Cameroon (Effiom, Ekpenyong) Department of Medicine and Surgery, University of Calabar, Calabar, Nigeria (Bill-Smith Anyinkeng) Faculty of Health Sciences, University of Buea, Buea, Cameroon (Nwajei, Patel) Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada (An) Division of Cardiac Surgery, Department of Surgery, University of Toronto, Ontario, Canada (Okonta) Division of Cardiothoracic Surgery, Department of Surgery, University of Port Harcourt, Nigeria Publisher Wolters Kluwer Health Abstract Background: - Rheumatic heart disease (RHD) remains a major health challenge in Africa, where the prevalence is notably high. Valvular surgery is a crucial procedure for managing severe RHD. However, the current state and historical trend of research on this subject in African populations is not well understood. Understanding the scope, subject matter, and quality of the literature on this topic over time is essential to inform future research and clinical practice. <br/>Objective(s): - This paper aims to assess the current published literature to evaluate vital outcomes such as surgical outcomes, survival rates, postoperative complications, long-term quality of life, morbidities, mortalities, and barriers to valve surgery for patients with RHD in Africa. <br/>Method(s): - This protocol adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). An extensive search will be conducted across different databases, including PubMed, Scopus, Web of Science, Cochrane Library, African Index Medicus, and African Journals Online. Studies will be identified through keyword searches and will be reviewed against predefined inclusion and exclusion criteria by two reviewers, with a third reviewer resolving any discrepancies. A narrative synthesis will be conducted to describe the findings. <br/>Conclusion(s): - The findings from this scoping review will provide an understanding of the current literature on valvular surgery for RHD in African contexts. This will help guide future research directions in this field.<br/>Copyright &#xa9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. <147> Accession Number 652592744 Title Perioperative hemostatic therapy in adult cardiac surgery: a narrative review highlighting human factors. Source Blood transfusion = Trasfusione del sangue. (no pagination), 2026. Date of Publication: 28 Oct 2026. Author Sebestyen A.; Picard J.; Evain J.-N.; Behouche A.; Chavanon O.; Albaladejo P. Institution (Sebestyen, Chavanon) Department of Cardiac Surgery, Grenoble Alpes University Hospital, Grenoble, France (Sebestyen, Picard, Albaladejo) Alps Research Assessment and Simulation Centre (CESAR), TIMC Laboratory, Grenoble Alpes University, Grenoble, France (Picard, Evain, Behouche, Albaladejo) Department of Anesthesia and Intensive Care, Grenoble Alpes University Hospital, Grenoble, France Abstract Severe bleeding remains a significant cause of morbidity and mortality in cardiac surgery, and hemostatic blood components, mainly platelet concentrates and fresh frozen plasma, are essential to perioperative hemostatic management. While restrictive strategies for packed red blood cell transfusions are now well established within Patient Blood Management, inappropriate prophylactic transfusions of these hemostatic therapies continue to receive less attention.This narrative review investigates variations in hemostatic therapy among centres for adult cardiac surgery, and examines the factors that might explain these differences. A review of fourteen original studies involving nearly 220,000 patients from over 1,000 centres worldwide revealed significant variations in platelet and fresh-frozen plasma transfusion rates across centres.Differences in patient and procedural characteristics cannot entirely explain these variations. Although viscoelastic hemostatic tests have improved bedside assessment and lowered exposure in some settings, they have not eradicated significant variations in practice. The available evidence indicates that hospital culture, local organization, transfusion thresholds, and human factors all have an impact on transfusion behaviour.Optimizing the use of hemostatic therapies in adult cardiac surgery will therefore not only require better tools and protocols, but also increased focus on the organizational and non-technical factors that influence decision-making. <148> Accession Number 2050172957 Title Evolution of coronary artery bypass grafting: conventional, minimally invasive, robotic, and hybrid revascularisation techniques. Source Journal of Robotic Surgery. 20(1) (no pagination), 2026. Article Number: 761. Date of Publication: 01 Dec 2026. Author Muafa H.M. Institution (Muafa) Department of Surgery, 21 September University for Medical and Applied Sciences, Sana'a, Yemen Publisher Springer Nature Abstract Coronary artery bypass grafting (CABG) remains one of the most durable treatments for obstructive coronary artery disease (CAD), particularly in anatomically complex multivessel disease, diabetes, left main disease and ischaemic cardiomyopathy. During the last three decades, the conventional operation performed through median sternotomy with cardiopulmonary bypass has been complemented by off-pump, minimally invasive direct coronary artery bypass (MIDCAB), multivessel minimally invasive coronary surgery, robotic-assisted CABG, totally endoscopic CABG (TECAB) and hybrid coronary revascularisation (HCR). This narrative review summarises the evolution of CABG, compares conventional and minimally invasive approaches, and discusses current evidence, indications, limitations, implementation challenges, future directions and a practical decision algorithm for patient selection. A narrative literature review was conducted using PubMed/MEDLINE, Google Scholar, major cardiology and cardiothoracic guideline documents, and recent open-access reviews and meta-analyses published up to June 2026. Priority was given to contemporary guidelines, landmark trials, systematic reviews, meta-analyses and large observational series. Because this is a narrative review, no formal pooled analysis or risk-of-bias grading was performed. Conventional CABG provides reliable complete revascularisation and remains the preferred strategy for many patients with complex multivessel CAD. The survival value of the left internal mammary artery to left anterior descending artery graft underpins both conventional and minimally invasive strategies. MIDCAB is most established for isolated LAD disease and as the surgical component of HCR. Robotic-assisted CABG and TECAB reduce access trauma and may improve recovery, transfusion requirements and wound morbidity, but they require dedicated training, a specialised team and a high-volume programme to overcome the learning curve. HCR offers a biologically attractive compromise by combining durable LIMA-LAD bypass with PCI to non-LAD vessels, yet randomised evidence remains limited. The proposed algorithm translates these data into a clinically practical Heart Team pathway rather than a purely technique-centred comparison. The future of CABG is not a replacement of conventional surgery by a single minimally invasive method, but a personalised revascularisation strategy selected by a Heart Team. The most clinically relevant question is not whether one technique is universally superior, but which patient, coronary anatomy and institutional environment are best suited to conventional CABG, MIDCAB, robotic/TECAB or HCR.<br/>Copyright &#xa9; The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature 2026. <149> Accession Number 2050193312 Title Effect of cardiac-index guided intraoperative haemodynamic therapy on postoperative outcome in non-cardiac surgery patients - a systematic review and meta-analysis. Source Perioperative Medicine. 15(1) (no pagination), 2026. Article Number: 96. Date of Publication: 01 Dec 2026. Author Omuro P.K.; Dinges H.-C.; Kammerer T. Institution (Omuro, Dinges, Kammerer) Department of Anaesthesiology and Intensive Care Medicine, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Kerpener Str. 62, Cologne, Germany Publisher BioMed Central Ltd Abstract Background: Optimal perioperative haemodynamic management is essential to reduce postoperative complications. While multiple technologies allow for advanced monitoring, clear evidence on the effectiveness of Cardiac Index-guided goal-directed therapy (CI-GDT) compared to standard care in non-cardiac surgery is lacking. This systematic review and meta-analysis aimed to investigate the impact of CI-GDT on postoperative outcome. <br/>Method(s): A systematic search using PubMed and Web of Science (2010-2025) identified randomised controlled trials (RCT) comparing CI-GDT to standard care in adult non-cardiac surgery. Study selection and data extraction were conducted according to PRISMA guidelines and registered under PROSPERO (CRD420251058399). Odds ratios (OR) with 95% confidence intervals (CI) and 95% prediction intervals (PI) were calculated using a random-effects model. Risk of bias was assessed via the RoB 2 tool. Heterogeneity was quantified with I<sup>2</sup>, tau<sup>2</sup>, and Cochran's Q. Reporting bias was evaluated by funnel plots, Egger's test, and trim-and-fill method. Sensitivity was assessed by leave-one-out analysis. <br/>Result(s): Twenty-one RCTs were included, of which 20 contributed data to the meta-analysis of postoperative complications. CI-GDT significantly reduced the incidence of postoperative complications (OR.59 [.45-.78]; PI.20-1.74; I<sup>2</sup> = 62.9%). Mortality did not differ significantly between groups (OR 0.77 [.57-1.05]; I<sup>2</sup> = 0%). Funnel plot and Egger's test indicated no significant publication bias (p=.15). Leave-one-out analysis confirmed robustness of findings. Trim-and-fill did not suggest missing studies. Certainty of evidence was graded high. Discussion/conclusion: CI-GDT was associated with a lower incidence of patients experiencing at least one postoperative complication, whereas mortality did not differ significantly. However, substantial heterogeneity and a prediction interval crossing the null indicate that the benefit may not be consistent across clinical settings. These findings do not establish an independent advantage of CI targeting over other GDT strategies.<br/>Copyright &#xa9; The Author(s) 2026. <150> Accession Number 2051252347 Title The latest guidelines for the perioperative management of the thoracic noncardiac patient: a critical appraisal of the literature. Source Current Opinion in Anaesthesiology. (no pagination), 2026. Date of Publication: 2026. Author Piccioni F.; Rispoli M.; Senturk M. Institution (Piccioni) Anesthesia and Perioperative Medicine Unit, Department of Anesthesia, Perioperative Medicine and Critical Care, IRCCS Humanitas Research Hospital, Rozzano, Italy (Rispoli) Department of Anesthesia and Intensive Care, Monaldi Hospital, Naples, Italy (Senturk) Department of Anesthesiology and Reanimation, School of Medicine, Acibadem University, Istanbul, Turkey Publisher Lippincott Williams and Wilkins Abstract Purpose of review - The management of patients before, during, and after surgical procedures on the thorax is influenced by a rapidly expanding set of guidelines that are only partially overlapping. The review is intended for clinicians who are interested in understanding how publication date influences their recommendations, and the points of agreement and divergence between sources. Recent findings - Across the preoperative, intraoperative, and postoperative phases, the reviewed documents converge strongly on core process measures. These measures encompass multimodal opioid-sparing analgesia, a single chest drain, early ambulation, and the avoidance of reflex ICU admission. However, there is less consistency in the numerical thresholds, including exercise-testing cut-offs, transfusion triggers, and drain-removal volumes. The most recent documents demonstrate a shift toward more permissive values and an increasing emphasis on frailty, sarcopenia, and patient-reported outcomes. Summary - The core enhanced recovery after surgery process measures have been demonstrated to be reliable. However, it is imperative for clinicians to ascertain the underlying guideline generation for any numerical threshold before its implementation. A significant number of intraoperative decisions are still made based on expert opinion rather than guideline-grade evidence, underscoring the necessity for future trials and consensus on patient-centered outcome measurement.<br/>Copyright &#xa9; 2026 Wolters Kluwer Health, LLC. All rights reserved. <151> Accession Number 2051479064 Title Evaluating the use of proactive surveillance and remote patient monitoring to guide the timing of valve intervention in patients with severe asymptomatic aortic stenosis (APRAISE-AS): results of a pilot randomised controlled trial. Source Heart. (no pagination), 2026. Date of Publication: 2026. Author Khan N.; Steeds R.P.; Mehta S.; Sun Y.; Kyte D.; Fabritz L.; Collis P.; Stubbs C.; Nulty M.; Cotton J.M. Institution (Khan) Department of Cardiology (QEHB), University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom (Khan, Steeds, Fabritz) Department of Cardiovascular Sciences, University of Birmingham College of Medical and Dental Sciences, Birmingham, United Kingdom (Steeds) Department of Cardiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom (Mehta, Sun, Stubbs, Nulty) Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom (Kyte) Institute for Applied Health Research, University of Birmingham, Birmingham, United Kingdom (Kyte) School of Health and Wellbeing, University of Worcester, Worcester, United Kingdom (Fabritz) Department of Diagnostic and Interventional Neuroradiology, University Heart and Vascular Centre, University Hospital Hamburg-Eppendorf, Hamburg, Germany (Collis) Department of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom (Cotton) Department of Cardiology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom (Cotton) Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, United Kingdom Publisher BMJ Publishing Group Abstract Background: The insidious nature of aortic stenosis (AS) combined with the advanced age of the affected population results in underreporting of symptoms and underestimation of impact on functional capacity and quality of life. Although guidelines recommend early valve replacement in severe asymptomatic AS when coupled with adverse prognostic features, capacity within healthcare systems may limit translation into clinical practice. The use of remote monitoring and proactive surveillance to inform clinical management of heart valve disease is an underexplored area. APRAISE-AS evaluated the utility of remote monitoring to pre-empt/detect a change in clinical status (incorporating a symptom tracker, frailty assessment and quality of life score) to inform patient management. <br/>Method(s): 12-month open-label, two-arm, parallel group randomised controlled pilot trial conducted in two tertiary cardiac centres. 38/66 participants (>=18 years) with asymptomatic severe AS were randomly assigned (1:1) to standard care or the APRAISE-AS intervention in addition to standard care. The primary aim of the study was to (1) test the trial protocol, (2) determine acceptability of the APRAISE-AS intervention and (3) inform the most appropriate outcome measure(s) and sample size for a full-scale randomised controlled trial. <br/>Result(s): 38 participants were assigned to standard care (n=19) or to standard care plus the APRAISE-AS intervention (n=19). Adherence rates were high: 81% for the weekly symptom assessments, 91% for the fortnightly timed up and go tests and 93% for the monthly health-related quality of life assessments using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Clinical review and onward referral for valve replacement were triggered by a change from baseline in symptoms and KCCQ scores. <br/>Conclusion(s): Remote monitoring of severe asymptomatic AS can be safely delivered in practice. Although the pilot did not recruit to target, a digitally enabled clinical pathway to optimise the management of asymptomatic severe AS is acceptable to clinicians and patients. Trial registration number: ISRCTN19413194.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. <152> Accession Number 652593319 Title TAVR in Patients with Moderate Aortic Stenosis with At-Risk Features. Source The New England journal of medicine. (no pagination), 2026. Date of Publication: 02 Nov 2026. Author Genereux P.; Makkar R.R.; Pibarot P.; Bax J.J.; Lindman B.R.; Muhammad K.; Oldemeyer J.B.; Pirwitz M.; Barker C.M.; Thourani V.H.; Yadav P.K.; Rodriguez R.; Strote J.; Sakhuja R.; Khalil R.; Sharma R.; Chhatriwalla A.; Mishell J.M.; Kar B.; Gafoor S.; Walsh J.; Spoon D.; Frutkin A.; Pop A.; Van Mieghem N.M.; Satpathy R.; Ando K.; Montarello J.; Webb J.; Vemulapalli S.; Cohen D.J.; Gupta A.; Park B.; Prince H.; Blanke P.; Mack M.; Leon M.B. Institution (Genereux) Atlantic Health, Gagnon Cardiovascular Institute at Morristown Medical Center, Morristown, NJ, United States (Makkar, Gupta) Cedars-Sinai Medical Center, Los Angeles, United States (Pibarot) Quebec Heart and Lung Institute-Laval University, Quebec, QC, Canada (Bax) Leiden University Medical Center, Leiden, Netherlands (Lindman, Barker) Vanderbilt University Medical Center, Nashville, United States (Muhammad) Oklahoma Heart Institute, Tulsa, United States (Oldemeyer, Strote) University of Colorado Health, Medical Center of the Rockies, Loveland, United States (Pirwitz) Ascension Texas Cardiovascular, Austin, United States (Pirwitz) University of Texas Dell Medical School, Austin, United States (Thourani, Yadav) Marcus Valve Center, Piedmont Heart Institute, Atlanta, United States (Rodriguez) Lankenau Medical Center, Wynnewood, PA, United States (Sakhuja) Massachusetts General Hospital, Boston, United States (Sakhuja) Mass General Brigham, Boston, United States (Sakhuja) Harvard Medical School, Boston, United States (Khalil) Allegheny Singer Research Institute, Pittsburgh, United States (Sharma) Stanford University Medical Center, Stanford, CA, United States (Chhatriwalla) Saint Luke's Mid America Heart Institute, Kansas City, MO, United States (Mishell) Kaiser San Francisco Medical Center, San Francisco, Mexico (Kar) University of Texas Health Science Center, Houston, United States (Gafoor) Providence St. Joseph Health, Swedish Heart and Vascular, Seattle, United States (Walsh) Saint Alphonsus Health System, Boise, ID, United States (Spoon) St. Patrick Hospital, Missoula, MT, Bulgaria (Frutkin) Desert Cardiology Consultants, Eisenhower Medical Center, Rancho Mirage, CA, United States (Pop) Alexian Brothers Medical Center, Elk Grove Village, IL, United States (Van Mieghem) Erasmus University Rotterdam, Rotterdam, Netherlands (Van Mieghem) Ziekenhuis Oost-Limburg, Genk, Belgium (Satpathy) Baptist Medical Center, Jacksonville, FL, United States (Ando) Kokura Memorial Hospital, Kitakyushu, Japan (Montarello) Royal Adelaide Hospital, Adelaide, SA, Australia (Webb, Blanke) St. Paul's Hospital, University of British Columbia, Vancouver, Canada (Vemulapalli) Duke University School of Medicine, Durham, NC, United States (Cohen) St. Francis Hospital, Roslyn, NY, United States (Cohen, Leon) Cardiovascular Research Foundation, NY, United States (Park, Prince) Edwards Lifesciences, Irvine, CA, United States (Mack) Baylor Scott and White the Heart Hospital Plano, Plano, TX, United States (Leon) NewYork-Presbyterian/Columbia University Irving Medical Center, NY, United States Abstract BACKGROUND: For patients with moderate aortic stenosis, current guidelines recommend clinical surveillance with echocardiographic assessment every 1 or 2 years. Whether transcatheter aortic-valve replacement (TAVR) will improve outcomes in these patients remains unknown. <br/>METHOD(S): We conducted an international, open-label, randomized trial to evaluate whether TAVR will result in better outcomes than clinical surveillance among patients with moderate aortic stenosis with at least one at-risk feature (i.e., a symptom or structural or functional abnormality that has been shown to be associated with faster disease progression or adverse cardiovascular outcomes). The patients were assigned in a 1:1 ratio to undergo transfemoral TAVR with a balloon-expandable valve or clinical surveillance. The primary effectiveness end point was a composite of death from any cause or a heart-failure event with or without hospitalization at 2 years. Superiority testing was performed in the intention-to-treat population. <br/>RESULT(S): A total of 744 patients underwent randomization: 373 patients were assigned to the TAVR group and 371 to the clinical-surveillance group. The mean age of patients was 78 years, 39.1% were women, and 45.6% were at low surgical risk. The mean aortic-valve area was 1.2 cm2, and the mean aortic-valve peak velocity was 3.3 m per second. At 2 years, the Kaplan-Meier estimate of the percentage of patients with a primary effectiveness end-point event was 16.7% in the TAVR group and 23.9% in the clinical-surveillance group (risk difference, -7.2 percentage points; 95% confidence interval, -13.1 to -1.3; P = 0.02 for superiority). The Kaplan-Meier estimate of the percentage of patients who died from any cause was 8.4% in the TAVR group and 7.3% in the clinical-surveillance group; the estimates for a heart-failure event were 10.8% and 19.0%, respectively. The incidence of procedure-related adverse events did not differ meaningfully between the patients in the TAVR group and those in the clinical-surveillance group who underwent aortic-valve replacement. <br/>CONCLUSION(S): Among patients with moderate aortic stenosis and at-risk features, a strategy of TAVR was superior to clinical surveillance in lowering the incidence of death or a heart-failure event at 2 years. (Funded by Edwards Lifesciences; PROGRESS ClinicalTrials.gov number, NCT04889872.).<br/>Copyright &#xa9; 2026 Massachusetts Medical Society.

No comments:

Post a Comment